











This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
• This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
• A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
• This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
• The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
• When referring to this work, full bibliographic details including the author, title, 




The Effect of Matrix Stiffness on the Behaviour of 
Liver Resident Cell Populations in Chronic Liver 










Timothy Thomas Gordon-Walker 







Submitted for the degree of Doctor of Philosophy 
University of Edinburgh 
2013 
 ii 





I declare that the thesis presented here has been produced in accordance with 
the regulations put forward by the University of Edinburgh as stated below: 
 
 
(a) The thesis has been composed by the student 
(b) Either that the work is the student’s own, or, if the student has been a 
member of a research group, that the student has made a substantial 
contribution to the work, such contribution being clearly indicated, and 
(c) That the work has not been submitted for any other degree or 
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Dr Timothy Thomas Gordon-Walker 
 
Introduction: The development of liver fibrosis is characterised by dramatic changes in the biomechanical 
composition and mechanical properties of the extracellular matrix (ECM).  Increases in matrix stiffness 
associated with inflammation and fibrosis are implicated in promoting cancer development.  Clinical studies 
have demonstrated a close association between increases in liver stiffness and the incidence of 
hepatocellular carcinoma (HCC).  The effect of changes in matrix stiffness on tissue-resident hepatic 
progenitor cells (HPC) is unknown.  Aberrant HPC proliferation has been implicated in the pathogenesis of 
HCC. 
It was hypothesised that changes in the stiffness of the cellular microenvironment are important in regulating 
the behaviour of liver-resident cell populations and may promote the development of HCC.   
Aims: i) to determine how changes in the stiffness of the cancer cell niche might regulate proliferation, 
differentiation and chemotherapeutic resistance in HCC; ii) to determine the relationship between changes in 
liver stiffness and hepatic progenitor cell (HPC) response in rodent models of chronic liver disease; and iii) 
to determine whether changes in the stiffness of the HPC niche regulate proliferation and differentiation in 
these cells. A secondary aim of the thesis was to characterise the pattern of histological changes observed in 
rodent models of chronic hepatic congestion and whether this might provide insight into the effect of 
oedema and congestion on the development of liver fibrosis.  
Methods: Cell culture experiments in HCC (Huh7/ HepG2) and HPC cell lines were performed using a 
system of ligand-coated polyacrylamide (PA) gel supports of variable stiffness. The stiffness of the PA 
supports (expressed as shear modulus) was altered across a physiological change (1-12kPa) corresponding to 
values encountered in normal and fibrotic livers.  Thiacetamide and carbon tetrachloride (CCl4) models of 
liver fibrosis were used to investigate the relationship between increasing liver fibrosis, changes in matrix 
stiffness and HPC response. The pattern of histological changes in the liver in response to hepatic congestion 
was assessed in two unrelated murine models of dilated cardiomyopathy; the python and CREB S133A 
mice.  
Results: Increases in matrix stiffness, as would be encountered in liver fibrosis, promote HCC cell 
proliferation.  Increasing matrix stiffness is associated with enhanced basal and hepatocyte growth factor-
mediated signalling though ERK, PKB/ Akt and STAT3. Stiffness-dependent HCC cell proliferation is 
modulated by β1-integrin and focal adhesion kinase. Increasing matrix stiffness is associated with a 
reduction in chemotherapy-induced apoptosis in HCC cells.  However, following chemotherapy there was an 
increase in the frequency of clone-initiating cells for cells maintained in a low stiffness environment.  Flow 
cytometry in HepG2 cells demonstrated that culture in a low stiffness environment was associated with an 
increase in the frequency of the stem cell markers CD44, CD133 and CXCR-4.  This effect was further 
enhanced in the presence of chemotherapy. 
There is a close association between HPC numbers and liver stiffness measurements in a rat CCl4 model of 
chronic liver fibrosis. The major expansion in HPC numbers in this model coincides with a similarly large 
increase in fibrous tissue deposition.  In vitro experiments using PA supports demonstrate that increasing 
matrix stiffness promotes the proliferation of both primary murine HPCs and an immortalised HPC line 
(BMOL).  Changes in matrix stiffness regulate the expression of hepatocyte and biliary markers in BMOL 
cells.   
Histological studies in both the Python and CREB S133A models reveal findings consistent with acute on 
chronic cardiac hepatopathy (ischaemic hepatitis).  Features of chronic passive congestion and centrilobular 
necrosis are present concurrently and develop rapidly.  Bridging fibrosis and cirrhosis are not present.   
Conclusions: Physiologically-relevant changes in matrix stiffness regulate proliferation, differentiation, 
chemotherapeutic-resistance and stem cell marker expression in HCC cells. Similarly, increases in matrix 
stiffness are closely correlated to HPC response in vivo and regulate HPC proliferation and differentiation in 
vitro.  
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Chapter 1: Introduction 
 
1.1. Chronic liver disease and hepatocellular carcinoma (HCC): a clinical 
perspective 
 
Liver fibrosis develops as a generic wound-healing response to chronic or repeated liver 
damage, which may due to a diverse range of aetiological factors (1).  These include; 
alcoholic liver disease, chronic viral hepatitis, autoimmune, metabolic and vascular 
disorders.  Progressive liver damage, accompanied by the deposition of a fibrotic 
extracellular matrix (ECM) leads to the development of liver cirrhosis.  Cirrhosis is defined 
histologically as the presence of advanced liver fibrosis in associated with regenerative 
nodules and prominent vascular abnormalities.  The formation of mature fibrous vascularised 
septa linking central veins and portal tracts is a critical feature of liver cirrhosis.  These 
structures are relatively resistant to proteolytic degradation and their formation creates a 
direct anastomosis between portal vessels and central veins leading to shunting of blood, 
liver cell dysfunction and portal hypertension.  These histological changes result in a number 
of clinical complications, including; hepatic encephalopathy, abdominal ascites, variceal 
haemorrhage and hepatorenal syndrome, impacting heavily upon the morbidity and mortality 
of patients with chronic liver disease.  In addition, factors associated with chronic liver 
disease promote the development of malignancy. Indeed, liver cirrhosis is the most important 
risk factor for the development of hepatocellular carcinoma (HCC), the fifth most common 
cancer worldwide.  The majority (80%) of HCCs develop in the context of either advanced 
liver fibrosis or cirrhosis (2).  Worldwide, chronic viral hepatitis due to persistent hepatitis B 
(HBV) and hepatitis C (HCV) infection is responsible for the majority (80%) of cases of 
HCC.  However, cirrhosis of any aetiology may be complicated by HCC.   
 
The overall prevalence of liver fibrosis is increasing.  Within the UK, the incidence of liver 
disease has increased dramatically in the past 20 years (3).  Between the periods 1987 to 
1991, and 1997 to 2001, rates of cirrhosis in men in Scotland have more than doubled (104% 
increase), while they have increased by more than two-thirds (69%) in England and Wales.  
In the same period, mortality rates from cirrhosis in women have also increased (46% 
increase in Scotland/ 44% increase in England and Wales).  These changes have been 
attributed to similarly dramatic increases in alcohol consumption.  Similarly, 
epidemiological studies have suggested that the incidence of HCC is also increasing (4-7).  
In the United States, between the periods 1976 to 1980, and 1991 to 1995, the incidence of 
histologically-proven HCC increased from 1.4 per 100,000 to 2.8 per 100,000 of the 
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population (6).  This is perhaps unsurprising since HCC is the main cause of liver-related 
death in patients with compensated cirrhosis (8).  HCC continues to carry a poor prognosis, 
with a median survival from diagnosis of only 12 months (9-11).  Only 10-20 percent of 
HCCs are suitable for surgical resection at the time of presentation (11).  However, even in 
this selected cohort, the effectiveness of both hepatic resection and liver transplantation for 
HCC are limited by tumour recurrence, occurring months or years after surgical resection of 
a primary tumour (12-14). Furthermore, systemic chemotherapy has proven ineffective, both 
in the treatment of advanced HCC and in an adjuvant/ neoadjuvant setting for the eradication 
of disseminated (dormant) tumour cells, the progenitors of clinically relevant metastases. 
The precise mechanism underlying chemotherapeutic resistance in HCC are incompletely 
understood.   
 
Overall, it is evident that chronic liver disease and the clinically important sequelae of liver 
cirrhosis and HCC represent a significant and increasing healthcare burden worldwide.  
There is therefore a clear imperative to develop a greater understanding of the fundamental 
mechanisms underpinning liver fibrosis and how these might promote carcinogenesis within 
the liver. 
 
1.2. Changes in composition and structure of the extracellular matrix (ECM) in 
chronic liver disease 
 
The histological structure of liver parenchyma is traditionally described in relation to the 
hepatic lobule (Figure 1.1) (15).  When viewed in cross-section, the hepatic lobule is roughly 
hexagonal in shape, reflecting its polyhedral three-dimensional structure. Terminal branches 
of the portal vein and hepatic artery are located in portal tracts at the angles of the lobule.  
Blood from the portal tracts drains across the lobule in sinusoids, which converge upon a 
terminal hepatic venule, a terminal branch of the hepatic vein.  Bile excreted by hepatocytes 
is transported across the lobule in canaliculi which drain into bile ducts located in the portal 
tracts.  Surrounding the central veins and separated by the vascular sinusoids are plates of 
hepatocytes which extend out towards the portal tracts.  Hepatocytes are separated from 
sinusoidal endothelial cells (SEC) by the space of Disse.  This narrow space, less than 1µm 
in diameter, lacks the continuous basement membrane found in most epithelial tissues.  In its 
place is a discontinuous layer composed of discrete deposits of collagen-III and collagen-IV, 
and more homogeneously arranged collagen-VI.  Abundant fibronectin deposits surround the 
hepatocyte microvilli.  Gradients exist in respect to the relative abundance of matrix 
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components across the sinusoids, and are believed to be important in determining the 
phenotype of both hepatocytes and SECs (16, 17).  An array of finely arranged collagen-I 
fibres extend across the hepatic lobule, and so provide structural support.  Inhabiting the 
space of Disse are hepatic stellate cells (HSCs).  These retinoid-storing cells have fine 
processes that surround the vascular sinusoids and are believed to play a prominent role in 
regulating blood flow through these vascular channels.  The term hepatic acinus is used in 
reference to the functional unit of the liver, consisting of a diamond shaped mass of liver 
parenchyma composed of a portal triad (hepatic artery branch/ portal vein branch/ bile duct), 
hepatic vein branch and intervening hepatocyte plates and bile canaliculi (Figure 1.1B). 
 
Chronic liver disease is characterised by changes in both the biochemical and physical 
properties of the ECM.  Damage to hepatocytes and cholangiocytes, resulting in necrosis and 
apoptosis, leads to the activation of resident inflammatory cells and the recruitment of 
further inflammatory cell populations (18). Prominent amongst these are cells of the 
monocyte/ macrophage lineage, with additional contributions from other immunocompetent 
cells in specific disease states, including lymphocytes, neutrophils and platelets (19).  
Inflammatory cytokines and other soluble mediators, both released in response to tissue 
damage or from recruited inflammatory cells, promote liver fibrosis and cellular 
regeneration.  In acute liver injury there is a temporary and limited deposition of ECM prior 
to restoration of normal liver architecture.  However, in chronic liver disease, sustained 
inflammation promotes significant expansion and alteration in the composition of the ECM 
(20-24).  This is a product of both enhanced matrix deposition and impaired degradation 
(25).  The discontinuous collagen-IV-rich basement membrane of the subendothelial space is 
replaced by a continuous interstitial matrix enriched in collagen-I, collagen-III, laminin, 
undulin, proteoglycans, hyaluronan and elastin (21). Fibrous ECM is deposited at sites of 
cellular necrosis and apoptosis, the purpose of which is to maintain tissue integrity and 
promote regeneration.  This fundamental relationship between tissue injury and fibrogenesis 
is responsible for the differing patterns of fibrosis found in specific liver disorders (26, 27).  
 
Under normal conditions, both hepatocytes and cholangiocytes retain the ability to 
proliferate following liver injury.  However, in cirrhosis and other conditions in which the 
regenerative capacity of hepatocytes is overwhelmed, regeneration is achieved by 
proliferation and differentiation of hepatic progenitor cells (HPCs).  HPCs are tissue resident 
bi-potential stem cells that have the potential to differentiate into either hepatocytes or 
cholangiocytes.  HPCs are believed to reside in a stereotyped stem cell compartment or niche 
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(28). The anatomical location of this stem cell compartment is believed to be the canals of 
Hering, which are remnants of the foetal ductal plates (29, 30).  Following severe or 
sustained liver injury, HPC proliferation is evident as streaming cords or ducts of small oval 
cells emanating from the portal tracts (“the ductular reaction”). 
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Figure 1.1 Schematic representation of the micro-architectural organisation of the (A) hepatic lobule 
and (B) hepatic acinus.  Hepatic acinus is the term used for the functional unit of the liver, comprising 
a diamond shaped mass of liver parenchyma including a portal triad (hepatic artery branch/ portal vein 
branch/ bile duct), hepatic vein branch and intervening hepatocyte plates and bile canaliculi. 
Abbreviations: hepatic venule (HV); hepatic artery (HA); portal venule (PV) and bile duct (BD). Red 
colouring indicates oxygenated arterial blood.  Blue colouring indicates deoxygenated venous blood.  
The black arrow indicates the normal direction of blood flow within the vascular sinusoid from the 
portal tracts into the central hepatic venule.  The white arrow indicates the normal direction of bile 
flow in the hepatic canaliculi, which drain into bile ducts located in the portal tracts. 
 
 6 
1.3 The role of the hepatic myofibroblast in liver fibrosis 
 
The hepatic myofibroblast (MFB) is the principle cell responsible for the deposition of ECM 
in, and regulation of, liver fibrosis.  Historically, HSCs were defined as the most prominent 
source of activated myofibroblasts within the liver.  However, it is now apparent that hepatic 
MFBs are derived from a number of distinct cell populations, each with discreet localisation 
and immunological characterisation (31).  These include activated HSCs, portal fibroblasts 
(PFs) and interface myofibroblasts.  There is also evidence that bone marrow-derived cells, 
including myofibroblast precursors (32, 33) and fibrocytes (34) contribute functionally to 
ECM deposition in liver fibrosis.  Nevertheless, there is evidence that HSCs account for the 
majority of ECM deposition in chronic liver disease (1).  Following liver injury, HSCs are 
activated (transdifferentiate), becoming contractile and ECM-producing MFBs.  Activation 
occurs in response to numerous factors, including; hypoxia, reactive oxygen species, 
ingestion of apoptotic debris, lipopolysaccharide and paracrine factors produced by 
hepatocytes, cholangiocytes, SECs and recruited inflammatory cells.  Perpetuation of the 
MFB activation is facilitated by numerous cytokines and soluble factors.  In addition, there is 
strong evidence that the biochemical and physical properties of the ECM in liver fibrosis 
may perpetuate MFB activation.  Indeed, specific interactions between cell surface receptors 
(including integrins and discoidin domain receptors) and collagen-I have been shown to 
promote MFB activation and proliferation (35-37).  
 
The accumulation of fibrotic scar is dependent upon both increased matrix deposition and a 
concurrent reduction in matrix degradation (38).  MFB activation is accompanied by a 
marked upregulation of potent tissue inhibitors of metalloproteinases (TIMPs).  The resulting 
inhibition of matrix-degrading metalloproteinases (MMPs) shifts the equilibrium towards 
matrix accumulation.  Similarly, the resolution of liver fibrosis is accompanied by MFB 
apoptosis, simultaneously removing both an important source of ECM deposition and TIMP 
production (39).  Liver fibrosis is a reversible process (1).  In both animal models and human 
disease, the resolution of liver fibrosis has been demonstrated following treatment/ removal 
of the underlying cause of tissue injury (38, 40, 41).  However, it is also clear that there are 
both reversible and irreversible components of liver fibrosis. The development of septal 
fibrosis is thought to define the extent to which fibrosis is reversible (26).  Septa may 
develop between portal tracts and central veins, and may extend over variable distances, in 
either direction.  Histological features have been identified that confer resistance to 
remodelling.  These include portal-central bridging, prominent angiogenesis and the 
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presence of mature paucicellular scars enriched in crosslinked collagen (42) and elastin (43). 
Collagen crosslinking confers upon the matrix resistance to enzymatic degradation (42) and 
is associated with tissue stiffening in a range of fibrotic conditions, including liver fibrosis 
(44-47). Cirrhosis is defined as a state of advanced liver fibrosis in association with septal 
fibrosis (incorporating vascular shunts) and nodular parenchymal regeneration.  As such 
cirrhosis has been viewed as an irreversible state of advanced liver fibrosis, although it is 
now apparent that in the absence of ongoing liver injury, significant remodelling can occur 
(26, 48). 
 
1.4  The cellular origin of hepatocellular carcinoma (HCC) 
 
In chronic liver injury there is a constant flux of cells transitioning from the stem cell 
compartment to terminally differentiated cells. It has been proposed that HCCs develop from 
a range of founder cells across this continuum, from HPCs through transient amplifying cells 
to fully differentiated hepatocytes (49, 50).  The proliferation of cells at the time of 
carcinogen exposure is essential for the propagation of genomic alterations in cancer 
development.  The clonality of HCC tumours has been clearly demonstrated through detailed 
genetic analysis of DNA alterations in tumour cells  (49).  A number of investigators have, 
through the analysis of HBV DNA viral integration sites in tumour cells, demonstrated that 
individual HCC tumours are monoclonal (51, 52).  However, there was previously some 
uncertainty as to the identity of the cell involved in cancer initiation. Sell was the first to 
propose that cancer within the liver may be derived from at least four distinct lineages, 
including hepatocytes, mature cholangiocytes, HPCs and periductular cells (50, 53).  This 
proposal was based upon detailed histological examination of different experimental models 
of hepatocarcinogenesis and this model has been confirmed in subsequent immunological 
and genetic studies.  Using monoclonal antibodies generated against an oval cell line, Hixson 
et al demonstrated that HCC induced by choline-deficient ethionine-supplemented (CDE) 
diet express many of these HPC/ cholangiocyte markers, suggesting a transitional state 
between HPC and hepatocytes (54). Furthermore, it has also been shown that HPCs isolated 
from p53-deficient mice produce HCCs when transplanted into athymic nude mice (55).  
Subsequent to this, genetic profiling has been used to demonstrate that HCCs can been sub-
divided within established differentiation stages based upon the genetic profile of cancer 
cells (56).  HCCs with progenitor cell phenotype (e.g. EpCAM+) demonstrate characteristics 
of tumour-initiating stem cells, including bi-potentiality, self-renewal and increased tumour-
initiating capacity, in comparison to EpCAM- tumour cells (57).  Similarly, CK-19 
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expression defines a sub-population of progenitor-derived HCC with features of tumour 
initiating stem cells (58).   CK-19 expression in human HCC is associated with a poorer 
prognosis and increased risk of tumour recurrence.   
 
1.5  Changes in composition and structure of the ECM in HCC 
 
The development of liver fibrosis and cirrhosis is characterised by distinct changes in the 
histological structure and biochemical composition of the liver (2).  The majority of HCCs 
develop in the setting of cirrhosis (80%) in which the ECM is significantly modified.   In 
cirrhotic patients with HCC, the predominant underlying causes of chronic liver disease 
include: HCV infection (27-73%), HBV infection (12-55%) and alcoholic liver disease (4-
38%) (59-63).  In the minority of patients who develop HCC in a non-cirrhotic liver, 
underlying chronic liver disease is typically present: HCV infection (3-54%), HBV infection 
(4-29%) and alcoholic liver disease (0-28%).  Thus, even in the absence of cirrhosis, HCC 
seldom occurs in a histologically normal liver. Therefore, irrespective of specific viral 
mediated mechanisms that may promote carcinogenesis within the liver, factors related to 
chronic inflammation appear to promote HCC development.  These may include changes in 
the composition and properties of the ECM associated with chronic liver disease.  In 
addition, the development and progression of HCC is associated with further modification of 
the ECM (64). 
 
HCC development is characterised by disturbance of the lobular architecture of the liver.  As 
discussed earlier, hepatocytes in the normal liver are arranged in single-cell thick plates 
separated by vascular sinusoids. In HCC the thickness of these plates is increased to a 
variable extent.  This abnormal trabecular pattern is the most common architectural variant 
of HCC, although solid and tubular HCC growth patterns are also described.  An absence of 
portal tracts within tumour tissue is a consistent feature of HCC that is helpful in aiding 
histological diagnosis.  HCC growth is often associated with the formation of a fibrous 
capsule (65).  Histological studies have shown that the capsule is composed of type-I- and 
type-III collagen (66).   This is thought to be produced by mesenchymal α-smooth-muscle-
positive cells located at the interface of the tumour nodule and surrounding liver tissue (65).  
While malignant cells from well-differentiated tumours retain morphological features of 
fully differentiated hepatocytes, cells from more poorly differentiated tumours lose these 
characteristics and there is an increased frequency of nuclear and cytological atypia.  The 
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most poorly differentiated tumours are characterised by a solid growth pattern, with large 
tumour nodules separated by thick fibrous bands.   
 
The ECM located in and around HCC is different to that found in the normal liver (64, 67, 
68).  As seen in cirrhosis, there is ‘capillarisation’ of the vascular sinusoids with 
development of a continuous thickened basement membrane (69). There is increased 
deposition of a number of ECM components, including laminin, tenascin, vitronectin and 
fibronectin.  The expression of collagen-IV may be identical or increased in comparison to 
that seen in the cirrhotic liver, but is reduced in more poorly differentiated HCC (67).  In 
HCC, laminin, which is not present along the sinusoids in normal liver, is present as linear 
deposits between the sinusoidal epithelium and hepatoma cells, and as more heterogeneous 
deposits surrounding malignant cells (70). The expression of laminin-5, which is absent from 
the normal liver, is increased in metastatic HCC and may play a role in promoting cancer cell 
migration and metastasis (71, 72).  Fibronectin expression is increased in all HCCs, in 
comparison to cirrhosis, but the pattern of expression varies as a function of tumour 
differentiation (64).  Fibrous bands stain positively for fibronectin in all grades of HCC. 
Sinusoidal staining is seen in well-differentiated trabecular HCCs and pericellular staining is 
seen in moderately differentiated, but not poorly differentiated HCC.  Furthermore, the 
expression of EDB splice variants of fibronectin, and oncofetal forms of cellular fibronectin 
are seen exclusively in most HCCs but not in normal or cirrhotic liver.  It is thought that the 
expression of these variants of fibronectin may be involved in modulating cell-matrix 
interactions in cancer development (73).  Tenascin (an ECM glycoprotein) with multiple 
functions related to development, inflammation and tumorigenesis, is also upregulated in 
HCC in comparison to the cirrhotic liver (67, 74).  Tenascin is expressed both in the fibrous 
capsule and lobular septum of HCC, but is more variably expressed in the sinusoidal walls of 
tumours (64, 74).  Sinusoidal expression of tenascin appears to be reduced in poorly 
differentiated HCCs (64). 
 
Interactions between cells and the ECM are largely mediated by integrins, a family of 
heterodimeric transmembrane molecules, made up of interchangeable α- and β-chains (75).  
In the normal liver, hepatocytes express a limited repertoire of integrin dimers, including; a 
collagen and laminin receptor α1β1, a fibronectin receptor α5β1 and a tenascin receptor 
α9β1.  This is believed to represent an adaptation to the distinct ECM encountered by 
hepatocytes.  HCC development is associated with particular changes in the expression of 
both ECM components and their cognate receptors.  The development of HCC is 
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accompanied by changes in integrin expression, with up-regulation of α1β1, α2β1, α3β1, 
α6β1, αvβ1, αvβ3 and αvβ5 integrins (64, 76-78).  There is now a growing understanding as 
to the functional relevance of specific alterations in integrin expression by malignant cells.  
For example, it has been shown that laminin-5 promotes HCC cell proliferation through a 
α6β4- and α3β1-dependent mechanism (79).  Integrins are also implicated in modulation of 
cell adhesion and migration in HCC.  Induction of α6β1 integrin is recognised as an early 
event in hepatocellular carcinogenesis (77).  Inhibition of α6β1 integrin function is 
associated with reduced migration and cellular migration in HCC cell in vitro (77, 80).   
These effects are believed to mediated by disruption of α6β1 integrin-dependent activation of 
mitogen activated protein (MAP) kinase and focal adhesion kinase (FAK) (77).  Similarly, 
increased expression of αv-integrins, in response to stimulation with tumour necrosis factor-
α (TNFα) and transforming growth factor-β (TGFβ) promotes adhesion and migration in 
HCC cells (78).  Finally, β1-integrin has been found to be effective in protecting hepatoma 
cells from chemotherapy-induced apoptosis in vitro, via a MAP kinase-dependent pathway 
(81). 
 
1.6  The biomechanical properties of the ECM 
 
The development of liver fibrosis and hepatocellular carcinoma is accompanied by changes 
in both the biochemical and physical properties of the ECM. In turn, cell behaviour is 
governed by both biochemical and physical determinants (82, 83).  However, while there has 
been considerable research into how changes in the biochemical composition of the ECM 
regulate cellular behaviour, the role of physical factors in regulating cell behaviour is 
incompletely studied.   
 
1.6.1 Basic principles of cellular mechanotransduction 
 
It is evident that the mechanical properties of a cell and its surrounding environment, 
determine its phenotype (82).  The process of mechanotransduction allows cells to respond 
directly to changes in their physical environment.  This requires critical interpretation of 
complex mechanical loading conditions, including composite tensile, compressive and shear-
forces.  These loads may be applied externally, or generated internally within a contractile 
cytoskeleton.  The terminology that should be used in describing the biomechanical 
properties of cells and tissues is summarised below (Table 1.1).  Within tissues, most cells 
are embedded within an ECM, requiring adherance to a solid structure to promote cell 
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survival (anchorage-dependent growth).  Normal adherent cells fail to divide when confined 
to a spherical shape, either by placing them in suspension or permitting them to attach but 
not to spread (84).  The cytoskeleton is attached to the ECM through trans-cellular adhesions 
(focal complexes), centred on integrins, cadherins and other adhesion molecules.  These 
multi-molecular complexes represent sites of convergence for both internally- and 
externally-applied forces.  The cytoskeleton exists in a constant state of flux, enabling cells 
to attach to and pull on their surroundings.  Contractile forces are generated within cells by 
the interaction between myosin-based contractile motors and actin filaments.  These forces 
are transmitted to the ECM through transcellular adhesions and can be demonstrated 
experimentally in the deformation by adherent cells of soft rubber substrates (85).  
Importantly, this cellular contractility allows cells to probe the mechanical properties of their 
immediate surroundings.  Stress may only be generated at a transcellular adhesion if an equal 
and opposite force is provided by the ECM.  This, in turn, is dependent upon the substances 
resistance to deformation, or stiffness.  Using atomic force microscopy, it can be shown that 
within a range of stiffness spanning that of soft tissue, cells tune their internal stiffness to 
match that of their substrate, a process termed stiffness-sensing (86).   
 
The basic molecular mechanisms underlying the process of stiffness-sensing are poorly 
characterised.  It is hypothesised that forces applied to individual proteins, either at the site 
of adhesion between cells and the ECM, or within the cytoskeleton itself, cause 
conformational changes in these proteins that alter their binding affinity for other 
intracellular molecules (87).  The resulting incremental recruitment of focal adhesion 
components with distinct structural and signalling functions underlies the process of 
mechanotransduction.  For example, mechanical force is required for the recruitment of 
vinculin to focal adhesions (88).  It has been proposed that force-induced activation of 
vinculin-binding domains on the focal adhesion protein talin, may be responsible for force-
induced vinculin recruitment (87, 89).   
 
Forces applied to integrins at focal complexes produce stress-induced strengthening 
responses, accompanied by focal adhesion growth (maturation).  This has been shown using 
a number of experimental techniques in which well-defined tensile forces have been applied 
directly to cells. For example, in an elegant series of experiments, it was shown that force is 
required for the maturation of integrin-based focal complexes that form at the sites of 
attachment between the cell surface and collagen-coated magnetic beads (90).  When a 
magnetic field was applied to pull upon these attachment points, there was a progressive 
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increase in focal adhesion size, accompanied by activation of myosin-II and the recruitment 
of the adapter protein, filamin A.  As the focal adhesions mature, and with the recruitment of 
additional myosin-II motors, the cell is able to resist the applied force and subsequently pull 
the bead back.  Similarly, agents that increase actinomyosin contractility, such as 
lysophosphatidic acid or thrombin, promote focal adhesion growth in cells plated on rigid 
substrates (91, 92).  Thus cellular responses to externally-applied and internally-derived 
forces are inextricably linked.  Indeed, cellular responses to applied forces are lost when 
myosin-based contractility is inhibited (93, 94).   
 
A similar process of focal adhesion maturation is observed in cellular responses to increasing 
substrate stiffness.  In a landmark study, Pelham and Wang used a system of collagen-coated 
polyacrylamide gels of varying stiffness to investigate the effect of substrate stiffness on 
fibroblast behaviour (95).  They showed that fibroblasts cultured on soft substrates displayed 
increased motility and reduced cellular spreading in comparison to cells cultured on stiff 
substrates.  Focal adhesions of cells on soft substrates were highly dynamic, in contrast to the 
more stable adhesions seen in cells on stiffer substrates.  Increasing substrate stiffness was 
accompanied by increased vinculin recruitment and tyrosine phosphorylation at adhesion 
sites.  Cellular responses to changes in substrate stiffness were inhibited by myosin-II 
inhibition.  ECM stiffness has subsequently been shown to be an important regulator of 
cellular homeostasis and affects numerous cellular processes, including cell migration, 
proliferation and differentiation (96-98).  The stiffness of different organs and tissues spans 
many orders of magnitude (Figure 1.2) (83).  The stiffness of most soft tissues, including 
liver, lung and kidney is in the range 0.2-4 kPa (99).  In contrast, the stiffness of tendon and 
bone is expressed in Megapascals.  Within these tissues, under normal conditions, 
differentiated cells operate within a narrow range of environmental stiffness (10-15%) (100).  
However, tissue stiffness may change dramatically throughout development and during 
pathological processes, such as inflammation, fibrosis and tumourigenesis.  Understanding 
how cells respond to pathophysiological changes in tissue stiffness may provide important 




Figure 1.2 Schematic representation of the range of stiffness values (kPa) 




Adapted from: Nemir et al.  Annals of Biomedical Engineering. 2010 (83) 
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Table 1.1 Terminology used in describing key biomechanical concepts 
 
Mechanical Terminology Definition 
  
Mechanical Stress Stress can be defined as the mean force per unit surface area 
exerted on a deformable body.  The S.I. unit of stress is the 
Pascal (Pa) or N/m2.  Forces exerted perpendicular to a surface 
result in extension or compressive stress.  Forces exerted 
parallel to a surface result in shear stress. 
  
Mechanical Tension Tension is defined as the magnitude of opposing/ balanced 
forces that would cause extension.  The S.I. unit of tension is 
the Newton (N).  Tension is only generated by the interaction 
of opposing active and reactive forces (in accordance with 
Newton’s third law of motion). 
  
Strain Strain is a dimensionless number that refers to the geometrical 
deformation of an object in response to an applied force.   
  
Stiffness Stiffness is a measure of the resistance of a substance to 
deformation in response to an applied force.  The term is often 
used interchangeably with elasticity. 
  
Compliance Compliance is the reciprocal of stiffness.  It is a measure of a 
substances capacity to deform in response to an applied force. 
  
Elasticity Elasticity describes the property of a material to deform to a 
defined extent in response to an applied force and then return 
to its original state upon removal of this force. 
  
Elastic Modulus Elastic modulus is a constant that describes the resistance of a 
material to deformation, defined as the ratio of stress to strain.  
As strain is a dimensionless number, if stress is measured in 
Pascals then the unit of elasticity is also the Pascal (Pa).  
  
Young’s Modulus (E) Young’s modulus (E) is a constant used to quantify elastic 
resistance to elongation or compression. 
  
Shear Modulus (G) Shear Modulus (G) is a constant used to quantify elastic 
resistance to shear force. 
  
Linear Elasticity Linear elasticity describes the situation where there is a linear 
relationship between stress and strain, i.e. the elastic modulus 
of a material remains constant during deformation. 
  
Non-linear Elasticity Non-linear elasticity describes the situation where there is a 
non-linear relationship between stress and strain.  Many 
complex biological materials exhibit non-linear elasticity, 
whereby elastic modulates changes as a function of increasing 
strain. 
 
Adapted from: Janmey PA et al.  Journal of Cell Science. 2011 (82) 
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 1.6.2 Changes in matrix stiffness in chronic liver disease 
 
Alterations in ECM stiffness in chronic liver disease have long been recognised, as 
demonstrated in the firm liver edge indicative of liver fibrosis and the hard liver nodules 
found in hepatocellular carcinoma.  Histological examination of liver tissue obtained by 
percutaneous liver biopsy is still considered as the gold-standard in the assessment of liver 
fibrosis.  However, this technique is associated with potentially life-threatening 
complications.  Furthermore, the utility of liver biopsy is limited by problems with intra-
/inter-observer variability and sampling error that may lead to either an over- or under-
estimation of the degree of liver fibrosis (101, 102).  More recently, ultrasound and magnetic 
resonance (transient) elastography have been developed as non-invasive methods of 
assessing liver fibrosis.  In studies of patients with chronic HCV infection, it has been shown 
that liver stiffness values obtained by ultrasound elastography correlate strongly with the 
Metavir fibrosis stage (103, 104). Similarly, ultrasound elastography can be used to 
accurately assess the degree of liver fibrosis in patients with chronic HBV infection (105), 
alcoholic liver disease (106), cholestatic liver disease (107) and non-alcoholic steatohepatitis 
(108).  In comparison to standard laboratory tests and non-invasive scores, ultrasound 
elastography has been shown to have superior diagnostic performance in the early diagnosis 
of cirrhosis (103).  Transient elastography measurements have been shown to correlate 
closely with portal pressure measurements in patients with chronic HCV infection (109) and 
may be useful in predicting the presence of oesophageal varices (110). There has been 
significant debate as to how best to interpret liver stiffness values in clinical practice.  
Normal liver stiffness has been assessed in a study of 429 healthy subjects with no evidence 
of liver disease and normal liver enzymes (111).  In this cohort, the mean liver stiffness 
value was 5.5 ± 1.6 kPa.  In patients with chronic HCV infection, when liver stiffness values 
are between 2.5-7.5kPa, liver biopsies will typically show absent or mild liver fibrosis (112).  
In contrast, liver stiffness estimations exceeding 12.5 kPa are strongly predictive of 
underlying cirrhosis (Figure 1.3). It must be stressed that factors other than fibrosis may 
affect liver stiffness measurements.  Liver stiffness values may be increased transiently in 
the absence of significant fibrosis by acute hepatitis (inflammation) (113, 114) or hepatic 
congestion (right-heart failure) (115). 
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Adapted from: Castera et al.  Journal of Hepatology. 2008 (116) 
 
 
1.6.3 Changes in matrix stiffness in HCC 
 
Liver cirrhosis represents the single most important risk factor for the development of HCC.  
Recent studies involving ultrasound elastography have demonstrated that, even after 
adjustment for other risk factors, increased liver stiffness measurement (LSM) was a strong 
predictor of HCC development (117, 118).  In one prospective study of patients with chronic 
HCV infection it was shown that in comparison to patients with a baseline LSM of ≤ 10kPa, 
the hazards ratio for HCC development increased progressively from 16.7 (95% confidence 
interval 3.71-75.2 p<0.001), in patients with LSM 10.1-15kPa, to 45.5 (9.75-212.3, p<0.001) 
in patients with baseline LSM ≥25 kPa (118).  Furthermore, using both transient 
elastography (119) and atomic force microscopy (120), it has also been shown that HCC 
development is associated with further increases in tissue stiffness to values markedly 
greater that of the surrounding parenchyma.  In a small study of 40 patients, increased tissue 
stiffness (assessed by transient elastography) was found to be a feature not only of HCC, 
with median tumour stiffness (E) of 55kPa, but also of other liver tumours, including 
cholangiocarcinoma (E 75 kPa) and liver metastases (E 66.5 kPa) (119).    
 
Liver stiffness is considered to be a surrogate marker for liver fibrosis.  It is unclear whether 
increasing matrix stiffness, or indeed liver fibrosis, plays a mechanistic role in 
hepatocarcinogenesis.  Liver fibrosis itself may be a surrogate marker for DNA damage/ 
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genomic instability as a consequence of chronic inflammation and regeneration.  However, it 
has been shown in animal studies that the induction of liver fibrosis is associated with 
accelerated tumour growth following orthotopic HCC implantation (121, 122).  Furthermore, 
histological examination of human HCC specimens has demonstrated an association between 
the presence of hepatic fibrosis and enhanced tumour cell proliferation (123).  This, in turn, 
may be related to matrix stiffness.  It has been one of the aims of this thesis to determine 
whether alterations in stiffness directly affect the behaviour of HCC cells.  
 
1.7 The effect of substrate stiffness on cellular proliferation 
 
Matrix stiffness is an important regulator of cellular proliferation in non-transformed cells 
(97, 124).  Fibroblasts cultured in tethered (mechanically stressed) matrices proliferate in 
response to growth factor stimulation, while cells in free-floating (relaxed) matrices are more 
refractory to mitogenic stimulation (125).  Similarly, when cultured in sheets of different 
shape, endothelial cells show increased levels of proliferation in areas under the highest 
degree of tensional stress (126).  Cell cycle progression is regulated by the expression of cell 
cycle regulators, including; cyclins, cyclin-dependent kinases (CDKs) and cyclin-dependent 
kinase inhibitors.  Type-D cyclins are critical regulators of cell cycle progression and have 
been implicated in the stiffness-dependent regulation of cell proliferation (127).  Cyclin D1 
expression and its subsequent binding to CDK4/6 and CDK2 is a rate-limiting step in the 
regulation of G1 progression.  Cyclin D1 represents a convergence point for multiple 
signalling pathways, relaying information both from the ECM and numerous soluble 
mediators.  ECM proteins signal by binding to and activating integrins.  Numerous studies 
have demonstrated that integrin-dependent signalling events support G1 phase progression 
through both induction of cyclin D1and downregulation of the cip/kip family of CDK 
inhibitors (128).  A number of integrin-dependent signalling pathways have been identified 
that regulate the expression both of cyclin D1 and cip/kip family of CDK inhibitors.  These 
include extracellular-regulated kinase (ERK), mitogen-activated protein (MAP) kinases, 
Rho-family GTPases and focal adhesion kinase (FAK). 
 
Studies have been performed using collagen gels to investigate the effect of matrix stiffness 
on integrin signalling and cell cycle progression.  It has been shown that human foreskin 
fibroblasts in compliant free-floating collagen gels do not express cyclin D1, have high 
levels of the CDK inhibitor p27kip1 and do not phosphorylate ERK (129, 130).  In contrast, 
cells in mechanically-loaded tethered collagen gels have higher levels of cyclin D1, down-
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regulate expression of p27kip1 and have higher basal levels of ERK phosphorylation. 
Similarly, in experiments using matrix protein-coated PA hydrogels, Klein et al 
demonstrated that matrix stiffness regulates proliferation in mouse embryonic fibroblasts, 
mammary epithelial cells, vascular smooth muscle cells and osteoblasts (97).   Matrix 
stiffness, across a physiologically-relevant range (G’ 2-24 kPa), was found both to regulate 
the expression of cyclin D1 and the ability of ectopically-expressed cyclin D1 to stimulate 
retinoblastoma protein (Rb) phosphorylation and S-phase entry.  Interestingly, although 
mitogen-dependent induction of cyclin D1 mRNA was strongly affected across the range of 
matrix stiffness that affected mitogenesis, other mitogenic events, previously thought to be 
integrin-dependent, including CDK inhibitor expression (p21cip1/ p27kip1) and ERK 
activation, were relatively resistant to changes in matrix stiffness.  Overall, it was their 
conclusion that physiological stiffness acted as an inhibitor of cell cycle progression.  In 
contrast, it has been proposed that increases in matrix stiffness (≥12kPa) may promote 
aberrant cell cycle progression (46, 97, 124, 131). 
 
1.8 The effect of substrate stiffness on cellular differentiation 
 
The stiffness of the cellular environment is important in both determining and maintaining 
cellular differentiation.  Matrix stiffness has been shown to direct differentiation of 
mesenchymal stem cells as evident in cellular morphology, marker proteins and transcript 
profiles (98).  Soft matrices (E 0.1-1 kPa), mimicking the stiffness of brain tissue, were 
found to promote neuronal differentiation.  Intermediate matrices (E 8-17 kPa), mimicking 
striated muscle stiffness promote myoblast differentiation.  Stiff matrices (E 25-40 kPa) with 
stiffness characteristics similar to the cross-linked collagen of osteoid, yielded polygonal 
cells with morphological and transcript profiles indicative of osteoblast differentiation.   It is 
also thought that the stiffness of a cell’s environment might be important in maintaining its 
stem cell characteristics.  Mouse muscle stem cells when freshly isolated from striated 
muscle and immediately injected into mouse tibialis muscle, differentiate into mature 
myocytes (132).  It has been shown that the ability of these cells to differentiate into mature 
myocytes in vivo is lost if they are pre-cultured on standard tissue culture plastic (E >109 Pa).  
However, if isolated muscle stem cells are cultured on hydrogels with stiffness 
characteristics similar to striated muscle (E 12kPa) prior to transplantation, then the stemness 
characteristics of these cells were maintained.   
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It is also apparent that the range of stiffness across which cells will respond, in respect to 
alteration in morphology, proliferation or differentiation, differs between individual cell 
types.  Matrix stiffness has been shown to modulate the growth characteristics of both 
neurones and astrocytes in mixed culture in vitro (100).  Cells derived from embryonic 
cortical dissociations were cultured on laminin-coated polyacrylamide gels and fibrin 
scaffolds of varying stiffness.  Laminin-coated soft gels encouraged the attachment and 
growth of neurones while suppressing astrocytes growth.  In contrast, the number of 
neurones on stiff gels was lower, and neurones plated on stiff gels adhered preferentially to 
astrocytes rather than forming direct contacts with the stiff substrate.  Increasing substrate 
stiffness promoted astrocyte proliferation.  Importantly, astrocytes on soft gels did not spread 
and had disorganised F-actin staining in comparison to cells grown on stiff matrices.  In 
contrast, neurones developed stress fibres and neurite growth on both soft and stiff gels.  
This is important as the stiffness range across which F-actin organisation occurs is thought to 
represent the stiffness-sensing potential of a cell.  Mechanisms that regulate a cells stiffness-
sensing potential have yet to be determined.   
 
1.8.1. The effect of liver stiffness on myofibroblast function 
 
Liver stiffness measurements (provided by transient elastography) are now widely used in 
clinical practice as a non-invasive marker of liver fibrosis.  However, it has more recently 
become apparent that changes in the stiffness of the liver may be mechanistically important 
in regulating the behaviour of a number of liver-resident cell populations.  The relevance of 
changes in matrix stiffness to cellular function and differentiation are best illustrated in 
respect to hepatic MFBs.  The response of hepatic MFBs to alterations in matrix stiffness has 
been investigated using collagen-I-coated polyacrylamide gels with stiffness characteristics 
(400Pa-12kPa) similar to those encountered in normal and fibrotic/ cirrhotic livers (133, 
134).  After 10-days in culture, both HSCs and PFs cultured on soft supports (400 Pa) 
retained characteristics similar to freshly isolated cells.  With increasing support stiffness, 
these cells developed features of increasing myofibroblast phenotype.  These included 
enhanced cell spreading, α-smooth-muscle actin (αSMA) expression and stress fibre 
organisation. Functional analysis revealed that these cells had a fibrogenic phenotype with 
enhanced expression of mRNA for type-1 and type-3 collagens.  Thus, rather than simply 
accompanying the development of liver fibrosis, increased liver stiffness may promote 
hepatic scar formation.  In support of this hypothesis, it has been shown that increases in 
liver stiffness (based on shear modulus measurements) precede the development of fibrosis 
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(collagen deposition) in an iterative carbon tetrachloride (CCl4) model of rat liver fibrosis 
(135).  The factors responsible for this early increase in liver stiffness are uncertain but may 
include matrix cross-linking or interstitial oedema (136).  It is tempting to speculate that this 
early increase in liver stiffness may be mechanistically important in regulating cellular 
responses to tissue injury.  Finally, it is important to note that although transient elastography 
can provide an accurate estimation of the stiffness characteristics of the whole liver, it does 
not provide information in respect to regional variation in stiffness (137).  Individual cells 
sense stiffness over a limited distance.  Therefore regional variations in stiffness across the 
hepatic acinus may be important in determining individual cell behaviour in liver disease. 
 
1.8.2 The effect of substrate stiffness on hepatocyte differentiation 
 
As previously discussed, within the normal liver, hepatocytes reside in a unique 
biomechanical niche.  Hepatocytes are notoriously difficult to maintain in a differentiated 
state in tissue culture (138).  There is a significant body of evidence that suggests that the 
mechanical properties or stiffness of this environment are important in maintaining 
hepatocyte differentiation (137).  Primary hepatocytes cultured on stiff substrates coated 
with monomeric collagen proliferate and de-differentiate. However, hepatocytes cultured on 
soft collagen gels remain rounded and growth arrested (139, 140).  A differentiated 
phenotype is also maintained when hepatocytes are cultured on soft substrates such as dilute 
collagen or matrigel (138, 140, 141).  It is thought that this may be a function of the 
mechanical properties of these materials.  The relationship between substrate stiffness and 
hepatocyte differentiation has been more directly addressed using a model system in which 
the stiffness of matrigel was manipulated by cross-linking with glutaraldehyde (142).  
Hepatocytes maintained on softer substrates demonstrated higher levels of albumin excretion 
and differential responses to growth factor stimulation, indicative of a more differentiated 
phenotype.  Hepatocytes on stiffer substrates were more proliferative and demonstrated 
progressive de-differentiation.  Substrate stiffness has also been found to regulate cellular 
responses to fibronectin (143).  Hepatocytes grown on soft supports (G’ 1.9 kPa) maintained 
spheroid morphology and were relatively insensitive to changes in fibronectin ligand density, 
in contrast to the highly spread cells seen on supports of intermediate matrix stiffness (G’ 5.6 
kPa).  Mechanical factors have also been shown to influence hepatocyte morphology and 
differentiation in three-dimensional culture (144-146).  In general, hepatocytes grown in 
conditions of low mechanical stiffness remain growth arrested and differentiated, whereas as 
at higher levels of substrate stiffness they are increasingly proliferative and de-differentiated.  
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The effect of changes in matrix stiffness on HPC proliferation and differentiation is poorly 
characterised. 
 
1.9 A biomechanical model of cancer development 
 
What effect might changes in the biomechanical properties of the ECM have in relation to 
cancer development within the liver?  The process of cancer development has traditionally 
been viewed as a multi-step process, reflecting progressive acquisition of genetic mutations 
that drive the malignant transformation of cells.  Through this process - analogous to 
Darwinian evolution - cells acquire a set of functional capabilities that have been defined as 
the ‘Hallmarks of Cancer’ (147). These include; evasion of apoptosis; self-sufficiency in 
growth signals; insensitivity to anti-growth signals; sustained angiogenesis; tissue invasion 
and metastasis; and limitless replicative potential.  However, it is increasingly apparent that 
cell behaviour is dictated by networks of molecular interactions with extensive cross-talk 
both at a regulatory protein and genome-wide level.   This is perhaps best exemplified by the 
manner in which fibroblasts can be induced to revert to pleuripotent embryonic stem cells by 
simultaneous co-expression of a limited number of transcription factors, which in turn effect 
the expression of multiple downstream genes (148-150).  Thus, environmental factors with 
wide-ranging effects on cellular behaviour may be important in promoting cancer 
development (151).  This principle is supported by the manner in which cell fate 
(differentiation, proliferation, apoptosis and motility) can be regulated by changes in ECM 
structure and cell shape (152-155). 
 
It has previously been demonstrated that certain cancers can be induced to differentiate and 
normalise their growth in response to manipulation of their cellular microenvironment (156-
160).  For example, poorly differentiated (anaplastic) rat tumour tissue of renal origin can be 
induced to form tubules when cultured on filter rafts supported by nutrient agar (157).  In 
addition, it has been shown that co-culture with normal mesenchymal elements is sufficient 
to enhance differentiation and attenuate tumour cell proliferation in pancreatic carcinoma 
cells (158, 159).  Similar attenuation of the ‘cancer phenotype’ has been demonstrated when 
carcinoma cells of breast (161) and prostatic (160) origin are cultured with embryonic 
mesenchymal tissue.   Conversely, the transplantation of malignant human epithelial cells 
into nude mice results in the formation of tumours composed of both engrafted epithelial 
cells and host stroma (162).  Host mesenchymal cells derived from these tumours appear 
transformed and are tumourigenic in nude mice.   On this basis, it has been proposed that 
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cancer development is in essence a disease of tissue development (151).  Tumour 
development may occur in part due to alterations in ECM structure and epithelial-
mesenchymal interactions.  Indeed it has been shown that manipulation of the physical 
characteristics of the ECM may be sufficient to promote cancer development (46, 163).  
Further support for this model of cancer development comes from the observation that 
phenotypically normal mammary epithelial cells, which normally form epithelial glandular 
structures in vivo, can be induced to form invasive mesenchymal-like tumours in response to 
tetracycline-regulated MMP3/ stromolysin-1 expression (164).  Once initiated, tumour 
growth becomes independent of ongoing MMP3/ stomolysin-1 expression.  Furthermore, 
these cells, transformed as a result of manipulation of ECM structure, demonstrate genomic 
abnormalities (164, 165).  This suggests that there may be mutual potentiation between 
genetic and structural determinants of cancer development. 
 
Is it the structural or biochemical properties of the ECM that promote cancer development?  
There is a growing body of evidence to suggest that changes in the mechanical properties of 
tissues may contribute to tumour development. Landmark observations made by Bischoff et 
al, demonstrated that implantation of  rigid pieces of plastic or metal could induce tumour 
formation in animals, while tumours did not form if the same material was introduced as a 
powder (166).  It has been suggested, on this basis, that changes in the biomechanical 
properties of the cellular micro-environment may contribute to tumour development. It is 
now widely accepted that chronic inflammation, a process associated with wide-ranging 
alterations in the biochemical and physical properties of the cellular microenvironment, may 
promote cancer development (167, 168).  However, the precise mechanisms through which 
this may occur remain incompletely characterised. 
 
1.9.1 Matrix stiffness and cancer development 
 
Cancer development is typically associated with alterations in the mechanical properties of 
tissues.  Indeed, the diagnosis of cancer is frequently heralded by the palpation of an 
abnormally hard mass or lump.  Alterations in the physical characteristics of cancerous 
tissues (based on tissue density) are utilised in cancer diagnosis by a range of imaging 
modalities, including; plain radiography, computed tomography and ultrasound.  
Furthermore, it has been shown that the presence of a “stiff” fibrotic focus in breast 
carcinomas is an independent risk factor for early metastasis and poor prognosis (169).  The 
factors responsible for enhanced stiffness characteristics of cancerous tissue are 
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multifactoral, including; elevated interstitial tumour pressure and solid stress due to tumour 
expansion and aberrant tumour vasculature (170); increased elastic modulus of transformed 
cells mediated by changes in cytoskeletal organisation (171); and matrix stiffening linked to 
fibrosis (172). However, there is an increasing body of evidence that changes in the stiffness 
of the cellular microenvironment may actively promote malignant transformation (155). 
 
In a detailed series of experiments, Paszek et al, investigated the relationship between tissue 
rigidity and cancer cell behaviour at a molecular level (155).  Using tissue micro-indentation 
they demonstrated that cancer development in mouse mammary pads (analogous to breast 
cancer) was associated with a marked increase in the stiffness of both the stromal matrix 
adjacent to transformed cells and the tumour itself.  Matrix-coated PA hydrogels were then 
used to recapitulate the range of stiffness values encountered by cells between normal 
mammary glands and malignant tumours.  Mammary epithelial cells (MECs) grown on 
supports with stiffness characteristics matched to normal mammary glands (170 Pa), formed 
well-differentiated/ polarised glandular structures with a central lumen. However, even a 
small increase in support stiffness disrupted tissue organisation, enhancing cell growth, while 
inhibiting lumen and adherens junction formation.   
 
It has previously been demonstrated that mammary epithelial cells differentiate into tubules 
when cultured in free-floating three-dimensional (3D) collagen gels, but not when cultured in 
an identical matrix that is tethered to the tissue culture dish (173).  Tubulogenesis required 
the contraction of floating collagen gels through Rho and Rho-mediated kinase (ROCK)-
mediated contractility. Rho, a small GTPase, has been implicated in the regulation of 
multiple steps in cancer development, including: proliferation, invasion, anti-apoptosis and 
metastasis (174).  Rho can stimulate cellular contractility through its ability to activate Rho-
associated kinase (ROCK), which, in turn inhibits myosin light chain (MLC) phosphatase 
and activates MLC kinase, favouring net MLC phosphorylation (promoting cellular 
contractility).  Rho activity is frequently elevated in a range of tumours (175).  ROCK 
activation is associated with enhanced tumour invasion, angiogenesis (176) and metastatic 
potential (172). ROCK-mediated contractility reduced Rho activity in floating 3D collagen 
gels, a process that was accompanied by loss of focal adhesion kinase (FAK) 
phosphorylation (Y397) at matrix adhesions.  These results indicated the presence of a 
ROCK-dependent feedback loop, regulating Rho activity. Increased matrix density disrupted 
tubule formation, promoted FAK phosphorylation and resulted in sustained Rho activity.    
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FAK – the canonical mediator of integrin-related signalling – is a non-receptor tyrosine 
kinase that functions as a signalling-protein scaffold for the assembly and subsequent 
maturation of focal contacts (177).  FAK is implicated in multiple aspects of cancer 
development (178).  FAK may be activated by either ECM or growth factor signalling and 
FAK phosphorylation is an early event associated with the formation of focal contacts. 
Localisation to integrins is mediated by the focal adhesion targeting (FAT) domain on FAK.  
Engagement of integrins with the ECM and subsequent integrin-clustering promotes 
autophosphorylation of FAK at Tyr397.  Tyr397 phosphorylation promotes interactions 
between FAK and various Src-homology-2 proteins.   These interactions result in 
phosphorylation of other sites on FAK and other focal adhesion proteins including paxillin 
and p130Cas (177).  FAK also possesses a proline-rich C-terminal domain that provides 
binding sites for SH3-domain containing proteins.  These interactions, in turn allow FAK 
activation to be linked to multiple signalling pathways, including: extracellular signal-
regulated kinase (ERK), mitogen-activated protein kinase and small GTPases including Rho 
and Rac.  FAK also contributes indirectly to focal adhesion structure and function by 
phosphorylating and activating a range of focal adhesion proteins, including the F-actin 
cross-linking protein α-actinin (179).  FAK Tyr397 phosphorylation is closely associated 
with focal adhesion growth and FAK plays an important role in regulating cytoskeletal 
tension (178).  FAK knockout mice have an embryonic lethal phenotype.  However, using 
cell derived from FAK knockout embryos, it has been shown that while wild-type fibroblasts 
increase their traction forces as substrate stiffness increases, cells derived from FAK 
knockout mice (FAK -/-) maintain lower traction forces (180).  It is believed that FAK may 
itself function as a mechanosensor. Indeed, computer simulations suggest that the application 
of tractional force to the FAT domain of FAK may increase its binding affinity for vinculin 
(181).  FAK is widely over-expressed in tumour cells and its expression is correlated with 
increasing tumour malignancy (177, 182).  For this reason, FAK has become an important 
therapeutic target in cancer and the efficacy of small molecular inhibitors of FAK is 
currently being investigated in phase I clinical trials (178). 
 
The experiments of Paszek et al more explicitly investigated the relationship between matrix 
stiffness and Rho-mediated cellular contractility in respect to cancer cell biology.  They 
showed that MECs interacting on either a soft or stiff matrix could form integrin-based 
adhesions, indicated by the co-localisation of FAK and talin with β1-integrin (155).  
However, MECs could only phosphorylate FAK (Y397) and recruit vinculin to their 
integrin-based adhesions when interacting on a stiff matrix.  Increased matrix stiffness 
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disrupted tissue architecture and enhanced tumour growth by inducing Rho-generated 
cytoskeletal tension, promoting focal adhesion assembly and growth factor-dependent ERK 
activation.  Furthermore, it was shown that highly contractile epithelial growth factor 
receptor (EGFR)-transformed epithelium with high basal Rho and ERK-activity could be 
induced to revert to a well-differentiated acinus-forming phenotype if either Rho-generated 
cytoskeletal tension or ERK-activity was reduced.  This observation forms the basis for a 
model of tensional homeostasis and force-dependent malignant transformation (Figure 1.4).  
It is proposed that a chronic increase in cytoskeletal tension, mediated either by increased 
matrix stiffness (chronic inflammation), or elevated ERK activation (as a result of oncogene 
activation), if of sufficient magnitude or duration, could drive the assembly/ maturation of 
focal adhesions to enhance growth and disrupt cellular differentiation, driving malignant 
transformation.  Many cancer cells overcome tensional control of growth and are able to 
proliferate in conditions with limited ECM and cell-cell interactions (anchorage-independent 
growth).  This occurs as a result of genomic instability and disruption to the normal 
regulatory processes that govern cellular proliferation.  However, in other situations in vivo, 
tumours appear to modify their microenvironment in order to create a rigid environment 
(“desmoplastic reaction”) in order to stimulate growth (183).  Further support for the concept 
of force-dependent malignant transformation comes from detailed in vivo experiments, in 
which it has been shown that a reduction in tissue stiffness by inhibition of collagen-cross-
link formation impedes malignant growth and tumour development in a murine model of 
breast cancer (46).  Increasing matrix stiffness has also been shown to promote the in vitro 
migration and proliferation of transformed glioma cells (184).  Furthermore, the 
manipulation of integrin-mediated attachment to the ECM has been shown  to restore normal 
growth pattern and tissue organisation in transformed mammary epithelial cells in vitro and 
inhibit tumour formation in vivo (185).  The characteristics of HCC make it an attractive 
model in which to explore the relationship between matrix stiffness and cancer cell 
phenotype.  HCC is a tumour that develops in the context of an altered biomechanical 
environment characterised by increased environmental stiffness (118).  It has also been 
established that tumour development is associated with a further increase in stromal stiffness 
(119, 120).  It is the principle aim of this thesis to investigate whether changes in the 
stiffness of the tumour microenvironment perform a mechanistic role in modulating the 
malignant phenotype of HCC, in respect to tumour proliferation, differentiation and 
resistance to chemotherapy. 
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Schematic representation of proposed model for tensional homeostasis and force-dependent malignant 
transformation Abbreviations: extracellular regulated kinase (ERK); epidermal growth factor receptor 
(EGFR), Rho-associated protein kinase (ROCK); phospho-myosin light chain (MLC-P). 
Adapted from: Paszek et al.  Cancer Cell. 2005 (155) 
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1.10 Experimental methods for modelling physiological stiffness for in vitro 
cell culture 
 
The response of cells to alterations in matrix stiffness has been studied in a number of model 
systems (83, 186).  ECM gels composed of collagen and Matrigel provide culture conditions 
with mechanical properties approximating that found in normal tissues.  Substrates including 
fibrin, collagen, or a mixture of collagen, laminin and other proteins (Matrigel), can be used 
to produce two- or three-dimensional substrates of controlled stiffness.  Cross-linked 
polysaccharides, including alginate and agar, have also been employed for cell culture.  The 
behaviour of cells on soft substrates has been widely used to identify important changes in 
cell phenotype, e.g. the growth of cells on soft agar has been widely employed as an assay to 
identify cancer cells (187).  The elastic moduli of these substrates can be regulated by 
altering polymer mass.  Proteins in solution can be induced to polymerise by alteration in 
electrolyte concentration, temperature or the addition of specific enzymes.  The elastic 
modulus of a polymerized network is approximately proportional to the square of the protein 
concentration (188).  In addition, a range of other techniques have been employed to 
modulate the stiffness characteristics of polymerised matrices.  For example, the stiffness of 
Matrigel can be manipulated by chemical cross-linking with glutaraldehyde (142).  The 
addition of fibronectin increases the tensile strength of collagen networks (189) and variation 
in calcium and zinc ion concentration can stiffen fibrin gels at physiological pH (190).  
Hydrogel-based systems allow independent control of biochemical and mechanical 
properties, but with the additional advantage that cells are fully encapsulated within the gel 
matrix, and so the influence of stiffness can be studied in three-dimensional culture.  
However, the major disadvantage of ECM gels is the difficulty that exists in separating 
biological effects related to changes in substrate stiffness, from those which might be 
mediated by changes in ligand density or cross-linker concentration.  In addition, protein and 
polysaccharide gels interact directly with the cell surface and bind serum proteins in a 
manner that is difficult to control or quantify.  
 
Anchorage can be used to manipulate the tensile properties of ECM gels without altering the 
biochemical composition of the polymer used.  Cells can be embedded in collagen gels that 
are physically tethered to the container in which they have been fabricated (polymerised).  
The subsequent release of these gels from the sides of their container is associated with a 
reduction in the tension across the gel.  Cells embedded in physically tethered gels show 
distinct morphological characteristics when compared to those in free-floating (released) 
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gels.  For example, fibroblasts cultured in constrained gels develop prominent F-actin stress 
fibres and assemble fibronectin into fibrils, whereas cells on untethered gels do not (191).  
Similarly, mammary epithelial cells form tubules when cultured on relaxed free-floating 
collagen gels, while this architectural organisation is lost when cells are maintained in 
tethered gels (173).  The rate of contraction of untethered ECM gels can be used as a 
measure of cell contractility and gel contraction assays been widely employed to investigate 
factors that may influence cell contractility (192).  The disadvantage of this system is the 
inability to fine-tune the tensile properties of tethered and released gels. 
 
Ligand-coated polyacrylamide (PA) supports have become established as a widely used and 
versatile system in which to investigate stiffness-dependence of cytoskeleton-regulated cell 
behaviour (193).  This system allows cells to be cultured in conditions of defined and 
tailored stiffness, without altering the biochemical properties of the surface to which cells are 
exposed.  The biochemical properties of polyacrylamide are ideally suited to allow 
separation of chemical and mechanical signalling.  Polyacrylamide is almost completely 
inert as an adhesive surface.  It is this property that underlies its utility as a medium for the 
separation of proteins and nucleic acids by electrophoresis.  This also ensures that cell 
surface receptors and adhesive proteins cannot bind to the gel directly. Indeed, only 
molecules (ECM components) covalently cross-linked to the PA matrix can act as ligands for 
cell attachment.  This provides added benefits over tissue culture substrates such as plastic, 
where there is considerable uncertainty in respect to the mechanism of cell attachment.  The 
stiffness of polyacrylamide can be varied over many orders of magnitude (G' 100 Pa – 
100kPa) by changing the concentration of dimeric bis-acrylamide cross-linker, while the 
polymer concretration is kept constant.  This prevents concomitant changes in surface texture 
and ligand density.  The pore size of these PA gels is in the order of 100nm, which is 
sufficiently small that cells (~15µm) and cellular processes (~5µm) are too large to enter the 
gel matrix (194).  A potential disadvantage of this system is that covalent attachment of 
fragile proteins to polyacrylamide may be difficult.  However, techniques have been 
developed to overcome these difficulties, including the use of poly-D lysine to promote 
ligand attachment to polyacrylamide (194). 
 
For the purpose of this thesis, PA gels of variable stiffness were prepared on glass coverslips 
using a modification of the method initially described by Pelham and Wang (95).  The use of 
PA supports for cell culture has previously undergone extensive validation at the University 
of Pennsylvania (194-196).  PA matrix stiffness has been determined by two independent 
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methods.  Atomic force microscopy (AFM) was used to measure nano-scale stiffness across 
the gels (195).  Macroscopic or bulk elastic measurements were also made using AFM-
probed samples by a simple tension method as described by Pelham et al (95, 195).  It has 
been shown that PA gels demonstrate linear elasticity, and macroscopic tests show that this 
linearity extends over a broad range of strain measures.  Both AFM and bulk measurements 
have been made for gels with a range of bis-cross-linker concentrations.  It has been shown 
that the ECM coating does not affect the overall stiffness of the system (194, 195). Gel 
porosity, which varies as a function of bis-cross-linker concentration, could influence cell 
accessible ligand density by allowing these molecules to migrate into the gel itself.  This 
may produce uncertainty in respect to surface ligand density.  However, it has been 
demonstrated that micron-sized beads, much larger than the pores and bearing anti-collagen 
antibodies, bind almost identically to collagen-coated gels of very different porosity (96).  
Furthermore, it has been shown that bis-acrylamide cross-linker concentration does not 
affect the relative surface ligand density.  Pelham et al used a modified radio-immunoassay 
(RIA) employing a monoclonal antibody against collagen-I and 125I-labelled anti-mouse IgG 
to determine the relative amount of collagen bound to PA sheets (95).  This demonstrated 
that the relative concentration of collagen differed by less than 3% between PA substrates of 
different stiffness. Finally, in order to exclude the possibility that observed changes in the 
behaviour of cells on different PA supports were due to differential loss of covalently bound 
ligands from the substrate, cells were cultured on either 0.25% or 0.03% bis-acrylamide gels, 
then lysed with 0.5% Triton-X-100 (95).  RIA with anti-collagen-I antibodies indicated that 
the collagen-concentration did not decrease on either soft or stiff PA supports as a result of 
cell growth, when compared to control supports not used in cell culture.  Thus, ligand-coated 
PA supports represent a robust and well-characterised system in which to investigate the 
stiffness-dependence of cytoskeleton-regulated biological processes. 
 
1.11 The role of in vivo models to investigate the impact of physical factors on 
cell behaviour 
 
Advances in our understanding of how mechanical factors regulate cell behaviour have come 
about predominantly as a result of experiments undertaken in an in vitro setting.  This 
approach has enabled investigators to attempt to separate the effects of biochemical and 
physical signalling, while minimising the impact of potential confounding factors that may 
independently affect cell behaviour.  However, these in vitro systems will never be able to 
recapitulate the complexity inherent to the in vivo environment.  Important insight has been 
 30 
gained into how mechanical factors might influence pathophysiological processes including 
chronic liver disease (135) and tumour development (155), with the use of detailed in vivo 
measurements of mechanical properties such as tissue stiffness.  Interventions that attempt to 
modulate the physical properties of tissues in vivo will almost inevitably have secondary 
effects that may impact upon the observed outcome.  For example, the increase in 
parenchymal stiffness associated with the induction of liver fibrosis in rodents is 
accompanied by dramatic changes in both the cellular composition of the liver and the 
prevailing cytokine milieu.  Even more modest interventions to modulate the physical 
properties of the cellular microenvironment will have potentially confounding effects.  For 
example, lysyl oxidase (LOX) is a copper dependent amine oxidase which initiates intra- and 
inter-molecular cross-linking of collagen.  It has been shown that active LOX stiffens tissues 
and can compromise their function.  Furthermore, reducing LOX activity with β-
aminopropionitrile (BAPN) attenuates tissue stiffness and prevents liver fibrosis (135).  In 
addition, it has been shown that BAPN treatment (LOX inhibition) is associated with a 
reduction in tissue stiffness, and attenuated tumour growth in a murine model of breast 
cancer (46).  However the activities of LOX and other members of the LOX family are 
manifold and complex (197).  LOX has been shown to regulate events including chromatin 
compaction, gene transcription and cell differentiation.  Hydrogen peroxide released as a 
consequence of LOX-mediated catalysis triggers phosphorylation and activation of two key 
signal transcription pathway activators (FAK and Src) and as such may have pervasive 
effects on cell biology.   
 
Clearly there are considerably limitations to the utility of in vivo models in advancing our 
understanding of how mechanical factors such as stiffness may modulate cell behaviour in 
pathological processes such as chronic inflammation or tumourigenesis.  In complex 
pathological processes, such as liver fibrosis, it will prove extremely difficult to disentangle 
the complex web of solid-state and soluble regulators of cell behaviour.  However, important 
insight may be gained by the characterisation of convergent models of liver fibrosis in which 
physical factors may play an important regulatory role.  Tissue oedema, as occurs in both 
acute inflammation and passive congestion (right-heart failure), will result in a number of 
distinct biochemical and physical changes to the environment in which cells reside.  
Therefore, models of chronic hepatic congestion may provide us with the opportunity to 








Changes in the stiffness of the cellular microenvironment are important in regulating the 
behaviour of liver-resident cell populations in chronic liver disease and 
hepatocarcinogenesis. 
 
1.12.2 Principle Aims 
 
• To determine whether changes in the stiffness of the cancer cell niche regulate 
proliferation, differentiation and chemotherapeutic resistance in HCC cells 
 
• To determine the relationship between changes in liver stiffness and HPC response 
in rodent models of chronic liver disease 
 
• To determine whether changes in the stiffness of the HPC niche regulate the 
proliferation and differentiation of HPCs. 
 
1.12.3 Secondary Aim 
 
• To characterise the pattern of histological changes observed in rodent models of 
chronic hepatic congestion and assess whether these might provide insight into the 
effects of oedema and congestion on the development of liver fibrosis 
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Chapter 2: General Materials and Methods 
 
Appropriate home office licence and local ethical committee approval was obtained prior to 
animal experiments being undertaken.   
 
2.1 Experimental models of liver fibrosis and congestive cardiac hepatopathy 
 
Animals were maintained in high health status facilities, with access to food and water ad 
libitum. Experiments were conducted in accordance with UK Home Office licence 
regulations. 
 
2.1.1 Thioacetamide (TAA) model of rat liver fibrosis 
 
A thioacetamide (TAA) model of liver fibrosis in rats was used as previously described (198, 
199).  The intrahepatic metabolism of TAA results in the formation of reactive intermediates 
that both bind to hepatic macromolecules (including proteins and nucleic acids) and facilitate 
glutathione depletion (200).   Oral administration of thioacetamide reliably induces 
hepatocyte damage and liver fibrosis/ cirrhosis in rats (199).  Rat liver tissue from 
experiments with TAA was kindly donated by Dr Andrew Robson (University of 
Edinburgh).  Cohorts of adult male Sprague-Dawley (SD) rats (weight 300-350g) were used 
in these experiments. Animals in the experimental group obtained TAA (Sigma, Poole, UK) 
in drinking water at a concentration of 300mg/l (0.03%) ad libitum.  Animals in the control 
group were housed in identical conditions and supplied with standard drinking water ad 
libitum.  Animals were then sacrificed and liver tissue analysed at 4, 8, 10, 14, 18, 20 and 26 
weeks. 
 
2.1.2 Carbon tetrachloride (CCl4) model of rat liver fibrosis 
 
Carbon tetrachloride (CCl4) administration to mice and rats is a widely-accepted and well-
characterised model of liver fibrosis (201, 202). CCl4 is oxidised in the liver by cytochrome 
P450 to the highly reactive trichloromethyl (CCl3) radical.  This free radical can initiate lipid 
peroxidation and react with sulphydrol- groups in proteins.  This, in turn, leads to the 
development of steatosis and centrilobular (zone 3) hepatocyte necrosis, accompanied by 
HSC-activation and subsequent liver fibrosis.  The pattern of histological changes seen with 
CCl4-induced liver injury mirrors in many respects that seen with toxic liver injury (e.g. 
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alcoholic liver disease) in humans.  Repeated administration of CCl4, either by intraperitonial 
injection or oral gavage, can be used to predictably induce bridging fibrosis (4 weeks of bi-
weekly administration) or cirrhosis (8-12 weeks of bi-weekly administration).   
 
Rat liver tissue from experiments involving CCl4-induce liver injury was kindly donated by 
Prof Rebecca Wells (University of Pennsylvania).  All animal studies were approved by the 
University of Pennsylvania Institutional Animal Care and Use Committee.  Male SD rats 
(Charles River Laboratories, Wilmington, USA) received twice weekly intraperitonial 
injection with 0.2ml/100g of a 1:1 mixture of CCL4 (Sigma-Aldrich, St Louis, USA) in olive 
oil, or olive oil alone.  After 2 weeks the dose of this mixture was reduced to 0.1mg/ 100g.  
Animals were sacrificed after CO2 inhalation at 7, 14, 28, 42, 56 and 70 days.  Six uninjected 
animals were used as controls.  At each time point, there were two vehicle-injected control 
rats and five or six CCl4-injected rats.  Following sacrifice the livers were removed and 
systematically divided for rheometry, formalin-fixation and snap freezing in liquid nitrogen.   
 
Additional experiments were undertaken by Prof Rebecca Wells (University of 
Pennsylvania) to investigate the effect of β-aminopropionitrile (BAPN) on HPC responses 
following CCL4-induced liver fibrosis.  BAPN is an inhibitor of lysyl oxidase (LOX): a 
copper dependent amine oxidase that initiates intra- and inter-molecular cross-linking of 
collagen.  In these experiments liver fibrosis was induced by twice-weekly injection of 
0.2mg/100mg of a 1:1 mixture of CCL4 in olive oil for between 6-14 days.  In a second 
cohort, rats also received treatment with BAPN (2mg/ml) in drinking water ad libitum for the 
duration of CCL4-induced injury.  Both vehicle treated (olive oil alone), non-injected and 
non-injected/ BAPN treated animals were used as controls.  At each time point animals (n=5-
6) were sacrificed and harvested as described above.  Formalin fixed tissue from these 
experiments was kindly donated for the purpose of investigating the effect of liver stiffness/ 
BAPN on HPC responses in the liver. 
 
2.1.3 Python model of congestive cardiac hepatopathy 
 
Python mice (Py/+) were a gift from Prof Neil Dear (University of Leeds) and were 
generated as part of the MRC rodent mutagenesis program based at the MRC Mary Lyon 
Centre, Harwell.  The Py/+ mice were produced using N-ethyl-N-nitrosurea (ENU) 
mutagenesis, as previously described (203).  All experiments undertaken in python mice and 
littermate controls, was approved by the Animal Ethical Review Committees of MRC 
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Harwell, University of Sheffield and University of Leeds, and the UK Home Office.  These 
experiments were undertaken under the guidance of Prof Neil Dear (University of Leeds).  
Experiments were conducted using male python (Py/+) mice and littermate wild-type (+/+) 
controls on a C3H/ HeN.  Male python (Py/+) spontaneously develop a dilated 
cardiomyopathy.  Overt features of congestive cardiac failure (CCF) include; shallow-
breathing, piloerection, weight gain, ascites and peripheral oedema.  The median onset of 
features on overt CCF in male mice on a C3H/ HeN genetic background develop is 83 days.  
Experiments were undertaken to characterise the pattern of pathological changes in the liver 
in this spontaneous model of dilated cardiomyopathy.  Groups of python (Py/+) mice and 
aged-matched wild-type (+/+) controls were culled at 5, 7, 9 and 11 weeks, and at the onset 
of overt features CCF. 
 
2.1.4 CREB S133A of congestive cardiac hepatopathy 
 
Liver specimens from CREB S133A mice were kindly donated by Dr Gordon Huggins 
(Tufts University School of Medicine, Boston) and Dr Nicolas Birdsey (University of 
Colorado, Denver).  All experiments undertaken CREB S133A mice and littermate controls 
was approved by local Animal Care Committees of Tufts University and the University of 
Colorado.  The CREB S133A is a transgenic murine model of dilated cardiomyopathy, the 
generation of which has previously been described (204).  CREB S133A transgenic mice 
have been developed ( ICR/CD1 background) that express this dominant-negative repressor 
of CREB-mediated signalling under the transcriptional control of the cardiac myocyte-
specific alpha-myosin heavy chain (MHC) promoter (204). Expression of the CREB S133A 
transgene is restricted to the heart, as demonstrated by Northern blot analysis (204). It has 
been demonstrated that CREB S133A transgenic mice develop a form of dilated 
cardiomyopathy (DCM) that closely resembles idiopathic dilated cardiomyopathy in 
humans.  Histological analysis of hearts from CREB S133A mice demonstrates progressive 
four chamber dilatation.  Experiments were conducted in male CREB S133A mice in order 
to characterise the morphological changes occurring within the liver during the development 
of progressive cardiac failure.  Cohorts (n=3-5) of male CREB S133A mice (ICR/CD1 
background) and age-matched wild-type controls were culled at 4, 8 and 12 weeks, during 
which period male CREB S133A mice developed clinical features of progressive cardiac 
failure.     
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2.2 Tissue collection and processing 
 
Following each experimental protocol, all mice were culled by a Schedule 1 method (UK 
Home Office Guidelines).  Tissue was harvested in accordance with a defined experimental 
protocol.  Tissue specimens (including the left lobe of the liver, spleen, heart and kidneys) 
were fixed in formalin solution (12 hours) and embedded in paraffin.  The right lobe of each 
liver was snap frozen in liquid nitrogen and stored at -80oC prior to protein and RNA 
analysis.  Blood samples were obtained by direct cardiac puncture post-mortem.  Serum 
samples were prepared by centrifugation (10 minutes/ 5000g) in 1.5ml tubes containing 
lithium heparin solution (Sigma, Poole, UK). 
 
2.3 Histological analysis     
 
Basic histological analysis was performed on 5µm formalin fixed sections stained with 
haematoxylin and eosin solutions. 
 
2.3.1 Picosirius red (PSR) staining 
 
PSR staining was performed on 5µm liver sections.  Sections were de-paraffinised in xylene 
and rehydrated in ethanol (50-100%) and distilled water.  Sections were then incubated for 2 
hours in saturated picric acid solution containing 0.1% Sirius red and 0.1% Fast green.  
Sections were then rinsed in distilled water to remove excess dye and dehydrated in ethanol 
(50-100%) and xylene.  Slides were mounted on glass cover slips with aqueous PermountTM 
mounting media (Fischer Scientific, Loughborough, UK).  Sirius red staining of liver 
specimens was quantified by digital image analysis (Photoshop, Adobe, San Francisco, 
USA) of 20-30 randomly selected and blinded high magnification (x200) photomicrographs.  
Detection thresholds were set for the red colour of PSR stained collagen from an area of 
intense staining and an arbitrary colour threshold range was applied.  
 
2.3.2 Reticulin staining 
 
Reticulin staining was performed on 5µM liver sections using a modification of the protocol 
described by Gordon and Sweet (205).  Sections were deparaffinised in xylene and 
rehydrated in ethanol (50-100%) and distilled water.  Sections were immersed in acidified 
potassium permanganate (0.5%) solution for 3 minutes and then rinsed in distilled water.  
 36 
Sections were then treated with 2% oxalic acid for 1 minute, rinsed in distilled water and 
immersed in 4% alum solution for 10 minutes.  After a further rinse in distilled water, the 
sections were impregnated with ammoniacal silver solution (10 seconds), rinsed in distilled 
water and immersed in formalin solution (10%) for 2 minutes.  Sections were then fixed in 
2% sodium thiosulphate solution, rinsed in distilled water and counterstained with neutral 
red.  Slides were dehydrated in ethanol (50-100%) and xylene and mounted on glass cover 




Immunohistochemistry was performed on formalin-fixed paraffin-embedded 3µM sections 
mounted on glass slides (Thermo-Fischer, Loughbourgh, UK).  Primary and secondary 
antibodies were used at different concentrations (Appendix 1).  For some targets, an antigen 
retrieval step was required to unmasked epitopes hidden by cross-linking formed during the 
fixation process. 
 
2.4.1 General immunohistochemistry protocol with paraffin sections 
 
Immunohistochemistry was carried out at room temperature unless otherwise stated. 
Formalin-fixed and paraffin embedded sections were de-paraffinised twice in xylene (for 5 
min each time) and rehydrated in ethanol (50-100%) and distilled water.  Antigen retrieval 
(if required) was performed at this stage (Appendix 1) and the sections were then washed 3 x 
5 min in phosphate buffered saline solution (PBS).  Endogenous peroxidise activity was 
blocked by incubation with hydrogen peroxide (2%) solution in PBS for 10 minutes. Slides 
were then washed 3 x 5 minutes in PBS.  Slides were then mounted into Shandon Sequenza 
slide racks (Thermo-Fischer, Loughbourgh, UK).  An endogenous avidin-biotin block 
(Vector Laboratories, Peterborough, UK) was performed by applying 3 drops of avidin 
solution to each slide for 15 min.  Slides were then washed 3 x 5 min in PBS, then 3 drops of 
biotin reagent were applied for a further 15 min.   Sections were then washed 3 x 5 min in 
PBS.  Non-specific protein-binding was inhibited by incubation with blocking buffer 
containing species-specific serum diluted (1:5) in PBS for 30 min.  Species-specific serum 
was chosen to match the species in which the relevant secondary antibody was raised.  
Without washing, samples were then incubated with a primary antibody solution 
(appropriately diluted in blocking buffer) for 1 hour at room temperature (Appendix 1).  
Slides were then washed 3 x 5 min in PBS.  A secondary antibody solution appropriate to 
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each primary antibody was made by appropriate dilution (Appendix 1) of secondary 
antibody in blocking solution.  Samples were incubated with secondary antibody solution for 
1 hour and then washed 3 x 5 min in PBS.  Slides were then treated with 3 drops of 
streptavidin ABC-horseradish peroxidise (HRP) reagent (DAKO, Ely, UK) for 30 min and 
then washed 3 x 5 min in PBS.  A chromogen solution containing 3, 3’-diaminobezidine 
(DAB) (Invitrogen, Paisley, UK) was applied to each slide for between 1-5 min, until a 
colour change was observed.  The slides were washed in PBS solution 3 x 5 min.  Slides 
were then counterstained in Harry’s haematoxylin solution (10 seconds), rinsed in running 
tap water and immersed in Scott’s tap water (10 seconds).  Sections were then rinsed in 
running tap water and dehydrated in graded ethanol solutions (50-100%) and xylene for 5 
minutes each. Slides were then mounted on glass cover slips with aqueous PermountTM 
mounting media. 
 
Negative controls were performed in all immunohistochemistry experiments.  First, the 
primary antibody was replaced by a relevant isotype control antibody chosen to match the 
concentration, species and immunoglobulin class of the primary antibody.  In a second 
control, the primary antibody was simply omitted.  
 
2.4.2 Pimonidazole-adduct immunohistochemistry 
 
Experiments to quantify tissue hypoxia were conducted using pimonidazole hydrochloride, a 
2-nitroimidazole hypoxic marker that forms adducts with thiol groups in proteins, peptides 
and amino acids under hypoxic conditions (PaO2<1.3kPa).  Animals were injected with 
pimonidazole (60mg/kg) (Hypoxyprobe Inc, Burlington, USA) by intraperitonial injection 30 
minutes prior to sacrifice.  Liver specimens were harvested and fixed in formalin solution 
(12 hours) and embedded in paraffin.  Immunohistochemistry for pimonidazole adducts was 
performed on 3µM sections in accordance with our standard immunohistochemistry protocol 
(as previously described).  Tissue was subjected to microwave antigen retrieval (15 minutes) 
in a Tris-ETDA solution (pH9.0).  Non-specific binding was minimised by incubating tissue 
sections in proprietary blocking solution (DAKO, Ely, UK).    Hypoxyprobe-1™ OMNI anti-
pimonidazole adduct primary antibody (Hypoxyprobe Inc, Burlington, USA) was used at a 
1:200 dilution.  Swine anti-rabbit secondary antibody was used at a dilution of 1:200.  
Positive staining was detected with Vector ABC reagent (Vector, Peterborough, UK) and 3, 
3-diaminobenzidine (DAB) substrate (DAKO, Ely, UK). 
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2.4.3 Immunohistochemistry on human HCC specimens 
 
Human HCC tissue from surgical resection specimens was obtained from archived tissue 
held by Tayside Tissue Bank and the Department of Pathology, University Medical Centre 
Hamburg-Eppendorf with appropriate ethical approval (UK-LREC: TR000216).  
Immunohistochemistry was performed as described above in collaboration with Rebecca 
Aucott.  The primary antibodies and antigen retrieval regimes used were anti-pFAK (pY397) 
(Invitrogen, Paisley, UK/ Microwave pH9) and anti-β1-integrin (Abcam, Cambridge, UK/ 
Microwave pH9).  Negative controls with isotype immunoglobulins (Santa Cruz, Heidelberg, 
Germany) and species-specific serum alone showed no specific staining. 
 
2.5 Microscopy and histological analysis 
 
Microscopic examination of tissue specimens was performed using an inverted Zeiss 
Axiovert-200 microscope and Axiovision image acquisition software (Zeiss, Heidenheim, 
Germany).  
 
2.5.1 Digital image analysis of immunostained sections 
 
Quantification of αSMA immunostaining in liver specimens was quantified by digital image 
analysis (Photoshop, Adobe, San Francisco, USA), of 20-30 randomly-selected and blinded 
high magnification (x200) photomicrographs per section.  Values are expressed as the mean 
percentage area of positive staining per high power field (x200 magnification) from 3-8 
independent samples.  Detection thresholds were set for the brown colour of DAB from an 
area of intense staining and an arbitrary colour threshold range was applied. 
 
2.5.2 Hepatic progenitor cell (HPC) quantification in immunostained sections 
 
HPC numbers in rat/ mouse livers were quantified by direct cell counting from sections 
immunostained for the HPC marker cytokeratin-19 (CK-19).  CK19 staining and cell 
counting was undertaken by Dr Andrew Robson. Cell counts were made using Image J 
(Nation Institute of Health, USA) from 40-60 randomly selected and blinded high power 
(x320 magnification) photomicrographs.    Cell counts are expressed as the mean number of 
non-bile-duct-associated CK-19-positive cells per 60 high power portal vein fields from 2-6 
independent samples. 
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2.5.3 Macrophage quantification in immunostained sections 
 
Macrophage numbers in mouse livers were quantified by direct cell counting from sections 
immunostained for the macrophage marker F4/80.  Cell counts were made using Image J 
from 10 randomly selected and blinded high power (x200 magnification) photomicrographs 
of portal vein fields.  Cell counts are expressed as the mean number of F4/80-positive cells 
per high power portal vein field from 6-8 independent samples. 
 
2.6 Shear rheometry measurements with rat liver tissue 
 
Rheometry measurements were made by Prof Rebecca Wells (University of Pennsylvania) as 
previously described (135).  Briefly, cylindrical samples were prepared from the posterior 
lobe of freshly removed liver using a scalpel and 25mm-diameter stainless-steel punch 
(McMaster-Carr, New Brunswick, USA).  Samples with a thickness of 3mm (measured with 
a micrometer built into the rheometer) were placed between two 25mm serrated steel plates.  
Shear storage modulus (G') values were measured within 30 minutes of the tissue cores 
being cut.  Control experiments had previously shown that G' measurements were unchanged 
for several hours of liver storage in HBSS and did not change with the plane of dissection 
used for disc construction.  In addition, there was minimal variation in G' measurements 
taken from different lobes from a single animal.  Perfusions of livers with heparin did not 
alter G' values in control experiments and therefore experiments were conducted without 
prior perfusion. 
 
Shear storage modulus (G') measurements were made using a Rheometrics RFS-3 controlled 
strain rheometer (Rheometric Scientific, Piscataway, USA) and are reported in Pascals (Pa).  
G' measured by oscillatory deformation is dependent upon the frequency of oscillation and 
magnitude of deformation (strain).  The liver samples were found to be only weakly 
dependent on the frequency of deformation, but G' decreased with increasing deformation.  
G' was measured at a frequency of 1 rad/second over a range of strain values.  The G' Vs 
strain plot was linear to 2% strain.  Reported values were recorded for 2% strain.  In order to 
minimise drying and ageing of the samples, a moisture trap enclosed the test area and 




2.7 Multiplex cytokine assay 
 
2.7.1 Sample preparation for multiplex cytokine assay 
 
Protein samples for multiplex cytokine assays were prepared from snap frozen whole liver 
samples.  Small pieces (~0.1cm3) of frozen tissue were added to 300µl of proprietary Tissue 
Protein Extraction Reagent (TPER) (Pierce, Rockford, USA).  The tissue was disrupted by 
repeated passage through a 2ml syringe and 19 gauge needle, sonicated and centrifuged 
(12,000rpm at 4oC) for 10 minutes.  The supernatants were transferred to sterile 1.5ml tubes 
and assayed to establish protein concentration.  Prior to use, protein samples were then 
diluted to a final concentration of 500µg/ml. 
 
2.7.2 Bradford protein determination assay 
 
The protein concentration of tissue lysates or cell extracts was determined using a 
modification of the Bradford Protein Assay (206).  Briefly, 5µl of protein extract was added 
to 150µl of Bradford Reagent (Sigma, Poole, UK) diluted (1:1) in distilled water in a 96-well 
plates.  Parallel standards were made using bovine serum albumin (Sigma, Poole, UK) (0-
1000µg/ml)   Absorbance was measured at 595nm using a Biotek Synergy HT microplate 
reader (Biotek, Potton, UK).  A standard curve was plotted and the protein concentration 
determined from the standard curve equation using Excel software (Microsoft, Redmond, 
USA).    
 
2.7.3 General multiplex cytokine assay protocol 
 
Multiplex cytokine assays were performed on a Bio-Plex 200 Suspension Array system and 
Bio-Plex Pro Wash Station (Bio-Rad, Hemel Hempstead, UK).  Multiplex cytokine assays 
for MCP-1, MIP-2, IL-6 and VEGF were performed using a Bio-Plex Pro Magnetic 
Cytokine Assay kit and proprietary standards.  Cytokine assays were performed in 
accordance with the manufacturer’s instructions using a modification of the method 
described by Molls et al (207).  The cytokine assay plate layout consisted of eight standards 
in duplicate (32000-1.95pg/ml), two blank wells (for fluorescence background subtraction) 
and sample wells.  The multiplex cytokine assay uses a flow-based microbead protein 
detection system based on Luminex X-MAP technology.  The surface of each fluorescently-
coded bead is coated with specific antibodies directed against a specific cytokine or growth 
factor.  Each supernatant sample (50µl) is incubated (30 min, room temperature) with a 
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mixture of microbeads, each conjugated to a specific capture antibody.  Samples are washed 
three times (100µl) in proprietary Wash buffer (Bio-Rad, Hemel Hempstead, UK).  The 
samples are then incubated (30 min, room temperature) with a mixture of secondary 
biotinylated antibodies, each directed against a specific secondary epitope on each target 
molecule.  The samples are then washed three times in wash solution and incubated with a 
streptavidin-conjugated phycoerythrin (PE) reporter for 10 min at room temperature.  The 
samples are then washed three times in wash solution and following the final wash step the 
samples are resuspended in proprietary Assay buffer (Bio-Rad, Hemel Hempstead, UK).  
The samples are then subjected to flow cytometric analysis on a Bio-Plex 200 Suspension 
Array system.  This system uses fluidics, laser excitation, fluorescence detection and digital 
signal processing for identification and scanning of individual microbeads.  Each individual 
microbead is identified on the basis of its internal fluorescence (defining the target molecule) 
and the PE reporter signal associated with each bead is quantified, which is in turn dependent 
upon the concentration of target molecule present in each sample.  The data is analysed using 
Bio-Plex Manager 3.0 software (Bio-Rad, Hemel Hempstead, UK) and the concentration of 
each target molecule calculated against the standard curve.  The final concentration of each 
cytokine/ growth factor is expressed in pg/mg liver tissue.   
 
2.8 RNA methods 
2.8.1 Prevention of contamination 
 
All consumables and equipment used in RNA work was DNAse/ RNAse-free.  All buffer 
solutions were either certified as DNAse/ RNAse-free or made using DNAse/ RNAse-free 
water.  All surfaces and equipment was treated with RNAseZap™, RNAse decontamination 
solution (Applied Biosystems, Warrington, UK), prior to use.  
 
2.8.2 RNA extraction for real-time quantitative PCR  
 
RNA extraction was performed using an RNeasy Mini-kit protocol (Qiagen, Crawley, UK). 
 
For RNA extraction from cultured cells, culture media was aspirated from cultured cells and 
the cells were washed twice in ice-cold PBS.  An appropriate aliquot of RLT lysis buffer 
containing β-mercaptoethanol (10µl/ml) was added to each culture dish and the cells 
harvested with a cell scraper into a sterile 1.5ml Eppendorf microfuge tube.  Samples were 
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vortexed for 30 seconds and homogenised using QIShredder microfuge columns (Qiagen, 
Crawley, UK).   
 
For RNA extraction from animal tissue, small (~0.1cm3) pieces of frozen tissue were added 
to an appropriate aliquot of RLT lysis buffer containing β-mercaptoethanol (10µl/ml).  The 
tissue was disrupted by repeated passage through a 2ml syringe and 19 gauge needle.  
Samples were vortexed for 30 seconds and homogenised using QIShredder microfuge 
columns.   
 
The homogenised extracts were then loaded onto RNeasy Mini-kit microfuge columns and 
RNA purification performed according to the manufacturer’s instructions.  The purified 
RNA was then eluted from each column into an appropriate volume (30µl) of RNAse-free 
water.  The concentration and purity of extracted RNA was quantitated by measuring 
absorbance at 260nm and 280nm, using a Nanodrop ND-1000 Spectrophotometer (Thermo-
Scientific, Wilmington, USA).  Samples were stored at -80oC until use. 
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2.8.3 Preparation of cDNA from total RNA-reverse transcription 
 
Total RNA was extracted from liver homogenates or cultured cells as described.  Reverse 
transcription was performed using a Superscript-II kit (Invitrogen, Paisley, UK) according to 
the manufacturers instructions.  RNA was thawed on ice and briefly vortexed prior to use.  
Briefly, 0.1-1µg of template RNA was added to a 0.2ml microcentrifuge tube containing 
0.8µl DNAse I solution, 1µl 10x DNAse I Reaction Buffer and DNAse/ RNAse-free water to 
a final volume of 8.2µl.  The tubes were incubated at room temperature for 15 min and 0.8µl 
of 25mM EDTA solution was added to the reaction mixture.  The tubes were then incubated 
at 65oC for 10min.  2µl of random primers (1µg/µl) (Invitrogen, Paisley, UK) was then added 
to each tube, which was then incubated at 70oC for 10min then chilled on ice.  A mastermix 
was prepared containing: 
 
Reagent Volume per reaction Final Concentration 
5X RT Buffer 4µl 1X 
10mM dNTP mix 0.5µl 0.5mM 
0.1M DTT 2µl 5mM 
Superscript II 0.5µl 10 units/ 20µl 
RNAse Inhibitor 0.5µl 20 units/ 20µl 
DNAse/ RNAse-free water 1.5µl  
Template RNA 11µl  
Total Volume 20µl  
 
Mastermix (9µl) was then to each tube to give a final volume of 20µl.  Samples were 
incubated at 37oC for 60 min.  cDNA was stored at -20oC prior to use. 
 
2.8.4 Reverse transcription-polymerase chain reaction (RT-PCR) 
 
2.8.4.1 Principles of SYBR-Green RT-PCR 
 
A PCR reaction can be divided into three phases; an exponential phase, a linear phase and a 
plateau.  During the exponential phase of the PCR run there should be an exact doubling of 
product at each cycle (assuming 100% reaction efficiency).  This phase of the reaction is 
very specific and precise.  Theoretically, there is a quantitative relationship between the 
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amount of starting target sample and the amount of PCR product at any given cycle number, 
this relationship being most consistent during the exponential phase of the PCR reaction. 
 
Real-time PCR measures the accumulation of amplicons during the PCR reaction, with data 
being measured during the exponential phase.  SYBR-Green RT-PCR is a method of real-
time PCR that relies upon the fluorescence properties of the cyanine dye SYBR-green.  
SYBR-green binds to the minor groove of double stranded DNA.  The binding of SYBR-
green to DNA in this manner results in an increase in the intensity of fluorescent emission.  
Thus, with each thermal cycle, as more double stranded amplicons are produced the intensity 
of the SYBR-green signal increases. When the fluorescence signal increases to a detectable 
level it can be displayed as an amplification plot.  The threshold line (∆Rn) is the level of 
detection at which a reaction reaches a set fluorescent intensity above background, and is set 
within the exponential phase of the PCR reaction.  The cycle at which the sample reaches 
this threshold is the cycle threshold (Ct).  Through this method Ct values can be determined 
for target genes and reference housekeeping genes in each sample.  Standard curves are then 
produced by plotting Ct values for known cDNA standards against Log of cDNA 
concentration.  Comparative changes in cDNA concentrations can then be calculated by 
extrapolation from standard curves.   
 
2.8.4.2 SYBR-Green RT-PCR protocol 
 
PCR work was undertaken in a protective hood and all equipment was UV irradiated prior to 
use.  Template cDNA was diluted in DNAse/ RNAse-free water prior to use.  2-20ng of first 
strand cDNA was used per reaction.  A standard curve (S1-7) was produced by serial 
dilution of a high standard (S1), which was obtained by pooling equal amounts of cDNA 
from each sample into a single tube. A reaction mixture consisting of 5µl SYBR-Green 
master mix, 0.2µl primers, 0.8µl DNAse/ RNAse-free water and 4µl cDNA was made up, 
giving a final reaction volume of 10µl.  Samples were added to a 96-well optical plate.  The 
optical plate was covered with a protective film and the plate was briefly centrifuged.  All 




The following reaction conditions were used: 
 
Fast DNA polymerase 
activation: 
95oC for 20 seconds 1 cycle 
   
Denature: 95oC for 3 seconds 40 cycles 
Anneal/ extend: 60oC for 30 seconds  
 
The expression of each gene of interest was determined relative to the expression of the 
housekeeping ribosomal 18S gene.  All reactions were undertaken in triplicate.  Standard 
curves were produced for each gene by plotting Ct values for each standard against Log of 
cDNA concentration.  After determination of the threshold cycle (Ct) for each target gene 
and 18S for each sample, comparative change in each sample was calculated by 
extrapolation from the standard curves using Excel software (Microsoft, Redmond, USA).  
Primer specificity was confirmed using melt curve analysis.   
 
2.8.5 Primer design 
 
Custom designed primers for mouse albumin, cytochrome 7A1 (CYP7A1), cytokeratin-19 
(CK-19), aquaporin and gamma glutamyl transferase (γGT) were purchased directly from 
Qiagen (Crawley, UK). Custom designed primers for human Oct4, NANOG and the 
eukaryotic housekeeping gene 18S were purchased directly from Applied Biosystems 
(Warrington, UK).  Other primer sequences were designed using the Primer3 plus program 
with the assistance of Dr Antonella Pellicoro (University of Edinburgh).  Specifically 
designed primers were purchased from Eurogentec Ltd (Southampton, UK).  Primer and 
probe sequences are provided in Appendix 2. 
 
Primer characteristics used in design: 
• Amplicon size of 100-200bp 
• Primer size 18-27bp 
• Primer CG percentage of 20-80% 
• Maximum number of mononucleotide repeats: 5 
• Primer temperature of 57-63oC 
• Primer sequences were matched to the original amplicon sequence in the 5’-3’ 
orientation. 
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2.9 Western blotting 
 
Western blotting experiments were undertaken in collaboration with, and under the 
supervision of Dr Joerg Schrader (University of Edinburgh)  
 
2.9.1 Protein extraction for Western blotting 
 
An appropriate volume of cell lysis buffer was prepared (see Appendix 3.1).  Biochemical 
reagents were purchased from Sigma (Poole, UK) unless stated.  A mixture of protease and 
phosphatase inhibitors was added to the cell lysis buffer immediately prior to use: 
benzamidine (10mM); orthovanodate (2mM); leupeptin (2µg/ml); aprotinin (3.4µg/ml); and 
phenylmethanesulfonyl fluoride (PMSF) (1mM).   
 
For protein extraction from cultured cells, culture media was aspirated from cultured cells 
and the cells were washed twice in ice-cold PBS.  An appropriate aliquot of cell lysis buffer 
(150µl/ 50mm dish) was added to each culture dish and cells harvested with a cell scraper 
into a sterile 1.5ml Eppendorf microfuge tube. Samples were kept on ice.  Each sample was 
sonicated and centrifuged (12,000rpm at 4oC) for 10 minutes.  The supernatants were 
transferred to sterile 1.5ml Eppendorf microfuge tubes, stored at -80oC and assayed to 
establish protein concentration prior to use (Bradford protein determination assay, as 
described earlier). 
 
For protein extraction from animal tissue, small (~0.1cm3) pieces of frozen tissue were added 
to an appropriate aliquot of cell lysis buffer (200µl).  The tissue was disrupted by repeated 
passage through a 2ml syringe and 19 gauge needle, sonicated and centrifuged (12,000rpm at 
4oC) for 10 minutes. The supernatants were transferred to sterile 1.5ml Eppendorf microfuge 
tubes, stored at -80oC and assayed to establish protein concentration prior to use. 
 
Following determination of protein concentration, protein concentration was standardised 
(0.1-2µg/µl) in cell lysis buffer.  Samples were prepared for sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) with the addition of an appropriate volume 
of 5X Laemmli buffer (see Appendix 3.2).  Samples were stored at -20oC.  Samples were 
defrosted and boiled for 10 minutes prior to use. 
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2.9.2 Sodium dodecyl sulphate (SDS) gel electrophoresis 
 
SDS polyacrylamide gels were cast using a Mini Protean 3 Gel Casting Chamber (Bio-Rad, 
Hemel Hempstead, UK).  Single percentage gels were produced by the sequential 
introduction to the casting chamber of resolving (10-12%) and stacking (5%) monomer 
solutions to which had been added 10% ammonium persulfate (APS) and 
tetramethlyethylenediamine (TEMED) (see Appendix 3.3).  Polyacrylamide gels are left to 
polymerise at room temperature for 30 minutes prior to disassembly of the casting apparatus. 
 
Following gel polymerisation, an upright Mini Protean 3 Gel Electrophoresis Tank (BioRad, 
Hemel Hempstead, UK) was assembled and filled with 1X running buffer (see appendix 
3.4).  Equal quantities of protein were loaded (2-40µg) were carefully pipetted into 
submerged wells.  Additionally, 5µl of precision plus protein kaleidoscope standard (BioRad, 
Hemel Hempstead, UK) was loaded into a separate well.  Electrophoresis was run at 100 
volts (V) for ~2 hours.  The equipment was then disassembled and the stacking gel removed.  
 
2.9.3 Western transfer 
 
Western transfer was performed using a Mini-Trans-Blot Cell (BioRad, Hemel Hempstead, 
UK).  Two pieces of high grade filter paper and two transfer sponges were soaked in 1x 
transfer buffer (see appendix 3.4).  An appropriately-sized piece of OptitranTM nitrocellulose 
membrane (Whatman GmbH, Dassel, Germany) was also soaked in 1x transfer buffer.  A 
transfer ‘sandwich’ was assembled consisting of: transfer sponge, filter paper, 
polyacrylamide electrophoresis gel, nitrocellulose membrane, followed by a second filter 
paper and transfer sponge.  The transfer ‘sandwich’ was inserted into a cassette and loaded 
into the Mini-Trans-Blot Cell.  An ice-block was inserted into the tank and the reservoir 
filled with 1x transfer solution.  The transfer apparatus was connected to a power supply and 
the transfer run at 300mA for 1 hour.  The equipment was then disassembled and the 
nitrocellulose membrane removed.  Successful transfer was indicated by visualisation of the 
Bio-Rad Kaleidoscope marker protein ladder (BioRad, Hemel Hempstead, UK). 
 
2.9.4 Membrane protein detection 
 
Following successful transfer, the membrane was air dried at room temperature for 30 
minutes and transferred to a 50ml tube.  Approximately 10ml of 5% milk solution (Marvel, 
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UK) in Tris buffered saline solution with 0.1% Tween-20 (TBS-T) was then added to each 
50ml tube to block non-specific protein binding and tubes were then placed on a rotator for 1 
hour at room temperature.  The blocking solution was then decanted and the membranes 
washed once in 5ml TBS-T solution for 5 minutes on a rotator.  The wash solution was then 
decanted and 5ml of primary antibody solution (appropriately diluted in 5% milk solution/ 
TBS-T) was added and the tubes placed on a rotator overnight at 4oC.  The primary antibody 
solution was then removed and the membranes washed 3 times in TBS-T solution (as 
described above).  A comprehensive list of primary antibodies and the concentrations used 
for immunoblotting is provided in Appendix 4.  A secondary antibody solution appropriate 
to each primary antibody was made by 1:2000 dilution of a species-specific horseradish 
peroxidase (HRP) conjugated antibody (Cell Signalling, Danvers, USA) in 5% milk/ TBS-T 
solution. The wash solution was then decanted and 5ml of secondary antibody solution was 
added to each membrane and the tubes placed on a rotator for 1 hour at room temperature.  
The secondary antibody solution was then discarded and the membranes washed 3 times in 
TBS-T solution (as described above). 
 
Signal detection was performed using Immobilon Western chemoluminescent HRP substrate 
(Millipore, Watford, UK).  Each nitrocellulose membrane was placed on a clean transparent 
acetate sheet.  The detection solution was prepared by mixing an equal volume of HRP 
substrate peroxide solution to the HRP substrate luminol solution (400µl/membrane).  The 
detection solution was then carefully pipetted over each nitrocellulose membrane.  A second 
transparent acetate sheet was placed on top of the membrane and taped down, ensuring no air 
bubbles were present.  The membranes were placed inside a film cassette.  In a dark room, a 
sheet of photographic film (Fuji, Bedfordshire, UK) was placed on top of the membrane and 
exposed for 30 seconds prior to being developed in a developer unit.  The duration of 
subsequent exposures was varied according to the appearance of the initial film. For 
quantification, blots from a minimum of three independent experiments were scanned at high 
resolution and the resulting images analyzed by densitometry (ImageJ). 
 
2.9.5 Western blotting membrane stripping protocol 
 
Nitrocellulose membranes were stripped prior to repeated immunoblotting by incubation at 
65oC for 15 minutes in a stripping buffer containing; 1g SDS, 2ml β-mercaptoethanol and 
0.75g Trizma Base in 100ml distilled water, pH6.7.  Membranes were then washed 6 times 
in TBS-T prior to incubation with blocking solution (as described above).  
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2.10 Production of matrix-coated polyacrylamide (PA) gel supports for tissue 
culture 
 
PA gels of variable stiffness were prepared on glass coverslips using a modification of the 
method initially described by Pelham and Wang (95).  In brief, glass coverslips were soaked 
in 0.1N sodium hydroxide and air dried.  A small aliquot of 3-aminopropyltrimethoxysilane 
(APTMS) (Sigma, Poole, UK) is spread across each coverslip and the coverslips are 
extensively washed in distilled water and then soaked in 0.5% glutaraldehyde (Sigma, Poole, 
UK) in PBS.  The coverslips are then coated in a thin layer of gel containing a mixture of 
7.5% acrylamide and 0.01-0.3% bis-acrylamide (National Diagnostics, UK).  In each case, 
the shear modulus (G’) of the resulting PA gels has been determined by our collaborators in 
the University of Pennsylvania (see Appendix 5) (195).  The gels are then washed in 50mM 
HEPES (Sigma, Poole, UK) and sufficient 50mM sulfosuccinimidyl 6 (4’-azido-2’-
nitrophenylamido) hexanoate (Sulfo-SANPAH) (Perbio, Cramlington, UK) to fully cover the 
gel surface.  The coverslips are then exposed to UV light for 5 minutes to facilitate cross-
linker activation.  Excess Sulfo-SANPAH is removed by extensive washing in 50mM 
HEPES.  A thin layer of collagen-I, collagen-IV, fibronectin (Sigma, Poole, UK) and laminin 
(R&D, UK) is then cross-linked to the gels at room temperature for 90 minutes.  Collagen-I 
and Collagen-IV (Sigma, Poole, UK) were dissolved in 0.1M acetic acid at a stock 
concentration of 1mg/ml and then diluted to a final concentration (0.1mg/ml) in distilled 
water.  Laminin was dissolved in PBS at a stock concentration of 20µg/ml, and used at this 
concentration in PBS.  Fibronectin was dissolved in PBS at a stock concentration of 
0.1mg/ml, and further diluted to a final concentration (50µg/ml) in PBS.  Adhesion of ECM 
proteins to PA gels may be increased by the addition of a layer of poly-D-lysine (Sigma, 
Poole, UK).  Poly-D-lysine is dissolved in distilled water to a stock concentration of 
0.1mg/ml, and further diluted to a final concentration of 10µg/ml.  It can then be cross-linked 
to PA gels at room temperature for 90 minutes.  Excess poly-D-lysine is washed off prior to 
the addition of ECM proteins.  Excess ECM is then washed off and any remaining cross-
linker is blocked with 1% ethanolamine (Sigma, Poole, UK) in 50mM HEPES for 30 
minutes at 4oC.  Gels are then soaked in serum free culture media overnight before plating of 
cells.   
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Figure 2.1: Schematic representation of the structure of ligand-coated 
polyacrylamide gel (PA) supports 
 
Figure 2.1 Schematic representation of a ligand-coated PA gel support. A multistep process is 
employed in which glass coverslips are treated with APTMS, an alkoxysilane that binds to hydroxyl 
groups in glass.  This, in turn, is linked to glutaraldehyde, an amine reactive cross-linker that binds 
covalently to a thin layer of polyacrylamide (100µm thickness).  The stiffness of the polyacrylamide 
layer can be altered (1-12kPa) by changing the concentration of bis-acrylamide cross-linker in the 
polyacrylamide matrix.  The polyacrylamide is then treated with Sulfo-SANPAH.   This is a UV-
activated bivalent cross-linker that covalently links the polyacrylamide gel matrix to extracellular 
matrix components (e.g. collagen-I, collagen-IV, laminin or fibronectin).   
 
2.11 Cell culture techniques  
 
2.11.1 Culture of human epithelial cell lines 
 
HCC cell lines Huh7 and HepG2 were kindly provided by Prof S. Wigmore (University of 
Edinburgh, UK).  Human cell lines MCF7, MDA and LNCap were kindly donated by Dr P. 
Saunders (University of Edinburgh, UK).  The human lung cancer cell line A549 was kindly 
donated by Prof T. Sethi (University of Edinburgh UK).  Cell culture and chemical reagents 
were purchased from Sigma (Poole, UK), unless otherwise stated.   
 
The Huh7 is a well-differentiated hepatocyte-derived cellular carcinoma-derived cell line 
taken from a 57-year-old Japanese male (208). The HepG2 is a well-differentiated liver 
carcinoma-derived cell line taken from a 15-year-old Caucasian man (209). The MCF7 is a 
breast adenocarcinoma cell line derived from a 69-year-old Caucasian woman (210). The 
MDA is believed to be a breast adenocarcinoma cell line, which was derived from a 
malignant pleural effusion in a 31-year-old woman (211). However, the MDA cell line has 
been shown to produce both breast-differentiation-specific proteins and melanocyte-specific 
proteins (212).  There has been some debate as to whether the MDA cell line is a breast 
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epithelial cell line that has undergone lineage infidelity or may be of melanocyte origin 
(213). The A549 is an alveolar cell-derived adenocarcinoma cell line isolated from a 57-
year-old Caucasian male (214).  The LNCap is an androgen-sensitive human prostate 
adenocarcinoma derived from a left supraclavicular node metastasis in a 50-year-old 
Caucasian male (215).  
 
The Huh7, HepG2, MCF7, MDA and A549 cell lines were maintained in Dulbecco’s 
Modified Eagle Medium (DMEM) (Gibco, Paisley, UK) supplemented with 10% foetal calf 
serum (FCS), penicillin/streptomycin and L-glutamine, LNCap cells were cultured in 
Roswell Park Memorial Institute media (RPMI) (Gibco, Paisley, UK).    In all experiments 
cells were plated at semi-confluent density in 1% FCS.  Cells were cultured in a humidified 
atmosphere with 5% CO2 at 37 °C. 
 
Transforming growth factor-beta (TGFβ) and hepatocyte growth factor (HGF) (Peprotech, 
London, UK) were used at concentrations of 5ng/ml and 10ng/ml, respectively.  Anti-β1-
integrin, clone 6S6 (Millipore, Watford, UK) and control IgG1 immunoglobulin (AbD 
Serotec, Oxford, UK) were used for cell culture experiments at 50µg/ml.  Echistatin (Tocris, 
Bristol, UK) was solubilised in PBS and used in cell culture experiments at a concentration 
of 100nM.  Mitomycin c was solubilised in PBS and used in cell culture experiments at a 
concentration of 100µM-10mM.  The ROCK inhibitor Y-27632 was solubilised in water and 
used in cell culture experiments at a concentration of 10-50mM.  The chemical FAK 
inhibitor, PF573228 (Tocris, Bristol, UK) was solubilized in dimethyl-sulfoxide (DMSO) 
and used for cell culture experiments at a concentration of 1-5µM.  The myosin-II inhibitor 
(blebbistatin) was solubilised in DMSO and used in cell culture experiments at a 
concentration of 10-50µM.   
 
2.11.2 Culture of murine hepatic progenitor cell (HPC) lines 
 
The bi-potential murine oval cell line (BMOL) was kindly donated by Dr B. Knight 
(University of Edinburgh).  The BMOL is a clonally derived, spontaneously immortalised 
cell line that was derived from primary murine progenitor cells following prolonged 
maintenance in culture using a “plate and wait” strategy (216). Briefly, primary murine 
progenitor cells (HPCs) were isolated from male C57 BL6 mice that had been fed with a 
choline-deficient ethanolamine-supplemented diet for 2-3 weeks to promote HPC expansion. 
Following initial plating, epithelioid colonies were selected, trypsinized and replated.  
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Visually verified single cell cloning was carried out by serial dilution and inoculation into a 
96-well plate.  After initial growth inhibition, some cells overcame crisis and formed 
colonies.  These were expanded, replated at low density and clonally derived cell lines 
established.  The cells were passaged weekly until the cell line became stable, displaying 
consistent morphology and growth. BMOL cells express markers of both hepatocyte and 
biliary differentiation.  They retain the ability to differentiate towards either a hepatocyte or 
biliary lineage.  They differ from primary murine HPCs in a number of important respects.  
As immortalised cells they can be maintained indefinitely in cell culture.  In comparison to 
primary HPCs they are more homogeneous in respect to their morphology and demonstrate 
higher rates of cell proliferation.  The genetic alterations underlying their spontaneous 
immortalisation have not been characterised. As such care should be taken in extrapolating 
the results of experiments conducted in BMOL cells to hepatic progenitor cells more 
generally. 
 
BMOL cells were maintained in specialised media containing: DMEM (50%), Ham’s F10 
media (50%) supplemented with 10% FCS, gentamicin, L-glutamine, sodium pyruvate, 
hydrocortisone and insulin.  In all experiments cells were plated at semi-confluent density in 
1% FCS.  Cells were cultured in a humidified atmosphere with 5% CO2 at 37 °C. 
 
2.11.3 Isolation and culture of primary murine hepatic stellate cells (HSCs) 
 
Primary hepatic stellate cells (HSC) were isolated as previously described (217).  Briefly, 
mouse livers (4-6 per cell preparation) were flushed with Hank’s buffered salt solution 
(HBSS) following cannulation of the hepatic portal vein. The livers are then dissected, 
mechanically disrupted and suspended in HBSS containing 0.05% DNAse (Roche 
Diagnostics, West Sussex, UK).  The resulting cell suspension was transferred to a solution 
containing 0.05% Collagenase (Roche Diagnostics, West Sussex, UK), 0.3% Pronase 
(Sigma, Poole, UK) and 0.02% DNAse.  This was then agitated/ incubated on an orbital 
rocker for 20 minutes at 37oC at 120rpm.  The cell suspension is then passed through a fine 
nylon mesh and then centrifuged at 1800rpm for 5 minutes.  The resulting cell pellet is 
resuspended in 9ml HBSS and 6ml Optiprep (Sigma-Aldrich, Poole, UK) to a final volume 
of 15ml.  The resulting cell suspension in divided between two tubes and carefully layered 
over Optiprep (7.5ml).  A layer (0.5ml) of HBSS is then carefully layered over the cell 
suspension prior to centrifugation at 2500ml at 4oC for 20 minutes.  The upper pale cellular 
band, containing HSCs was carefully aspirated from each tube and resuspended in HBSS 
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prior to centrifugation at 1800rpm for 7 minutes.  The supernatant was discarded and the cell 
pellet resuspended prior to plating.  HSCs were maintained in DMEM media supplemented 
with FCS (20%), sodium pyruvate, L-glutamine, penicillin and gentamicin, In all 
experiments, cells were plated at semi-confluent density in 1% FCS and only low passage 
cells were employed (P1-3).  Cells were cultured in a humidified atmosphere with 5% CO2 at 
37 °C. 
 
2.11.4 Isolation and culture of primary murine hepatic progenitor cells (HPCs) 
 
Primary murine HPCs were isolated in collaboration with Dr L Boulter (University of 
Edinburgh).  HPC isolation and culture from C57BL/6 mice was performed as previously 
described (216, 218).  Briefly, 4-week-old male mice were maintained on a choline deficient, 
ethionine-supplemented (CDE) diet for 2-3 weeks.  Mice were anaesthetised and HPCs 
isolated by modification of a two-step perfusion protocol (219).  The livers were perfused via 
the portal vein with EGTA buffer (0.5 mM EGTA, 137mM NaCl, 4.7mM KCl, 1.2mM 
KH2PO4, 0.65mM MgSO4 and 10.07 mM HEPES, pH7.4) followed by collagenase buffer 
(67 mM NaCl, 6.7 mM KCl, 4.76 mM CaCl2, 100.7 mM HEPES, 0.035% collagenase type I, 
pH 7.6).  The livers were then mechanically disrupted into William’s E media (Gibco, 
Paisley, UK) and dissociated by pipetting.  The cell suspension was then centrifuged 
(1800rpm, 5 minutes). The resulting cell pellet was transferred to a flask containing 0.1% 
collagenase type VIII, 0.09% Pronase (Roche Diagnostics, West Sussex, UK), 0.025% 
trypsin/0.01% EDTA (Invitrogen, Paisley, UK), 0.004% DNase in PBS.  The cell suspension 
was incubated for 50 min at 37 °C prior to the addition of an equal volume of William’s E 
media containing 2% FCS.  The cell suspension was passed through a 40µM BD FalconTM 
cell strainer (BD Biosciences, Oxford, UK).  The cells were centrifuged at 50g for 3 minutes 
to pellet any hepatocytes or large clumps that may have passed through the filter.  The 
supernatant was removed and this step was repeated, following which the supernatant was 
centrifuged at 160g for 10 minutes.  The resulting cell pellet was resuspended in 5-10ml of 
ammonium chloride cell lysis buffer (8.26g ammonium chloride, 1g potassium bicarbonate 
and 0.036g EDTA in 1 litre sterile water) and left on ice for 5 minutes.  Following this 10ml 
of PBS was added and cells pelleted by centrifugation at 160g for 10 minutes.  The cell 
pellet was washed three times in PBS and the resulting cell pellet was resuspended in 
William’s E media and underlayed with 20% and 50% PercollTM (Amersham Biosciences) in 
PBS.  HPCs were purified by density gradient centrifugation at 1400g for 20 minutes, with 
the resulting cell band collected and transferred to a tube containing an equal volume of 
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William’s E media supplemented with 2% FCS.  The cells were pelleted by centrifugation 
(160g, 5 minutes) and washed twice in PBS.  Trypan-blue excluding HPCs were counted 
prior to plating.  HPCs were maintained in oval cell media consisting of DMEM (50%), 
Ham’s F10 media (Gibco, Paisley, UK) supplemented with L-glutamine, gentamicin, sodium 
pyruvate, 10% FCS and insulin (10µg/ml). Cells were cultured in a humidified atmosphere 
with 5% CO2 at 37 °C.  In proliferation experiment cells were cultured at semi-confluent 
density in oval cell media containing 1% FCS.  As primary cells, primary HPCs have a 
limited lifespan in culture and in all experiments passage 1 (P1) cells were used exclusively. 
 
2.11.5 Isolation and culture of primary murine hepatocytes 
 
Experiments using primary murine hepatocytes were kindly performed by Dr Joerg Shrader 
(University Medical Center Hamburg-Eppendorf).  Hepatocytes isolation and culture from 
male C57BL/6 mice was performed as previously described (220).  Briefly, mouse livers 
were perfused via the portal vein with 0.05% collagenase solution in DMEM.  The liver 
tissue was then dissected/ mechanically disrupted and suspended in DMEM.  The cell 
suspension was centrifuged (30g for 3 minutes) and the supernatant discarded.  Following 
resuspension of the cell pellet, residual non-hepatocyte cells were removed by incubation 
with anti-CD8, anti-F4/80, anti-CD13, anti-CD45R, anti-CD11B, MAR18.5 (anti-B-
lymphocyte) monoclonal antibodies and rabbit complement for 20 minutes at 37oC.  The cell 
suspension was then centrifuged (30g x 3 minutes) and hepatocytes were resuspended in 
DMEM containing 10% FCS.  In proliferation experiments, identical numbers of cells (1 x 
105) were plated onto 24mm collagen-I-coated PA gel supports and maintained in culture for 
48 hours.  The cells were then fixed in 4% paraformaldehyde solution and immunostaining 
undertaken for the Ki67 antigen. A total of 25 low power fields (x50 magnification) were 
counted for Ki67 positive cells for each slide (n=3). 
 
2.12 Microscopy and digital image analysis of cultured cells 
 
Microscopic examination and representative photomicrographs (x200 magnification) of cells 
in culture was performed using an inverted Zeiss Axiovert-200 microscope and Axiovision 
image acquisition software (Zeiss, Heidenheim, Germany). Cell spreading measurements 
were obtained by quantifying the mean projected surface area from 50 cells visualized by 
phase-contrast microscopy (ImageJ, National Institutes of Health, USA).  Stress fibre 
orientation was quantified by digital image analysis.  Stress fibre orientation was defined as 
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the mean angle of intersection between a line representing the predominant direction of 
stress fibre organisation in a single cell and a line representing the direction of applied 
uniaxial stress.  In each experiment digital image analysis was undertaken using fully 
blinded and randomised images.  Confocal microscopy was performed using an inverted 
Leica SP5C spectral confocal laser scanning microscope and image acquisition via LASAF 
software (Leica Microsystems GmbH, Wetzlar, Germany).  DAPI, Alexafluor 488 and 
Alexafluor-546 were detected using band paths of 430-470, 495-540 and 550-600 for 405, 
488 and 546nm lasers respectively. 
 
2.13 Uniaxial cyclical strain application to cultured cells using FlexcellTM 
apparatus 
 
HSCs were cultured at sub-confluent density on collagen-I-coated deformable silicon 
membranes and subjected to uniaxial mechanical strain for 4-24 hours using Flexcell FX-
2000 apparatus (Flexcell International Corporation, Hillsborough, USA).  The FlexcellTM 
system allows cells to be cultured on deformable silicon membranes in 6 well plates, which 
are mounted on a sealed vacuum-base unit that is attached to a computer controlled vacuum 
pump.  Each membrane is suspended above a central arctangularTM support.  Negative 
pressure applied to the base of each well from a computer controlled vacuum pump leads to 
indrawing of the peripheral (unsupported) section of each well.  This results in uniaxial 
deformation of the central (supported) section and the cell monolayer (CM) adherent to this 
region (Figure 5.15B).  Computer settings determine the extent of uniaxial stain imposed on 
the flexible-bottomed wells (expressed as a percentage). The apparatus is calibrated to 
produce cyclical (1Hz) uniaxial strain in the range 2.5-10%.  The cell culture plates and base 
unit are maintained in a custom-modified incubator at 37oC with atmosphere containing 5% 
CO2.  In experiments with primary murine HSCs, cells were cultured in collagen-I-coated 
Flexcell plates for 48 hours in standard HSC media containing 20% FCS.  The cells were 
then transferred to serum free media and exposed to uniaxial strain (2.5-10%) for 4-24 hours.  
Cells were then either fixed in 1% paraformaldehyde for immunofluorescent staining or 
harvested for RNA analysis.  
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2.14 Immunofluorescent staining 
 
2.14.1 General immunofluorescent staining protocol of cultured cells   
 
Immunofluorescent staining was carried out at room temperature unless otherwise stated.  
Media was aspirated from culture plates and cells were washed twice in PBS.  Cells were 
fixed in 4.5% paraformaldehyde for 10 minutes and then aspirated to dryness.  Culture plates 
were rinsed twice in PBS and cells permeabilised with 0.2% Triton X-100 in PBS for 5 
minutes.  The cells were then rinsed twice with PBS.  Non-specific staining was blocked by 
incubation with 10% bovine serum albumin solution (BSA) in PBS for 30 minutes.  Without 
washing, samples were then incubated with a primary antibody solution (appropriately 
diluted in a blocking buffer containing species-specific serum) for 1 hour. (Appendix 6).  
Species-specific serum was chosen to match the species in which the relevant secondary 
antibody was raised.  Cells were then washed 3 x 5 minutes in PBS.  A secondary antibody 
solution appropriate to each primary antibody was made by appropriate dilution of secondary 
antibody in blocking solution.  Cells were incubated with secondary antibody solution for 1 
hour and then washed 3 x 5 minutes in PBS.  Nuclear DNA was counterstained with 4’, 6’-
diamidino-2-phenyl-indole dihydrochloride (DAPI) in hard setting mounting media (Dako, 
Ely, UK).  Slides were mounted on glass coverslips and sealed with transparent nail varnish 
(Rimmel, London, UK).  In each experiment antibody-conjugated fluorophores were 
carefully chosen to avoid overlap between excitation and emission spectra.  
  
2.14.2 Actin stress fibre staining 
 
Actin stress fibre staining was performed using a modification of the general 
immunofluorescent staining protocol.  Cells were fixed and permeabilised as outlined above.  
Non-specific binding was blocked by incubation with 10% BSA in PBS.  Without washing, 
cells were then incubated in a solution containing Alexa 488-phalloidin (Invitrogen, Paisley, 
UK) in PBS (1:40 dilution) for 30 minutes and then washed 3 x 5 minutes in PBC.  Nuclear 
DNA counterstaining and slide mounting was performed as outline above (section 2.14.1). In 
selected experiments, actin stress fibre staining was included in a dual staining protocol.  In 
this setting, following the removal of the secondary antibody solution, cells were washed 3 x 
5 minutes in PBS prior to incubation with the Alexa 488-phalloidin solution. Slides were 
then washed 3 x 5 minutes in PBS prior to proceeding to nuclear DNA counterstaining and 
mounting. 
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2.14.3 Ki67 immunostaining and cell proliferative index measurement 
 
Ki67 immunostaining was performed using a modification of the general immunofluorescent 
staining protocol with polyclonal rabbit anti-Ki67 primary antibody (1:200 dilution) and 
Alexa 568-labelled goat anti-rabbit secondary antibody (1:400 dilution). Nuclear DNA was 
counterstained using DAPI hard-setting mounting media as described above.   Ki67 antigen 
is present within the cell nucleus during all active phases of the cell cycle, but is absent from 
resting cells.  Cellular proliferative index (Ki67 positive cells/ total cells) was calculated by 
direct cell counting from 15 randomly selected high magnification photomicrographs from 
Ki67- and DAPI-stained slides (n=3). 
 
2.15 MTT cell assay 
 
Assays utilising the reduction of the tetrazolium salt 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) were employed as a marker of viable cell numbers in 
proliferation and chemotherapy experiments.  The MTT reagent was purchased from Sigma 
(Poole, UK).  MTT solution (5mg/ml) in PBS was freshly prepared prior to each experiment. 
At the end of the culture period, an appropriate volume of MTT solution was added to the 
cell culture media and incubated with the cells for a further 90 minutes.  The culture media 
was then aspirated and cells washed twice in PBS.  The formazan end product was then 
solubilised in an appropriate volume of dimethyl-sulfoxide (DMSO).  The absorbance of the 
insoluble reduced formazan end product was measured at 590nm using a Biotek Synergy HT 
microplate reader (Biotek, Potton, UK).  
 
2.16 Gene silencing with siRNA transfection 
 
Specific gene silencing in Huh7 and HepG2 cells was achieved by transient transfection with 
gene targeting siRNA. Targeting and non-targeting siRNA pools (siGENOME Smartpool) 
were purchased from Dharmacon (Lafayette, USA).  Each siRNA pool consisted of 4 
annealed double-stranded RNA oligonucleotide sequences designed to silence specific target 
genes or function as non-targeting (control) siRNA.  Transfection of siRNA was performed 
using DharmaFECT 4 (Dharmacon, Lafayette, USA) according to the manufacturer’s 
instructions.  Briefly, HCC cell lines were plated in DMEM media supplemented with 10% 
FCS and penicillin/ streptomycin (Huh7: 1.5 x 104cells/ cm2 and HepG2: 3 x 104 cells/ cm2).  
The cells were then cultured overnight in standard culture conditions.  In each siRNA 
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experiment, cells were transfected using DharmaFECT 4 (Huh7: 0.05µ/100µl and HepG2: 
0.4µl/ 100µl) and siRNA at a final concentration of 50nM in antibiotic-free media.  
Transfection media was replaced after 12 hours with standard antibiotic-containing media.  
For each experiment cells were trypsinized and transferred to PA gel supports after 48 hours 
and experiments terminated at 72 hours following transfection.  Gene silencing at 72 hours 
was assessed by Western blot analysis of cell lysates using antibodies specific for FAK and 
β1-integrin (as previously described in section 2.9).      
 
2.17 Clonogenic Assays 
 
Clonogenic assays were performed using HepG2 and Huh7 cell lines.  In each experiment 
cells were plated at semi-confluent density onto PA gels in DMEM supplemented with 1% 
FCS.  After 48 hours in culture, cells either received cisplatin (HepG2 10µM/ Huh7 20µM) 
or 5-fluorouracil (5FU 25µM), or were left untreated in plating medium.  After 24 hours, the 
medium was changed to normal culture medium and the cells were incubated for a further 48 
hours, for a total of 5 days of culture.  Cells were then retrieved by trypsinization, counted 
and plated at clonal density (10,000 cells/well) into 12-well plates in normal culture medium.  
Cells were fixed at between 5 and 10 days in 4% paraformaldehyde and stained with 0.5% 
crystal violet solution.  The plates were subsequently imaged with a VersaDoc system 
(BioRad, Hercules, USA) and the numbers of individual quantities counted automatically 
using Quantify-One software (BioRad, Hercules, USA). 
 
2.18 Flow cytometric analysis 
 
Flow cytometry experiments were undertaken under the supervision of Dr Joerg Schrader 
(University of Edinburgh).  Flow cytometry was performed on Huh7 and HepG2 that had 
been cultured on PA gel supports.  Cells were dissociated from PA gel supports by 
incubation with EDTA (5mM) and subsequent trypsinization. A single cell suspension was 
generated by passing cells through a 40µM cell strainer. Non-specific antibody staining was 
blocked by incubating cells with PBS containing 10% FCS for 30 minutes on ice.  Cells were 
then washed in 1ml PBS containing 0.1% FCS prior to centrifugation (1300rpm, 5 minutes).  
The resulting cell pellet was resuspended in a primary antibody solution diluted in PBS with 
0.1% FCS and incubated on ice for 30 minutes. The following phycoerythrin-conjugated 
(PE) antibodies/ dilutions were used: CD44-PE (1:50), CD117-PE (c-kit) (1:50), CD133-PE 
(1:10), CD184-PE (CXCR-4) (1:10) and corresponding PE-labelled isotype controls.  All 
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antibodies were purchased from E-Biosciences (Hatfield, UK).  Each sample was then 
subjected to centrifugation (1300 rpm, 5 minutes) and washed three-times in 1ml PBS 
containing 0.1% FCS.  The cells were then fixed for 5 minutes in 1% paraformaldehyde 
solution.  The cells were then centrifuged (1300 rpm, 5 minutes) and resuspended in PBS 
with 0.1% FCS.  After staining and fixation cells were analysed on a FACScan analyser (BD 
Biosciences, Franklin Lakes, USA).  Data analysis was performed using FlowJo software 
(Tree-Star Inc, Ashland, USA). 
 
2.19 Statistical analysis  
 
Statistical analysis was performed using GraphPad Prism™ (GraphPad Software, La Jolla, 
USA). Mean (±standard error of mean) were calculated for each variable.  Statistical 
differences between mean values were compared using unpaired two-way student t-tests for 
parametric and Mann-Whitney test for non-parametrically distributed variables. The 
unpaired student t-test is used for comparing the means of two unmatched groups, assuming 
normal distribution.  In contrast a Mann-Whitney test is used for comparing the means of 
two unmatched groups, where the variables are non-normally distributed.  Conventionally, a 
p value of less than 0.05 is used to define results of statistical significance. For purposes of 
clarity, the number of samples/ replicates (n) used in each experiment and in calculations of 
statistical significance is clearly described in the results sections. Similarly, the nature of 
each statistical test used is stated in the legend of relevant figures in the results chapters. 
Statistical correlations between variables were made using Spearman correlation co-efficient 
(R).  The correlation co-efficient provides a measure of the degree of correlation between 
two variables. A value of 1.0 indicates a perfect correlation, whereas a value of minus 1.0 
indicates a perfect negative or inverse correlation.  A value of zero indicates that the two 
variables do not vary together at all.  A D’Agostino-Pearson normality test was used to 
determine whether the variables were normally distributed. In each case where a correlation 
co-efficient was required the data was found to be non-normally distributed and the non-
parametric Spearman correlation co-efficient was used.  In tests of correlation, the p-value 
answers the null hypothesis; if there is no correlation between two variables, what is the 
probability that a random sampling would result in a correlation co-efficient as far from zero 
as that observed in the experiment.  Conventionally, a p value of less than 0.05 is used to 
define results of statistical significance.  
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Chapter 3:  Studies to determine the effect of changes in stiffness on the 




Hepatocellular carcinoma (HCC) is a tumour that develops within the high stiffness 
environment that characterises liver fibrosis/ cirrhosis (2).  Studies using transient 
elastography have demonstrated that increased liver stiffness is a strong predictor of HCC 
development  (117, 118).  In a cohort of patient with chronic HCV infection, the cumulative 
incidence for HCC development in patients with a low baseline liver stiffness measurement 
(LSM) [<10kPa] was only 0.4% after 3 years follow-up (118).  In contrast, patients with a 
moderately elevated LSM [10.1-15kPa] had a 10% risk of HCC development over this same 
period.  HCC risk increases further at higher LSM.  Liver stiffness has conventionally been 
employed as a surrogate marker for liver fibrosis.  It is unclear whether alterations in liver 
stiffness (or the presence of liver fibrosis) are mechanistically important in promoting HCC 
development and aggressiveness (167).  Liver stiffness may in itself simply be a surrogate 
marker for chronic inflammation with its antecedent risk of DNA damage and genomic 
instability.  Previous studies have indicated that pathophysiologically relevant increases in 
matrix stiffness disrupt tissue organisation, enhance growth and promote tumour formation 
in murine models of mammary gland carcinoma (46, 155).  Similarly, increased matrix 
stiffness has been shown to enhance in vitro cell migration and proliferation in transformed 
glioma cells (184).  It has been suggested that the natural history of cancer progression, from 
tumour growth through to tumour invasion and metastasis, is accompanied by changes in 
both the mechanical properties of the cancer cell niche and intrinsic contractility of cancer 
cells (131).  Furthermore, changes in the mechanical properties of cancer cells and their 
surroundings throughout this ‘force journey’ may regulate multiple facets of cancer cell 
biology. HCC is ideally suited as a model in which to explore the link between tissue 
stiffness and cancer development.  Studies utilising transient elastography and atomic force 
microscopy have closely defined the range of stiffness values that would be encountered by 
cells during the development of liver cirrhosis and hepatocarcinogenesis.  It was the aim of 
this initial work to investigate the effect of pathophysiologically-relevant changes in matrix 
stiffness on HCC cell behaviour.  Ligand-coated PA supports were used to investigate the 
effect of changes in matrix stiffness on the morphology, differentiation and proliferation of 
HCC cells.  Ligand-coated PA gels are a valuable experimental tool, allowing separation of 
the biochemical and physical characteristics of the cell culture environment.  For the 
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purposes of these studies matrix stiffness (expressed as shear modulus G') was modelled 
across the range 1-12kPa, corresponding to the physical characteristics of liver tissue during 
the transition from a normal to a cirrhotic liver.   
 
A further aim of these studies was to investigate whether alterations in the stiffness of the 
cancer cell niche might influence susceptibility to chemotherapeutic agents.  A diagnosis of 
HCC continues to impose a poor prognosis, with a mean survival from diagnosis of less than 
12 months (9-11).  This is a reflection of both late presentation and a lack of available 
treatments.  Tumour recurrence, occurring months or years following resection of a primary 
tumour, limits the effectiveness of both hepatic resection and liver transplantation (12-14).  
Chemotherapy has been shown to be ineffective in the treatment of disseminated HCC and in 
an adjuvant/ neoadjuvant setting for eradication of disseminated (dormant) tumour cells.  
The mechanisms responsible for chemotherapy resistance in HCC are incompletely 
characterised.  While, it has been demonstrated that the composition of the ECM can 
enhance chemotherapy resistance in a range of epithelial cancers, the influence of matrix 
stiffness has not been addressed (183, 221).  It was therefore my intention to undertake 
preliminary studies to assess whether pathophysiologically-relevant changes in matrix 




• Changes in matrix stiffness across a pathophysiologically-relevant range will 
modulate HCC cell morphology and cytoskeletal organisation. 
• Increases in matrix stiffness will promote HCC cell proliferation. 
• Changes in matrix stiffness will modulate the activity of cytokine-mediated 
signalling pathways, including ERK, PKB, Akt and STAT3. 
• Changes in matrix stiffness will modulate chemotherapy-resistance in HCC cells. 
• Alterations in matrix stiffness will modulate the frequency of stem cell marker 
expression in HCC cell lines.  
 
3.2. Changes in matrix stiffness modulate cell morphology in HCC cells 
 
In experiments conducted in both Huh7 and HepG2 cells, a consistent morphological 
response was observed in response to changes in support stiffness.  HCC cells cultured on 
soft (1kPa) supports were small and rounded.  In contrast HCC cells on stiff (12kPa) 
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supports were flattened and well-spread with prominent cellular processes (Figure 3.1).  The 
effect of support stiffness on cell spreading was quantified with detailed measurement of 
projected cell surface area across a range of stiffness values (1-12kPa).  For the purpose of 
comparison, measurements were also taken on cells cultured on identically-treated collagen-
I-coated glass coverslips.  This is a relevant control as matrix-coated glass is conventionally 
employed for the purpose of cell culture.  The physical characteristics of matrix-coated glass 
are highly non-physiological, with shear modulus expressed in the gigapascal range. 
In Huh7 cells, mean projected surface area increased from 870µm2 on 1kPa supports to 
1413µm2 on 12kPa supports (p<0.001).  Similarly, HepG2 projected surface area on 1kPa 
supports was 322µm2, rising to 648µm2 on 12kPa supports (p<0.001).  In each case, maximal 
cell spreading was observed for cells cultured on collagen-I-coated glass.  However, the 
incremental component of the increase in cell spreading that was observed as a quasi-linear 
function of increasing support stiffness, occurred across a pathophysiologically-relevant 
range (1-12kPa).  
 
The results for projected surface area (value ± SEM) in Huh7 cells are: 1kPa, 870 ± 11.6µm2; 
2.5kPa, 1104 ±62.6 µm2; 12kPa, 1413 ± 85.0 µm2; and glass, 1480 ± 151 µm2.  For HepG2 
cells the values were: 1kPa 322 ± 17.8 µm2; 2.5kPa 387 ± 19.3 µm2; 12kPa, 648 ± 34.0 µm2; 
and glass, 857 ± 81.0 µm2. 
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Figure 3.1:  Phase contrast photomicrographs (x200 magnification) demonstrating the effect of 
changes in PA support stiffness (1-12kPa) on cellular morphology in (A) Huh7 and (B) HepG2 cells. 
Prominent cellular processes of cells on 12kPa gels are indicated by the white arrows. The projected 
surface area (square microns) of (C) Huh7 and (D) HepG2 cells was calculated by digital image 
analysis of phase contrast images of cells on collagen-I-coated PA supports and collagen-I-coated 
glass coverslips.  In each case, the bars represent the mean (±SEM) of measurements from 50 cells 
(n=50) randomly selected from photomicrographs of cells cultured from PA gels in three independent 
experiments. Mean measurements were compared using an unpaired student t test (*p<0.05, **p<0.01 
and ***p<0.001). 
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A time-course analysis of cellular spreading was performed in Huh7 and HepG2 cells plated 
onto 1kPa and 12kPa supports (Figure 3.2).  Differences in cell spreading, as a function of 
support stiffness, develop rapidly (within 1 hour).  The results for cell spreading (value ± 
SEM) in Huh7 cells are: 1 hour, 1kPa 408 ± 24.5µm2 / 12kPa 1749 ± 165.4µm2; 6 hours, 
1kPa 828 ± 65.2µm2 / 12kPa 2453 ±199.1µm2; 24 hours, 1kPa 773 ± 49.4/ 12kPa 2610 ± 
220.6.  In HepG2 cells, a similar trend is seen: 1 hour, 1kPa 200 ± 10.8µm2 / 12kPa 305 ± 
23.6µm2; 6 hours, 1kPa 214 ± 8.3µm2 / 12kPa 498 ±28.9µm2; 24 hours, 1kPa 230 ± 11.7µm2/ 
12kPa 680 ± 35.8µm2.    In order to assess whether differences in cell proliferation might be 
sufficient to account for the observed differences in cell spreading between PA supports, cell 
spreading was measured in the presence of low dose mitomycin c (100-200nM).  The dose of 
mitomycin c used (Huh7 100nM/ HepG2 200nM) was informed by dose finding experiments 
(data not shown).  No change in the relationship between cell spreading and support stiffness 
was observed following pharmacological inhibition of cell division with mitomycin c. For 
Huh7 cells mean projected surface area after 24 hours in the presence of mitomycin c was: 
1kPa 698 ± 50.0 µm2 / 12kPa 2614±223.2µm2.  In HepG2 cells mean projected surface area 









Figure 3.2 Graphs showing a time-course analysis of cell spreading of (A) Huh7 and (B) HepG2 cells 
plated on 1kPa and 12kPa collagen-I-coated PA supports in low serum conditions.  In each case, the 
projected surface area (square microns) of the cells was measured by digital image analysis of phase-
contrast images of cells on PA supports. In each case, the bars represent the mean (±SEM) of 
measurements from 50 cells (n=50) randomly selected from photomicrographs of cells cultured from 
PA gels in three independent experiments. Mean measurements were compared using an unpaired 
student t test.   In control experiments, cell spreading was measured in the presence of mitomycin c (as 
indicated) at concentrations sufficient to inhibit cell division (Huh7 100nM/ HepG2 200nM). 
 
 67 
3.3. Increased matrix stiffness promotes epithelial-mesenchymal transition in 
HCC cells 
 
Confocal microscopy was employed to investigate the effect of changes in matrix stiffness 
on cytoskeletal organisation.  Increasing matrix stiffness was associated with formation of 
prominent actin stress fibres terminating in mature (vinculin-positive) focal adhesions in 
both Huh7 and HepG2 cells (Figure 3.3).  These features are absent in HCC cells cultured on 
1kPa supports.  In Huh7 cells stress fibres (green) terminate in discreet focal adhesions (red).  
This is less obvious in the smaller HepG2 cells that do not form prominent stress fibres.  Co-
localisation of actin-positive stress fibres and vinculin is indicated by overlapping (yellow) 
staining. 
 
The appearance of stress fibres has been linked to the acquisition of a mesenchymal 
phenotype (epithelial-mesenchymal transition).  To investigate this further, immunoblot 
analysis was performed against a panel of markers of epithelial-mesenchymal transition 
(Figure 3.4).  HCC cells cultured on 12kPa supports showed upregulation of the 
mesenchymal markers N-cadherin (Huh7/ HepG2) and vimentin (Huh7) in comparison to 
cells maintained on 1kPa supports.  HepG2 cells did not express vimentin under either 
condition.  There was no difference in the expression of the epithelial marker E-cadherin.  
Huh7/ HepG2 cells maintained on 1kPa supports had higher expression of albumin, 
hepatocyte nuclear factor-4α (HNF4α), α1-antitrypsin and alpha-fetoprotein (AFP) than cells 
from stiff supports.  Overall, the results suggest that alterations in environmental stiffness 
may be important in regulating differentiation in HCC cells.  A soft environment, modelling 
the physical characteristics of the normal liver, promotes a differentiated hepatocyte 
phenotype.  In contrast, increasing support stiffness is associated with loss of differentiated 
epithelial cell function and a transition towards a mesenchymal phenotype.     
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Figure 3.3: The effect of PA support stiffness on stress fibre and focal 
adhesion organisation in Huh7 and HepG2 cells 
 
 
Figure 3.3:  Confocal photomicrographs (x320 magnification) of (A/B) Huh7 and (C/D) HepG2 cells 
cultured on 1kPa and 12kPa collagen-I-coated PA supports, as indicated.  Cells have been stained for 
the presence of actin stress fibres (phalloidin-green), mature focal adhesions (anti-vinculin-red) and 
nuclear DNA (4',6'-diamidino-2-phenyl-indole dihydrochloride (DAPI)-blue).  The merged images are 
reconstructed from stacked images to demonstrate the spatial relationship between actin stress fibres 
and mature focal adhesions.  Inserts show high magnification images of cells cultured on 12kPa 
supports, highlighting the insertion of stress fibres (green) into mature (vinculin-positive) focal 
adhesions (blue).  This is less convincingly demonstrated in the HepG2 cells.  In each image, the scale 
bar represents 20 microns.  
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Figure 3.4: Western blot analysis demonstrating the effect of changes in PA 
stiffness on Huh7/ HepG2 differentiation  
 
Figure 3.4: (A) Western blots from whole cell lysates showing expression of E-cadherin, N-cadherin 
and vimentin in Huh7/ HepG2 cells cultured on 1kPa and 12kPa collagen-I-coated PA supports (as 
indicated).  (B)  Western blots from whole cell lysates showing expression of albumin, HNF4α, α1-
antitrypsin and AFP in Huh7/ HepG2 cells.  In each Western blot equal quantities of protein were 
loaded and equal loading confirmed in relation to glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) expression.  The immunoblots shown are representative examples from 3 independent 
experiments.   
 
It has been proposed that epithelial-mesenchymal transition (EMT) is an important process 
in the development and progression of cancer. EMT is associated with alterations in cells 
that contribute to cell migration and metastasis (222).   Transforming growth factor-β 
(TGFβ) has been implicated in both the initiation and maintenance of EMT (223).  
Experiments were therefore performed to investigate whether matrix stiffness regulated 
TGFβ-induced Smad signalling in HCC cells.  Huh7 cells were plated on soft (1kPa) and 
stiff (12kPa) collagen-I-coated PA supports.  After 48 hours of culture in low serum 
conditions, the cells were treated with TGFβ (5ng/ml).  Cell lysates were then harvested for 
immunoblot analysis at baseline, 1 hour and 48 hours.  Huh7 cells cultured on stiff supports 
demonstrated increased basal activity of the TGFβ signalling pathway, as indicated by 
increased Smad3 phosphorylation.  Furthermore, following TGFβ stimulation there was 
enhanced Smad2 and Smad3 phosphorylation in cells from stiff supports.  However, 
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densitometry analysis did not demonstrate any statistically significant difference between 
TGFβ-induced pSMAD2 and pSMAD3 (relative to GAPDH staining) on 1kPa and 12kPa 
supports at the time points analysed. 
 
Figure 3.5: Time-course analysis of Smad2/3 signalling in response to TGFß 




Figure 3.5: (A) Western blots from whole cell lysates of Huh7 cells showing the expression of 
phosph-Smad2, phospho-Smad3 and total Smad2/3 following stimulation with TGFβ (5ng/ml).  In 
each Western blot, equal quantities of protein were loaded and equal loading was confirmed in 
relation to GAPDH expression.  The Western blots shown are representative examples from 3 
independent experiments.  (B)  Line graphs showing schematic representation of phosphorylated 
Smad2 and Smad3, expressed relative to GAPDH.  Each line represents the mean of 3 independent 
experiments. The dot plots show the densitometry values of pSMAD2 and pSMAD3 staining relative 
to GAPDH in individual experiments (blue circles – 1kPa / black triangles – 12kPa). There were no 
significant differences between TGFβ-induced pSMAD2 and pSMAD3 upregulation on the 1kPa and 
12kPa supports (unpaired student t-test). 
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3.4. Increased matrix stiffness promotes proliferation in HCC cells 
 
In both Huh7 and HepG2 cells, increases in matrix stiffness regulate cell proliferation 
(Figure 3.6).  The proliferative index of HCC cells was assessed by nuclear localisation of 
Ki67 antigen.  The proliferative index of HCC cells increased as a function of increasing 
support stiffness. The proliferative index (value ±SEM) for Huh7 cells on supports of 
different stiffness were: 1kPa, 0.220 ± 0.015; 2.5kPa, 0.477 ± 0.035; 12kPa, 0.587 ± 0.007; 
and glass, 0.687 ± 0.028.  The proliferative index (value ±SEM) for HepG2 cells on supports 
of different stiffness were: 1kPa, 0.054 ± 0.003; 2.5kPa, 0.557 ± 0.008; 12kPa, 0.156 ± 
0.003; and glass, 0.692 ± 0.011.  In Huh7 and HepG2 cells respectively, the proliferative 
index was 2.7-fold (p<0.001) and 12.2-fold (p<0.001) higher when cells were cultured on 
12kPa versus 1kPa supports.  Mean measurements were compared using an unpaired student 
t test (n=3).  Maximal proliferation was observed when cells were cultured on collagen-I-
coated glass.  However, the major part of the observed increase in cell proliferation occurred 
across a pathophysiological range of stiffness values, as would be encountered by cells 
during the development of liver fibrosis.  In parallel experiments, Huh7 and HepG2 cells 
were cultured on PA supports of defined stiffness (1-12kPa) for 5 days at identical initial 
plating density. MTT assay confirmed that there was an increase in total cell number/ 
viability as a function of increasing support stiffness. The absorbance measurement (580nm) 
was standardised to the value obtained in experiments conducted on 1kPa supports. In Huh7 
cells the absorbance ratios (value ± SEM) were: 1kPa, 1.000 ± 0.034; 2.5kPa, 1.600 ± 0.072; 
12kPa, 1.480 ± 0.052; and glass, 2.047 ± 0.106.  In HepG2 cells the absorbance ratios (value 
± SEM) were: 1kPa, 1.000 ± 0.037; 2.5kPa, 1.384 ± 0.135; 12kPa, 1.702 ± 0.136; and glass, 
1.802 ± 0.143. Mean measurements were compared using an unpaired student t test (n=9).   
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Figure 3.6: The effect of changes in PA support stiffness on proliferation in 




Figure 3.6: (A) Bar graphs showing the mean proliferative index (Ki67 positivity) of Huh7 and 
HepG2 cells cultured on collagen-I-coated PA supports across a pathophysiologically-relevant range 
(1-12kPa), as indicated, and collagen-I-coated glass (n=3). Mean measurements from 3 experiments 
were compared using an unpaired student t test.   The cell counting data from which these graphs are 
derived is from presented in Appendix 7.  (B) Bar graphs showing MTT assay measurements 
(representative of total cell number/ viability) of Huh7 and HepG2 cells cultured for 5-days on 
collagen-I-coated PA supports and collagen-I-coated glass (n=9). Mean measurements from 9 
experiments (n=9) were compared using an unpaired student t test.   Error bars are SEM, *p<0.05, 
**p<0.01 and ***p<0.001. 
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Experiments were also performed to investigate whether the effect of cell plating density on 
the stiffness-dependent regulation of cell proliferation (Figure 3.7).  In both Huh7 and 
HepG2 cells, differences in proliferative index (Ki67-positivity) as a function of matrix 
stiffness were seen across a wide-range of plating densities (1000-25000 cells/cm2).  The 
values for proliferative index (value ± SEM) for Huh7 cells at different plating densities 
were: 1000 cells/mm2, 1kPa 0.175 ±0.025/ 12kPa 0.368 ±0.024; 5000 cells/mm2, 1kPa 0.106 
±0.019/ 12kPa 0.442 ±0.044; and 25000 cells/mm2, 1kPa 0.210 ±0.028/ 12kPa 0.533 ±0.003.  
The values for proliferative index (value ± SEM) for HepG2 cells at different plating 
densities were: 1000 cells/mm2, 1kPa 0.161 ±0.032/ 12kPa 0.595 ±0.028; 5000 cells/mm2, 
1kPa 0.250 ±0.031/ 12kPa 0.672 ±0.007; and 25000 cells/mm2, 1kPa 0.332 ±0.014/ 12kPa 
0.639 ±0.024.     
 
Figure 3.7: The effect of cell plating density on the stiffness-dependent 




Figure 3.7: Graphs showing the effect of initial cell plating density on the mean proliferative index 
(Ki67-positivity) of (A) Huh7 and (B) HepG2 cells cultured on 1kPa (white) and 12kPa (black) 
collagen-I-coated PA supports.  In these experiments, both Huh7 and HepG2 cells were plated at 3 
initial plating densities (1000-25000 cells/cm2), as indicated.  The proliferative index was calculated 
following 48 hours culture (n=3 for each condition).  Mean measurements were compared using an 
unpaired student t test. Error bars represent SEM, **p<0.01 and ***p<0.001. The cell counting data 
from which these graphs are derived is presented in Appendix 8. 
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Experiments were subsequently performed to investigate whether differences in the 
biochemical composition of the ECM altered the fundamental relationship between cell 
proliferation and support stiffness.  This was necessary in order to exclude the possibility of 
a specific effect related to collagen-I.  Both Huh7 and HepG2 cells were therefore cultured 
on PA supports coated with a range of matrix proteins including: collagen-I, collagen-IV, 
laminin and fibronectin.  In both cell types, minor differences were observed in respect to 
cellular morphology and spreading between supports of defined stiffness coated with 
different matrix proteins (Figure 3.8).  In Huh7 cells the values for projected surface area 
(value ± SEM) for the different support stiffness and matrix proteins were: collagen-1, 1kPa 
829 ± 61µm2/ 12kPa 1556 ± 92µm2; collagen-IV, 1kPa 970 ± 62µm2/ 12kPa 2109 ± 128µm2; 
laminin, 1kPa 1007 ± 51µm2/ 12kPa 2632 ± 151µm2; and fibronectin, 1kPa 1038 ± 59µm2/ 
12kPa 1604 ± 125µm2. In HepG2 cells the values for projected surface area (value ± SEM) 
for the different support stiffness and matrix proteins were: collagen-1, 1kPa 377 ± 24µm2/ 
12kPa 501 ± 36µm2; collagen-IV, 1kPa 327 ± 20µm2/ 12kPa 569 ± 29µm2; laminin, 1kPa 
283 ± 18µm2/ 12kPa 667 ± 32µm2; and fibronectin, 1kPa 214 ± 13µm2/ 12kPa 381 ± 28µm2.  
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Figure 3.8: The effect of ECM composition on Huh7/ HepG2 cell spreading on 
ligand-coated PA supports 
 
 
Figure 3.8: The effect of ECM composition on HCC cell spreading.  Graphs showing the projected 
surface area (square microns) of (A) Huh7 and (B) HepG2 cells cultured on 1kPa (white) and 12kPa 
(black) PA supports coated with collagen-I, collagen-IV, laminin and fibronectin (as indicated).  
Projected surface area was calculated by digital image analysis of phase contrast images.  In each case 
the bars represent the mean (±SEM) of measurements from 50 cells (n=50) randomly selected from 
photomicrographs of cells cultured from PA gels in three independent experiments. Mean 
measurements were compared using an unpaired student t test.  Error bars represent SEM, **p<0.01 
and ***p<0.001.  
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The biochemical composition of the surface ligand did not significantly alter the stiffness-
dependent regulation of cell proliferation (Figure 3.9).  Across the range of matrix proteins 
tested, it was the physical rather than the biochemical properties of the PA gels that exerted 
the predominant effect on cell proliferation.   In Huh7 cells the values for proliferative index 
(value ± SEM) for the different support stiffness and matrix proteins were: collagen-1, 1kPa 
0.297 ± 0.030/ 12kPa 0.659 ± 0.026; collagen-IV, 1kPa 0.251 ± 0.046/ 12kPa 0.637 ± 0.017; 
laminin, 1kPa 0.316 ± 0.017/ 12kPa 0.774 ± 0.022; and fibronectin, 1kPa 0.283 ± 0.001/ 
12kPa 0.762 ± 0.031.  In HepG2 cells the values for proliferative index (value ± SEM) for 
the different support stiffness and matrix proteins were: collagen-1, 1kPa 0.128 ± 0.001/ 
12kPa 0.641 ± 0.006; collagen-IV, 1kPa 0.105 ± 0.005/ 12kPa 0.637 ± 0.008; laminin, 1kPa 
0.111 ± 0.005/ 12kPa 0.642 ± 0.008; and fibronectin, 1kPa 0.156 ± 0.007/ 12kPa 0.651 ± 
0.007. 
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Figure 3.9: The effect of ECM composition on Huh7/ HepG2 proliferation on 




Figure 3.9: The effect of ECM composition on HCC cell proliferation as a function of support 
stiffness.  Graphs showing the mean proliferative index (Ki67-positivity) of (A) Huh7 and (B) HepG2 
cells on 1kPa (white) and 12kPa (black) PA supports coated with collagen-I, collagen-IV, laminin and 
fibronectin (n=3). Mean measurements were compared using an unpaired student t test. Error bars 
represent SEM, **p<0.01 and ***p<0.001. The cell counting data from which these graphs are 
derived is presented in Appendix 8.In each case error bars represent SEM and ***p<0.001. The cell 
counting data from which these graphs are derived is presented in Appendix 9. 
 
It was my hypothesis that stiffness-dependent regulation of cell proliferation may be a 
fundamental mechanism in promoting tumour development across a range of epithelial 
malignancies.  Experiments were therefore performed to establish the effect of changes in 
support stiffness on cell morphology and proliferation across a range of epithelial cancer cell 
lines, including prostate, breast and lung adenocarcinoma cell lines (Figure 3.10).  In each 
case, increasing matrix stiffness promoted enhanced cell spreading and proliferation.   
 
In respect to cell spreading, the values (mean ± SEM) for projected surface area between 
1kPa and 12kPa supports in different cell lines were: LNCAP, 1kPa 225 ± 12µm2/ 12kPa 451 
± 15µm2; A549, 1kPa 183 ± 9 µm2/ 12kPa 530 ± 31µm2; MCF7, 1kPa 223 ± 10µm2/12kPa 
687 ± 63µm2; MDA, 1kPa 301 ± 13µm2/ 12kPa 881 ± 50µm2; HepG2, 1kPa 322 ± 18µm2/ 
12kPa 648 ± 34µm2; and Huh7, 1kPa 869 ± 134µm2/ 12kPa 1413 ± 85µm2. 
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In respect to proliferation, the values (mean ± SEM) for proliferative index between 1kPa 
and 12kPa supports in different cell lines were: LNCAP, 1kPa 0.144 ± 0.036/ 12kPa 0.687 ± 
0.086; A549, 1kPa 164 ± 0.008/ 12kPa 0.783 ± 0.058; MCF7, 1kPa 0.147 ± 0.037/12kPa 
0.793 ± 0.416; MDA, 1kPa 0.083 ± 0.011/ 12kPa 0.650 ± 0.021; HepG2, 1kPa 0.054 ± 
0.003/ 12kPa 0.656 ± 0.003; and Huh7, 1kPa 0.220 ± 0.015/ 12kPa 0.587 ± 0.007. 
 
Figure 3.10: The effect of PA support stiffness on cellular spreading and 




Figure 3.10: (A) Graph showing the effect of changes in PA support stiffness on cell spreading in 
LNCap (prostate), A549 (lung adenocarcinoma), MCF7 (breast), MDA (breast), HepG2 (HCC) and 
Huh7 (HCC) epithelial cancer cells.  Cancer cells were cultured on 1kPa (white) or 12kPa (black) 
collagen-I-coated PA supports.  Cell spreading (projected surface area) was calculated by digital 
image analysis of phase contrast images.  In each case, the bars represent the mean (±SEM) of 
measurements from 50 cells (n=50) randomly selected from photomicrographs of cells cultured from 
PA gels in three independent experiments. Mean measurements were compared using an unpaired 
student t test (n= 50).    (B) Graph showing the mean proliferative index (Ki67-positivity) of human 
epithelial cancer cell lines as a function of PA support stiffness (as detailed above). In each case, 
values represent the mean (±SEM) of measurements from three independent experiments. Mean 
measurements (n=3) were compared using an unpaired student t test (***p<0.001). The cell counting 
data from which these graphs are derived is presented in Appendix 10. 
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3.5 The effect of matrix stiffness on cell cycle regulation in HCC cells 
 
Having established that physiological changes in matrix stiffness regulate HCC cell 
proliferation, experiments were undertaken to investigate the effect of changes in matrix 
stiffness on the expression of cell cycle regulators of G1 progression (Figure 3.11).  
Immunoblot analysis revealed a strong reduction in the expression of cyclin D1 and cyclin-
D3 in Huh7/ HepG2 cells cultured on 1kPa versus 12kPa supports.  The reduction in cell 
proliferation seen in Huh7 and HepG2 cells maintained on 1kPa supports was not 
accompanied by upregulation of the cyclin-dependent kinase inhibitors p21cip or p27kip.  
Indeed, a modest downregulation of p27kip was observed for both cell lines when maintained 
on 1kPa versus 12kPa supports.  Overall, the results suggest that physiological stiffness 
(modelling that encountered in the normal liver) is inhibitory to cell cycle progression.  
Conversely, increased matrix stiffness promotes G1 progression with an associated increased 
in cyclin D1/D3 expression.  Induction of terminal senescence on 1kPa supports was 
excluded by showing that on transfer to a stiff environment (tissue culture plastic) cells 
resumed proliferation to levels comparable to cells initially cultured on 12kPa supports 
(Figure 3.12).  In Huh7 cells, the values for proliferative index on tissue culture plastic 
(value ± SEM) for cells pre-cultured on 1kPa and 12kPa supports were: 1kPa, 0.645 ± 0.019 
and 12kPa, 0.631 ±0.033, p = 0.73).  In HepG2 cells, the values for proliferative index on 
tissue culture plastic (value ± SEM) for cells pre-cultured on 1kPa and 12kPa supports were: 
1kPa, 0.639 ± 0.012 and 12kPa, 0.608 ±0.026, p = 0.34). The differences between mean 









Figure 3.11: Western blots from whole cell lysates showing expression of (A) Type D cyclins (cyclin 
D1 and D3) and (B) cyclin-dependent kinase inhibitor (p21cip/ p27kip) in Huh7 and HepG2 cells 
cultured on soft (1kPa) and stiff (12kPa) supports, as indicated. In each Western blot, equal quantities 
of protein were loaded and equal loading confirmed in relation to GAPDH expression.  The 
immunoblots displayed are representative examples from 3-6 experiments. 
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Figure 3.12: The reduction in cell proliferation observed in cells cultured on 
soft PA supports is reversible on transfer to a stiff substrate  
 
Figure 3.12:  Graph showing the mean proliferative index (Ki67-positivity) of Huh7 and HepG2 cells 
re-plated to tissue culture plastic following 5-days culture on either 1kPa (white) or 12kPa (black) 
collagen-I-coated PA supports (n=3).  Proliferative index (Ki67-postive cells/ total cells) was 
measured 2-days after re-plating.  In each case, error bars represent SEM. Mean measurements (n=3) 
were compared using an unpaired student t test (ns indicates lack of statistical significance).   Upon 
transfer to stiff tissue culture plastic, HCC cells initially cultured on a 1kPa support resume 
proliferation to levels comparable to cells coming from a 12kPa support.  The cell counting data from 




3.6 Changes in matrix stiffness regulate morphology and proliferation in 
primary murine hepatocytes 
 
Experiments were conducted with primary hepatocytes to investigate the effect of changes in 
support stiffness on cellular morphology and proliferation.  Primary hepatocytes cultured on 
stiff supports showed morphological features of de-differentiation with acquisition of a 
mesenchymal morphology with prominent cell processes, in contrast to the more polygonal 
morphology of cells maintained on 1kPa supports. There was a trend towards increased 
proliferation of hepatocytes when cultured on 12kPa versus 1kPa supports, but this result 
was not statistically significant (Figure 3.13).  The values for the number of Ki67-positive 
hepatocytes per low power field (value ± SEM) on 1kPa and 12kPa supports were: 1kPa, 
1.10 ± 0.22 and 12kPa, 2.50 ± 0.60, p=0.09). 
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Figure 3.13: The effect of PA support stiffness on cell morphology and 





Figure 3.13 Primary murine hepatocytes were cultured on 1kPa (white) and 12kPa (black) collagen-I-
coated PA supports.  The bar graph (A) shows the effect of matrix stiffness on the proliferation of 
primary murine hepatocytes.  Proliferation was assessed by the mean number of Ki67 positive cells 
per low power field after 48 hours in culture. Mean measurements (n=3) were compared using an 
unpaired student t test.  Error bars are SEM, p values are as indicated. The photomicrographs 
displayed show phase contrast images of primary murine hepatocytes cultured on (B) 1kPa and (C) 
12kPa supports. 
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3.7 Matrix stiffness regulates basal and HGF-induced signalling responses 
 
It has previously been demonstrated that increasing matrix stiffness promotes growth factor-
induced ERK activation in an in vitro model of murine mammary cancer (155).  Experiments 
were therefore undertaken to determine whether matrix stiffness might regulate growth 
factor-induced mitogenic signalling in HCC cells. Huh7 and HepG2 cells were cultured on 
1kPa and 12kPa collagen-I-coated PA supports for 24 hours in low serum conditions.  
Western blot analysis of whole cell lysates was then undertaken to investigate stiffness-
dependent differences in the basal activity of critical mitogenic pathways, including FAK, 
STAT3 and PKB/Akt.  In comparison to cells maintained on 1kPa supports, HCC cells 
cultured on 12kPa supports demonstrated increased basal levels of FAK, STAT3 and PKB/ 
Akt phosphorylation (Figure 3.14 A).   
 
Subsequent experiments were undertaken to investigate whether matrix stiffness modulates 
cyclin D1 expression following hepatocyte growth factor (HGF) stimulation. Huh7 and 
HepG2 cells were cultured on 1kPa and 12kPa PA supports for 24 hours in the presence or 
absence of HGF (10ng/ml).  Western blot analysis was then used to assess cyclin D1 
expression.  In each cell type, HGF stimulation was associated with increased cyclin D1 
expression, but the magnitude of cyclin D1 upregulation was substantially higher in cell 
cultured on 12kPa supports (Figure 3.14 B). 
 
 85 






Figure 3.14: (A) Western blots showing basal expression of phosphorylated and total focal adhesion 
kinase (FAK), extracellular-regulated kinase (ERK), protein kinase B (PKB/Akt) and signal 
transducer and activator of transcription 3 (STAT3) in Huh7 and HepG2 cells cultured for 24 hours in 
low serum conditions on 1kPa and 12kPa collagen-I-coated PA supports, as indicated.  (B) Western 
blots showing cyclin D1 expression in Huh7 and HepG2 cells cultured for 24 hours on PA supports 
(1-12kPa) in the presence (+) and absence (-) of HGF (10ng/ml). 
 
 
Experiments were then performed to investigate how support stiffness might regulate growth 
factor-induced mitogenic signalling in response to HGF stimulation.  HCC cells were 
cultured on 1kPa and 12kPa supports for 24 hours and then subjected to HGF stimulation 
(10ng/ml).  An increase in the magnitude of ERK, STAT3 and PKB/Akt phosphorylation 
following HGF stimulation was observed in both Huh7 (Figure 3.15) and HepG2 cells 
(Figure 3.16) cultured on 12kPa versus 1kPa supports.  These results would suggest that the 




Figure 3.15: The effect of matrix stiffness on HGF-induced mitogenic 




Figure 3.15: Western blots showing a time-course analysis for expression of phosphorylated and total 
ERK, PKB/Akt and STAT3 in Huh7 cells cultured on 1kPa and 12kPa collagen-I-coated PA supports.  
Whole cell lysates were harvested at baseline and specific time points (as indicated) following the 
addition of HGF (10ng/ml) to culture media.  The line graphs (right panel) showing densitometry 
analysis of phosphorylated ERK, PKB/Akt and STAT3 expression relative to GAPDH.  Individual 
replicates are represented as blue circles (1kPa) and black triangles (12kPa).  The line (blue 
continuous- 1kPa/ black dotted- 12kPa) represents the mean of the 3 independent experiments (n=3). 
At each time point, there was no significant difference between pSMAD2 and pSMAD3 expression 
(relative to GAPDH) between 1kPa and 12kPa supports (unpaired student t-test). 
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Figure 3.16: The effect of matrix stiffness on HGF-induced mitogenic 




Figure 3.16: (A) Western blots showing a time-course analysis for expression of phosphorylated and 
total ERK, PKB/Akt and STAT3 in HepG2 cells cultured on 1kPa and 12kPa collagen-I-coated PA 
supports.  Whole cell lysates were harvested at baseline and specific time points (as indicated) 
following the addition of HGF (10ng/ml) to culture media.  (B) The line graphs (right panel) showing 
densitometry analysis of phosphorylated ERK, PKB/Akt and STAT3 expression relative to GAPDH.  
Individual replicates are represented as blue circles (1kPa) and black triangles (12kPa).  The line (blue 
continuous- 1kPa/ black dotted- 12kPa) represents the mean of the 3 independent experiments (n=3). 
At each time point, there was no significant difference between pSMAD2 and pSMAD3 expression 
(relative to GAPDH) between 1kPa and 12kPa supports (unpaired student t-test). 
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3.8 Beta-1 integrin and phospho-FAKTyr397 are expressed in human HCC and 
regulate the proliferation of HCC cells in vitro 
 
FAK, the canonical mediator of integrin-based signalling, is implicated in multiple aspects of 
cancer development.  FAK activation has been linked to the modulation of multiple 
downstream signalling pathways including ERK, PKB/ Akt, Rho and Rac (177, 224).  
Experiments were undertaken to investigate the prevalence of β1-integrin and phospho-
FAKTyr397 expression in HCC specimens.  Immunohistochemistry studies were performed on 
an unselected cohort of 15 human HCC specimens (Tayside Tissue Bank), obtained at the 
time of tumour resection or biopsy (Figure 3.17).  β1-integrin was expressed in 15/15 of the 
specimens tested.  There was increased phospho-FAKTyr397 staining in tumour tissue, relative 
to the surrounding liver parenchyma in 8/15 (53%) of the HCC specimens.  These results are 
consistent with published histological studies that have analysed patterns of β1-inetgrin and 
FAK expression in HCC (225, 226).  
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Figure 3.17: β1 Integrin and phospho-FAKTyr397 are expressed in human HCC specimens.  (A) Low 
lower (x50 magnification) photomicrographs of HCC specimens stained with haematoxylin and eosin 
(left panel), anti-β1-integrin (centre panel) and anti-phospho-FAKTyr397 (right panel).  Negative control 
(isotype) staining is represented by the indented images in the top right corner of each image.  β1-
integrin is expressed in both the tumour tissue (HCC) and surrounding normal parenchyma.  Phospho-
FAKTyr397 is strongly expressed in the tumour tissue relative to parenchyma (P).  Scale bar represents 
200 microns.  (B) Table showing the prevalence of β1-integrin and phospho-FAKTyr397 
immunostaining in HCC tumour tissue in a cohort of human HCC resection/ biopsy specimens (n=15). 
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Experiments were subsequently conducted to determine the effect of inhibition of β1-integrin 
and FAK function on the proliferation of Huh7 and HepG2 cells in vitro.  β1-integrin was 
disrupted using a function blocking anti-β1-integrin antibody (6S6) and the dysintegrin, 
echistatin (Figure 3.18).  Treatment with both the anti-β1-integrin (6S6) and echistatin 
promoted cellular rounding in Huh7 and HepG2 cells cultured on collagen-I-coated 12kPa 
PA supports.  Cell proliferation was assessed by determination of proliferative index after 
Ki67 immunohistochemistry (Ki67-positivity).  
 
In Huh7 cells (Figure 3.18A), the values for proliferative index (value ±SEM) under each 
experimental condition were: untreated control, 0.413 ± 0.019; isotype control, 0.426 ± 
0.026; echistatin (100nM), 0.293 ± 0.060; and 6S6 (50µg/ml), 0.265 ± 0.043.  Huh7 
proliferation was reduced by treatment with both 6S6 antibody (38% reduction, p<0.05) and 
echistatin (29% reduction, p=0.07) relative to relevant controls.   
 
In HepG2 cells (Figure 3.18B), the values for proliferative index (value ±SEM) under each 
experimental condition were: untreated control, 0.624 ± 0.010; isotype control, 0.658 ± 
0.024; echistatin (100nM), 0.495 ± 0.022; and 6S6 (50µg/ml), 0.078 ± 0.019.  In HepG2 
cells, cell proliferation was reduced by both 6S6 antibody (92% reduction, p<0.001) and 
echistatin (21% reduction, p<0.01).   
 
The effect of FAK on HCC cell proliferation was investigated in experiments conducted with 
the small molecular FAK inhibitor PF573228.  PF573228 binds to the ATP-binding pocket 
of FAK and effectively blocks FAK catalytic activity (227).  Treatment of cells with 
PF573228 inhibits the auto-phosphorylation of tyrosine 397 and downstream activities of 
FAK.  There are conflicting reports as to the effect of FAK inhibition on cancer cell 
proliferation (227-229).   
 
Treatment of Huh7 and HepG2 cells with PF537228 (1-5µM) resulted in a demonstrable 
reduction on FAK phosphorylation at tyrosine 397 (Figure 3.18C).  Similarly, treatment of 
both Huh7 and HepG2 cells with PF537228 (1-5µM) was associated with a reduction in cell 
proliferation.  In Huh7 cells under each experimental condition (Figure 3.18A), the values 
for proliferative index (value ± SEM) were: DMSO control, 0.393 ± 0.035; PF537228 
(1µM), 0.338 ± 0.033; and PF537228 (5µM), 0.228 ±0.026.  In HepG2 cells under each 
experimental condition (Figure 3.18B), the values for proliferative index (value ± SEM) 
were: DMSO control, 0.680 ± 0.021; PF537228 (1µM), 0.465 ± 0.010; and PF537228 
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(5µM), 0.373 ±0.013.  Treatment of cells cultured on 12kPa supports with PF563228 (Figure 
3.18) at a concentration of 5µM was associated with a reduction in proliferation for both 
Huh7 (42% reduction, p<0.01) and HepG2 cells (45% reduction, p<0.001). 
These results suggested that inhibition of either β1-integrin or FAK function attenuated HCC 
cell proliferation.  In order to corroborate these findings proliferation assays were performed 
on Huh7 and HepG2 cells after siRNA-dependent knockdown of β1-integrin and FAK.  
Western blotting was used in each cell type to confirm the efficiency of siRNA knockdown 
of β1-integrin and FAK protein expression (Figure 3.19A/B).  In Huh7 cells, the values for 
proliferative index (value ± SEM) for each experimental condition were: 1kPa untreated, 
0.092 ± 0.021; 12kPa untreated, 0.536 ± 0.019; scrambled siRNA, 0.546 ± 0.036; β1-integrin 
siRNA, 0.455 ± 0.039; and FAK siRNA, 0.469 ± 0.023.  In HepG2 cells, the values for 
proliferative index (value ± SEM) for each experimental condition were: 1kPa untreated, 
0.124 ± 0.008; 12kPa untreated, 0.704 ± 0.022; scrambled siRNA, 0.734 ± 0.006; β1-integrin 
siRNA, 0.482 ± 0.051; and FAK siRNA, 0.566 ± 0.025.  In each cell type, transfection with 
scrambled siRNA did influence β1-integrin or FAK expression relative to controls.  In 
HepG2 cells (Figure 3.19D), a reduction in proliferative index was observed following 
siRNA-dependent knockdown of both β1-integrin (34% reduction, p<0.01) and FAK (23% 
reduction, p<0.001).  In Huh7 cells (Figure 3.19C), a trend towards reduced cell proliferation 
was seen following siRNA-dependent knockdown of β1-integrin and FAK, but in each case 





Figure 3.18: Inhibition of β1-integrin and focal adhesion kinase (FAK) activity 
reduces Huh7 and HepG2 cell proliferation in vitro  
 
 
Figure 3.18: Graphs showing the mean proliferative index (Ki67-positivity) of (A) Huh7 and (B) 
HepG2 cells cultured on collagen-I-coated 12kPa PA supports.  Cells were treated with echistatin 
(100nm), anti-β1-integrin antibody (6S6) (50µg/ml), isotype control IgG1 antibody (50µg/ml), 
PF573228 (1µM), PF573228 (5µM), DMSO (vehicle control) or left untreated in media (untreated 
control) for 24 hours.  The number of replicates (n) for each condition is indicated beneath the x-axis 
of each graph.  Mean measurements were compared using an unpaired student t test.  Error bars are 
SEM, *p<0.05, **p<0.01, and ***p<0.001.  (C)  Western blots showing phospho-FAKTyr397 
expression in Huh7 and HepG2 cells, either left untreated or treated with PF573228 (1-5µM), as 
indicated.  In each immunoblot, equal amounts of protein were loaded and equal loading confirmed in 
relation to GAPDH expression. The cell counting data from which these graphs are derived is 
presented in Appendix 12. 
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Figure 3.19: Inhibition of β1-integrin and FAK expression with siRNA reduces 
proliferation of Huh7 and HepG2 cells on stiff PA supports 
 
Figure 3.19: Western blots showing the expression of β1-integrin and FAK protein in (A) Huh7 and 
(B) HepG2 cells that were left untreated or transfected with siRNA for β1-integrin, FAK or control 
(scrambled sequences).  Western blots show levels of protein expression 72 hours following 
transfection.  Graphs show the mean proliferative index (Ki67-positivity) of (C) Huh7 and (B) HepG2 
cells cultured on 1kPa and 12kPa collagen-I-coated PA supports following the transfection procedure.  
Transfected cells and untreated controls were trypsinized and transferred to PA supports 48 hours 
following the transfection procedure.  Cells were fixed at 72 hours and proliferation determined by 
nuclear localisation of Ki67 antigen (n=5). Mean measurements were compared using an unpaired 
student t test.  Error bars are SEM, ns = not significant, **p<0.01 and ***p<0.001. The cell counting 
data from which these graphs are derived is presented in Appendix 13. 
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3.9. Matrix stiffness regulates chemotherapeutic response in HCC cells 
HCC is characterised by a resistance to conventional chemotherapeutic agents (9, 10).  It has 
previously shown that chemotherapy resistance in HCC is regulated by Rho pathway 
signalling.  Rho is an important regulator of cell morphology and the actin cytoskeleton that 
has been implicated in mediating cancer cell responses to changes in matrix stiffness (155).  
Experiments were conducted to determine whether alterations in matrix stiffness might 
regulate chemotherapy responses in HCC cells.  Huh7 and HepG2 cells were cultured on 
collagen-I-coated PA supports (1-12kPa) and subjected to treatment with cisplatin for up to 
24 hours.  HCC cell apoptosis was assessed by immunoblot analysis for poly-ADP-ribose 
polymerase (PARP) cleavage in whole cell lysates (Figure 3.20A).  In each cell line, 
increased susceptibility to apoptosis (PARP cleavage) was observed in cells cultured on soft 
(1kPa) supports.  In addition, there was a non-significant trend towards increased numbers of 
surviving cells following cisplatin treatment on 12kPa supports (data not shown).   
It has been suggested that tumour-initiating stem cells (TISCs) may play an important role in 
HCC development (230, 231).  TISCs have been defined in relation to four criteria : high 
efficiency self-renewal, differentiation along at least two independent lineages, 
chemotherapy-resistance and the ability to form tumours that recapitulate the original tumour 
phenotype (clonogenic potential) (232).  Clonogenic assays were used to investigate whether 
alteration in matrix stiffness might influence the survival and behaviour of TISCs following 
chemotherapy (Figure 3.20B).  Cells were cultured for 48 hours on PA supports (1-12kPa).  
The cells were then either left untreated, treated with cisplatin [HepG2 10µM/ Huh7 20µM] 
or 5FU [25µ] for 24 hours prior to a media change.  After a further 48 hours, cells were 
trypsinized and equal numbers of viable (trypan-blue excluding) cells were replated at clonal 
density in 12-well plates.  Clonogenic capacity was calculated by direct counting of the 
resulting colonies.  The results are expressed as the percentage colony formation relative to 
the number of colonies obtained from 1kPa supports.  
In Huh7 cells, the values for percentage colony formation (value ± SEM) under each 
experimental condition were: untreated, 1kPa 100 ± 8.4/ 12kPa 85.6 ± 7.6; cisplatin (20µM) 
1kPa 100 ± 8.8/ 12kPa 40.6 ± 8.8; and 5FU (25µM), 1kPa 100 ± 17.7/ 12kPa 27.8 ± 2.7.  In 
HepG2 cells, the values for percentage colony formation (value ± SEM) under each 
experimental condition were: untreated, 1kPa 100 ± 5.0/ 12kPa 103.9 ± 7.1; cisplatin (10µM) 
1kPa 100 ± 17.0/ 12kPa 44.5 ± 8.7; and 5FU (25µM), 1kPa 100 ± 19.5/ 12kPa 53.9 ± 8.4. 
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Amongst surviving viable cells following cisplatin treatment, there was an increased 
frequency of clone-initiating cells for both Huh7 (2.2-fold, p<0.05) and HepG2 cells (2.4-
fold, p<0.001) cultured on 1kPa versus 12kPa supports (Figure 3.20B).  In addition, there 
was a non-significant trend towards an increase in the total number of clone-forming cells 
derived from 1kPa versus 12kPa supports (data not shown).  The validity of these findings 
was tested in repeat experiments with a second unrelated chemotherapeutic agent, 5-
flurouracil (5FU).  Following 5FU chemotherapy, there was an increased frequency of clone-
initiating cells from Huh7 (1.9-fold, p<0.05) and HepG2 (3.6-fold, p<0.001) cultured on 
1kPa versus 12kPa supports.  In control experiments there was no difference in the frequency 
of clone-initiating cells in untreated Huh7 or HepG2 cells cultured on 1kPa versus 12kPa 
supports.  These results are intriguing.  The increase in PARP cleavage in cells cultured on 
soft (1kPa) supports might suggest that these cells are more susceptible to chemotherapy-
induced apoptosis.  However, the clonogenic assays indicate that HepG2 and Huh7 cells 
gown on 12kPa PA supports form fewer colonies than cells grown on 1kPa supports. This 
suggests that HepG2 and Huh7 are more sensitive to chemotherapy when maintained on a 
12kPa support. 
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Figure 3.20: The effect of matrix stiffness on HCC cell apoptosis and 
clonogenic potential following treatment with chemotherapeutic agents 
Figure 3.20:  (A) Western blot showing full length (116kPa) and cleaved poly-ADP-ribose 
polymerase (PARP) (89kDa) following treatment with cisplatin [HepG2 10µM/ Huh7 20µM] on 
collagen-I-coated PA supports (1-12kPa), as indicated.  The Western blots shown are representative 
examples from three independent experiments.  (B)  Graphs showing the frequency of clone-forming 
Huh7 and HepG2 cells following chemotherapy.  Huh7 and HepG2 cells were cultured for 48 hours 
on PA supports (1-12kPa).  Cells were then either left untreated (left panel) or treated with cisplatin 
[HepG2 10µM/ Huh7 20µM] (middle panel) or 5FU [25µM] (right panel) for 24 hours prior to a 
media change.  After a further 48 hours, cells were trypsinized and equal numbers of viable (trypan-
blue excluding) cells were replated at clonal density in 12-well plates.  Clonogenic capacity was 
calculated by direct counting of the resulting colonies.  The results are expressed as the percentage 
colony formation relative to the number of colonies obtained from 1kPa supports in 3 independent 
experiments (n =9).  Mean measurements were compared using an unpaired student t test.  Error bars 
are SEM, *p<0.05, ***p<0.001. 
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3.10 Matrix stiffness regulates cancer stem cell marker expression in HCC 
cells 
The increase in the clone-initiating capabilities of Huh7 and HepG2 cells from a low 
stiffness environment following chemotherapy might be explained by selective enrichment 
for clone-initiating cells with stem cell characteristics.  Experiments were therefore 
performed to investigate whether cisplatin treatment was associated with alteration in the 
frequency of stem cell marker expression.  Flow cytometric analysis was performed on 
HepG2 cells cultured on collagen-I-coated PA supports (1-12kPa), both without and 
following cisplatin chemotherapy (Figure 3.21A).   
The values for CD133 expression (percentage ± SEM) under each experimental condition 
were: untreated, 1kPa 3.27 ± 0.08/ 12kPa 2.17 ± 0.09; and cisplatin treated, 1kPa 5.10 ± 
0.32/ 12kPa 1.80 ± 0.58.  The values for c-kit expression (percentage ± SEM) under each 
experimental condition were: untreated, 1kPa 0.087 ± 0.057/ 12kPa 0.067 ± 0.033; and 
cisplatin treated, 1kPa 1.377 ± 0.186/ 12kPa 0.200 ± 0.058.  The values for CD44 expression 
(percentage ± SEM) under each experimental condition were: untreated, 1kPa 1.50 ± 0.10/ 
12kPa 0.23 ± 0.09; and cisplatin treated, 1kPa 2.53 ± 0.12/ 12kPa 0.43 ± 0.03.  The values 
for CXCR4 expression (percentage ± SEM) under each experimental condition were: 
untreated, 1kPa 10.70 ± 0.87/ 12kPa 3.67 ± 0.24; and cisplatin treated, 1kPa 12.09 ± 0.99/ 
12kPa 4.60 ± 1.00.  Culture on 1kPa versus 12kPa supports was associated with enrichment 
for the cell surface markers CD133 (2.9-fold, p<0.001), c-kit (1.3-fold, p=0.78), CD44 (6.4-
fold, p<0.001) and CXCR4 (2.9-fold, p<0.01).  Cisplatin chemotherapy (10µM) increased 
the prevalence of CD44 (1.7-fold, p<0.01), CD133 (1.6-fold, P<0.01) and c-kit (15.8-fold, 
p<0.01) cells when cells were maintained on 1kPa but not 12kPa supports.  Furthermore, 
quantitative PCR demonstrated upregulation of stem cell-associated transcription factors 
OCT4 and NANOG in HepG2 cells on 1kPa versus 12kPa supports, both in untreated 
controls (OCT4 2.0-fold increase, p<0.05; NANOG 2.7-fold increase, p<0.05) and following 
cisplatin chemotherapy (OCT4 2.0-fold increase, p<0.05; NANOG 3.4-fold, p<0.05) (Figure 
3.21B). Cisplatin treatment alone did not have any demonstrable effect on the expression of 
either OCT4 or NANOG, regardless of support stiffness.  The values for Oct4 mRNA 
expression (values ± SEM) relative to expression of the housekeeping gene 18S under each 
experimental condition were: untreated, 1kPa 3.70 ± 0.52/ 12kPa 1.82 ± 0.20; and cisplatin 
treated, 1kPa 3.71 ± 0.67/ 12kPa 1.89 ± 0.35.  Overall, these results show an increase in cells 
displaying stem cell markers when maintained on soft (1kPa) versus stiff (12kPa) supports. 
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This suggests that HCC cells maintained in a low stiffness environment may display a 
clinically more aggressive phenotype. 
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Figure 3.21: The effect of matrix stiffness and cisplatin treatment on stem cell 
marker expression in HepG2 cells  
 
Figure 3.21: (A) Graphs showing quantification by flow cytometry of cancer stem cell markers CD133, c-
kit, CD44 and CXCR-4 in HepG2 cells.  (B)  Graphs showing quantitative PCR analysis for OCT4 and 
NANOG expression in HepG2 cells.  Gene of interest expression is relative to the 18S housekeeping gene.  
In each experiment HepG2 cells were cultured for 5 days on collagen-I-coated PA supports (1-12kPa).  
Cells were either left untreated (black) or treated for 24 hours with cisplatin [10µM] (white).  Mean 
measurements were compared using an unpaired student t test (n=3). Error bars are SEM, *p<0.05, 
**p<0.01 and ***p<0.001. 
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3.11 Discussion 
The results of these experiments demonstrate that the stiffness of the sub-cellular matrix can 
regulate cell morphology, proliferation and chemotherapy resistance in HCC cells in vitro. 
Increases in matrix stiffness promote HCC cell proliferation.  Importantly, the major part of 
the increase in cell proliferation occurs across a pathophysiologically-relevant range (1-
12kPa) corresponding to the range of stiffness values encountered during the transition from 
a normal to a cirrhotic liver.  Previous epidemiological studies demonstrated a close 
relationship between increases in liver stiffness and prospective risk of HCC development 
(117, 118).  The data presented here provide evidence for a potential mechanism that may 
underlie these epidemiological findings and the results of previous in vivo studies 
demonstrating that the induction of liver fibrosis was associated with accelerated tumour 
growth following orthotopic HCC implantation (121, 122).  Overall, there is now a 
considerable body of evidence that suggests that increases in matrix stiffness associated with 
the development of liver fibrosis are mechanistically important in promoting HCC 
development. The counter to this observation is equally significant. A reduction in the 
stiffness of the cancer cell niche, as encountered by disseminated tumour cells entering an 
unaffected secondary site, might be sufficient to promote reversible cellular quiescence.   
The results of experiments in both Huh7 and HepG2 cells demonstrates that increases in 
matrix stiffness are associated with an increase in cell proliferative index.  Where the 
proliferative index increases, total cell number is also observed to increase, confirming that 
the increased proliferative index does indeed represent a higher number of cells in cycle , 
which is not balanced by increased rates of cell death. 
Physiological alterations in matrix stiffness have broad and pervasive effects in relation to 
both mitogenic signalling and cell cycle regulation.  The findings presented in this chapter 
are consistent with published results in non-transformed epithelial and mesenchymal cells, 
indicating that a moderate increase in matrix stiffness is associated with the induction of 
cyclins D1 and D3 (127, 128).  Conversely, the reduction in proliferation observed in HCC 
cells maintained on soft supports is associated with a downregulation of cyclin D expression 
without concurrent upregulation of cyclin-dependent kinase inhibitors, p21cip and p27kip. The 
expression profile of cell cycle regulators in HCC cells cultured on soft supports is in 
keeping with a quiescent G0 state.  In contrast to previous studies in which mammary 
epithelial cells (233) and fibroblasts (129) were cultured on soft collagen gel substrates, the 
stiffness-dependent reduction in cellular proliferation was not associated with an 
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upregulation of cyclin-dependent kinase inhibitors.  Overall, these findings confirm those of 
previous publications that suggest that physiological stiffness is inhibitory to cell cycle 
progression.   
 
I had postulated that alterations in mitogenic signalling responses, modified by matrix 
stiffness, may account for stiffness-dependent regulation of cellular proliferation.  Cyclin D1 
expression is strongly dependent upon the organisation of the actin cytoskeleton.  Across a 
physiological range, cells adjust the stiffness of the cytoskeleton to match that of their 
substrate (86).   A high tensional state is characterised by actin stress fibre formation.  The 
Rho-Rho kinase pathway promotes actin polymerisation and cellular contractility, thus 
promoting stress fibre development.    It has recently been suggested that G1 phase cyclin D1 
expression can be resolved into two distinct phases on the basis of cytoskeletal organisation 
(234).  Early-G1 expression of cyclin D1 (absent in mesenchymal cells) is regulated by the 
Rho-family GTPase, Rac.  Rac activation is inhibited by Rho-Rho kinase pathway activation, 
can proceed in a low tensional environment in the absence of cytoskeletal organisation and 
sustained ERK activation, but is insufficient to promote S-phase entry.  In contrast, mid-G1 
expression of cyclin D1 (occurring in epithelial and mesenchymal cells) sufficient to 
promote cell cycle progression is dependent upon co-ordinated Rac and ERK pathway 
activation.  Sustained ERK activation requires adequate intracellular tension that is in turn 
dependent upon both matrix stiffness and Rho-Rho kinase pathway activation.    In hepatoma 
cells, increasing matrix stiffness promoted the formation of both actin stress fibres and 
vinculin-containing focal adhesions in hepatoma cells.  This was associated with enhanced 
basal autophosphorylation of FAK and ERK pathway activation.  Indeed, it has previously 
been demonstrated in mammary epithelial cells that increasing matrix stiffness promotes 
both ERK and Rho activation, and that crosstalk between these pathways drives a positive 
feedback loop to further increase cytoskeletal tension.  However I believe that this model 
represents an over-simplification in relation to the stiffness-dependent regulation of cyclin 
D1 in particular, and cancer cell behaviour more generally. 
 
The results presented here show consistent evidence for the stiffness-dependent regulation of 
multiple signalling pathways implicated in the regulation of cyclin D1 expression, including 
FAK, ERK, PKB/ Akt and STAT3.   In other words, matrix stiffness modulates cellular 
responses to growth factor stimulation across a wide-range of signalling pathways. Stiffness-
dependent regulation of the STAT3 pathway has not previously been described.  The data 
points towards a critical role for matrix stiffness and the cytoskeleton in regulating STAT3 
 102 
expression.  STAT3 is frequently activated in malignant cells and plays a key role in 
regulating the expression of genes involved in cancer-associated inflammation (235).  
Downstream targets of STAT3 include genes involved in multiple aspects of cancer biology, 
including proliferation (e.g. cyclin D1, c-myc), anti-apoptosis (e.g. Bcl-2, MCL-1) and 
angiogenesis (e.g. VEGF).  The magnitude of STAT3 activation in response to HGF is 
regulated by matrix stiffness.  Indeed I would propose a model in which cellular behaviour is 
regulated by a network of molecular interactions, with extensive cross-talk between multiple 
signalling pathways.  Interactions between pathways conveying information from both 
soluble mediators and the extracellular matrix is integrated at the level of the cytoskeleton.  
In this context, the role of cytoskeletal tension has been likened to a cellular rheostat, acting 
to dampen or augment the responses of multiple signalling pathways to external stimuli (155, 
172).  Matrix stiffness determines the level at which a mitogenic stimulus can elicit a growth 
response.   
 
Both β1-integrin and FAK are important in mediating HCC proliferation.  In accordance 
with previous histological studies I have confirmed that both β1-integrin and phospho-
FAKTyr397 are upregulated in HCC specimens in vivo (225, 226).  It has previously been 
shown that FAK expression in HCC correlates significantly with clinically meaningful 
endpoints including tumour size and disease-free survival (225).  FAK expression also 
correlates to invasive potential in a range of human malignancies (236-238).  In colorectal 
cancer, FAK expression in liver metastases is higher that that in primary colorectal tumours, 
suggesting that FAK activation may be important in the development of metastases. (238).  
The results in this chapter demonstrate that increased matrix stiffness promotes FAK 
activation.  Furthermore, inhibition of FAK is associated with a reduction in HCC cell 
proliferation in vitro.  This is consistent with a large body of evidence that FAK is important 
in cancer development and the progression of malignancy (228).  Expression of a dominant 
negative mutant form of FAK, lacking kinase activity (FRNK) reduces the proliferation of 
mammary cancer cells in vitro and reduces tumour growth following transplantation into 
syngeneic rats (239).  Similarly, inhibition of FAK with siRNA reduces colony formation in 
soft agar and inhibits migration in human lung cancer cells (240).  However, a similar 
strategy in murine breast cancer cells failed to produce a reduction in cell proliferation, 
although cells showed reduced invasion through Matrigel and following transplantation to 
mice formed fewer metastases (241).  The effects of FAK inhibition with the small 
molecular inhibitors have been similarly contradictory (227-229).  Experiments have also 
been undertaken using conditional FAK knockout in transgenic mice.  In mice heterozygous 
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for FAK, tumour formation following the topical application of carcinogens is reduced as 
compared to wild-type mice (242).  Furthermore, conditional knockout of FAK after benign 
skin tumour formation inhibits malignant progression (243).  While it is quite clear that FAK 
is important in mediating cancer development and progression, it is equally clear that FAK 
inhibition does not produce a consistent and reproducible phenotype in cancer cells.  The 
results presented here add to this existing body of evidence.  In the HCC cells tested, FAK 
inhibition using either siRNA or small molecular inhibition attenuated cell proliferation.  
However, it is likely that tumour-dependent variables will modify the response to FAK 
inhibition in different cancer cells.  Indeed, in a significant proportion of the HCC specimens 
I tested, there was no evidence of enhanced FAK activation relative to the surrounding liver 
parenchyma.  Thus while activation of FAK may promote cancer progression, it is not a 
consistent feature in HCC.  
 
It has been demonstrated that matrix stiffness affects both proliferation and differentiation in 
HCC cells.  A low stiffness environment promotes hepatocyte differentiation, as 
demonstrated by expression of hepatocyte markers, including: albumin, HNF4α, α1-anti-
trypsin and AFP.  This is consistent with previous reports investigating the effect of matrix 
stiffness on hepatocyte morphology and differentiation (142, 143, 146).  This would suggest 
that in order to maintain hepatocyte function in vitro, cells should be cultured in a 
biophysical environment that recapitulates the stiffness characteristics of the native liver.  
This has clear implications in respect to the development of bio-artificial livers, where the 
goal is to maintain hepatocytes in prolonged culture while preserving hepatocyte function.  
However, achieving a better understanding of the relationship between matrix stiffness and 
differentiation is also important in respect to cancer biology.   
 
Epithelial-mesenchymal transition (EMT) describes the process by which polarized epithelial 
cells, which normally interact with the basement via its basal surface, undertake a phenotypic 
shift to assume characteristics of mesenchymal cells (244, 245).  These include increased 
migratory capacity, resistance to apoptosis, invasiveness and increased production of matrix 
components.   Mesenchymal cells have the ability to invade and migrate through the ECM to 
create dramatic cell transpositions. EMT was originally described in relation to 
embryogenesis (classical EMT) (244, 246). Following fertilisation, the developing embryo 
undergoes gastrulation.  Gastrulation proceeds from the formation of the primitive streak 
from a furrowed invagination in the epiblast layer. The epithelial cells in this region initially 
express E-cadherin and demonstrate apical-basal polarity.  Through a process of invagination 
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the epiblast cells at the primitive streak separates to form the mesoendoderm, which 
subsequently separates through an EMT to form the mesoderm and endoderm. Definite 
mesenchyme with the potential to give rise to muscle and connective tissue arises from the 
epithelial mesoderm at the same time as neural crest mesenchyme develops from the 
ectoderm. EMT is subsequently employed in embryogenesis to remodel unwanted epithelial, 
for example that if the medial edge of the palate.  These are considered prototypical 
examples of classical EMT.  However, the use of the term EMT has subsequently been 
expanded to a range of situations, including cultured cells.  In a seminal paper EMT was first 
described in a three-dimensional culture model of corneal epithelial cells as epithelial-
mesenchymal transformation (247).  In this model, epithelial cells derived from the adult and 
embryonic anterior lens, when cultured in collagen gels developed pseudopodia and 
filopodia characteristic of migratory cells and developed morphological and ultrastructural 
features indistinguishable from mesenchymal cells. 
 
It has been proposed that EMT is encountered in distinct biological settings (244, 245).  
Type 1 EMT describes the form of EMT associated with implantation, embryo formation 
and organ development.  Type 2 EMT describes processes associated with tissue injury that 
generates fibroblasts and other cell types associated with wound injury and tissue 
regeneration (248, 249).  Type 3 EMT is described in relation to neoplastic cells that have 
undergone genetic and epigenetic changes promoting tumour development (222).  Through 
this process neoplastic epithelial cells develop the ability to invade the basement membrane 
and give rise to distant metastases.  EMT is associated with loss of proteins associated with 
the polarized epithelial phenotype and the acquisition of proteins associated with the 
mesenchymal, migratory phenotype of transitioning cells (245).  Cells undergoing EMT lose 
expression of E-cadherin, syndecan-1 and zona occludens 1, while increasing expression of 
cytoskeletal proteins, including N-cadherin, vimentin, collagen-I and collagen-II.  Additional 
proposed markers for EMT include increased nuclear expression of transcription factors 
(including CBF-A and β-catenin) and new expression of the transcription factors (including 
Snail, Slug and Twist).  Mesenchymal cells lose cell polarity and develop spindle shaped 
morphology with redistribution of stress fibres. Loss of E-cadherin is thought to be a crucial 
step in the process of EMT, both within embryogenesis and in pathological situations in the 
adult.   However, it has been shown that loss of E-cadherin is not a necessity for EMT in 
human breast cancer cells (250). 
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The results presented in this chapter suggest that human HCC cells cultured on stiff 
substrates demonstrate some features of classical EMT, which may represent a transition to a 
proliferative or migratory phenotype and contribute to cell behaviours associated with 
chronic disease processes, including tumorigenesis and malignant progression/ metastatic 
spread.  During the process of cancer development and tumour dissemination, cancer cells 
are believed to acquire mesenchymal properties, enabling them to migrate through and 
invade surrounding tissues, eventually entering the lymphatics and bloodstream (147, 251).  
Thus the process of EMT is believed to facilitate cancer progression.  However, at secondary 
sites, tumour cells are recognised by their epithelial characteristics and developing 
metastases usually recapitulate in part the epithelial phenotype of the primary tumour (252).  
At present there is limited understanding of this reverse process of mesenchymal to epithelial 
transition (MET).  The results presented in this chapter demonstrate that HCC cells lose 
mesenchymal features; including stress fibres, N-cadherin and vimentin expression, and up-
regulate hepatocyte markers when cultured in a soft environment.  This is consistent with 
previous studies showing that non-transformed mammary epithelial cells cultured on 
compliant PA supports revert to an organised epithelial phenotype (155).  Similarly, 
hepatocytes retain an epithelial phenotype when cultured on soft collagen gels (141). It has 
previously been shown that FAK signalling is required for induction of EMT in hepatocytes 
in response to TGFβ (253).  Our results suggest that the interlinked processes of EMT and 
MET are directly and reversibly regulated by changes in environmental stiffness.    
 
It is likely that changes in matrix stiffness might regulate multiple facets of cell behaviour 
throughout the natural history of a tumour.  Thus while increases in tissue stiffness, as 
encountered in liver fibrosis, may promote tumour development, we should also consider the 
effect of changes in matrix stiffness on disseminated tumour cells and potential links to 
tumour dormancy.  Cancer cell dormancy describes a state of reversible cellular quiescence 
in cells that have the potential upon reactivation to form micrometastases (254).  Solitary 
tumour cells may persist in a quiescent state for many years prior to initiating metastatic 
tumour growth (255).  Furthermore, chemotherapeutic agents that target actively dividing 
cells have proven ineffective in treating these solitary dormant cells (256).  It has been 
proposed that the ECM is a critical regulator of cellular dormancy (257); however the role of 
matrix stiffness in regulating this process has not been specifically addressed. The growth, 
invasion and dissemination of tumour cells are accompanied by dramatic changes in the 
mechanical properties (stiffness) of the cancer cell niche. The bone marrow, a common 
reservoir site for disseminated tumour cells (258), will provide a microenvironment with 
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stiffness significantly lower than would be encountered by cells in most epithelial tumours.  
Animal models of cancer cell dormancy have established inflammation and surgical trauma 
as mechanisms for the reactivation of dormant cells  (259, 260).  The induction of lung 
fibrosis, accompanied by type I collagen deposition is associated with the development of 
lung metastases in a murine model of disseminated mammary gland carcinoma (261).  
Furthermore, using a 3D-culture system to model cancer cell dormancy, it was shown that 
collagen-I promotes the proliferation of previously dormant cancer cells though β1-integrin 
activation of SRC and FAK.  Blockade of β1-integrin, ERK and myosin light chain kinase 
(MLCK) using both siRNA and pharmacological techniques inhibited cytoskeletal 
reorganisation and proliferation.  This strongly suggests that collagen-I deposition may be 
important in facilitating the proliferation of dormant tumour cells.  The role of changes in 
matrix stiffness in mediating this effect was not addressed in this study. 
  
Our findings suggest that a reduction in the stiffness of the cancer cell niche would be 
sufficient to promote reversible cellular quiescence (dormancy).  Furthermore, an increase in 
environmental stiffness (as may occur with inflammation, surgery or stromal reaction to 
tumour) or alteration in the stiffness-sensing machinery of the cell (occurring due to genomic 
instability) might facilitate reactivation of dormant cells.  Barkan and colleagues used a 3D 
in vitro culture system reconstituted from basement membrane to recapitulate solitary 
tumour dormancy and the transition to proliferation in vitro (262).  In this study, tumour cells 
with dormant behaviour in vivo remained growth arrested in 3D culture.  In contrast, tumour 
cells with marked in vivo tumour-forming capacity transitioned into cellular proliferation, a 
process that was accompanied by cytoskeletal reorganisation/ actin stress fibre formation.  
Importantly, both cell lines proliferated rapidly when cultured on 2D plastic substrates.  The 
effect of matrix stiffness on both the induction of cellular dormancy and transition to cellular 
proliferation was not addressed.  Both collagen-gel and Matrigel-based substrates have 
stiffness values that are substantially lower than those encountered in many physiological 
tissues and many orders of magnitude lower than that of plastic substrates (263).  Indeed, the 
major deficiency of existing models of cancer cell dormancy has been a failure to consider 
the effect of matrix stiffness on cellular behaviour.  Hence, the PA support with its precise 
regulation of both stiffness and ligand density provides what has been hitherto unavailable, a 
tractable in vitro model of cancer cell dormancy.   
 
HCC demonstrates a high rate of chemotherapy resistance, which explains in part the poor 
prognosis of patients with HCC.  The majority of HCC develop within the context of liver 
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fibrosis (a high stiffness environment).  In addition, tumour growth is associated with further 
stiffening of the ECM.  The results presented here suggest that increasing matrix stiffness 
reduces chemotherapy-induced apoptosis in HCC cells.  The mechanism for this observation 
requires further investigation.  The clinical effectiveness of systemic chemotherapy is also 
limited by a failure of adjuvant/ neoadjuvant chemotherapy to eradicate disseminated tumour 
cells that are responsible for tumour recurrence following surgery or liver transplantation 
(264, 265).  HCC recurrence occurs in 10-60% of patients following liver transplantation  
(12, 14).  The mean time to recurrence is in the range of 1-2 years, but very late recurrence is 
also described (14).  The results presented in this chapter demonstrate an increase in clone-
initiating capability following chemotherapy from cells maintained in a low stiffness 
environment.  There was no difference in the frequency of clone-initiating cells derived from 
soft or stiff supports not treated with chemotherapy.  I have shown that the expression of 
cancer stem cell markers is influenced by changes in matrix stiffness.  Culture on soft 
substrates is associated with an increase in the proportion of cells expressing cancer stem cell 
markers (CD44, CD133 and CXCR-4).  CD44, CD133 and CXCR4 have previously been 
shown to define populations of cells with cancer stem cell properties in HCC (266-269).  The 
defining properties of cancer stem cells include the ability to self-renew; differentiate; and 
initiate tumour formation.  Both immunogenic markers and functional properties (e.g. 
chemotherapy resistance) are used to identify cancer stem cells.  However, due to the 
inherent heterogeneity of carcinogenesis, it is unlikely that a single marker can be reliably 
used to define cancer stem cell populations.  I have demonstrated that chemotherapy is 
associated with an increase in the expression of a number of cancer stem cell markers, 
particularly for cells in a low stiffness environment.  It remains unclear whether the 
enrichment for cells with a cancer stem cell phenotype following chemotherapy is due to 
positive selection or active induction of cancer stem cell characteristics.  It has previously 
been reported that chemotherapy can lead to propagation of cancer stem cells (232, 270).  In 
lung cancer, chemotherapeutic agents, including doxorubicin, cisplatin and etoposide, have 
been used to select drug-surviving cells (DSCs) (270). These cells are enriched for the 
expression of the cancer stem cell marker CD133 and demonstrate loss of markers of cell 
differentiation.  The DSCs maintained their self-renewal capacity and ability to differentiate.  
Differentiation was associated with loss of CD133 expresssion and re-acquisition of 
chemotherapy-sensitivity. Importantly, DSCs demonstrate higher tumorigenic and metastatic 
potential upon inoculation into immunodeficient mice, consistent with a stem cell phenotype. 
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The process of metastasis requires cells to migrate through the ECM into blood vessels and 
lymphatics prior to extravasation at secondary sites and initiation of tumour formation.  As 
discussed, both EMT and MET are believed to play a critical role in this process (271).  
Disseminated tumour cells that give rise to metastases are thought to be synonymous with 
cancer stem cells.  Both stem cell and epithelial-mesenchymal transition markers are 
frequently over-expressed in disseminated tumour cells (272).  Furthermore the expression 
of cancer stem cell markers is strongly associated with poor prognosis in HCC patients (273, 
274).  Attempts have been made to define a cancer stem cell signature in metastatic HCC.  
Yang and colleagues demonstrated that all HCC specimens tested and most blood samples 
from these patients contained highly tumourigenic CD90+/ CD45- cell populations which 
were absent from normal and cirrhotic livers (275).   The co-expression of both CD90 and 
CD45 defined an even more aggressive tumourigenic population.  Furthermore, the 
haematopoietic marker c-kit, which is not typically expressed in primary HCC , is 
abundantly expressed in metastatic HCC deposits in association with CD90 (57, 276).  These 
studies suggest that disseminated cancer stem cells are responsible for the development of 
metastases.  However, the mechanisms and signals responsible for the growth of 
disseminated tumour cells into clinically significant metastases are incompletely 
characterised.  It has been shown that cancer stem cells are regulated by a number of 
environmental factors (277).   However, to the best of my knowledge, the results presented 
in this chapter are the first to suggest that matrix stiffness regulates stem cell marker 
expression in cancer cells.  The results provide a potential mechanism for the long-term 
survival and clone-initiating capability of disseminated tumour cells in a soft environment 
(e.g. bone marrow or transplanted liver).  They also suggest that increases in matrix stiffness 
(as would be encountered in acute inflammation or fibrosis) may be sufficient to promote the 
activation and outgrowth of these cells. 
 
In this chapter I have investigated the effect of changes in matrix stiffness on the 
proliferation, differentiation and chemotherapeutic responsiveness of two unrelated HCC 
cells lines.  While the results of experiments conducted in highly passaged cells lines should 
be interpreted with some caution, the results presented here are consistent with a large body 
of evidence that suggests that matrix stiffness is important in regulating cancer development.  
Overall, these results suggest that increases in matrix stiffness encountered in liver fibrosis 
may foster HCC progression by promoting cell proliferation and mesenchymal phenotype, 
whilst also enhancing chemotherapeutic resistance.  In contrast, a reduction in the stiffness of 
the cellular environment (as might be encountered by disseminated tumour cells) induces 
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cellular dormancy, a stem cell phenotype and enhanced clonogenic capacity following 
chemotherapy. 
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Chapter 4: Studies to determine the effect of changes in stiffness on hepatic 




Hepatic progenitor cells (HPCs) are tissue resident bi-potential stem cells that have the 
potential to differentiate into either hepatocytes or cholangiocytes (278).  Under normal 
conditions, both hepatocytes and cholangiocytes retain the ability to proliferate following 
liver injury.  However, in cirrhosis and other conditions in which the regenerative capacity of 
hepatocytes is overwhelmed, regeneration is achieved by proliferation and differentiation of 
HPCs.  HPCs are believed to reside in a stereotyped stem cell compartment or niche (28). 
The anatomical location of this stem cell compartment is believed to be the canals of Hering, 
which are remnants of the foetal ductal plates (29, 30).  The properties of this stem cell 
compartment are responsible for regulating stem cell behaviour, maintaining an appropriate 
balance between stem cell quiescence, proliferation and differentiation.   The hepatic 
progenitor cell niche has both cellular and extracellular components (28).  Cellular 
components of the HPC niche include macrophages and activated hepatic MFBs.  Following 
liver injury, macrophages cluster at sites of HPC proliferation. Similarly, activated MFBs are 
intimately associated with streaming cords of HPCs, forming an almost continuous layer 
adjacent to the progenitor cell compartment.  More recently it has been demonstrated that 
different forms of liver injury differentially affect the cellular composition of the HPC niche, 
and thus may direct hepatic progenitor cell fate (218).  Biliary injury results in a marked 
accumulation of αSMA-positive MFBs which express the Notch ligand Jagged1 and are 
responsible for the deposition of large amounts of fibrillar collagen. Adjacent HPCs 
demonstrate Notch pathway activation and express cholangiocyte-associated transcription 
factors.  The acquisition of this biliary phenotype can be suppressed by treatment with a 
Notch inhibitor.  In contrast, following hepatocyte injury, WNT3a-expressing macrophages 
localise close to HPCs which it can be shown demonstrate WNT pathway activation.   This 
results in activation of downstream transcriptional targets of the WNT pathway including the 
Notch pathway inhibitor, Numb.  This in turn leads to suppression of Notch pathway 
activation in these HPCs, favouring a hepatocyte phenotype.  Through this mechanism, the 
cellular elements of the HPC niche may direct stem cell fate. 
 
Extracellular components of the HPC niche are dominated by the presence of a laminin-rich 
matrix.  Both the basement membrane and ECM that surrounds the bile ducts is principally 
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composed of type-IV collagen and laminin (17, 21, 22).  Immunohistological studies in a 
range of animal models  have demonstrated that HPCs are always surrounded by a laminin-
rich matrix or sheath (28, 279).  Laminin gene expression has been demonstrated in a 
number of non-parenchymal liver cells, including HSCs and endothelial cells. However, it 
has also been shown that laminin can be produced by HPCs, both in respect to an 
immortalised rat HPC cell line (28) and primary murine HPCs in vitro (Dr M Williams: 
personal communication).  Using in vitro culture of primary murine HPCs, it has previously 
been demonstrated that laminin markedly up-regulates progenitor (DLK1) and biliary (GGT, 
Aquaporin-1) gene expression in freshly isolated primary murine HPCs, while suppressing 
expression of the early hepatocyte gene (CEBP/a). Thus it is thought that laminin may play 
an important role in maintaining HPCs in an undifferentiated phenotype.  This would be 
consistent with results which suggest that laminin isoforms are effective at maintaining 
undifferentiated growth of human embryonic stem cells in vitro (280).   
 
HPCs are characterised histologically as small round cells with an oval nucleus and scanty 
cytoplasm (281).  A number of immunohistochemical markers have been used that identify 
HPCs.  The most widely recognised markers include cytokeratin-7 (CK-7) and cytokeratin-
19 (CK-19), which are components of intermediate filaments (282, 283).  Both CK-7 and 
CK-19 are expressed both by HPCs and mature cholangiocytes.  Additional 
immunohistochemical markers for HPCs include EpCAM (284), OV-6 (285) and E-cadherin 
(286).  HPCs can also express markers in common with mature hepatocytes (albumin, 
cytokeratin-8), foetal hepatoblasts (AFP), haematopoietic stem cells (c-kit, CD133) and 
neuro-epithelial cells (neural cell adhesion molecule [NCAM]) (281, 285, 287).  The 
expansion of the HPC compartment and the differentiation of these cells towards mature 
hepatocytes, is characterised by the appearance of trans-amplifying cell populations with 
histological features intermediate between HPCs and mature hepatocytes (281). This is 
accompanied by progressive loss of the CK-7 and CK-19 expression.  In contrast, mature 
cholangiocytes retain expression of both CK-7 and CK-19, although the expression of 
neuroendocrine markers such as NCAM is lost.  
 
HPC proliferation has been described in a number of human liver diseases, characterised by 
damage and impaired regeneration of either cholangiocytes or hepatocytes.  HPC 
proliferation is described histologically as the “ductular reaction”, which is characterised by 
anastomosing strands of proliferating of HPCs that may differentiate into either hepatocytes 
or cholangiocytes (288).  While it has been established that both the cellular and extracellular 
 112 
components of the HPC niche may be important in regulating HPC fate, relatively little is 
known regarding the effect that changes in the biomechanical properties of the niche might 
have in regulating HPC responses (289). As previously discussed, an increase in the stiffness 
of the liver is typically seen in association with acute tissue injury and the subsequent 
development of liver fibrosis and cirrhosis.  HPC proliferation is often seen in association 
with the development of liver fibrosis.  This is particularly true during biliary regeneration, 
in which HPCs are closely associated with activated MFBs expressing copious amounts of 
fibrillar collagen (218).  A prominent ductular reaction is a feature of fibrosing cholestatic 
hepatitis (28).  This condition is frequently seen as a complication of active HCV infection in 
immunosuppressed patients following liver or renal transplantation (290, 291). It is 
characterised histologically by prominent HPC proliferation, in association with more rapid 
development of liver fibrosis and cirrhosis.  Detailed histological analysis reveals that there 
is close topographical alignment between HPCs and activated MFBs.  This is an important 
finding as hepatic MFBs are believed to be the predominant source of fibrillar collagen 
production in chronic liver disease (38).  Furthermore, it has been shown that increased 
matrix stiffness is required for MFB activation (133, 134, 292). It has previously been 
demonstrated that (in the absence of known hepatocyte inhibitors) oval cell proliferation is 
enhanced in a carbon tetrachloride model of rat liver fibrosis (289).  Furthermore, both the 
number of CK19 positive and Ki67 positive HPCs were higher with more advanced stages of 
fibrosis.  This would suggest that factors associated with liver fibrosis may promote HPC 
responses.   
 
Kallis et al investigated the functional role of ECM degradation in regulating HPC responses 
(293).   Using the collagen 1α1 (r/r) mouse, which synthesises a mutated form of collagen-I 
that is resistant metalloproteinase-mediated degradation, they demonstrated that following 
repeated injury with CCl4, r/r mice had markedly attenuated HPC responses, This was 
accompanied by persistence of collagen-I and a failure to deposit ECM laminin.  Similar 
results were obtained in experiments with r/r mice given the CDE diet, a further model of 
HPC response.  This has been interpreted as showing that impairment of ECM remodelling 
following fibrotic liver injury may inhibit HPC response/ migration. These results, which 
appear to emphasise the importance of ECM remodelling in facilitating HPC response would 
be consistent with data showing the existence of clonal proliferative units within the liver, 
with a probable origin in the periportal region (294).  The spatial organisation of these clonal 
units would be in keeping with migration of either HPCs themselves, or their progeny, from 
the periportal region to the hepatic veins.  Such cellular migration would necessitate 
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significant ECM remodelling.  What is less certain is whether the results obtained in the r/r 
mouse are mechanistically informative in respect to determining the relationship between 
liver fibrosis and HPC responses.  The impairment of r/r collagen degradation and 
consequent increase in collagen-I accumulation following liver injury, may both 
independently modulate HPC responses.  Importantly it remains unclear whether physical 
factors associated with liver fibrosis (including alterations in liver stiffness) influence the 
HPC response.  Thus further studies are required to more closely characterise this aspect of 
the HPC-matrix relationship. 
 
The aim of this chapter was to more fully characterise the temporal relationship between the 
development of liver fibrosis, parenchymal stiffness and HPC responses in animal models of 
chronic liver injury. In addition I aimed to undertake detailed in vitro experiments to more 
fully characterise the effect of alterations in environmental stiffness on HPC morphology, 




• Increases in matrix stiffness, in the context of acute inflammation and chronic liver 
fibrosis will promote HPC proliferation. 
• HPC response should be closely correlated both the development of liver fibrosis 
and changes in matrix stiffness in animal models of progressive liver fibrosis. 
• Increases in matrix stiffness should precede HPC proliferation in animal models of 
liver fibrosis. 
• Increases in matrix stiffness, across a pathophysiologically-relevant range will 
promote HPC proliferation in vitro. 
• Changes in matrix stiffness will modulate HPC differentiation and may be involved 
in directing stem cell fate. 
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4.2. The relationship between liver fibrosis and HPC response in animal 
models of chronic liver disease 
 
4.2.1. Liver fibrosis and HPC response in a rat thioacetamide (TAA) model of 
liver fibrosis 
 
A thioacetamide model of liver fibrosis was used to more closely characterise the temporal 
relationship between the development of liver fibrosis and HPC response in chronic liver 
disease.  Liver fibrosis was induced by oral administration of low dose TAA (0.03%) in 
drinking water in male SD rats.  Animals were sacrificed and liver tissue analysed at 4, 8, 10, 
14, 18, 20 and 26 weeks.  Comparison was made to tissue derived from untreated control 
animals. Histological analysis of PSR-stained sections from TAA-treated rats revealed 
evidence of bridging fibrosis from 20 weeks.  In rats treated with 26 weeks TAA there was 
evidence of established cirrhosis, with dense bridging fibrosis and regenerative nodules.  
Liver fibrosis was quantified by digital image analysis of PSR-stained sections (Figure 
4.1A).  Values for percentage PSR-staining (value ± SEM) were: control untreated, 0.57 ± 
0.04; 4 weeks, 0.61 ± 0.10; 8 weeks, 0.65 ± 0.19; 10 weeks, 0.95 ± 0.26; 14 weeks, 0.68 ± 
0.36; 20 weeks, 0.95 ± 0.14; and 26 weeks, 3.59 ± 0.46.  Prior to week 20, there was no 
significant increase in liver fibrosis in comparison to untreated control animals.  Following 
20 weeks of low dose TAA treatment there was a modest but significant increase in PSR-
staining (1.7 fold, p=0.01).  However, at week 26 there was a marked increase in PSR-
staining (6.3-fold, p<0.0001) relative to untreated controls.  HPC response was assessed by 
direct cell counting of CK-19-positive cells (Figure 4.1B).  Values for HPC numbers per 20 
high power fields (value ± SEM) were: control untreated, 65.4 ± 17.9; 4 weeks, 131 ± 26.0; 8 
weeks, 118.3 ± 15.7; 10 weeks, 136.8 ± 5.6; 14 weeks, 133.0 ± 12.9; 20 weeks, 175.8 ± 24.4; 
and 26 weeks, 1676.0 ± 659.5.  A modest increase in HPC numbers (relative to untreated 
controls) was seen from 4 weeks (2.0 fold, p=0.07).  The increase in HPC numbers in TAA-
treated animals was statistically significant from week 10 (2.1-fold, p=0.01).  HPC response, 
as assessed the numbers of CK-19-positive cells, was markedly increased following 26 
weeks of TAA (25.6-fold, p=0.03), in comparison to untreated control animals.  The major 
expansion in HPC numbers at 26 weeks corresponds to a similar increase in PSR-staining at 
this time point. Further analysis reveals a positive correlation between HPC numbers and 
PSR staining in the TAA model of liver fibrosis (R=0.665, p<0.001) (Figure 4.1C).  
However, the more modest early increase in HPC numbers from week 4 onwards occurred 
prior to the development of significant liver fibrosis.   
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Figure 4.1 Quantification of liver fibrosis and HPC response in a TAA model of rat liver fibrosis. (A-C) 
Photomicrographs showing representative high power (x200) images of PSR-stained liver sections from 
(A) untreated control rats (B) 14 week TAA-treated rats and (C) 26 week TAA-treated rats.  (D) 
Quantification of pico-sirius red staining by digital image analysis of liver sections derived from rats 
treated with low dose (0.03%) TAA sacrificed at the time points indicated (4-26 weeks).  Comparison is 
made to liver tissue derived from untreated control animals. Each bar represents the mean percentage 
area of PSR-staining per high power (x200) field (HPF).  The number of replicates (n) at each time point 
is indicated beneath the x-axis of the graph.  The 4-20 week time points show only a modest increase in 
periportal PSR-staining.  After 26-weeks TAA-treatment there is a more dramatic increase in PSR-
staining with evidence of bridging fibrosis/ cirrhosis. Statistical comparisons between mean values are 
made using an unpaired student t-test.  (E) Quantification of CK-19-positive HPCs in liver sections in the 
low dose TAA model.  Each bar represents the mean number of non-bile duct associated CK-19 positive 
cells per high power (x320) field from 3-6 animals.  The precise number of animals (n) at each time point 
is indicated beneath the x-axis of the graph.  Statistical comparisons between mean values are made using 
an unpaired student t-test.  (F)  Graph showing the statistical correlation between HPC number and liver 
fibrosis (percentage PSR staining) in the low dose TAA model of liver fibrosis (n=23) (R= Spearman 
correlation co-efficient).  In each case error bars represent SEM, *p<0.05, **p<0.01, ***p<0.001. 
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4.2.2. Liver fibrosis and HPC response in a rat carbon tetrachloride (CCL4) 
model of liver fibrosis 
 
A CCl4 model of liver fibrosis was used as confirmatory model in order to characterise the 
relationship between liver fibrosis and HPC response. Liver fibrosis was induced by twice 
weekly intra-peritoneal injection of 0.2ml/100g of a 1:1 mixture of CCL4 in olive oil.  After 
2 weeks the dose of this mixture was reduced to 0.1ml/ 100g.   Animals were sacrificed and 
liver tissue analysed (including rheometry measurements) at 7, 14, 28, 42, 56 and 70 days.  
Both vehicle-injected (olive oil alone) and uninjected animals were used as controls (135).  
Liver fibrosis was quantified by digital image analysis of PSR-stained sections (Figure 
4.2A).  Early liver fibrosis was characterised by portal tract expansion, with subsequent 
development of portal bridging fibrosis.  Digital image analysis reveals a progressive 
increase in PSR-staining with increasing duration of injury.  The values for percentage PSR-
staining (value ± SEM) were: 7 days, control 1.27 ± 0.40/ CCl4 0.54 ± 0.17; 14 days, control 
0.41 ± 0.19/ CCl4 1.46 ± 0.30; 28 days, control 0.31 ± 0.21/ CCl4 4.75 ± 0.71; 42 days, 
control 0.45 ± 0.05/ CCl4 6.11 ± 0.68; 56 days, control 0.49 ± 0.02/ CCl4 10.13 ± 2.49; 
control 0.46 ± 0.18/ CCl4 8.08 ± 0.89.
  At 28 days, PSR-staining was increased 15.6-fold 
(p=0.03) relative to vehicle treated controls, increasing to 17.6-fold (p=0.004) at 70 days.   
 
The pattern of MFB activation in this model, as assessed by digital image analysis of αSMA-
staining, has previously been quantified (135).  The values for percentage αSMA-staining 
(value ± SEM) were: 7 days, control 0.04 ± 0.01/ CCl4 0.38 ± 0.10; 14 days, control 0.06 ± 
0.01/ CCl4 0.33 ± 0.07; 28 days, control 0.55 ± 0.04/ CCl4 1.23 ± 0.41; 42 days, control 0.05 
± 0.01/ CCl4 1.52 ± 0.51; 56 days, control 0.06 ± 0.01/ CCl4 1.65 ± 0.31; control 0.07 ± 0.03/ 
CCl4 5.11 ± 1.82.
  There is a modest early increase in MFB activation from as early as 7 days 
(Figure 4.2B).  The majority of the increase in αSMA staining occurs at later time points (28-
70 days).   
 
HPC response was assessed by direct cell counting of CK-19-positive cells (Figure 4.2C).  
The values for HPC numbers per 60 high power fields (value ± SEM) were: 7 days, control 
28.5 ± 7.5/ CCl4 78.5 ± 13.5; 14 days, control 41.5 ± 24.5/ CCl4 93.6 ± 12.8; 28 days, control 
39.0 ± 4.0/ CCl4 56.5 ± 1.5; 42 days, control 26.0 ± 2.0/ CCl4 116.0 ± 24.4; 56 days, control 
40.0 ± 11.0/ CCl4 156.0 ± 30.0; control 18.0 ± 3.0/ CCl4 492.2 ± 179.7.
 Overall, HPC 
numbers are increased in animals treated with CCl4 (p< 0.05, two-way ANOVA), however 
absolute differences at each time point relative to vehicle-treated controls were not 
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statistically significant (unpaired student t-test). There is a trend towards an early increase in 
HPC numbers at 7 days (2.8-fold, p=0.09) relative to vehicle-treated controls.  However, the 
majority of the increase in HPC numbers appears to occur after 70 days of treatment (27.3-
fold, p=0.17).  HPC numbers are positively correlated to both PSR staining (R=0.65, p<0.05) 
and αSMA staining (R=0.78, p<0.001) (Figure 4.3). 
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Figure 4.2: Liver fibrosis, αSMA expression and HPC response in a CCl4 model 
of rat liver fibrosis 
 
 
Figure 4.2 Quantification of liver fibrosis, MFB-activation and HPC response in a CCl4 model of rat 
liver fibrosis. (A) Quantification of PSR staining by digital image analysis of liver sections derived 
from rats treated with twice weekly CCl4 injection (black) (7-70 days).  Comparison is made to liver 
tissue derived from vehicle (olive oil) treated control animals (white bars). Each bar represents the 
mean percentage area of PSR-staining per high power (x200) field (HPF) from 2-6 animals.  (B)  
Quantification of MFB activation as assessed by digital image analysis of αSMA-stained liver sections 
in the rat CCl4 model.  Each bar represents the mean percentage area of PSR-staining per high power 
(x200) field (HPF) from 2-6 animals.  The number of animals used (n) in each analysis is indicate 
below the x-axis of each graph. (C) Quantification of CK-19-positive HPCs in liver sections in the 
CCL4 model. Each bar represents the mean number of non-bile duct associated CK-19 positive cells 
per 60 high-power (x320) fields from 2-6 animals.  The differences between mean measurements were 
compared using a student t test. In each case error bars represent SEM, *p<0.05, **p<0.01, 
***p<0.001, ns= not statistically significant. The number of animals used (n) in each analysis is 
indicate below the x-axis of each graph. 
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Figure 4.3: Statistical correlation of HPC numbers to PSR and αSMA-staining 




Figure 4.3 Graphs showing the statistical correlation between mean HPC numbers (non-bile duct-
associated CK-19 positive cells/ 60 high power fields) and (A) liver fibrosis [PSR-staining] and (B) 
myofibroblast activation [αSMA-staining] in a CCl4 model of rat liver fibrosis. In each case R= 
Spearman correlation co-efficient and p values are as indicated (n= 37).  
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4.2.3 Relationship between changes in liver stiffness and HPC response in a 
rat CCl4 model of liver fibrosis 
 
It has previously been demonstrated that liver stiffness increases with duration of CCl4 
administration in a rat model of liver fibrosis (Figure 4.4 A) (135).  The values liver stiffness 
(G') in rats untreated control animals, olive oil controls and CCl4 treated animals (value ± 
SEM) were: untreated baseline control, 374.1 ± 49.7Pa; 7 days, olive oil control 413.5 ± 
2.2Pa/ CCl4 763.6 ± 84.2Pa; 14 days, olive oil control 532.7 ± 73.0Pa/ CCl4 642.8 ± 28.0Pa; 
28 days, olive oil control 587.3 ± 30.9Pa/ CCl4 829.6 ± 51.3Pa; 42 days, olive oil control 
637.5 ± 29.8Pa/ CCl4 1349.0 ± 61.9Pa; 56 days, olive oil control 548.9 ± 24.5Pa/ CCl4 
1471.0 ± 251.2Pa; olive oil control 425.7 ± 54.6Pa/ CCl4 1504 ± 150.2Pa.
  Liver stiffness 
(G') is increased after 7 days of CCl4 treatment (2.0-fold, p<0.001), relative to untreated 
controls.  G' continues to increase to day 42 of CCl4 treatment (3.6-fold, p<0.0001) and then 
stabilises.  The values for HPC numbers per 60 high power fields with increasing duration of 
CCl4 treatment were: day 7, 78.5 ± 13.5; day 14, 76.0 ± 7.5; day 28, 54.0 ± 4.0, day 42, 
116.0 ± 24.4; day 56, 196.2 ± 43.0; and day 70, 492.2 ± 179.7.  There is positive correlation 
between liver stiffness and HPC numbers (R=0.79, p<0.0001) (Figure 4.4 B).  It is evident 
that the major increase in liver stiffness (G') precedes the major expansion in HPC numbers 
in this CCl4 model of rat liver fibrosis (Figure 4.4 C). 
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Figure 4.4: Relationship between changes in liver stiffness and HPC response 
in a CCl4 model of rat liver fibrosis 
 
Figure 4.4: Graphs showing the relationship between liver stiffness (G') and HPC numbers in a CCl4 
model of liver fibrosis.  (A) Liver stiffness increases with duration of CCl4 administration (black bars) 
relative to untreated control animals (grey bars) and vehicle-treated controls (white bars).  The precise 
number of animals (n) represented by each bar is indicated below each graph.   (B) There is a positive 
correlation between mean liver stiffness measurements and mean HPC numbers (assessed by direct 
cell counting of non-bile-duct-associated CK19-positive cells per 60 high-power fields).  (C)  Graph 
showing the relationship between G' (grey line) and HPC numbers (black line) in this CCl4 model of 
rat liver fibrosis. In respect to liver stiffness, statistical comparison to the baseline liver stiffness in 
untreated animals is made using an unpaired student t test.  In each case error bars represent SEM, 
*p<0.05, **p<0.01, ***p<0.001, ns= not statistically significant and R= Spearman correlation co-
efficient.
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4.2.4. The effect of BAPN on liver stiffness and HPC response in a rat CCl4 
model of liver fibrosis 
 
It has been shown, both in vitro and in vivo, that enhanced collagen cross-link formation may 
increase collagen stiffness (G') independent of collagen deposition (44-47).  As previously 
discussed, LOX is a copper-dependent amine oxidase that initiates intra- and inter-molecular 
cross-linking of collagen.  LOX is upregulated early after liver injury and has been shown 
that reducing LOX activity with β-aminopropionitrile (BAPN) attenuates tissue stiffness and 
prevents liver fibrosis in a rat model of liver fibrosis (135).  In these experiments liver 
fibrosis was induced by twice-weekly injection of 0.2ml/100mg of a 1:1 mixture of CCl4 in 
olive oil.  A second cohort of rats also received treatment with BAPN (2mg/ml in drinking 
water) for the duration of CCl4 injury.  Both vehicle-treated (olive oil alone), non-injected 
and non-injected/ BAPN treated animals were used as controls.  It has previously been 
shown that CCl4-treated animals have increased liver stiffness (G') in comparison to normal 
(uninjured) and vehicle-treated control animals (135).  It has also been demonstrated that 
BAPN treatment of CCl4-injured rats results in a marked blunting of the early increase in 
liver stiffness.  In rats receiving CCl4-treatment the mean liver stiffness (G') after 14 days 
treatment was 506Pa compared to a liver stiffness value of 359Pa in CCl4/ BAPN-treated 
animals (p= 0.003).  HPC response in this model was subsequently assessed by direct cell 
counting of CK-19-positive cells (Figure 4.5).  The values for HPC number per 60 high 
power fields were: day 0, uninjected, 42.5 ± 8.5; day 6, CCl4 76.8 ± 11.4/ CCl4 + BAPN 66.5 
± 4.0; day 14, CCl4 99.2 ± 17.0/ CCl4 + BAPN 81.2 ± 12.4/ BAPN alone 37.8 ± 6.4. 
 
Overall there was a trend towards a reduction in HPC numbers in CCl4/ BAPN-treated 
animals in comparison to those receiving CCl4 alone, but this difference was not statistically 
significant.  In our earlier CCl4-model of rat liver fibrosis, it was shown that the major 
expansion in HPC numbers does not occur until after 42 days of injury.  Therefore it might 
be expected that a longer duration of injury would be required in order to evaluate whether 
BAPN-treatment might attenuate HPC responses in CCl4-induced liver injury.   
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Figure 4.5: The effect of BAPN treatment on HPC response in a CCl4 model of rat liver fibrosis.  
Quantification of CK-19 positive HPCs in liver sections from rats treated for between 6 and 14 days 
with either CCl4-alone (black bars) or CCl4/ BAPN (white bars), as indicated.  Comparison is made to 
non-injected (hatched bar) and non-injected/ BAPN-treated control animals (grey bar). Each bar 
represents the mean number of non-bile duct associated CK-19 positive cells per 60 high-power 
(x320) fields from 2-6 animals.  The number (n) of animals represented by each bar is indicated below 
the x-axis of the graph.  Comparison between mean measurements was made using a student t test.  In 




4.3. Changes in environmental stiffness regulate HPC morphology and 
cytoskeletal organisation in vitro 
 
In order to investigate how changes in the stiffness of the cellular microenvironment might 
affect HPC responses, experiments were undertaken in which HPCs were cultured on matrix-
coated PA supports of defined stiffness.  The stiffness of the PA supports was modelled 
across a pathophysiologically relevant range (1-12kPa) corresponding to changes in stiffness 
that would be encountered by cells in the transition from a normal to a fibrotic (or cirrhotic) 
liver.  Initial experiments were undertaken using an immortalised bi-potential murine oval 
cell line (BMOL).  It has previously been shown that in proliferating culture conditions 
BMOL cells express abundant oval cell and biliary cell markers (including CK-19) (216).  
However under conditions favouring differentiation, BMOL cell up-regulate markers of 
hepatocyte differentiation.  BMOL cells were cultured on PA gel supports of defined 
stiffness that were coated with either laminin or collagen-IV.  The effect of changes in 
support stiffness on the organisation of the actin cytoskeleton was assessed following 
staining with fluorescently-labelled phalloidin (Figure 4.6).  Cells cultured on laminin-coated 
1kPa supports were generally small and rounded with homogeneously distributed F-actin 
staining.  In contrast, cells cultured on laminin-coated 12kPa supports demonstrated 
enhanced cell spreading and prominent F-actin stress fibre formation.  A similar trend in 
respect to cytoskeletal organisation was seen when BMOL cells were cultured on collagen-
IV-coated PA supports (data not shown).  Changes in cell spreading as a function of support 
stiffness were quantified by digital image analysis of phase contrast photomicrographs.  Cell 
spreading was measured in relation to projected cell surface area (µm2).  In BMOL cells 
cultured on laminin-coated PA supports, values for projected surface area (value ± SEM) 
were: 1kPa, 379 ± 21µm2; 2.5kPa, 531 ± 26µm2; 12kPa, 687 ± 47µm2; and laminin-coated 
glass, 1808 ± 95µm2.  In BMOL cells cultured on collagen-IV-coated PA supports, values 
for projected surface area (value ± SEM) were: 1kPa, 709 ± 26µm2; 2.5kPa, 904 ± 45µm2; 
12kPa, 1008 ± 66µm2; and laminin-coated glass, 1808 ± 128µm2.  In BMOL cells cultured 
on both laminin- and collagen-IV-coated PA supports, projected surface area increased as a 
function of increasing support stiffness (Figure 4.6 C).  Cell spreading was maximal when 
cells were cultured on matrix-coated glass, which has a supra-physiological stiffness (giga-
pascal range). 
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Figure 4.6: The effect of PA support stiffness on cytoskeletal organisation and 
cell spreading in BMOL cells 
 
 
Figure 4.6 (A/B) Photomicrographs (x 320 magnifications) showing BMOL cells cultured on soft 
(1kPa) and stiff (12kPa) laminin-coated PA supports and stained for the presence of actin stress fibres 
(phalloidin-green) and nuclear DNA (4’, 6’-diamidino-2-phenyl-indole dihydrochloride) (DAPI-blue).  
The scale bar indicates 200 microns. (C) Graph showing the relationship between cells spreading and 
polyacrylamide support stiffness for BMOL cells cultured on laminin (white) and collagen-IV (black) 
coated supports.  Comparison is made to cells cultured on matrix-coated glass supports. Cell 
spreading is expressed as projected surface area (µm2) calculated by digital image analysis of phase 
contrast photomicrographs. In each case, the bars represent the mean (±SEM) of measurements from 
50 cells (n=50) randomly selected from photomicrographs of cells cultured from PA gels in three 
independent experiments. Mean measurements were compared using an unpaired student t test 
(***p<0.001).   
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4.4 Increases in support stiffness promote HPC proliferation in vitro 
 
Increasing substrate stiffness enhances cell proliferation in BMOL cells (Figure 4.7A).  In a 
series of experiments BMOL cells were cultured on matrix-coated PA supports of defined 
stiffness (1-12kPa) coated with either laminin or collagen-IV.  In BMOL cells cultured on 
laminin-coated PA supports, values for proliferative index (value ± SEM) were: 1kPa, 0.025 
± 0.005; 2.5kPa, 0.178 ± 0.045; 12kPa, 0.298 ± 0.057; and laminin-coated glass, 0.467 ± 
0.267.  In BMOL cells cultured on collagen-IV-coated PA supports, values for proliferative 
index (value ± SEM) were: 1kPa, 0.040 ± 0.013; 2.5kPa, 0.245 ± 0.063; 12kPa, 0.315 ± 
0.045; and laminin-coated glass, 0.560 ± 0.019.  In cells cultured on laminin-coated supports, 
the proliferative index of BMOL cells (assessed by nuclear localisation of Ki67 antigen) was 
11.7-fold (p<0.001) higher when cells were cultured on 12kPa versus 1kPa supports.  
Similarly, in cells cultured on collagen-IV-coated PA supports, the proliferative index of 
BMOL cells was 8.0-fold (P<0.001) higher when cells were cultured on 12kPa versus 1kPa 
supports.  In each case, the proliferative index of BMOL cells was maximal when cells were 
cultured at supra-physiological stiffness on matrix-coated glass (laminin or collagen-IV).  
Across a pathophysiologically relevant range (1-12kPa), there was no significant difference 
in the proliferative index of BMOL cells as a function of surface ligand identity (laminin Vs 
collagen-IV).  These results would suggest that in the culture conditions employed in these 
experiments, it is the physical (as opposed to the biochemical properties) of the PA supports 
that exerts the dominant effect on BMOL proliferation.  In each experiment, BMOL cells 
were plated at constant initial plating density.  Direct cell counting of adherent cells 1 hour 
after plating confirmed that there was no significant difference in the initial adherance of 
cells as a function of PA support stiffness (data not shown).  The results of proliferation 
experiments were replicated in experiments in which an MTT- assay was used to confirm 
that increasing matrix stiffness was associated with an increase in MTT conversion (as a 
proxy for total cell number) after a period of culture on laminin- or collagen-IV-coated 
supports (data not shown). 
 
Experiments were subsequently undertaken using freshly isolated primary cells to confirm 
that increasing support stiffness promotes cell proliferation in primary murine HPCs (Figure 
4.7B).  Freshly isolated primary murine HPCs were cultured on matrix-coated PA supports 
of defined stiffness (1-12kPa) coated with either laminin or collagen-IV.   The values for 
mean proliferative index (value ± SEM) in primary HPCs cultured on laminin-coated 
supports were: 1kPa, 0.044 ± 0.007; and 12kPa, 0.075 ± 0.005.  The values for mean 
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proliferative index (value ± SEM) in primary HPCs cultured on collagen-IV-coated supports 
were: 1kPa, 0.037 ± 0.008; and 12kPa, 0.087 ± 0.011.  In cells cultured on laminin-coated 
supports, the proliferative index (Ki67 positivity) of primary HPCs was 1.7-fold higher 
(p<0.05) in cells cultured on 12kPa versus 1kPa supports.  Similarly, on collagen-IV-coated 
supports, the proliferative index of primary HPCs was 2.4-fold higher (P<0.05) when cells 
were cultured on 12kPa versus 1kPa supports. 
 
Immunoblot analysis of cell lysates from BMOL cultured on laminin- and collagen-IV-
coated PA supports demonstrates that increasing support stiffness promotes upregulation of 
cyclin D1 (Figure 4.8). The values from densitometry analysis (arbitrary units) of cyclin D1 
expression (value ± SEM) relative to GAPDH expression are: collagen-IV, 1kPa 1.0, 2.5kPa 
2.98 ± 0.10, 12kPa 6.24 ± 0.75, and collagen-IV-coated glass 9.13 ± 0.90; and laminin, 1kPa 
1.0, 2.5kPa 1.77 ± 0.62, 12kPa 2.32 ± 0.99, and laminin-coated glass 2.04 ± 0.87.  All results 
are expressed relative (standardised) to cyclin D1 expression on the relevant 1kPa support.  
Cyclin D1 expression is 6.2-fold higher (p<0.01) in BMOL cells cultured on collagen-IV-
coated 12kPa versus 1kPa supports. Similarly cyclin D1 expression is 2.3-fold higher 
(p=0.26) on laminin-coated 12kPa versus 1kPa supports.  Similar results have been obtained 
in respect to cyclin D3 (data not shown). 
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Figure 4.7: Effect of changes in PA support stiffness on proliferation in BMOL 




Figure 4.7 (A) Graph showing the effect of changes in support stiffness (kPa) on the proliferative 
index (Ki67-positivity) of BMOL cells.  Experiments were conducted on laminin (white) and 
collagen-IV-coated (black) PA gel supports (1-12kPa) and matrix-coated glass, as indicated.  (B) 
Graph showing the effect of changes in support stiffness on the proliferative index of primary murine 
HPCs.  In each case, values reflect the mean (±SEM) of measurements from 3 independent 
experiments (*p<0.05, **p<0.01 and ***p<0.001).  Statistical comparisons between mean 
measurements were made using a student t-test (n=3).  The cell counting data from which these graphs 
are derived is presented in Appendix 14. 
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Figure 4.8 Western blot analysis of cyclin D1 expression in BMOL cells cultures on collagen-IV 
(black) and laminin-coated (white) PA gels of defined stiffness (1-12kPa) and collagen-IV-coated 
glass.  In each western blot equal quantities of protein were loaded and equal loading confirmed in 
relation to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression.  The bar graph shows 
the results of densitometry analysis of cyclin D1 expression relative to GAPDH.  In each case, values 
represent the mean (±SEM) of measurements from 3 independent experiments (n=3).  Results are 
standardised to expression of cyclin D1/ GAPDH in cell cultured on 1kPa supports. 
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4.5 Changes in support stiffness modulate cell differentiation in HPCs  
 
Experiments were undertaken to assess whether changes in matrix stiffness might modulate 
HPC differentiation (progenitor cell fate).  BMOL cells were cultured in low serum 
conditions on either 1kPa or 12kPa laminin-coated polyacrylamide supports.  After six days 
in culture, cells were harvested for mRNA.  The effect of support stiffness on cell 
differentiation was assessed by real-time quantitative PCR against a panel of progenitor cell, 
biliary and hepatocyte-specific markers (Figure 4.9).  The values for mRNA expression 
(value ± SEM) of selected genes (expressed as fold induction standardised to GAPDH 
relative to expression of gene of interest on 1kPa supports) are: albumin, 1kPa 1.00 ± 0.05/ 
12kPa 0.66 ± 0.06; Cyp7A1, 1kPa 1.00 ± 0.06/ 12kPa 0.62 ± 0.04; cytokeratin-19, 1.00 ± 
0.07/ 12kPa 1.57 ± 0.20; aquaporin, 1.00 ± 0.08/ 12kPa 0.96 ± 0.14; gamma-glutamyl 
transferase, 1kPa 1.00 ± 0.16/ 12kPa 0.90 ± 0.11.  BMOL cells cultured on 12kPa supports 
down-regulated the expression of hepatocyte-specific markers including albumin (1.5-fold, 
p<0.01) and CYP7A1 (1.6-fold, p<0.01), in comparison to cells grown on 1kPa supports.  In 
contrast, expression of cytokeratin-19, a marker of biliary and progenitor cell differentiation, 
was up-regulated (1.6-fold, p<0.01) in cells maintained on 12kPa supports, relative to cells 
on 1kPa supports.  There was no significant difference in the expression of the biliary 
epithelial markers aquaporin and gamma-glutamyl transferase (γGT) in BMOL cells as a 
function of support stiffness. 
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Figure 4.9: The effect of PA support stiffness on BMOL differentiation 
 
 
Figure 4.9 Graph showing the effect in BMOL cells of changes in support stiffness on mRNA 
expression of a panel of progenitor cell, biliary and hepatocyte markers.  BMOL cells were cultured 
for 6 days in low serum conditions on either 1kPa (white) or 12kPa (black) laminin-coated PA 
supports.  For each gene of interest mRNA expression, relative to the 18S housekeeping gene, was 
measured using real-time quantitative PCR.  Values are expressed as fold-induction relative to mRNA 
expression in cells cultured on 1kPa supports.  Statistical differences between mean values (n=6) were 
determined using an unpaired student t-test (**p<0.01, ns = not significant).   
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4.6 FAK, ROCK and myosin-II regulate cell proliferation in HPCs in vitro 
 
Immunofluorescent staining of BMOL cells cultured on laminin-coated PA supports 
demonstrates that increasing support stiffness promotes FAK activation.  BMOL cells 
cultured on 12kPa demonstrate strong staining for phospho-FAKTyr397, which is absent from 
cells cultured on 1kPa supports (Figure 4.10).  FAK, ROCK and myosin-II have previously 
been identified as being important mediators of mechanotransduction and stiffness-sensing 
responses.  BMOL cells were cultured on both laminin- and collagen-IV-coated tissue 
culture plastic, in the presence and absence of small molecular inhibitors of FAK 
[PF573228], ROCK [Y-27632] and myosin-II [blebbistatin] (Figure 4.11).  Experiments 
were performed in low serum conditions in the presence of supplemental epithelial growth 
factor (EGF) [20mg/ml].  An MTT assay was employed to assess cell proliferation.  MTT 
conversion is a measure of cell viability and is an indirect measure of cell number.  In each 
case, the addition of contractile inhibitors significantly reduced BMOL cell numbers/ 
proliferation.  In experiments in which BMOL cells were cultured on laminin-coated tissue 
plastic the values for MTT conversion (value ± SEM) were: water control, 0.206 ± 0.001; Y-
27632 (10mM), 0.156 ± 0.008; Y-27632 (50mM), 0.127 ± 0.006; DMSO control, 0.174 ± 
0.010; PF-573228 (1mM), 0.095 ± 0.005; PF-573228 (5mM), 0.081 ± 0.059; blebbistatin 
(10µM), 0.152 ± 0.007; blebbistatin (50µM), 0.128 ± 0.005.  BMOL proliferation (as 
assessed by MTT measurement) was reduced by treatment with PF573228 both at 1µM 
(46% reduction , p<0.001) and 5µM (54% reduction, p<0.0001), relative to suitable vehicle 
controls (DMSO).  Similarly, BMOL proliferation was reduced by treatment with Y-27632 
both at 10µM (24% reduction, p<0.01) and 50µM (39% reduction, p<0.001) relative to 
vehicle control (water).  Treatment with blebbistatin was associated with more modest 
reductions in BMOL proliferation both at 10µM (13% reduction, p<0.001) and 50µM (26% 
reduction, p<0.001), relative to vehicle control (DMSO). 
 
A similar trend was seen in MTT experiments conducted in BMOL cells cultured on 
collagen-IV-coated tissue culture plastic.  Values for MTT conversion (value ± SEM) were: 
water control, 0.185 ± 0.008; Y-27632 (10mM), 0.145 ± 0.003; Y-27632 (50mM), 0.125 ± 
0.008; DMSO control, 0.166 ± 0.011; PF-573228 (1mM), 0.093 ± 0.003; PF-573228 (5mM), 
0.078 ± 0.004; blebbistatin (10µM), 0.118 ± 0.016; blebbistatin (50µM), 0.095 ± 0.006.  
BMOL proliferation was reduced by FAK inhibition with PF573228 at both at 1µM (44% 
reduction, p<0.001) and 5µM (53% reduction, p<0.001).  ROCK inhibition with Y-27632 
reduced BMOL proliferation at 10µM (22% reduction, p<0.001) and 50µM (32% reduction, 
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p<0.001).  Similarly, myosin-II inhibition with blebbistatin reduced BMOL proliferation at 
both 10µM (29% reduction, p<0.05) and 50µM (43% reduction, p<0.001). 
 
 
Figure 4.10: Immunofluorescent staining showing the effect of PA stiffness on 




Figure 4.10 Photomicrographs (x 320 magnifications) showing BMOL cells cultured (A) soft (1kPa) 
and (B) stiff (12kPa) laminin-coated polyacrylamide supports and stained for the presence of 
phospho-FAKTyr397 (red), actin stress fibres (phalloidin-green) and nuclear DNA (4’,6’-diamidino-2-
phenyl-indole dihydrochloride) (DAPI-blue).  Cells cultures on the stiffer (12kPa) supports 
demonstrate strong staining for activated FAK, which is absent from cells cultured on softer (1kPa) 
supports.  The scale bar indicates 200 microns.  
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Figure 4.11: The effect of small molecular inhibitors of FAK, ROCK and 
myosin-II on proliferation in BMOL cells 
 
Figure 4.11 Graphs showing the effect of contractile inhibitors on MTT conversion (reflecting cell 
number/ viability) in BMOL cells. BMOL cells were cultured in low serum conditions for 120 hours 
on (A) laminin-coated plastic and (B) collagen-IV-coated plastic, in the presence and absence of small 
molecular inhibitors of FAK (PF573228), ROCK (Y-27632) and myosin-II (blebbistatin) at the 
concentrations indicated.  Comparison is made to suitable vehicle controls corresponding to the 
solvent used in the solubilisation of the small molecular inhibitors [Y-27632 (water) and PF573228/ 
blebbistatin (DMSO)].  In each case, bars represent the mean (±SEM) from 3 experiments (*p<0.05, 
**p<0.01 and ***p<0.001).  Statistical comparisons between means (n=3) were made using an 




The results of these experiments suggest that alterations in the stiffness of the extracellular 
environment may be important in regulating HPC responses in chronic liver disease.  
Normally following liver injury, cell loss is restored through the replication of mature 
hepatocytes and cholangiocytes, as illustrated following bile duct ligation or partial 
hepatectomy (281).  The HPC compartment represents a reserve compartment that is 
activated when mature hepatocytes or cholangiocytes are subjected to chronic or repeated 
injury, or where the regenerative capacity of these cells is overwhelmed following severe 
tissue damage.  This can be demonstrated experimentally in animal models where hepatocyte 
injury (e.g. choline-deficient diet or partial hepatectomy) is accompanied by the 
administration of substances that inhibit the replicative capacity of hepatocytes (e.g. 
ethionine or 2-acetylaminofluorine) (279, 295).  The choline-deficient ethionine 
supplemented (CDE) diet has become established as a reliable model of hepatocellular 
regeneration with marked HPC expansion (295).  Similarly, a dramatic expansion in HPC 
numbers has been observed in transgenic models in which hepatocyte regeneration is 
inhibited by conditional over-expression of the cell cycle inhibitor p16 (296).  As previously 
discussed, oval cell proliferation is also enhanced in animal models of liver fibrosis in the 
absence of known hepatocyte inhibitors (289).  However, it is unclear whether factors 
associated with liver fibrosis may promote HPC proliferation, or whether the severity of liver 
fibrosis is simply a surrogate marker for hepatocyte damage and impairment of hepatocyte-
mediated regeneration.  Our results in both the TAA and CCl4 models of rat liver fibrosis 
demonstrate a close association between HPC expansion and liver fibrosis severity.  In both 
models, the major expansion in HPC numbers corresponds temporally to a similar large 
increased in scar tissue deposition.  However, more modest early increases in HPC numbers 
occur prior to the development of significant fibrosis.   
 
We have proposed that changes in liver stiffness may be important in regulating HPC 
behaviour.  It has previously been shown that liver stiffness increases with both the duration 
and severity of liver fibrosis (135).  However, the early increase in liver stiffness precedes 
the major increase in scar deposition.  Similarly, in our model of CCl4-induced liver fibrosis, 
increases in liver stiffness precede the major expansion in HPC numbers.  The factors 
responsible for this early increase in liver stiffness are uncertain but may include interstitial 
oedema due to acute inflammation or early increases in collagen fibril cross-linking.  This is 
the first study to explicitly explore the relationship between hepatic stiffness and HPC 
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response in vivo. Our in vivo observations demonstrate a close association between liver 
stiffness measurements and HPC expansion, suggesting that alterations in the mechanical 
properties (stiffness) of the stem cell niche may be important in regulating HPC 
proliferation. This is backed up by detailed in vitro experiments that demonstrate that 
increases in environmental stiffness, across a pathophysiologically-relevant range (1-12kPa) 
promote HPC proliferation.  These results were obtained in both an immortalised rat oval 
cell line (BMOL) and primary murine HPCs.  In each case, it is the physical characteristics, 
rather than the biochemical composition of the matrix, that exerts the dominant effect on 
HPC proliferation.  Our results suggest that increasing matrix stiffness promotes cell cycle 
progression with increased expression of cyclin D1.  This would be consistent with 
published results showing that physiological stiffness is inhibitory to cell cycle progression 
(97).  Conversely, increases in the stiffness of the stem cell niche, as occur following tissue 
injury and liver fibrosis may be mechanistically important in promoting HPC proliferation.  
Further experiments are required to more closely characterise the effect of changes in matrix 
stiffness on other regulators of cell cycle progression, including the cyclin-dependent-kinase 
inhibitors p21 and p27. 
 
If increased matrix stiffness is an important factor in promoting HPC proliferation, then it 
would be expected that therapeutic interventions to either attenuate increases in ECM 
stiffness, or disrupt mechanotransduction responses, would impair HPC proliferation.  It has 
previously been shown that BAPN can attenuate increases in both liver stiffness and liver 
fibrosis in a CCL4 model of rat liver fibrosis (135).   This is believed to be due to inhibition 
of LOX-mediated collagen cross-linking.  Using liver tissue derived from this two-week 
CCl4 model we demonstrated a trend towards a reduction in HPC numbers in CCl4/ BAPN-
treated animals in comparison to those receiving CCl4-alone.  This difference was not 
statistically significant.  We have previously shown in a more protracted model of CCl4 
injury that the major expansion in HPC numbers did not occur until 42 days of twice weekly 
CCl4 administration.  As such, we would anticipate that a longer duration of injury would be 
required in order to properly assess whether BAPN can attenuate HPC responses in CCl4-
induced liver injury, and so reduce the probability of type II statistical error. Further 
experiments with a more protracted model of fibrotic liver injury are required.  
 
Our in vitro experiments with matrix-coated PA gels show a close relationship between 
support stiffness and HPC proliferation.  We have shown that increases in matrix stiffness, 
across of pathophysiologically-relevant range (1-12kPa), promotes FAK activation.  FAK 
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activation is a pivotal event in integrin-mediated signalling.  Our experiments in HPCs 
maintained on stiff substrates show that biochemical inhibition of FAK reduces cell 
proliferation.  This is consistent with previous studies which have shown that FAK activation 
promotes cell cycle progression/ cellular proliferation  (297, 298).  Similarly, biochemical 
inhibition of ROCK and myosin-II (critical mediators of mechanotransduction responses) 
attenuate HPC proliferation on stiff substrates. ROCK and FAK are known to interact with 
each other through multiple signalling molecules.  It has also been shown that ROCK is 
required for FAK activation (tyr397 phosphorylation) in response to mechanical stretch (299).  
Inhibition of mechanotransduction responses (stiffness-sensing) may therefore represent an 
effective method of modulating HPC proliferation. 
 
The effects of changes in ECM stiffness on HPC differentiation remain poorly characterised.  
Our results suggest that a low stiffness environment, with characteristics similar to that of the 
normal liver, promotes a modest up-regulation of hepatocyte-specific markers in BMOL 
cells.  Conversely, HPCs exposed to stiffer substrates demonstrated up-regulation of the 
biliary/ progenitor cell marker CK-19.  These results are consistent with published results in 
hepatocytes and our own results looking at the effect of matrix stiffness on HCC 
differentiation.  Hepatocytes maintained on softer substrates demonstrate higher levels of 
albumin excretion and differential responses to growth factor stimulation, indicative of a 
more differentiated phenotype (142).  Similarly, Lozoya et al investigated the effect of 
matrix stiffness on foetal-derived human hepatic stem cell differentiation in three-
dimensional hyaluronic acid (HA) based hydrogels (300).  They demonstrated that changes 
in hydrogel stiffness affected the both viability of hepatic stem cells and levels of urea, 
albumin and AFP secretion (hepatic metabolism).  The effect of changes in matrix stiffness 
on BMOL differentiation in vitro, are less pronounced.  This may in part relate to the 
specific properties of the BMOL cell line.   
 
Overall, these results are consistent with a biomechanical model of HPC regulation.  It is 
proposed that a low stiffness environment, as encountered in the normal liver, may be 
important in maintaining HPC quiescence. In contrast, pathophysiological increases in niche 
stiffness that would be encountered in the context of acute inflammation or liver fibrosis, 
would promote progenitor cell expansion.  Further experiments are required to explore the 
effect of changes in matrix stiffness on mitogenic signalling in HPCs. 
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Finally, it is important to consider to the extent to which results may provide insight into the 
pathogenesis of HCC.  HCC may be derived from at least four distinct lineages, including 
hepatocytes, mature cholangiocytes, HPCs and periductular cells (50, 53).  It has previously 
been demonstrated that increasingly matrix stiffness promotes tumour develop in a murine 
model of breast cancer (46).  I have also shown that alterations in matrix stiffness modulate 
proliferation and stem cell characteristics in HCC (chapter 3).  Our results demonstrate that 
increasing matrix stiffness, as would be encountered in the cirrhotic liver, promotes 
proliferation in HPCs.  As such, alterations in the biochemical properties of the HPC niche 
associated with acute inflammation and liver fibrosis may be important in promoting 
hepatocarcinogenesis.  
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Hepatic injury as a consequence of cardiac dysfunction is a commonly encountered clinical 
syndrome that remains incompletely characterised.  The term cardiac hepatopathy describes 
the spectrum of pathological changes occurring in the liver as a consequence of cardiac 
dysfunction.  The principle histological features observed in this context are chronic passive 
congestion (CPC) and centrilobular necrosis (CLN) (301).  These are distinct morphological 
entities that are frequently observed concurrently.  CPC is regarded as a consequence of 
elevated hepatic venous pressure, as will occur in right-heart failure.  In contrast, CLN (or 
ischaemic hepatitis) is commonly seen in the context of severe hypotension due to 
cardiogenic shock or circulatory collapse. A number of studies have suggested the existence 
of reciprocal potentiation of CPC and CLN, whereby local alterations resulting from one 
lesion may enhance the underlying pathological features of the other (301-303).   
 
Longstanding cardiac dysfunction is associated with the development of liver fibrosis (304).  
Histological studies in humans have defined the pattern of morphological changes in the 
liver resulting from chronic hepatic congestion.  In mild hepatic congestion, liver histology is 
minimally disrupted, with a normal reticulin pattern.  Progressive hepatic congestion results 
in centrilobular reticulin condensation, with loss of hepatocytes from the centrilobular region 
resulting in collapse of the reticulin stroma.  This is followed by de novo centrilobular 
fibrosis with pronounced thickening of the centrilobular vein wall and variable extension of 
fibrous tissue spurs outward into the parenchyma.  In severe heart failure there is progressive 
liver fibrosis with bridging fibrosis connecting adjacent central veins (reversed lobulation).  
This histological pattern is described as cardiac cirrhosis.  The portal tracts are initially 
unaffected in this condition but may become involved in advanced disease and liver 
progenitor cell (oval cell) proliferation has been described in this context (304).  Cardiac 
cirrhosis remains a rare condition, reflecting the low prevalence of and poor prognosis 
associated with prolonged heart failure (305).  
 
The effect of chronic hepatic congestion on the development of liver fibrosis has been 
investigated in patients with chronic right heart failure occurring secondary to specific forms 
of congenital heart disease (306-309).  The Fontan procedure was developed as a palliative 
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treatment for tricuspid atresia (310).  The classical Fontan procedure involves the formation 
of a direct connection between the right atrium and pulmonary arteries.  The circulation is 
supported by left ventricular contraction, with passive flow of blood into the lungs.  This 
operation has been superseded by total cavo-pulmonary anastomosis, which avoids long-
term complications related to right atrial enlargement and subsequent cardiac arrhythmias 
(atrial tachycardia).  However, both operations result in chronic central venous hypertension, 
depressed dynamic cardiac output and late ventricular dysfunction.  The long-term 
consequences of the Fontan procedure include alterations in the hepatic microvasculature 
with central venous hypertension, sinusoidal arterialisation, portal hypertension and 
progressive liver fibrosis.  Liver fibrosis and cirrhosis are common complications of the 
Fontan procedure. Indeed, in an autopsy study, cirrhosis was present is all four long-term 
survivors of the Fontan procedure (306).  In a detailed morphological study Kendall et al 
demonstrated that the histological features in the livers of Fontan patients are similar to those 
encountered in cardiac cirrhosis (307).  In these patients, the liver is exposed to high venous 
pressure, with superimposed deep intra-hepatic reflux secondary to atrial contraction.  
Sinusoidal dilation is a prominent feature. Liver fibrosis was centred on the perivenular 
region with fibrous spurs extending outward into the parenchyma. Perisinusoidal fibrosis – 
similar to that typically encountered in steatohepatitis – was also prominent.  Interestingly, 
inflammation (as defined by the presence of a lymphocytic infiltrate) was not a prominent 
feature in this cohort.   The authors postulated that liver fibrosis in patients with the Fontan 
circulation might develop independently of inflammation.  This effect may be mediated as a 
response to chronic hypoxia or mechanical stretch of the hepatic sinusoids and consequently 
the cells surrounding them.  Sinusoidal dilation is a consequence both of elevated central 
venous pressure and intra-hepatic reflux secondary to atrial contraction.  It has been shown 
in a related study that the extent of cirrhosis is positively correlated with hepatic vein 
pressures (308).  Furthermore, there is a positive correlation between the duration of central 
venous hypertension and liver fibrosis score.  However, it is also the case that inflammatory 
changes may be present prior to time of biopsy or may not be represented in the biopsy 
material (due to sampling error).  In a large autopsy study of patients with both right- and 
left-sided congestive cardiac failure, CPC and CLN (with an associated inflammatory cell 
infiltrate) were frequently observed concurrently (301).   
 
The precise aetiological factors responsible for the pathogenesis of liver fibrosis in cardiac 
hepatopathy remain poorly characterised.  These may include: (1) Impaired cardiac output 
and diminished hepatic blood flow resulting in decreased hepatic oxygen delivery; (2) 
 142 
Perisinusoidal oedema restricting diffusion of oxygen and nutrients; (3) Elevated central 
venous pressure (CVP) resulting in sinusoidal dilatation and hepatocyte plate compression; 
and (4) Cellular responses to alterations in matrix stiffness and cellular tension.  A more 
detailed understanding of the sequence of pathological events contributing to liver fibrosis in 
chronic passive congestion requires the development of tractable animal models of cardiac 
hepatopathy.  I have therefore undertaken studies to characterise the sequence of histological 
events in the liver in two unrelated models of murine dilated cardiomyopathy, with the 
intention that this would permit characterisation of the early events in the congested liver 
that contribute to the development of liver fibrosis.  In particular, I wished to investigate the 





• Chronic hepatic congestion, as encountered in murine models of dilated 
cardiomyopathy, may provide a model system analogous to the situation 
observed in human patients following the Fontan procedure. 
• Mechanical factors, including alterations in matrix stiffness and cell strain 
consequent upon sinusoidal dilatation may promote liver fibrosis. 
• Increases in matrix stiffness, across a pathophysiologically-relevant range, will 
enhance profibrotic gene expression in hepatic MFBs in vitro. 
• Repetitive uniaxial stretch will enhance profibrotic gene expression in hepatic 
MFBs in vitro. 
 
5.2 Murine models of cardiac hepatopathy 
 
5.2.1 The python model of cardiac hepatopathy 
 
The python model of dilated cardiomyopathy (DCM) was generated by Prof Neil Dear 
(University of Leeds) using N-ethyl-N-nitrosurea (ENU) mutagenesis, as previously 
described (203).  The phenotype is inherited in an autosomal dominant fashion with 
complete penetrance in both sexes.  Features of congestive cardiac failure included shallow 
rapid breathing, piloerection, subcutaneous oedema, ascites and pleural effusions.  The 
median onset of overt symptoms on a C3H/ HeN genetic background is 83 days for males 
and 91 days for females.  The pattern of cardiac histology and haemodynamic changes 
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occurring in the python model has been extensively characterised (203).  At the time that 
mice demonstrate overt evidence of congestive cardiac failure (CCF) there is gross dilatation 
of both the right and left atria and ventricles.   
 
Detailed haemodynamic measurements in male python mice on a C3H/ HeN background 
aged 71-78 days (Table 5.1) were undertaken by Dr Craig Lygate (MRC Centre for Human 
Genetics, Oxford), i.e. approximately 2 weeks prior to the onset of overt congestive cardiac 
failure (203).  Left ventricular catherisation demonstrated impaired left ventricular systolic 
pressure (value ± SD) in python mice relative to littermate controls (75±3 versus 97±8 
mmHg, p<0.001).  In addition, left ventricular end-diastolic pressure (LVEDP) was 
significantly higher in python mice (17.7±2 versus 3.8±1.1 mmHg, p<0.01) indicating 
impaired left ventricular contractility.  Mean arterial pressure was also significantly lower in 
python mice relative to controls (60±6 versus 75±9 mmHg, p<0.01).  At this time point, 
there was no difference in central venous pressure between the two groups (1.6±0.8 versus 
1.8±2.0 mmHg, p=0.83). 
 
Positional cloning has identified the python mutation as a single missense mutation in the 
dynamin-like gene (dnm1l) on chromosome 16.  The python mutation results in a 
replacement of a cysteine residue by a phenylalanine at position 452 in the dmn1l protein.  
This C452F mutation is in a highly conserved region of M domain of the dnm1l protein.  
This mutation has been shown to alter protein interactions in a yeast two-hybrid system 
suggesting that the residue may affect intramolecular interactions within the dnm1l monomer 
(203).  Dnm1l is a member of the dynamin family of large GTPases implicated in tubulation 
and fission events in peroxisomes and mitochondria (311-314).  Homozygosity for the 
python mutation (Py/Py) results in an embryonic lethal phenotype.  Mouse embryonic 
fibroblasts (MEFs) from Py/Py homozygous embryos survive poorly in culture and have 
grossly abnormal mitochondria.  In contrast, skin fibroblasts from heterozygous python mice 
(Py/+) have less pronounced abnormalities in mitochondrial morphology.  The mitochondria 
in Py/+ skin fibroblasts are highly elongated in comparison to wild type (+/+) controls, but 
there is no difference in total cellular mitochondrial volume.  The phenotype observed in the 
python (Py/+) mouse is, at a gross level, restricted to the cardiac myocytes. Indeed, with the 
exception of the development of congestive cardiac failure, the python mice do not 
demonstrate any other features of mitochondrial cytopathy, i.e. neurological, skeletal muscle 
and metabolic abnormalities.  This is believed to be a consequence of the peculiar nature of 
the python mutation (203).  In contrast, a previous report of a mutation in the M region of the 
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DLP1 gene, the human homologue of dnm1l, described a severe phenotype characterised by 
abnormal brain development, persistent lactic acidosis and elevated levels of long-chain fatty 
acids (314).  Defects in energy metabolism in the python mouse show considerable tissue 
specificity.  Adenosine triphosphate (ATP) production – the endpoint of respiratory chain 
function – was measured in 10 week-old mice and littermate controls (203).  Both ATP and 
total adenine nucleotide (TAN) levels were reduced by 50 percent in python hearts.  
Importantly, both ATP and TAN levels in liver (and brain) tissue were similar in python 
mice and littermate controls.  While these findings are reassuring, the nature of the germline 
mutation responsible for the python phenotype must raise concerns in relation to the utility 
of the python mouse as a model of cardiac hepatopathy.  However, the apparent tissue 
specificity of the observed defects in energy metabolism suggests that the python model 
might provide some valuable insight into the pathophysiology of this condition. 
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5.2.1.1 Hepatic changes in the python model of cardiac hepatopathy 
 
Preliminary experiments in male C3H/ HeN mice, undertaken by Dr Michael Cheeseman 
and Dr Tertius Hough (Mary Lyon Centre and Mammalian Genetics Unit, MRC Harwell, 
UK) found evidence of hepatic congestion concurrent with features of overt CCF.  This was 
preceded by increases in the serum levels of the liver enzymes alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) (Figure 5.1). The values for ALT (U/L) 
expression in wild-type controls and python mice at different time points (value ± SEM) are: 
week 5, wild-type 33.1 ± 0.9/ python 60.7 ± 3.0; week 7, wild-type 32.4 ± 2.1/ python 48.1 ± 
3.8; week 9, wild-type 36.4 ± 1.7/ python 109.0 ± 20.8; overt CCF, wild-type 32.0 ± 2.9/ 
python 157.6 ± 27.9.  Serum ALT (value ± SEM) was significantly elevated in 5-week-old 
python mice relative to littermate controls (60.6±3.0 vs. 33.1±0.9, p<0.001). The 
development of overt CCF was associated with a further increase in serum ALT relative to 
littermate controls (157.6±27.9 vs. 32.0±2.9, p<0.01).  A similar pattern was observed in 
respect to serum AST.  The values for AST (U/L) expression in wild-type controls and 
python mice at different time points (value ± SEM) are: week 5, wild-type 58.7 ± 5.9/ python 
101.5 ± 7.1; week 7, wild-type 56.2 ± 3.5/ python 94.5 ± 5.2; week 9, wild-type 53.1 ± 3.1/ 
python 158.9 ± 18.4; overt CCF, wild-type 45.3 ± 2.2/ python 167.1 ± 17.5. At no time 
points was a significant difference observed in respect to serum albumin concentration 
between python mice and age-matched littermate controls.  The values for AST (U/L) 
expression in wild-type controls and python mice at different time points (value ± SEM) are: 
week 5, wild-type 32.9 ± 0.6/ python 32.9 ± 0.7; week 7, wild-type 35.4 ± 2.4/ python 32.7 ± 
0.5; week 9, wild-type 34.2 ± 0.4/ python 32.4 ± 0.6; overt CCF, wild-type 32.7 ± 0.7/ 
python 32.6 ± 0.5. 
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Figure 5.1 Measurement of serum markers of liver injury in the python mouse.  The serum levels of the 
liver enzymes (A) alanine aminotransferase (ALT) and (B) aspartate aminotransferase (AST) were 
measured in serum taken from python (Py/+) mice and age-matched littermate controls (+/+).  Serum 
samples were taken from mice aged 5, 7 and 9 weeks and at the time that mice developed features of overt 
congestive cardiac failure (CCF).  In 5-week-old python mice, serum ALT was significantly elevated (1.8-
fold increase, p<0.001) relative to controls.  The development of overt CCF was associated with a further 
increase in ALT (4.9-fold increase, p<0.01) relative to controls.  A similar pattern was seen in respect to 
serum AST.  (C) No difference in serum albumin concentration was observed between python mice and 
littermate controls at any time point.  Error bars are SEM, **p<0.01, ***p<0.001.  Statistical comparison 
between groups was made using an unpaired student t-test.  The number of samples/ animals represented by 
each bar is represented below each x-axis. 
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Experiments were conducted to define the early events in the congested liver that may 
contribute to the development of liver fibrosis.  Cohorts of male python (Py/+) mice and age-
matched wild-type (+/+) controls were culled at 5, 7, 9 and 11 weeks, and at the 
development of overt features of CCF.  At 5-weeks of age the python mice were 
macroscopically indistinguishable from age-matched control animals (Figure 5.2).  At the 
time that python mice develop features of overt congestive cardiac failure, there is evidence 
of gross cardiac enlargement (Figure 5.3A) and macroscopic evidence of hepatic congestion 
(Figure 5.3B).  Histological examination of the hearts taken from python mice manifesting 
features of overt CCF demonstrates dilatation of both the right and left atria and ventricles 
(Figure 5.3C).  There was a visible increase in the size of python mice with overt CCF due to 
substantial peripheral oedema and ascites (Figure 5.3D). 
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Figure 5.2: The macroscopic appearance of 5-week-old python mice 
 
 
Figure 5.2  Photographs showing the macroscopic appearance of (A) hearts and (B) livers taken from 
5-week-old python (Py/+) and littermate wild-type (+/+) mice on a C3H/ HeN genetic background 
(scale bar=1cm). (C) Photomicrographs (x10 magnification) of haematoxylin and eosin stained 
sections through the hearts taken from 5-week-old python (Py/+) and littermate wild-type (+/+) mice 
on a C3H genetic background (scale bar=1mm) showing a normal appearance of both the right (R) 
and left (L) ventricles. (D) Photographs showing the gross macroscopic appearance of 5-week-old 
python (Py/+) and wild-type mice on a C3H/ HeN genetic background (scale bar = 1cm).  
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Figure 5.3: The macroscopic appearance of 12-week-old python mice 
 
 
Figure 5.3 Photographs showing the microscopic appearance of  (A) hearts and (B) livers taken from 
12-week-old python (Py/+) and littermate wild-type (+/+) mice on a C3H/ HeN genetic background 
(scale bar=1cm). (C) Photomicrographs (x10 magnification) of haematoxylin and eosin stained 
sections through the hearts taken from a 12-week-old python (Py/+) manifesting features of CCF and 
an unaffected littermate wild-type (+/+) control (scale bar=1mm).  The heart taken from the 12-week-
old python mouse displays features of cardiomyopathy with dilatation of the right ventricle (R) and 
left ventricles (L) with associated thinning of the ventricular walls.  (D) Photographs showing the 
gross macroscopic appearance of 12-week-old python (Py/+) and wild-type mice on a C3H genetic 
background.  In the terminal phase of cardiomyopathy/ congestive cardiac failure, the python mouse 
develops features of right ventricular failure, including peripheral oedema and ascites. 
 
The livers taken from 5-9 week-old python (Py/+) mice show a progressive increase in 
hepatocyte nuclear size in comparison to from those taken from wild-type (+/+) littermate 
controls in the absence of any other significant histological abnormalities. (Figure 5.4).   
Histological features consistent with cardiac hepatopathy were not observed in Py/+ mice 
until 11 weeks.  This would be consistent with previous haemodynamic measurements 
demonstrating no significant difference in central venous pressure between python mice and 
wild-type controls at 10 weeks (section 5.2.1).  It has been recognised that in male python 
mice on a C3H/ HeN background, features of cardiac decompensation develop unpredictably 
from around 11 weeks.  This may reflect the situation observed in clinical practice with 
DCM whereby cardiac decompensation often occurs secondary to an unpredictable cardiac 
arrhythmia or thromboembolic event.  Liver histology from python mice with overt features 
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of CCF is grossly abnormal.  Within the perivenous region of 12-week-old (Py/+) mice there 
is marked perivenular sinusoidal congestion and dilatation/ ectasia.  This is accompanied by 
irregular plate atrophy and hepatocyte degeneration.  There are areas of vacuolation and 
finely granular cytoplasmic change that are thought to form part of a spectrum of hepatocyte 
degeneration. These changes are absent from the centrilobular region (Figure 5.4 F). There is 
a mild to moderate inflammatory cell infiltrate. Immunohistochemistry with lineage-specific 
markers confirms a mixed inflammatory cell infiltrate comprising macrophages, neutrophils, 
B-lymphocytes and T-lymphocytes (Appendix 15).  Macrophage infiltration is concentrated 
around the central veins at areas of CLN (Figure 5.5).  Quantification of the number of 
F4/80-positive cells in liver sections from python mice and age-matched controls 
demonstrates that increased numbers of F4/80-positive cells are not evident until such time 
that overt features of cardiac hepatopathy are present. The values for the number of F4/80-
positive cells per high power field (value ± SEM) in wild-type and python mice, at the 
different time points were: 7 weeks, wild-type 47.1 ± 4.4/ python 42.9 ± 42.9; 9 weeks, wild-
type 38.2 ± 2.9/ python 43.0 ± 6.3; 11 weeks, wild-type 51.7 ± 7.3/ python 102.6 ± 25.8; and 
at the onset of overt CCF, wild-type 55.1 ± 4.4/ python 203.1 ± 6.3.  There is only a minor 
increase in GR1-staining (neutrophil staining) in liver sections from 12-week-old Py/+ mice, 
relative to age-matched controls.  However, the onset of clinical features of overt CCF is 
accompanied by a more significant and dramatic increase in both CD3 (T-lymphocyte) and 
B220 staining (B-lymphocyte) in Py/+ liver section, relative to age-matched controls 
(Appendix 15).  
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Figure 5.4 High magnification (x200) photomicrographs of haematoxylin and eosin stained liver 
tissue taken from (A) 7-week-old python (Py/+) mice, (B) age-matched wild-type (+/+) controls, (C) 
9-week-old Py/+ and (D) age-matched (+/+) control mice.  There is a clear increase in nuclear size 
amongst hepatocytes from 7-9-week-old Python (Py/+) mice but no other significant histological 
abnormalities are seen.  (E/F) Liver tissue taken from 12-week-old Py/+ mice displaying clinical 
features of overt congestive cardiac failure have gross histological abnormalities.  In the (E) 
perivenular region of 12-week-old Py/+ mice there is marked perivenular sinusoidal congestion and 
dilatation/ ectasia (SD) accompanied by irregular plate atrophy and hepatocyte degeneration (HD).  
Areas of hepatocyte vacuolation (V) and granular cytoplasm (GC) represent part of this degenerative 
process.  These changes are not present in the (F) periportal zone.  (G) Liver tissue from age-matched 









Figure 5.5 Macrophage recruitment to the liver in the python model of cardiac hepatopathy  High 
magnification (x200) photomicrographs of F4/80-immunstained liver tissue from (A) python (Py/+) 
mice demonstrating features of overt congestive cardiac failure, and (B) age-matched wild-type (+/+) 
controls.  Isotype-control staining is represented by the indented image (top right).  Scale bar indicates 
50 microns  (C) Quantification of the number of F4/80-positive cells in liver sections taken from Py/+ 
mice at 7, 9 and 11 weeks, and at the development of features of overt CCF.  In each case comparison 
is made to age-matched +/+ control animals.  F4/80-positive cell numbers are expressed as the mean 
number of cells/ high power (x200) central vein field.  Statistical comparison between means was 
made using a student t-test.  The number of animal (n) represented by each car is indicated beneath the 
x-axis of the graph.  Error bars indicate SEM, ***p<0.001, ns = not significant. 
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5.2.1.2 Fibrous tissue changes in the python model of cardiac hepatopathy 
 
Alterations in fibrous tissue architecture in the python mouse are evident from 11-weeks 
(Figure 5.6).   Early alterations in fibrous tissue architecture are evident as condensation of 
collagen fibres around the central veins.  In python mice exhibiting overt feature of CCF 
there is extension of collagen fibrils outward into the parenchyma (fibrous spur formation).  
Fibrous tissue changes occur in a perivenular distribution around the central veins and in 
areas of more marked sinusoidal dilatation.  However, even in python mice demonstrating 
features of advanced CCF there was no evidence of either bridging fibrosis or cirrhosis.  This 
may reflect the acute time course of cardiac decompensation in the python model, such that 
there is insufficient time for advanced fibrosis, and ultimately cirrhosis to develop.  The 
accumulation of fibrillar collagen in the python model was quantified by digital image 
analysis of PSR stained liver sections (Figure 5.6 D).  The values percentage (%) PSR-
staining (value ± SEM) in wild-type and python mice, at the different time points were: 7 
weeks, wild-type 1.04 ± 0.18/ python 1.08 ± 0.22; 9 weeks, wild-type 1.41 ± 0.14/ python 
1.10 ± 0.14; 11 weeks, wild-type 1.19 ± 0.14/ python 1.93 ± 0.14; and at the onset of overt 
CCF, wild-type 1.66 ± 0.16 / python 4.85 ± 0.52. This confirmed that prior to the onset of 
overt features of CCF there was no significant increase in fibrillar collagen content in the 
python liver relative to age-matched controls.  The onset of overt CCF was accompanied by 
a dramatic increase (2.9-fold, p<0.001) in PSR staining relative to controls. 
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Figure 5.6: Quantification of liver fibrosis (PSR staining) in the python liver 
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Figure 5.6 Quantification of PSR staining in the python model of cardiac hepatopathy 
Photomicrographs (x200magnification) of PSR stained liver sections from (A/B) 12 week-old python 
(Py/+) mice demonstrating overt features of CCF and (C) age-matched wild-type (+/+) littermate 
controls. (D)  Quantification of PSR staining by digital image analysis of liver sections derived from 
python mice at 7, 9 and 11 weeks, and at the onset of overt symptoms of CCF.  At each time point 
comparison is made to age-matched wild-type littermate controls.  Each bar represents the mean 
percentage area of PSR staining per high power (x200) field.  The number of animals (n) represented 
by each bar is indicated beneath the x-axis of the graph.  Statistical comparisons between means were 
made using a student t-test.  Error bars indicate SEM, ***p<0.001. 
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Real-time quantitative PCR of cDNA derived from whole liver lysates was used to quantify 
the expression profile of ECM components and profibrotic mediators, implicated in the 
pathogenesis of chronic liver disease (Figure 5.7).  Gene expression is expressed as fold 
induction relative to 18S expressions.  Values are standardised to expression values in 5-
week-old wild-type mice.  The values for fold induction of COL1A1 (value ± SEM) are: 5 
weeks, wild-type 1.00 ± 0.16/ python 1.73 ± 0.34; 7 weeks, wild-type 0.32 ± 0.08/ python 
0.24 ± 0.43; 9 weeks, wild-type 0.14 ± 0.02/ python 0.17 ± 0.03; 11 weeks, wild-type 0.15 ± 
0.03/ python 0.61 ± 0.42; and at the onset of overt CCF in python mice, wild-type 0.08± 0.02 
/ python 11.98 ± 3.57.  The values for fold induction of COL3A1 (value ± SEM) are: 5 
weeks, wild-type 1.00 ± 0.11/ python 1.64 ± 0.17; 7 weeks, wild-type 0.42 ± 0.09/ python 
0.39 ± 0.05; 9 weeks, wild-type 0.24 ± 0.03/ python 0.26 ± 0.03; 11 weeks, wild-type 0.24 ± 
0.04/ python 0.37 ± 0.15; and at the onset of overt CCF in python mice, wild-type 0.15± 0.03 
/ python 3.67 ± 0.55.  The values for fold induction of αSMA (value ± SEM) are: 5 weeks, 
wild-type 1.00 ± 0.19/ python 1.32 ± 0.31; 7 weeks, wild-type 0.18 ± 0.02/ python 0.13 ± 
0.04; 9 weeks, wild-type 0.73 ± 0.13/ python 0.63 ± 0.09; 11 weeks, wild-type 0.67 ± 0.13/ 
python 1.49 ± 0.57; and at the onset of overt CCF in python mice, wild-type 0.70± 0.10 / 
python 70.65 ± 14.13.  The values for fold induction of TIMP1 (value ± SEM) are: 5 weeks, 
wild-type 1.00 ± 0.10/ python 2.97 ± 0.68; 7 weeks, wild-type 0.44 ± 0.08/ python 0.56 ± 
0.15; 9 weeks, wild-type 0.35 ± 0.07/ python 0.73 ± 0.06; 11 weeks, wild-type 0.44 ± 0.08/ 
python 2.00 ± 1.20; and at the onset of overt CCF in python mice, wild-type 0.46± 0.14 / 
python 17.88 ± 4.11. The values for fold induction of TIMP2 (value ± SEM) are: 5 weeks, 
wild-type 1.00 ± 0.06/ python 1.26 ± 0.07; 7 weeks, wild-type 0.74 ± 0.06/ python 0.88 ± 
0.06; 9 weeks, wild-type 1.01 ± 0.09/ python 1.17 ± 0.10; 11 weeks, wild-type 0.77 ± 0.04/ 
python 0.93 ± 0.02; and at the onset of overt CCF in python mice, wild-type 0.64± 0.08 / 
python 2.98 ± 0.34.  In python mice demonstrating features of overt CCF there is marked up-
regulation of COL1A1 (142-fold, p<0.05), COL3A1 (25-fold, p<0.001), αSMA (102-fold, 
p<0.01), TIMP1 (39-fold, p<0.01) and TIMP2 (5-fold, p<0.001) mRNA, relative to controls.  
There is no significant difference between python mice and controls in the expression of 
COL1A1, COL3A1 or αSMA prior to the onset of overt CCF.  However, TIMP1 gene 
expression in python liver is consistently upregulated relative to age-matched wild-type 
control liver from as early as 5 weeks (3-fold increase, p<0.05).  The biological relevance of 
this observation is uncertain.  Consistent with previous published findings (315), 
immunohistochemical examination of serial liver sections suggests that TIMP1 is derived 
from both macrophages and HSCs (data not shown). 
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Figure 5.7: Real-time PCR analysis for fibrosis marker expression in the 
python liver  
 
Figure 5.7 Real-time quantitative PCR analysis for (A) COL1A1, (B) COL3A1, (C) αSMA, (D) 
TIMP1 and (E) TIMP2 mRNA expression in whole liver lysates derived from python (Py/+) mice 
(black bars) at 5, 7, 9 and 11 weeks, and at the onset of overt CCF.  At each time point comparison is 
made to mRNA from whole liver lysates derived from age-matched wild-type (+/+) control animals 
(white bars). In each case, target mRNA expression is calculated relative to the expression of the 18S 
housekeeping gene and fold-induction expressed relative to target mRNA expression in the +/+ 
control group at 5 weeks.  Statistical comparisons between means were made using an unpaired 
student t-test.  The number (n) of animals represented by each bar is indicated below the x-axis of 
graph E.  In each case error bars represent SEM, *p<0.05, **p<0.01, ***p<0.001.     
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5.2.1.3 Myofibroblast (MFB) activation in the python model of cardiac 
hepatopathy 
 
Immunohistochemical staining for the αSMA – a marker of activated MFBs – was 
undertaken in order to characterise the pattern of MFB activation in the python model.  The 
development of overt features of CCF was accompanied by a marked increase in αSMA-
staining in the python liver.  MFB activation was centred on the central veins and dilated 
sinusoids radiating out into the parenchyma.  The most prominent accumulations of activated 
αSMA-positive MFB were seen in areas of sinusoidal dilatation/ ectasia.  These are the areas 
in which haematoxylin and eosin staining has demonstrated the presence of hepatocyte 
degeneration/ hepatocyte plate atrophy (Figure 5.4).  The presence of activated MFBs around 
dilated sinusoids suggests that mechanical factors related to sinusoidal dilatation might be 
implicated in the activation of these cells.  The portal tracts appeared relatively normal until 
late in the disease process.  In those livers with the most florid histological changes, αSMA-
positive MFBs were identified around the portal tracts.  This may reflect sequential 
activation of MFB populations in response to progressive cardiac hepatopathy.  Digital 
image analysis was used to quantify the pattern of αSMA-expression in the python model 
relative to age-matched wild-type controls (Figure 5.8).  The values for percentage αSMA 
staining (value ± SEM) in wild-type and python mice at the different time points are: 5 
weeks, wild-type 0.0010 ± 0.0006/ python 0.0054 ± 0.0052; 7 weeks, wild-type 0.0063 ± 
0.0029/ python 0.0025 ± 0.0013; 9 weeks, wild-type 0.0937 ± 0.0263/ python 0.1481 ± 
0.0478; 11 weeks, wild-type 0.1917 ± 0.081/ python 0.2394 ± 0.1049; and at the onset of 
overt CCF in python mice, wild-type 0.1797± 0.0519 / python 14.27 ± 2.840. This showed 
that there is no significant difference in the expression of αSMA in the python liver relative 
to age-matched wild-type controls prior to the onset of overt CCF in python mice.  At the 
onset of overt cardiac decompensation there is a marked and rapid increase (79-fold, p<0.01) 
in αSMA staining, relative to age-matched wild-type controls.  These results have been 
confirmed with Western blotting for αSMA in whole liver lysates (data not shown). 
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Figure 5.8 Quantification of αSMA staining in the python model of cardiac hepatopathy 
Photomicrographs (x200magnification) of αSMA-immunostained (brown) liver sections from (A/B) 
python (Py/+) mice demonstrating overt features of CCF and (C) age-matched wild-type (+/+) 
littermate controls. Slides stained with an isotype control primary antibody showed no significant 
staining (indented images) Scale bar indicates 50 microns. (D)  Quantification of αSMA-
immunostaining by digital image analysis of liver sections derived from python mice at 5, 7, 9 and 11 
weeks, and at the onset of overt symptoms of CCF.  At each time point comparison is made to age-
matched wild-type littermate controls.  Each bar represents the mean percentage area of αSMA-
immunostaining per high power (x200) field.  The number (n) of animals represented by each bar is 
indicated below the x-axis of the graph.  Error bars indicate SEM, **p<0.01.  Statistical comparisons 
are made using a student t test.
 166 
5.2.1.4 Expression of inflammatory chemokines/ cytokines in the python 
model of cardiac hepatopathy 
 
Studies were undertaken to quantify levels of relevant inflammatory chemokines in whole 
liver lysates taken from python mice and age-matched wild-type controls (Figure 5.6).  The 
development of overt features of CCF is associated with a 2.3-fold increase (p<0.001) in 
whole liver MCP-1 expression, relative to controls.  There was no evidence of upregulation 
of MCP-1 in livers lysates from python mice at earlier time points.  The values for MCP-1 
protein expression (pg/mg tissue) in wild-type and python mice at the different time points 
(value ± SEM) are: 5 weeks, wild-type 73.5 ± 10.9/ python 77.6 ± 5.4; 7 weeks, wild-type 
69.7 ± 5.2/ python 58.3 ± 2.8; 9 weeks, wild-type 59.5 ± 5.5/ python 65.6 ± 4.0; 11 weeks, 
wild-type 61.6 ± 4.0/ python 69.5 ± 7.8; and at the onset of overt CCF in python mice, wild-
type 47.2± 5.3 / python 109.8 ± 9.5.  Macrophage-chemoattractant-protein-1 (MCP-1/ 
CCL2) is an important mediator of monocyte/ macrophage recruitment in acute and chronic 
liver injury (316).   MCP1 is produced by a range of cells; including monocytes/ 
macrophages, activated myofibroblasts and cholangiocytes.  Furthermore, MCP-1 is released 
by Kupffer cells in response to ischaemia/reperfusion injury (317).  
 
Macrophage inhibitory protein-2 (MIP2/ CXCL2) is a potent neutrophil chemoattractant and 
was also found to be markedly up-regulated (7.2-fold increase, p<0.01) in python mice 
demonstrating overt features of CCF.  Interestingly MIP2 levels were consistently higher in 
python mice relative to controls from as early as 5 weeks, although this trend was not 
statistically significant until 11 weeks.  The values for MIP2/ CXCL2 protein expression 
(pg/mg tissue) in wild-type and python mice at the different time points (value ± SEM) are: 5 
weeks, wild-type 20.7 ± 3.5/ python 34.3 ± 5.1; 7 weeks, wild-type 10.5 ± 1.7/ python 15.4 ± 
1.9; 9 weeks, wild-type 10.4 ± 1.4/ python 12.9 ± 1.5; 11 weeks, wild-type 10.1 ± 1.5/ 
python 16.7 ± 2.6; and at the onset of overt CCF in python mice, wild-type 8.8 ± 0.9 / python 
64.1 ± 11.4. Both hepatic and serum MIP2 levels have previously been shown to correlate 
with the extent of necroinflammatory change in animal models of alcoholic liver disease 
(318).  MIP2 has also been implicated in mediating responses to ischaemia/ reperfusion in 
the liver (319).   
 
There was no detectable difference in hepatic IL-6 levels between python mice and wild-type 
mice at any time point. The values for IL-6 protein expression (pg/mg tissue) in wild-type 
and python mice at the different time points (value ± SEM) are: 5 weeks, wild-type 36.3 ± 
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5.4/ python 35.6 ± 7.3; 7 weeks, wild-type 30.5 ± 2.5/ python 20.3 ± 1.6; 9 weeks, wild-type 
27.8 ± 2.4/ python 25.3 ± 1.0; 11 weeks, wild-type 31.2 ± 3.4/ python 26.8 ± 3.2; and at the 
onset of overt CCF in python mice, wild-type 27.9 ± 2.7 / python 26.4 ± 1.7. 
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Figure 5.9: Quantification of MCP1, MIP2α and IL6 expression in the python liver 
 
Figure 5.9 Quantification of inflammatory chemokine/ cytokine levels in the python (Py/+) liver relative to 
wild-type (+/+) controls at the time points indicated and at the onset of overt CCF.  The concentration of 
the inflammatory chemokines (A) MCP-1, (B) MIP2 and (C) the cytokine IL-6 are expressed as pg/mg 
liver tissue.  The number (n) of animals/ samples represented by each bar is indicated below the x-axis of 
graph C.  Statistical comparisons between mean values were made using an unpaired student t-test.  In each 
case error bars indicate SEM, *p<0.05, **p<0.01, ***P<0.001 and ns= not significant. 
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5.2.1.5 Quantification of tissue hypoxia in the python model of cardiac 
hepatopathy 
 
It has been postulated that tissue hypoxia might be a key mechanism underlying the 
pathogenesis of hepatocyte injury and fibrogenesis in chronic hepatic congestion.  Studies 
were conducted to determine the degree of liver hypoxia present in the python liver during 
the development of features of overt CCF.  Experiments were conducted using pimonidazole 
hydrochloride, a 2-nitroimidazole hypoxic marker that forms adducts with thiol groups in 
proteins, peptides and amino acids under hypoxic conditions (PaO2<1.3kPa).  Experiments 
were performed in python (Py/+) mice aged 5 weeks, 9 weeks and at the onset of overt 
features of CCF.  Control experiments were performed in age-matched littermates.  
Pimonidazole binding was assessed by immunohistochemical staining for the presence of 
pimonidazole adducts in liver tissue sections (Figure 5.10).  In normal wild-type liver   
intense staining of pimonidazole adducts is restricted to the area immediately surrounding 
the central veins.  A similar pattern is observed in liver sections from python mice prior to 
the onset of overt features of CCF.  In contrast, in python mice with overt features of CCF, 
there is increased intensity of staining around the central veins, with extension of 








Figure 5.10 Quantification of tissue hypoxia with pimonidazole staining in the python model of 
cardiac hepatopathy.  Photomicrographs of liver sections following immunohistochemical staining for 
pimonidazole-adducts (brown).  Experiments were conducted in python (Py/+) mice aged 5 weeks and 
9 weeks, and at the onset of overt CCF (upper panel).  Control experiments were conducted with age-
matched littermate controls (as indicated).  Control staining with an isotype primary antibody showed 







5.2.2 The CREB S133A model of cardiac hepatopathy 
 
The CREB S133A is a transgenic murine model of dilated cardiomyopathy, the generation of 
which has previously been described (204).  Signalling through cyclic adenosine 
monophosphate (cAMP) is known to play an important role in the pathogenesis of cardiac 
failure.  The downstream targets of cAMP include the cAMP response element binding 
protein (CREB), a 43kDa leucine zipper transcription factor, which performs an important 
role in regulating cardiomyocyte function (320, 321).  The transcriptional activity of CREB is 
positively regulated by phosphorylation of the CREB protein at a critical serine residue 
(S133).  This phosphorylation event facilitates the interaction of CREB with CREB-binding 
protein (CBP) resulting in activation of the basal transcription complex.  In the absence of 
S133 phosphorylation CREB binds DNA but cannot activate transcription.  The mutated 
CREB S133A molecule, incorporating a serine to alanine mutation at position 133, is a 
dominant negative repressor of CREB-dependent gene transcription (322, 323).  CREB 
S133A transgenic mice have been developed ( ICR/CD1 background) that express this 
dominant-negative repressor of CREB-mediated signalling under the transcriptional control 
of the cardiac myocyte-specific alpha-myosin heavy chain (MHC) promoter (204). 
Expression of the CREB S133A transgene is restricted to the heart, as demonstrated by 
Northern blot analysis (204). It has been demonstrated that CREB S133A transgenic mice 
develop a form of dilated cardiomyopathy (DCM) that closely resembles idiopathic dilated 
cardiomyopathy in humans.  Histological analysis of hearts from male CREB S133A mice 
demonstrates progressive four chamber dilatation. Histological changes were present in a 
proportion of CREB S133A mice from as early as 4 weeks, and in all animals at 8 weeks.  
Intracardiac thrombus formation was a common finding in animals with DCM.  
Echocardiography demonstrated an increase in left ventricular end-systolic and end-diastolic 
dimensions, in CREB S133A mice relative to littermate wild-type controls (204, 324).  CREB 
S133A mice also had diminished left-ventricular contractility in response to beta-adrenergic 
stimulation (isoproterenol).  Haemodynamic measurements confirm that CREB S133A mice 
have depressed LV systolic function in association with significant reductions in both 
systemic systolic and diastolic blood pressure (204, 324).  CREB S133A mice develop 
clinical features of overt congestive cardiac failure from 8-20 weeks of age, characterised by 
peripheral oedema, ascites, lethargy and dyspnoea. Liver histology is reported as showing 
features consistent with nutmeg liver with central venous congestion and centrilobular 
necrosis.  However, more detailed morphological studies of hepatic changes during the 
course of progressive cardiac failure have not been undertaken in this model. 
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5.2.2.1 Hepatic changes in the CREB S133A model of cardiac hepatopathy 
 
Experiments were conducted in male CREB S133A mice in order to characterise the 
morphological changes occurring within the liver, during the development of progressive 
cardiac failure.  Cohorts (n=3-5) of male CREB S133A mice (ICR/CD1 background) and 
age-matched wild-type controls were culled at 4, 8 and 12 weeks.  In male mice there were no 
demonstrable histological features suggestive of cardiac hepatopathy in 8-week-old CREB 
S133A mice, relative to wild-type controls.  Histological changes consistent with cardiac 
hepatopathy were present in all mice from 12 weeks of age (Figure 5.11).  There was 
considerable heterogeneity in the time of onset of cardiac decompensation in CREB S133A 
mice.   In some specimens, histological changes were restricted to mild CPC with sinusoidal 
dilatation.  In mice demonstrating more severe features of congestive cardiac failure, more 
florid histological abnormalities were present (Figure 5.11 C/D).  There was marked 
sinusoidal congestion and ectasia centred on the hepatic veins (perivenular region). 
Hepatocyte degeneration was evident with vacuolation and hepatocyte plate atrophy was 
seen.  Apoptotic hepatocytes (acidophil bodies) could also be identified in the 12 week CREB 
liver, which were less conspicuous in the Python model.  Areas of extra-medullary 
haematopoiesis were identified as areas of cohesively clustered cells, likely reflecting the 
systemic condition of the animals at the time of sacrifice.  Liver fibrosis was not a prominent 
feature.  In some specimens with more florid histological changes, there was extension of 
fibrous spurs outwards from the central vein into the hepatic parenchyma.  Bridging fibrosis 
was not seen.  Mild to moderate inflammatory changes were seen, centred in the perivenular 
region.  Macrophage infiltration was concentrated around central veins and at sites of 
hepatocyte necrosis but was not present prior to 12 weeks (data not shown).  MFB activation, 
as assessed by αSMA-staining, was evident at sites of sinusoidal dilatation centred on dilated 
central veins, in the vicinity of hepatocyte degeneration (Figure 5.12).  The values for 
percentage αSMA staining (%) in wild-type and CREB S133A mouse livers (value ± SEM) at 
the time points investigated were: week 4, wild-type 0.011 ± 0.002/ CREB S133A 0.019 ± 
0.010; week 8, wild-type 0.001 ± 0.0007/ CREB S133A 0.004 ± 0.002; and week 12, wild-
type 0.005 ± 0.002/ CREB S133A 0.473 ± 0.302.  These differences were not statistically 
significant.  In CREB S133A mice with histological changes consistent with mild hepatic 
congestion, MFB activation was restricted to the centrilobular region with variable extension 
outwards into the liver parenchyma.  In liver samples with the most marked histological 
abnormalities, αSMA-staining extended throughout the hepatic lobule in a perisinusoidal 
distribution.  Digital image analysis of αSMA-stained sections shows a dramatic increase (92-
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fold) in αSMA-staining in 12 week-old CREB S133A mice relative to wild-type controls, 
although this did not achieve statistical significance. This reflects the degree of heterogeneity 
observed in this cohort with respect to the onset of severe right-heart failure.  There was no 
evidence of MFB activation prior to the development of overt congestive cardiac failure. 
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Figure 5.11: Histological appearance of the CREB S133A liver (haematoxylin 












Figure 5.11 Continued 
 
 
Figure 5.11 Photomicrographs (x200-magnification) of haematoxylin and eosin stained liver sections 
taken from CREBS133A transgenic mice and age-matched wild-type controls at various time points 
(as indicated).  The histological appearance of the liver in (A) 8-week-old CREB S133A transgenic 
mice is indistinguishable from that of (B) 8-week-old wild-type control animals.  Histological 
abnormalities consistent with cardiac hepatopathy develop from 12 weeks of age in CREB S133A 
animals.  (C/D) Liver tissue taken from 12-week-old CREB S133A mice displaying clinical features 
of overt congestive cardiac failure has gross histological abnormalities.  There is perivenular 
sinusoidal congestion and dilatation/ ectasia (SD) accompanied by hepatocyte plate atrophy (HPA) 
and apoptotic hepatocytes are also seen. Hepatocyte degenerative vacuolation is also seen (V).  There 
are also areas of apparent extra-medullary haematopoiesis (EH).  (D) The immediate periportal region 
is relatively spared. BD = bile duct. (E) Liver tissue from age-matched 12-week-old wild-type mice 
showed normal liver histology.  In each image the scale bar indicates 50µm. 
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Figure 5.12 Quantification of myofibroblast activation (αSMA staining) in the 
CREB S133A liver 
 
 
Figure 5.12.Quantification of αSMA staining in the CREB S133A model of cardiac hepatopathy.  (A) 
Photomicrograph (x50-magnification) of αSMA stained liver tissue from a 12-week-old CREB S133A 
transgenic mouse with right-heart failure.  MFB activation predominates in the centrilobular region 
with radiation outwards into the liver parenchyma.  (B) Photomicrograph (x200-magnification) of 
αSMA stained liver tissue from a 12-week-old CREB S133A transgenic mouse with more advanced 
right-heart failure.  Isotype control staining is represented by the indented image at the right hand 
corner. (C) Quantification of αSMA staining by digital image analysis of liver sections derived from 
CREB S133A (tgCREB) mice at 4, 8 and 12 weeks.  At each time point comparison is made to age-
matched wild-type (WT) littermate controls.  Statistical comparisons between means were made using 
an unpaired student t-test.  Each bar represents the mean percentage area of αSMA staining per high 
power (x200) field (p value as indicated).  The number of animals/ samples represented by each bar is 
indicated below the x-axis.  Abbreviations: CV, central vein and PT, portal tract. 
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5.2.2.2 Fibrous tissue changes in the CREB S133A model of cardiac 
hepatopathy 
 
The accumulation of fibrillar collagen in the CREB S133A model was quantified by digital 
image analysis of PSR stained liver sections (Figure 5.13).  The values for percentage PSR 
staining (%) in wild-type and CREB S133A mouse livers (value ± SEM) at the time points 
investigated were: week 4, wild-type 0.071 ± 0.035/ CREB S133A 0.071 ± 0.023; week 8, 
wild-type 0.172 ± 0.061/ CREB S133A 0.157 ± 0.043; and week 12, wild-type 0.364 ± 
0.054/ CREB S133A 0.445 ± 0.120. In 12 week-old CREB S133A mice, there was 
considerable heterogeneity in the extent of fibrous tissue deposition, which reflected the 
variability/ severity of hepatic congestion seen.  In those CREB S133A mice displaying 
features of overt congestive cardiac failure there was a dramatic increase in PSR staining.  In 
these specimens, the increase in PSR staining was centred on central veins, radiating 
outwards into the parenchyma.  However, overall, there was no significant increase in PSR 
staining in CREB S133A mice at 12 weeks, relative to wild-type controls.  Furthermore, 
there was no difference in PSR staining between CREB S133A mice and wild-type controls 
at earlier time points. 
 
Real-time quantitative PCR of cDNA derived from whole liver lysates was used to quantify 
the expression profile of ECM components and profibrotic mediators at 4, 8 and 12 weeks 
(Figure 5.14).  Gene expression is expressed as fold induction relative to 18S expressions.  
Values are standardised to expression values in 5-week-old wild-type mice.  The values for 
fold induction of COL1A1 (value ± SEM) are: week 4, wild-type 1.000 ± 0.227/ CREB 
S133A 1.316 ± 0.234; week 8, wild-type 0.209 ± 0.056/ CREB S133A 0.203 ± 0.052; and 
week 12, wild-type 0.306 ± 0.153/ CREB S133A 9.377 ± 4.202.  The values for fold 
induction of COL3A1 (value ± SEM) are: week 4, wild-type 1.000 ± 0.178/ CREB S133A 
1.256 ± 0.149; week 8, wild-type 0.335 ± 0.061/ CREB S133A 0.285 ± 0.045; and week 12, 
wild-type 0.230 ± 0.055/ CREB S133A 2.095 ± 0.689.  The values for fold induction of 
TIMP1 (value ± SEM) are: week 4, wild-type 1.000 ± 0.270/ CREB S133A 1.604 ± 0.373; 
week 8, wild-type 0.328 ± 0.017/ CREB S133A 0.255 ± 0.031; and week 12, wild-type 
1.448 ± 0.322/ CREB S133A 16.35 ± 5.862.  The values for fold induction of αSMA (value 
± SEM) are: week 4, wild-type 1.000 ± 0.483/ CREB S133A 1.429 ± 0.488; week 8, wild-
type 2.826 ± 0.835/ CREB S133A 3.223 ± 0.470; and week 12, wild-type 0.282 ± 0.073/ 
CREB S133A 90.92 ± 16.22. 
In 12 week-old CREB S133A mice there was marked upregulation of COL1A1 (31-fold, 
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p<0.05) COL3A1 (9-fold, p<0.05) and TIMP1 (11-fold, p<0.05) mRNA, relative to controls.  
Similarly, there was a dramatic upregulation in αSMA expression in 12-week-old CREB 
S133A mice, relative to controls.  There was no significant difference between CREB S133A 
mice and wild-type controls in COL1A1, COL3A1, TIMP1 or αSMA expression prior to the 








Figure 5.13 Quantification of PSR staining in the CREB S133A model of cardiac hepatopathy. 
Photomicrographs (x200 magnification) of PSR stained liver sections from (A) 12 week-old CREB 
S133A mice demonstrating overt features of CCF and (B) age-matched wild-type controls. Scale bar 
indicates 200µm. (C)  Quantification of PSR staining by digital image analysis of liver sections 
derived from CREB S133A (tgCREB) mice at 4, 8 and 12 weeks.  At each time point comparison is 
made to age-matched wild-type (WT) littermate controls.  Statistical comparisons between means 
were made using an unpaired student t-test.  Each bar represents the mean percentage area of PSR 
staining per high power (x200) field (ns = not significant).  The number of animals/ samples 
represented by each bar is indicated below the x-axis. 
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Figure 5.14: Real-time PCR analysis for fibrosis marker expression in the 




Figure 5.14  Real-time quantitative PCR analysis for (A) COL1A1, (B) COL3A1, (C) TIMP1 and (D) 
αSMA mRNA expression in whole liver lysates derived from CREB S133A mice (grey bars) at 4, 8 
and 12 weeks (n= 3-5 per time point). At each time point comparison is made to mRNA from whole 
liver lysates derived from age-matched wild-type (+/+) control animals (white bars). In each case, 
target mRNA expression is calculated relative to the expression of the 18S housekeeping gene and 
fold-induction expressed relative to target mRNA expression in the +/+ control group at 5 weeks.  
Statistical comparisons between means were made using an unpaired student t-test.  Error bars 
represent SEM, *p<0.05, **p<0.01, ***p<0.001.  The number of animals/ replicates represented by 
each bar is indicated below the x-axis of graph 5.14 A.   
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5.3 Uniaxial strain facilitates cytoskeletal realignment and promotes a 
fibrogenic phenotype in HSCs in vitro 
 
Physical factors, including both changes in matrix stiffness and stretch, may be important in 
promoting a fibrogenic phenotype in HSCs.  In each murine model of congestive cardiac 
failure, αSMA-staining (a marker of myofibroblast activation) was observed in a 
perisinusoidal distribution in association with sinusoidal dilatation.  It was hypothesised that 
uniaxial stretch, consequent upon sinusoidal dilatation, might promote a fibrogenic 
phenotype in HSCs.  In order to investigate this hypothesis, HSCs were cultured on collagen-
I-coated deformable silicon membranes and subjected to uniaxial mechanical strain for 
between 4 and 24 hours (Figure 5.15).  Cyclical strain (1Hz) was applied to the membranes 
to give uniaxial strain of 2.5-10%.  Cytoskeletal organisation was assessed by digital image 
analysis following F-actin staining with fluorescently-labelled phalloidin. 
 
Figure 5.15  
 
Figure 5.15 (A) Schematic representation of the relationship between vascular sinusoids (VS) and hepatic 
stellate cells (HSCs) in vivo.  Sinusoidal dilatation, as encountered in hepatic congestion would result in 
uniaxial deformation of perisinusoidal HSCs.  (B)  Schematic representation of Flexcell FX2000 
apparatus.  HSCs are cultured in six-well plates on collagen-I-coated deformable membranes.  Each 
membrane is suspended above a central arctangularTM support.  Negative pressure applied to the base of 
each well from a computer controlled vacuum pump leads to indrawing of the peripheral (unsupported) 
section of each well.  This results in uniaxial deformation of the central (supported) section and the cell 
monolayer (CM) adherent to this region.  The apparatus is calibrated to produce cyclical (1Hz) uniaxial 
strain in the range 2.5-10%.
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HSCs subjected to cyclical uniaxial strain in 2-dimensional culture for 4-24 hours demonstrate 
reorientation of their actin stress fibres parallel to the direction of applied stress (Figure 5.16). 
After 4 hours, the values for mean stress fibre orientation (value in degrees ± SEM) relative to 
the direction of applied strain for different magnitudes of strain were: control/ unstrained, 41.60 
± 2.28o; 2.5% strain, 40.47 ± 2.52o; 5% strain, 33.45 ± 2.86o; and 10% strain, 38.40 ± 2.78o. 
After 24 hours, the values for mean stress fibre orientation (value in degrees ± SEM) relative to 
the direction of applied strain for different magnitudes of strain were: control/ unstrained, 47.95 
± 2.42o; 2.5% strain, 24.91 ± 2.90o; 5% strain, 32.52 ± 2.21o; and 10% strain, 37.93 ± 2.12o. 
 
Real-time quantitative PCR of cDNA derived from HSC cells subjected to cyclical (1Hz) 
uniaxial strain (2.5-10%) was used to investigate the effect of increasing strain on the expression 
of selected profibrotic genes including COL1A1, COL3A1, αSMA and TIMP1 (Figure 5.17).  
Gene expression is expressed as fold induction relative to 18S expressions.  Values are 
standardised to expression values in cells exposed to 2.5% strain.  The values for fold induction 
of αSMA (value ± SEM) are: 2.5% strain, 1.000 ± 0.104; 5% strain, 1.229 ± 0.130; and 10% 
strain, 1.030 ± 0.090.  The values for fold induction of COL1A1 (value ± SEM) are: 2.5% 
strain, 1.000 ± 0.041; 5% strain, 1.259 ± 0.076; and 10% strain, 1.201 ± 0.071.  The values for 
fold induction of COL3A1 (value ± SEM) are: 2.5% strain, 1.000 ± 0.085; 5% strain, 2.400 ± 
0.232; and 10% strain, 3.584 ± 0.371.  The values for fold induction of TIMP1 (value ± SEM) 
are: 2.5% strain, 1.000 ± 0.092; 5% strain, 1.466 ± 0.115; and 10% strain, 1.778 ± 0.132.  An 
increase in the magnitude of uniaxial strain from 2.5-10%, resulted in a statistically significant 
increase in the expression of COL1A1 (1.2-fold, p<0.05), COL3A1 (3.6-fold, p<0.001) and 
TIMP1 (1.8-fold, p<0.001).  Alterations in the magnitude of applied strain (2.5-10%) did not 
result in any significant alteration in αSMA expression (unpaired student t-tests). 
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Figure 5.16: Effect of cyclical uniaxial strain on cytoskeletal organisation and 
cell orientation in primary murine HSCs 
 
Figure 5.16 HSCs subjected to cyclical uniaxial strain (2.5-10%) demonstrate reorientation of stress 
fibres parallel to the direction of applied strain.  (A) The orientation of actin stress fibres in HSCs was 
measured relative to the direction of applied uniaxial strain.  (B) The predominant orientation of actin 
stress fibres in individual HSCs was measured by digital image analysis following immunofluorescent 
staining of the actin cytoskeleton with fluorescently-labelled phalloidin.  The graphs show the change 
in mean stress fibre orientation of HSCs subjected to cyclical uniaxial strain for (C) 4 and (D) 24 
hours.  Values represent the mean orientation of stress fibres relative to the direction of strain. Stress 
fibre orientation was determined for all cells in 20 randomly selected high power (x200) fields.  The 
number of cells represented by each bar is indicated below the x-axis of each graph.  Boxes represent 
25th to 75th percentiles and whiskers indicate 10th and 90th percentiles.  Statistical comparisons 
between means were made using a Mann-Whitney test (**p<0.01 ***p<0.001).
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Figure 5.17: Effect of cyclical uniaxial strain on pro-fibrotic gene mRNA 




Figure 5.17 Graphs showing the mRNA expression for selected pro-fibrotic genes in HSCs subjected 
to cyclical (1Hz) uniaxial strain with magnitude 2.5-10% (as indicated) for a period of 24 hours.  Gene 
expression (mRNA) was measured using SYBR-green quantitative PCR relative to the expression of 
the 18S housekeeping gene.  Values are represented as fold-induction relative to gene expression in 
cells subjected to 2.5% uniaxial strain.  Increasing the magnitude of uniaxial strain from 2.5 to 10% 
resulted in a significant upregulation of COL1A1 (1.2-fold, p<0.05), COL3A1 (3.6-fold, p<0.001) and 
TIMP1 (1.8-fold, p<0.001) expression.  The results reflect the mean of 3 replicates in 3 independent 
experiments (n=9).  Statistical comparisons between mean values were made using an unpaired 
student t-test. (ns = not significant, *p<0.05, **p<0.01 and ***p<0.001). 
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5.4 Increases in matrix stiffness promote cytoskeletal reorganisation and 
fibrogenic phenotype in HSCs in vitro 
 
Experiments were conducted to determine the effect of changes in matrix stiffness on HSC 
morphology and cytoskeletal organisation in vitro.  Primary murine HSCs were cultured on 
collagen-I-coated PA gel supports of defined stiffness (G’ 1-12kPa).  Cytoskeletal 
organisation was assessed by digital image analysis following F-actin staining with 
fluorescently-labelled phalloidin (Figure 5.18).  HSCs cultured on soft (1kPa) supports were 
small and rounded with absent stress fibres.  In contrast, HSCs cultured on stiff (12kPa) 
supports were well-spread and flattened with numerous fine cellular processes and prominent 
actin stress fibres.  Real-time PCR was used to investigate the effect of changes in matrix 
stiffness on the expression of selected profibrotic genes.  Gene expression is expressed as 
fold induction relative to 18S expressions.  Values are standardised to expression values in 
cells cultured on 1kPa supports.  The values for gene of interest expression (value ± SEM) 
for HSCs cultured on 1kPa and 12kPa supports are: αSMA, 1kPa 1.000 ± 0.156/ 12kPa 
1.888 ± 0.230; COL1A1, 1kPa 1.000 ± 0.143/ 12kPa 1.587 ± 0.140; COL3A1, 1kPa 1.000 ± 
0.152/ 12kPa 1.496 ± 0.130; and TIMP1, 1kPa 1.000 ± 0.089/ 12kPa 1.274 ± 0.090.  In 
comparison to cells cultured on soft (1kPa) supports, HSCs on stiff (12kPa) supports 
upregulated expression of αSMA (1.9-fold, p<0.05), COL1A1 (1.6-fold, p<0.05) and 
COL3A1 (1.5-fold, p<0.05).  There was a trend towards upregulation of TIMP1 in HSCs 
cultured on stiff supports but this was not statistically significant.  These results are 
consistent with published studies demonstrating that increases in matrix stiffness across a 
pathophysiologically-relevant range (1-12kPa) promote myofibroblast differentiation and 
collagen deposition in both HSCs (134) and PFs (133). 
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Figure 5.18: The effect of PA support stiffness on cytoskeletal organisation 
and pro-fibrotic gene expression in primary murine HSCs 
 
Figure 5.18 Confocal photomicrographs (x200 magnification) of primary murine HSCs cultured on 
1kPa and 12kPa collagen-I-coated PA supports, as indicated.  Cells have been stained for the presence 
of actin stress fibres (phalloidin- green), mature focal adhesions (anti-vinculin-red) and nuclear DNA 
(4',6'-diamidino-2-phenyl-indole dihydrochloride (DAPI)- blue). (C) Graphs showing mRNA 
expression for selected pro-fibrotic genes in HSCs cultured for 72 hours on 1kPa and 12kPa collagen-
I-coated PA supports, as indicated.  Gene expression (mRNA) was measured using SYBR-green 
quantitative PCR relative to the expression of the 18S housekeeping gene.  Values are expressed as 
fold-induction relative to gene expression on 1kPa supports.  The results reflect the mean of 3 
replicates in 3 independent experiments (n=9).  Statistical comparisons between means were made 




Cardiac hepatopathy defines a heterogeneous group of conditions that are perhaps best 
described in relation to the duration of cardiac dysfunction (325).  Acute cardiac dysfunction 
is typically associated with the development of ischaemic hepatitis. This syndrome is 
characterised clinically by marked elevation of serum transaminase levels and histologically 
as acute hepatitis with centrilobular necrosis (326). In contrast cardiac fibrosis and cirrhosis 
has been described in relation to patients with chronic congestive cardiac failure (304).   
Myers et al published a detailed description of the clinical, haemodynamic and histological 
characteristics of a cohort of 83 patients presenting with cardiac hepatopathy (325). Patients 
were sub-divided into clinical groups based on the duration of cardiac dysfunction.  Serum 
transaminase levels were markedly elevated in patients with either acute or acute on chronic 
cardiac dysfunction.  In contrast, serum transaminase levels were typically within the normal 
range, or more modestly elevated in patients with chronic cardiac dysfunction.  In respect to 
liver histology, centrilobular necrosis, inflammation and sinusoidal haemorrhage were more 
common in patients with acute, or acute on chronic cardiac dysfunction. Severe fibrosis 
sufficient to disrupt the normal microscopic architecture was uncommon (present in 19% of 
cases), and indeed was absent in all patients with acute cardiac dysfunction.  Cirrhosis was 
present in only one patient with chronic valvular heart disease.  This would suggest, as 
would be expected, that severe liver fibrosis and cirrhosis develops as a consequence of 
chronic cardiac dysfunction. 
 
Ischaemic hepatitis is traditionally believed to occur as a consequence of acute impairment 
of hepatic perfusion secondary to systemic hypotension.  However this model represents an 
oversimplification.  Hypotension alone would appear to be insufficient to precipitate 
ischaemic hepatitis (303).  Seeto et al published a case comparison study in which patients 
presenting with markedly elevated transaminase levels (>20x ULN) secondary to ischaemic 
hepatitis were compared to a control group of previously healthy individuals who had 
sustained non-hepatic trauma (303).  Despite similar reductions in systolic blood pressure, no 
patients in the control group developed ischaemic hepatitis.  Furthermore, all patients with 
ischaemic hepatitis had evidence of pre-existing heart disease with the overwhelming 
majority (94%) demonstrating features of right heart failure.  These results would suggest 
that ischaemic hepatitis is uncommon in patients without pre-existing heart disease.  This is 
consistent with the results of histological studies suggesting that chronic passive congestion 
may contribute to the development of  centrilobular necrosis in the context of systemic 
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hypotension (301).   
 
What then are the precise haemodynamic alterations that promote ischaemic hepatitis or liver 
fibrosis in patients with cardiac dysfunction?  Myers et al reported that in patients with acute 
cardiac dysfunction, transaminase elevation was highly correlated with right atrial pressure 
(RAP), free hepatic venous pressure (FHVP) and wedged hepatic venous pressure (WHVP), 
but interestingly was not correlated with cardiac index (325).  In patients with acute on 
chronic cardiac dysfunction, there was no correlation between transaminase levels and RAP, 
free hepatic venous pressure or wedged hepatic venous pressure.   In patients with chronic 
cardiac dysfunction transaminase elevation was only weakly correlated to RAP.  In respect 
to liver histology, as would be expected, elevated free hepatic vein pressure was associated 
with sinusoidal dilatation and patients with liver fibrosis had elevated WHVP, reflecting 
elevated portal pressure.  Liver fibrosis was not significantly associated with any particular 
haemodynamic variable.  These results would suggest that elevated venous pressure is an 
important factor in the pathogenesis of ischaemic hepatitis.  However the haemodynamic 
variables that contribute to chronic cardiac hepatopathy are less clearly defined.   
 
The haemodynamic changes described in patients following the Fontan procedure provide 
significant insight into the effects of chronic hepatic congestion.  Liver fibrosis and cirrhosis 
are common complications of the Fontan procedure (306-308).  Kiesewetter et al undertook 
detailed haemodynamic measurements in a cohort of patients assessed for surgical correction 
of failing Fontan circulations, the majority of which (7/12) had evidence of cirrhosis on liver 
biopsy (308).  There was a significant correlation between the Fontan duration and the extent 
of liver fibrosis.  More importantly the presence of cirrhosis was positively correlated with 
free hepatic vein pressure.  As discussed previously, detailed morphological analysis of liver 
histology in a related cohort of Fontan patients showed histological features similar to those 
described in cardiac sclerosis (307).  It was postulated that in these patients, the absence of 
inflammation or hepatocellular damage in biopsy specimens meant that fibrosis may be 
mediated by a non-inflammatory mechanism.  This is somewhat speculative and the absence 
of acute inflammation in these specimens may be related to sample bias.  Liver biopsies were 
only obtained from patients undergoing pre-operative assessment prior to surgical correction 
of failing Fontan circulations, whose livers would have been subject to chronically elevated 
right-sided pressures. The time course of histological events in the Fontan liver remains 
uncharacterised.  Ethical considerations would prevent serial liver biopsies being taken from 
these patients throughout the natural history of their condition.  Across a range of 
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inflammatory disorders, including autoimmune hepatitis and non-alcoholic fatty liver 
disease, it is not uncommon for liver biopsies from patients with advanced or ‘burnt out’ 
cirrhosis to demonstrate an absence of acute inflammation or hepatocellular damage.  It was 
hoped that a murine model of congestive cardiac failure would prove a better understanding 
of the histological events contributing to the development of liver fibrosis in chronic cardiac 
hepatopathy.  
 
The murine models described in this chapter are most appropriately defined as models of 
acute on chronic cardiac dysfunction.  In the python model of cardiac hepatopathy, features 
of overt congestive cardiac failure are associated with marked elevation in serum 
transaminase levels (>3x ULN).  Histological abnormalities in liver architecture are not 
present until mice demonstrate features of overt congestive cardiac failure and then develop 
rapidly.  In each model the principle histological abnormalities observed at the context of 
decompensated cardiac failure are sinusoidal dilatation/ ectasia with associated hepatocyte 
degeneration manifested as granular cytoplasmic change, vacuolation and hepatocyte plate 
atrophy.  Hepatocyte apoptosis was observed in the CREB S133A model but gross 
centrilobular necrosis was not seen.  Neither of these models provides a model of progressive 
liver fibrosis analogous to the Fontan liver.  Distinct sinusoidal pericellular αSMA 
immunopositivity is seen that would suggest MFB activation.  However, although fibrous 
spur formation is present in some specimens in association with sinusoidal dilation, bridging 
fibrosis and liver fibrosis is not observed.  However, it should be acknowledged that the 
natural history of cardiac failure in this model is such that there may be insufficient time for 
the development of organised liver fibrosis and cirrhosis.  With the notable exception of 
TIMP1, in the python model, and to a lesser extent TIMP2, there was no significant 
difference in the expression of selected ECM components/ profibrotic mediators and 
inflammatory cytokines prior to the onset of overt cardiac failure.  This would suggest that 
the histological changes observed in patients with overt congestive cardiac failure occur 
rapidly and without significant prodrome.   
 
In the python model there is a clear and progressive increase in hepatocyte nuclear size as 
the mice age.  It has been suggested that this may relate to impairment of nuclear fission due 
to the germline mutation in the dlp1 gene and a resulting increase in cell ploidy.  Further 
work would be required to investigate this further, but this observation raises clear concerns 
in respect to the use of the python mouse as a model of cardiac hepatopathy.  Such changes 
in hepatocyte nuclear appearance are not apparent in the CREB S133A model.  However, a 
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similar pattern of histological changes is otherwise observed in the CREB S133A model of 
dilated cardiomyopathy.  Importantly, expression of the CREB S133A transgene which 
disrupts CREB-related gene transcription is restricted to the heart.  Therefore the similarity 
in histological changes observed in the liver of both the CREB S133A and python models of 
cardiac hepatopathy does, to some extent, allay concerns that observed phenotype in the 
python liver is a consequence of a more general impairment of organelle fission or 
mitochondrial function .  Liver histology from CREB S133A mice prior to the onset of overt 
cardiac failure is indistinguishable from age-matched control animals.   
 
It is probable that the histological abnormalities observed in the livers taken from mice with 
overt cardiac failure are a consequence of both systemic hypotension and elevated right-
sided pressures.  Haemodynamic measurements in 10-11 week-old python mice demonstrate 
a significant reduction in mean arterial pressure relative to controls.  There was no difference 
in central venous pressure between the two groups at this time point.  However, in python 
mice, the development of overt cardiac failure was associated with clinical features of 
elevated right-sided pressure including: ascites, peripheral oedema and right atrial/ 
ventricular enlargement.  As the haemodynamic measurements obtained in the python model 
were taken prior to the development of advanced cardiac failure they do not properly reflect 
the conditions present during the evolution of hepatic dysfunction.  Further haemodynamic 
measurements would therefore be required, in both models, to delineate the relative 
importance of systemic hypotension and central venous pressure in promoting hepatic 
dysfunction in this model.    
 
The aim of the research presented in this chapter was to provide the first detailed 
characterisation of the sequence of histological events observed in murine models of cardiac 
hepatopathy.  Neither the Python or CREB S133A models of dilated cardiomyopathy 
provides a model of chronic liver fibrosis comparable to that observed in livers from patients 
with failing Fontan circulations. Instead they represent models of acute on chronic cardiac 
hepatopathy, more readily comparable to the ischaemic hepatitis observed in patients with 
pre-existing cardiac dysfunction.  In each model, the natural history of cardiac dysfunction is 
such that there is insufficient time for the development of organised liver fibrosis and 
cirrhosis.  It is unclear whether, were it possible to extend the time course of cardiac 
dysfunction in these models, we would observe the development of bridging fibrosis and 
ultimately cirrhosis. It is equally uncertain whether in human patients with the Fontan 
circulation, liver fibrosis is a consequence of chronic liver damage secondary to persistently 
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elevated right-sided pressures, or repetitive injury due to recurrent episodes of systemic 
hypotension and hypoxaemia.  These questions would be better addressed with the 
development of an animal model with a more protracted phase of right-sided heart failure.   
 
The precise aetiological factors responsible for the development of liver damage and fibrosis 
in cardiac hepatopathy are poorly characterised.  These may include: tissue hypoxia 
secondary to diminished hepatic perfusion; perisinusoidal oedema restricting diffusion of 
oxygen and nutrients; elevated central venous pressure resulting in sinusoidal dilatation and 
hepatocyte plate compression; and cellular responses to alteration in matrix stiffness and 
cellular tension.  Pimonidazole-adduct immunohistochemistry was used to determine the 
degree of liver hypoxia associated with the development of congestive cardiac failure.  In 
python mice with features of overt congestive cardiac failure, there was increased intenstity 
of staining around the central veins, with extension of pimonidazole-adduct formation 
outward into the liver parenchyma.  This pattern of increased tissue hypoxia paralleled the 
pattern of hepatocyte injury and hepatic myofibroblast activation.  Hypoxia is known to 
promote type I collagen production by activated HSCs (327) and hypoxia has been implicated 
as a possible aetiological factor in a range of liver diseases (328).  However a full discussion 
as to the role of tissue hypoxia in promoting liver fibrosis is beyond the scope of this thesis. 
 
It has been suggested that direct mechanical stimulation of liver resident cell populations 
consequent upon elevated central venous pressure may promote liver fibrosis. Elevated 
central venous pressure results in hepatic venous distension and sinusoidal dilatation.  In 
addition, in patients with tricuspid regurgitation, atrial contraction is associated with intra-
hepatic reflux resulting in cyclical sinusoidal dilatation and compression of hepatocyte cell 
plates (308).  HSCs residing within the space of Disse would therefore be subjected to 
repetitive strain.  The results presented in this chapter demonstrate that HSCs subjected to 
increasing cyclical uniaxial strain respond by up-regulation of profibrotic genes, including 
COL1A1, COL3A1 and TIMP1, that would be expected to promote liver fibrosis.  This is 
consistent with the results of previous research demonstrating that cyclical mechanical 
stretch enhances TGFβ expression by HSCs in vitro (329).  Another consequence of hepatic 
congestion is an increase in liver stiffness (115).  In experiments conducted using collagen-I-
coated PA gels of defined stiffness (1-12kPa) I have demonstrated that increasing matrix 
stiffness is associated with upregulation of markers of MFB activation and fibrillar collagen 
components.  This confirms the results of previous in vitro research showing that increases in 
matrix stiffness across a pathophysiological range promotes MFB differentiation and matrix 
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deposition in both HSCs and PFs (133, 134).   It is tempting to speculate that increased tissue 
stiffness due to oedema may render liver resident cells, including MFB precursors, more 
responsive to a range of factors, including inflammatory cytokines, toxins and hypoxic 
stimulation. However, more research is required to understand how changes in matrix 
stiffness/ intracellular tension might influence MFB responses to mitogenic and profibrotic 
stimulation.  
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The principle aim of this thesis was to explore how changes in matrix stiffness observed in 
liver disease might influence the development of hepatocellular carcinoma.  Previous 
research undertaken by Dr Rebecca Wells suggested that changes in matrix stiffness might 
be important mechanistically in the initiation and perpetuation of liver fibrosis (133-135, 
292). The ability of cells to respond to changes in the mechanical properties of the ECM has 
been shown to be critical to the regulation of both cell proliferation and differentiation (97, 
98).  The stiffness of the ECM in different tissues spans several orders of magnitude (83).  
However, within each tissue, under normal conditions, differentiated cells are exposed to a 
narrow range of environmental stiffness (100).  As discussed previously, matrix stiffness 
changes dramatically throughout embryological development and in pathological processes, 
including inflammation and cancer development.  Understanding how cells respond to these 
pathophysiologically-relevant changes in matrix stiffness will greatly enhance our 
understanding of these disease processes. Changes in matrix stiffness associated with 
inflammation and fibrosis are thought to be mechanistically important in promoting cancer 
development. The relationship between inflammation and cancer development has long been 
recognised (330, 331).  Cancer development involves both factors intrinsic to the cancer cells 
themselves (genetic instability), and extrinsic factors.  These include the stromal, endothelial 
and inflammatory cells that contribute to a heterocellular tumour, and the biochemical and 
mechanical properties of the extracellular matrix.   
 
Liver fibrosis is associated with an increased risk of cancer development (167, 168), with  
multiple mechanisms thought to account for this association.  The abundant ECM that 
characterises liver fibrosis promotes integrin signalling in hepatocytes, which may enhance 
the growth and survival of pre-cancerous cells.  Both collagen and integrin expression is 
closely correlated with tumour development in well-validated murine models of HCC (332).  
There is also extensive paracrine crosstalk between tumours and tumour-associated stromal 
cells.  Fibroblasts are associated with tumour cells at all stages of cancer progression.  
Tumour-associated stromal cells produce growth factors, chemokines and ECM proteins that 
promote tumour growth (333).  The expression profile of non-tumoral liver tissue is 
correlated to survival in patients with HCC (334). Genetic studies have demonstrated that a 
36-gene signature originating from the non-cancerous liver tissue can accurately predict the 
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risk of recurrence in patients with multifocal HCC (335).  The genes identified in this study 
were a heterogeneous group.  They include the Fps/Fes proto-oncogene that it known to 
promote angiogenesis and which is implicated in the development and progression of thyroid 
and colon cancer.  Another signature gene encodes oncoprotein 18, a protein that is 
phosphorylated in response to several extracellular signals and is highly expressed in 
leukaemia, breast and ovarian cancer.  A number of the genes have inflammatory or immune 
modulating functions, including: tumour necrosis factor-α (LITAF), T cell receptor β locus, 
DC class II histocompatibility antigen α chain (HLA-DQA1) and immunoglobulin-binding 
protein 1 (IGBP1).   Interestingly matrix proteins are not represented.  The ECM is also 
thought to play a role in regulating the availability of growth factors.  It has been 
demonstrated that growth factors, including TGFβ are sequestered in ECM that may 
subsequently been released in the context of inflammation, promoting tumour development 
(336).  Furthermore, the presence of liver fibrosis may impair immune surveillance by 
natural killer cells facilitating the development of HCC (337).  Finally, it has been proposed 
that changes in the mechanical properties of the ECM may promote the development of 
malignancy (155, 172). 
 
Seminal research undertaken by Paszek et al in the breast cancer field explored the 
relationship between matrix stiffness and tumour development (155).  As discussed 
previously, it was demonstrated that tumours were rigid due to both the presence of a stiff 
stroma and elevated cytoskeletal tension. Rho driven cytoskeletal tension promoted focal 
adhesion formation, disturbed tissue polarity and glandular differentiation while enhancing 
growth factor stimulated ERK activation.  Conversely, EGF-transformed epithelia with 
elevated ERK and Rho activity could be induced to revert to a non-malignant phenotype if 
either ERK or Rho-generated contractility was inhibited or cells were cultured on soft PA 
supports with stiffness approximating that of non-malignant mammary tissue.  These 
observations formed the basis of a model for tensional control of malignant transformation. 
Subsequent in vivo experiments demonstrated that a reduction in tissue stiffness through 
inhibition of collagen cross-linking could impede tumour growth in a murine model of breast 
cancer (46).  The premise that matrix stiffness might regulate cancer development has been 
extended to other malignancies, with increasing matrix stiffness shown to promote 
proliferation in both transformed glioma cells (184) and lung carcinoma cells (338).  
However, stiffness dependent-regulation of cell proliferation is not a universal property of 
cancer cells. Indeed, Tilghman et al have shown that cancer cell lines can be segregated on 
the ability to proliferate on soft (<1000Pa) collagen-coated gels (338, 339). However, the 
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precise mechanisms underlying the biomechanical regulation of cancer cell phenotype 
remain incompletely characterised. 
 
The experiments conducted in this thesis were intended to evaluate the effect of changes in 
matrix stiffness on proliferation, differentiation and growth factor-mediated signalling in 
HCC cells.  I have also examined the effect of matrix stiffness on the behaviour of hepatic 
progenitor cells, which have themselves been implicated in hepatocarcinogenesis. 
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6.2 Summary of key findings and suggestions for future research 
 
6.2.1 The effect of matrix stiffness on the pathophysiology of hepatocellular 
carcinoma (HCC) 
 
The liver provides an exemplary model in which to explore the relationship between tissue 
stiffness and cancer development.  Transient elastography and torsional rheometry have 
defined the range of stiffness values that would be encountered by cells during the evolution 
of liver fibrosis and hepatocarcinogenesis (117, 135, 340).  Experiments conducted with 
ligand coated PA supports have been used to explore the effect of changes in matrix stiffness 
on cancer cell phenotype.  These experiments demonstrate that increases in matrix stiffness 
are associated with both the development of liver fibrosis and tumour development, and 
enhance proliferation in HCC cells in vitro.  These findings are consistent with the published 
literature which argues that physiological stiffness is inhibitory to cell cycle progression 
(127).  Increases in matrix stiffness typically occur in the context of tissue damage or 
inflammation, where a loosening of cell cycle regulation may be desirable to facilitate tissue 
regeneration.  Thus, tensional control of cell cycle progression may represent a fundamental 
and primitive mechanism regulating cellular proliferation. However, an undesirable 
consequence of such tensional homeostasis in the context of chronic inflammation might be 
to promote cancer development. 
 
Alterations in matrix stiffness have broad and pervasive effects in relation to growth factor-
mediated signalling.  Increases in matrix stiffness are associated with more robust activation 
of the FAK, ERK, Akt/ PKB and STAT3 signalling pathways in response to HGF 
stimulation.  Stiffness-dependent regulation of STAT3-signalling has not previously been 
described.  The results are consistent with a model in which cytoskeletal tension regulates 
the activity of multiple signalling pathways.  The cytoskeleton functions as a central rheostat 
or computer processor, dampening or augmenting the responses of multiple signalling 
pathways to external stimulation (155).  β1-integrin is implicated as being an important 
regulator of stiffness-dependent cell proliferation.  Immunohistochemical analysis confirms 
that both β1-integrin and phospho-FAKTyr397 are upregulated in HCC specimens in vivo.  
Furthermore, in vitro inhibition of either β1-integrin or FAK was associated with a reduction 
in the proliferation of both HepG2 and Huh7 cells. 
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At a basic level, the results presented in this thesis provide evidence that increased matrix 
stiffness, as encountered in the cirrhotic liver, is mechanistically important in promoting 
HCC development.  However, these results also suggest that a reduction in matrix stiffness is 
sufficient to induce reversible cellular quiescence that may be analogous to cancer cell 
dormancy.  Genetic studies of disseminated breast cancer cells suggest that cancer cells 
dissemination is an early event in the natural history of many tumours (341).  Dormant 
cancer cells are thought to represent a quiescent population of disseminated cells that exist in 
a state of reversible growth arrest.  The mechanisms responsible for inducing cancer cell 
dormancy and the subsequent ‘reawakening’ of these disseminated cells remain poorly 
characterised.  This is in part due to the fact that disseminated tumour cells are difficult to 
detect in vivo and there is a lack of reliable in vitro models of cancer dormancy.  The results 
presented here are consistent with a model in which a reduction in the stiffness of cancer cell 
niche, as might be encountered by disseminated tumour cells, may be sufficient to induce 
reversible cellular quiescence.  In a low stiffness environment, disseminated tumour cells 
would be expected to have low levels of cell proliferation and relative insensitivity to growth 
factor signalling.  A subsequent increase in environmental stiffness secondary to localised 
inflammation, desmoplasia, or alterations in the stiffness-sensing machinery of the cell due 
to genomic instability, might facilitate the reactivation of dormant cells.  This hypothesis 
remains somewhat speculative.  However, it is clear that cell culture on low stiffness PA gel 
supports provides an interesting model of reversible cancer cell quiescence, with the 
potential to provide insight into mechanisms underlying cancer dormancy.  Indeed, using PA 
supports, Tilghman et al have shown that rigidity-dependent cell lines exhibit lower levels of 
cellular ATP and protein synthesis when cultured on soft supports (339).  They suggest that 
metabolic events may be key regulators promoting the slow growth of rigidity-dependent 
cells.  This example illustrates that PA supports have the potential of allowing cancer cell 
biology to be investigated under conditions of cellular quiescence and reflecting the 
biomechanical environment encountered by disseminated tumour cells. 
 
In this thesis, PA supports have also been used to investigate the effect of changes in matrix 
stiffness on chemotherapy resistance in HCC.  The results suggest that increasing matrix 
stiffness, as would be encountered in the setting of cirrhosis, is associated with a reduction in 
chemotherapy-induced apoptosis in HCC cells.  The mechanisms underlying this observation 
are unclear but may plausibly relate to alteration in the expression of multidrug resistance 
transporter proteins or increased resistance to chemotherapy due to EMT.  Rather 
unexpectedly it was shown that following chemotherapy, there was an increase in the 
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frequency of clone initiating cells for cells maintained in a low stiffness environment.  This 
phenomenon was observed in both the HepG2 and Huh7 cell line, and following treatment 
with both cisplatin and 5-flurouracil.  Using flow cytometry it was subsequently 
demonstrated that culture in a low stiffness environment was associated with an increase in 
the frequency of stem cell marker expression, including CD44, CD133 and CXCR-4.  This 
effect was further enhanced in the presence of chemotherapy.  A process of enrichment for 
cells with stem cell characteristics following treatment with chemotherapy may explain the 
results of these clonogenic assays.  However, a number of questions remain unanswered. 
Firstly, it is unclear whether these ‘stem cell markers’ accurately define the subset of cells 
with clone-initiating potential following chemotherapy.  It is also uncertain whether the 
enrichment for cells with clone-initiating potential (a stem cell trait) following 
chemotherapy, is due to positive selection of these cells from a mixed population or active 
induction of stem cell characteristics. These issues require further investigation.  It has 
previously been shown that stem cells can be regulated by the micro-environment (277).  
However, the results described here represent the first report that matrix stiffness regulates 
stem cell marker expression in cancer cells.    
 
6.2.2 The effect of matrix stiffness on hepatic progenitor cell (HPC) response 
 
Hepatic progenitor cells have been implicated in the pathogenesis of HCC.  Genetic studies 
have demonstrated that HCC can be categorised into genetically distinct subgroups (342, 
343).  It is believed that HCC develops from a range of founder cells, from HPCs through 
transient-amplifying cells to fully differentiated hepatocytes (53).  As previously discussed, 
markers of progenitor-derived HCC define a subgroup of tumours that are associated with 
poorer prognosis (58, 344). Factors that promote HPC proliferation may therefore be 
implicated in hepatocarcinogenesis.  It has been demonstrated that factors associated with the 
progression of chronic liver disease promote HPC proliferation in both the CCl4 and TAA 
models of liver fibrosis.  Using tissue derived from experiments undertaken by Prof R Wells 
(University of Pennsylvania) in a rat model of CCl4-induced liver injury, it has been shown 
that there is a close correlation between HPC numbers and liver stiffness measurements.  The 
major expansion in HPC numbers in this model coincides with a similarly large increase in 
fibrous tissue deposition.  Attenuation of liver stiffness in animals treated with BAPN, an 
inhibitor of collagen cross-linking, reduces HPC number, although this result was not 
statistically significant. Interestingly, an early increase in HPC number occurs in association 
with a more modest increase in liver stiffness, prior to the development of significant liver 
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fibrosis.  I would hypothesise that this early increase in liver stiffness may be a consequence 
of interstitial oedema in the context of acute inflammation.  Detailed in vitro experiments 
using PA supports demonstrate that increasing matrix stiffness promotes the proliferation of 
both primary murine HPCs and an immortalised HPC line.  Overall, these results are 
consistent with a model in which increased matrix stiffness, in the context of tissue damage 
and fibrosis may, in concert with soluble factors and other components of the progenitor cell 
niche, promote HPC expansion.  The development of progenitor-derived HCC may be an 
unfortunate consequence of this loosening in the biomechanical control of HPC proliferation.  
 
6.2.3 Murine models of cardiac hepatopathy 
 
Cardiac hepatopathy describes a heterogeneous group of conditions characterised by both 
acute and chronic liver injury.  As discussed, cardiac hepatopathy is best defined in relation 
to the duration of cardiac dysfunction.  Acute cardiac dysfunction is associated with the 
clinical syndrome of ischaemic hepatitis.  The results of studies conducted in patients with 
the Fontan circulation suggested that chronic hepatic congestion resulted in progressive liver 
fibrosis and cirrhosis in the absence of florid inflammation and hepatocellular damage (307). 
We had hypothesised that tissue oedema in the context of chronic hepatic congestion might 
be an important factor in promoting liver fibrosis.  Thus models of chronic hepatic 
congestion might allow us to define a common sequence of events through which cells 
respond to oedema and provide a model of the early changes associated with increased 
stiffness in an otherwise architecturally normal and non-inflamed liver.  Studies were 
therefore undertaken to define the sequence of histological events occurring in two unrelated 
murine models of dilated cardiomyopathy.  The murine models described in chapter 5 are 
most appropriately defined as models of acute on chronic cardiac dysfunction, and 
unfortunately do not recapitulate the histological features observed in the Fontan liver.  
Histological abnormalities within the liver are not present until mice develop features of 
overt and severe cardiac failure.  However, to the best of my knowledge, this study 
represents the first detailed characterisation of the histological events observed in murine 
cardiac hepatopathy.  In each case, features of chronic passive congestion (sinusoidal 
congestion/ ectasia) and perivenular hepatocyte injury develop concurrently.  Hepatocyte 
damage is evident as a spectrum of injury with granular cytoplasmic change, hepatocyte 
vacuolation and hepatocyte plate atrophy.  MFB activation is inferred by prominent αSMA –
staining around dilated sinusoids that radiate outwards from the central veins.  However, 
bridging fibrosis and cirrhosis is not present.  It is uncertain whether, were it possible to 
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extend the time course of cardiac dysfunction, we would observe the development of 
progressive liver fibrosis (and ultimately cirrhosis)?  What is required is an animal model 
with a more prolonged phase of right heart failure and elevated central venous pressure, 
without significant systemic hypotension that might contribute to the development of 
ischaemic hepatitis.  A model with these characteristics may provide some insight into the 
sequence of histological events and factors associated with hepatic congestion that may 
promote cardiac cirrhosis.  Multiple aetiological factors may be responsible for the 
pathogenesis of cardiac hepatopathy. In the python model, an increase in tissue hypoxia is 
observed around central veins, which parallels the pattern of hepatocyte necrosis and MFB 
activation seen in advanced cardiac failure.  The role of mechanical factors in promoting 
liver fibrosis remains uncertain.  However, the results of in vitro experiments with PA gels, 
confirmed that increases in matrix stiffness, as might be encountered in hepatic congestion, 
was associated with an upregulation of markers of  MFB activation and fibrillar collagen 
components.  Similarly, repetitive cyclical mechanical strain, as might be encountered by 
hepatic MFB precursors in the context of sinusoidal dilatation, was associated with similar 
changes in gene expression.  These experiments provide evidence for the importance of 
biomechanical factors in regulating the development of liver fibrosis. It must be emphasised 
that however closely these model systems attempt to recapitulate the biomechanical 
properties of in vivo environment, they are inherently artificial, and the results of these 
experiments should be viewed with some scepticism.  It would be extremely difficult to 
precisely define or replicate the complex range of mechanical stimuli to which cells are 
exposed within living tissues. However, the basis of our future understanding of 
biomechanics necessitates the use of these imperfect in vitro models of biomechanical cell 
stimulation. 
  
6.3 Suggestions for future study 
 
The data presented in this thesis raises questions that could form the basis of future research 
 
6.3.1 The effect of matrix stiffness cancer cell biology: wider perspectives 
 
The effect of changes in matrix stiffness on intracellular signalling needs further 
characterisation.  The results presented in this thesis demonstrate that matrix stiffness 
regulates the activity of multiple signalling pathways including FAK, ERK, PKB/ Akt and 
STAT3.  However, biochemical pathways do not operate in isolation.  Cellular behaviour is 
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governed by networks of molecular interactions with extensive crosstalk between different 
biochemical pathways.  A systems biology approach using phospho-proteomics would 
facilitate a global assessment of the impact of changes in cellular tension on intracellular 
signalling.  Similarly, array-based transcriptional analysis could be used to assess the effect 
of changes in matrix stiffness on gene expression.   A major limiting factor associated with 
the use of PA supports is the complex and time-consuming nature of gel fabrication.  A 
method for the rapid fabrication of PA supports in 96- and 384-well formats has recently 
been reported that has the potential to allow high-throughput screening of cultured cells 
(338).  It has been suggested that this technique could be used to more rapidly define the 
effect of matrix characteristics on cell growth and differentiation.  It could also be used as a 
screening tool to assess the interaction between matrix stiffness and exogenous factors, 
including cytokines and matrix components. 
 
6.3.2 In vivo models of cancer cell dormancy 
 
An assessment of the importance of the cytoskeleton in regulating the behaviour of dormant 
cancer cells would benefit from the development of tractable models of cancer cell 
dormancy.  Research has previously been undertaken in which mammary carcinoma cells 
were injected intravenously into rats that subsequently developed pulmonary metastases 
(260). No metastases were seen in other organs.  However, the implantation of glass 
fragments in the liver, spleen and mesentery of these animals, prior to the inoculation of 
tumour cells, resulted in the development of metastases at these sites.  Similarly, treatment of 
rats with CCl4 for three days prior to cancer cell inoculation was associated with increased 
tumour localisation and growth within the liver.  Comparable results have been shown in 
animal studies in which the induction of liver fibrosis is associated with increased tumour 
growth following orthotopic implantation of HCC cells (121, 122). These results are 
interpreted as showing that factors associated with acute inflammation and fibrosis promote 
tumour growth.  Preliminary experiments have been undertaken in collaboration with Dr 
Daniel Benton (University Medical Centre Hamburg-Eppendorf) to investigate the utility of 
using intravenous injection of human HCC cell lines into mice as a model of cancer cell 
dormancy.  In preliminary experiments, Huh7 cells were injected via tail vein into 
NOD/SCID mice.  Cells were subsequently identified following immunostaining for human-
specific CK18.  Initial results demonstrate the presence of isolated disseminated tumour cells 
and developing micrometastases within the liver (data not shown).  Refinement of this model 
would facilitate the study of disseminated tumour cells in vivo.  Experiments could then be 
 203 
undertaken to investigate factors associated with the reactivation of dormant cells, either by 
modification of the micro-environment (e.g. induction of liver fibrosis) or genetic 
modification of the transplanted cells themselves.  
 
6.3.3 The effect of matrix stiffness on cell signalling in hepatic progenitor cells 
(HPCs) 
 
The results presented in this thesis demonstrate that changes in matrix stiffness influence 
both proliferation and differentiation of HPCs.  Increased matrix stiffness promotes BMOL 
proliferation and the upregulation of the biliary/ progenitor marker CK19.  In contrast, a low 
stiffness environment, with characteristics similar to that of the normal liver, is associated 
with lower rates of cell proliferation and a modest upregulation of hepatocyte markers in 
BMOL cells.  This suggests that changes in matrix stiffness may be involved in directing 
HPCs towards either a hepatocyte or biliary phenotype. Research undertaken in our group 
has implicated both WNT and Notch signalling in directing stem cell fate (218).  The effect 
of changes in matrix stiffness on WNT and Notch signalling should be studied to assess 
whether changes in cytoskeletal tension associated with inflammation may modulate the 
activities of these critical signalling pathways.   
 
The suggestion that matrix stiffness may be important in directing HPC fate raises interesting 
question in respect to how local changes in matrix stiffness might affect HPC differentiation.  
Techniques such as torsional rheometry and transient elastography provide a measure of the 
mean stiffness across the liver, but provide no indication of how stiffness might vary across 
the hepatic lobule.   Following severe hepatocytic liver injury, the HPC cell response is 
evident as streaming cords of small cells emanating from their origin adjacent to the ductal 
tracts outwards into the liver parenchyma.  During this migration they are accompanied by 
activated MFBs and surrounded by a laminin-rich sheath, which is lost as they transition to 
fully differentiated hepatocytes.  The laminin-rich sheath is thought to be important in 
maintaining HPCs in an undifferentiated phenotype (345).  However, localised changes in 
matrix stiffness during the migration of cells away from the portal tracts might also be 
important in determining cell phenotype.  Preliminary discussions with investigators in the 
Department of Physics (University of Edinburgh) suggest that micro-indentation techniques 
could be developed to measure variation in stiffness across the liver at a microscopic level. 
Micro-indentation has previously been used to make elasticity measurements from soft 
tissues at sub-centimetre resolution. Levental et al undertook elasticity measurements from a 
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range of soft tissues including isolated mouse glomeruli and resected liver specimens (346).  
Using their micro-indentation device they demonstrated marked variation in stiffness 
measurements made at different points from individual livers derived from both CCl4-treated 
animals and oil-treated control specimens. They speculated that local variation in tissue 
stiffness would be expected given the structural variation in the regions of the liver at this 
scale, i.e. periportal, perivenous and parenchymal).  Unfortunately it was not possible to 
identify the region of the liver probed by individual stiffness measurements.  Further 
adaptation of this technique to incorporate microscopy is required to permit high resolution 
stiffness mapping of the liver parenchyma. Progress in this area would require considerable 
investment but would have the potential to provide insight into the biomechanical properties 
of the ECM across the hepatic lobule, both under normal conditions and in models of liver 
fibrosis.   
 
6.4 Concluding remarks 
 
Overall, I believe that the results presented in this thesis provide compelling evidence for the 
importance of changes in matrix stiffness in promoting both HCC development and HPC 
responses within the liver.  Perhaps most importantly I believe that this work highlights 
deficiencies in conventional cell culture conducted on stiff substrates such as tissue culture 





Primary antibodies/ antigen retrieval used in immunohistochemistry 
 
Primary Antibody Antigen (Ag) 
Retrieval 
Source Dilution Secondary  
Antibody 
Source Dilution 











1:50 Rabbit anti-mouse IgG DAKO 1:200 
































1:200 Swine anti-rabbit IgG DAKO 1:200 




1:100 Rabbit anti-rat IgG DAKO 1:100 









1:50 - - - 











Primer sequences used in SYBR-green quantitative PCR 
 
Target  Primer Sequence 
Collagen 1A1 Forward GATGACGTGCAATGCAATGAA 
 Reverse CCCTCGACTCCTACATCTTCTGA 
Collagen 3A1 Forward GTTCTAGAGGATGGCTGTACTAAACACA 
 Reverse TTGCCTTGCGTGTTTGATATTC 
Smooth Muscle Actin Forward TCAGCGCCTCCAGTTCCT 
 Reverse AAAAAAACCAGGAGTAACAAATCAA 
TIMP-1 Forward ATGGAAAGCCTCTGTGGATATG 
 Reverse AAGCTGCAGGCACTGATGTG 
TIMP-2 Forward AAGGAGATGGCAAGATGCAC 
 Reverse GTCCATCCAGAGGCACTCAT 
 
Custom designed primers for mouse albumin, cytochrome 7A1 (CYP7A1), cytokeratin-19 
(CK-19), aquaporin and gamma glutamyl transferase (γGT) were purchased directly from 
Qiagen (Crawley, UK). 
 
Custom designed primers for human Oct4 and NANOG were purchased directly from 
Applied Biosystems (Warrington, UK). 
 
Custom designed primers for the eukaryotic housekeeping gene 18S was purchased directly 
from Applied Biosystems (Warrington, UK). 
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Appendix 3: Solutions for sample preparation and Western blotting 
 
A3.1 Cell lysis buffer for protein extraction 
 
Reagent Quantity 
Sodium chloride 4.38g 
HEPES 5.95g 
Sodium fluoride 1.05g 
EDTA 372mg 
Glycerol 50ml 
Triton X-100 5ml 
 Dissolved in 500ml distilled H2O adjusted 





A3.2 Laemmli sample preparation buffer (5X) for Western blotting 
 
Reagent Quantity 
Trizma base 1.5g 
Sodium dodecyl sulphate (SDS) 5.0g 
Bromophenol blue 250mg 
Glycerol 25ml 
Β-mercaptoethanol 5ml 
Distilled water 20ml 
 Sample buffer stored at -20oC prior to use 
 
 
A3.3 Polyacrylamide gel preparation for Western blotting 
 




Polyacrylamide Gel Stocks    
Resolving Gel Buffer 
(90.8g Tris base, 2g SDS in 
500ml H20, pH8.8) 
N/A 40ml 40ml 
Stacking Gel Buffer 
(30g Tris base, 2g SDS in 500ml 
H20, pH6.8) 
50ml N/A N/A 
Acrylamide (30%) 32ml 53ml 64ml 
Glycerol N/A 36ml 36ml 
ddH20 118ml 31ml 20ml 
    
Polyacrylamide Gels (2 gels)    
Resolving Gel Stock N/A 11ml 11ml 
Stacking Gel Stock 6ml N/A N/A 
APS 40µl 60µl 60µl 
TEMED 20µl 25µl 25µl 
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A3.4 Running and transfer buffers for Western blotting 
 
Reagent Running Buffer (1x) Transfer Buffer (1x) 
   
SDS 1g N/A 
Glycine 14.4g 14.4g 
Tris base 3.03g 3.03g 
ddH2O 1000ml 800ml 








Antibodies used in Western blotting 
 
Antibody Source Dilution 
p21cip  Santa Cruz Biotechnology 1:1000 
p27kip  Santa Cruz Biotechnology 1:250 
HNF4alpha Santa Cruz Biotechnology 1:200 
Alpha-fetoprotein Santa Cruz Biotechnology 1:2000 
Cyclin D1 Cell Signalling  1:1000 
Cyclin D3 Cell Signalling 1:1000 
p-ERKThr202/Tyr204 Cell Signalling 1:2000 
ERK Cell Signalling 1:1000 
pAktSer473 Cell Signalling 1:2000 
Akt Cell Signalling 1:4000 
p-FAKTyr397 Cell Signalling 1:1000 
FAK Cell Signalling 1:1000 
p-STAT3Tyr705 Cell Signalling 1:1000 
STAT3 Cell Signalling 1:1000 
E-Cadherin Cell Signalling 1:1000 
Smad2/3 Cell Signalling 1:1000 
p-Smad2Ser465/467 Millipore 1:1000 
p-Smad3Ser423/425 Millipore 1:2000 
Albumin DAKO  1:2000000 
N-Cadherin DAKO 1:500 
α1-Antitrypsin QED Bioscience 1:2000 
Integrin β1 Abcam  1:1000 
PARP Cell Signalling 1:1000 
GAPDH Calbiochem 1:200000 
Anti-rabbit IgG-HRP Cell Signalling 1:2000 







Stock solutions for production of polyacrylamide (PA) gel supports 
 
 400Pa 1kPa 2.5kPa 6kPa 12kPa 22kPa 
2% bis-acrylamide (µl) 3.3 8.8 22 36 70 106 
30% acrylamide (µl) 125 125 125 125 125 125 
250mM HEPES, pH8 (µl) 70 70 70 70 70 70 
Distilled H2O (µl) 300 295 278 270 235 200 
TEMED (µl) 1.5 1.5 1.5 1.5 1.5 1.5 
10% APS (µl) 5 5 5 5 5 5 
 
*The protocol for polyacrylamide gel support fabrication was kindly provided 




Antibodies used in immunofluorescent staining 
 















1:200 Alexafluor 568 
Goat-anti-rabbit 
Invitrogen 1:400 





1:100 Alexafluor 568 
Goat-anti-rabbit 












A.  Huh7 Cells 
 










1 49/248 0.2 167/407 0.41 350/599 0.58 400/563 0.71 
2 54/255 0.21 184/379 0.49 262/449 0.58 333/405 0.72 
3 52/209 0.25 197/370 0.53 304/506 0.60 333/525 0.63 
Mean  0.22  0.48  0.59  0.69 
SEM  0.015  0.035  0.007  0.028 
 
 
B.  HepG2 Cells 
 










1 15/312 0.048 183/320 0.57 313/479 0.653 357/542 0.714 
2 13/244 0.053 344/620 0.555 404/622 0.651 386/570 0.677 
3 18/302 0.060 259/475 0.545 296/447 0.662 337/493 0.684 
Mean  0.054  0.557  0.656  0.692 
SEM  0.0033  0.0078  0.0034  0.0114 
 
 
The data presented here was used to determine the proliferative indices (PIs) presented in Figure 3.6.  In each experiment cellular proliferative index 
(Ki67-positive nuclei/ total DAPI-positive nuclei) was calculated by direct cell counting from 15 randomly selected high power photomicrographs from 






 1000 cells/cm2 5000 cells/cm2 25000 cells/cm2 



















1 17/76 0.224 26/69 0.377 17/127 0.133 94/194 0.485 65/410 0.159 396/747 0.530 
2 12/82 0.146 29/90 0.322 14/124 0.113 78/160 0.488 88/404 0.218 309/583 0.530 
3 14/91 0.154 42/104 0.404 9/125 0.072 64/181 0.354 117/460 0.254 311/578 0.538 
Mean  0.175  0.368  0.106  0.442  0.210  0.533 





 1000 cells/cm2 5000 cells/cm2 25000 cells/cm2 



















1 28/127 0.220 170/271 0.637 56/182 0.308 308/449 0.686 276/909 0.304 1282/2167 0.591 
2 16/106 0.151 190/307 0.619 37/155 0.229 250/375 0.667 350/1016 0.344 368/565 0.651 
3 17/151 0.113 153/284 0.539 30/148 0.203 190/287 0.662 156/450 0.347 471/700 0.673 
Mean  0.161  0.595  0.250  0.672  0.332  0.639 
SEM  0.032  0.028  0.031  0.007  0.014  0.024 
 
 
The data presented here was used to determine the proliferative indices (PIs) presented in Figure 3.7.  In each experiment cellular proliferative index 
(Ki67-positive nuclei/ total DAPI-positive nuclei) was calculated by direct cell counting from 15 randomly selected high power photomicrographs from 






 Collagen-I Collagen-IV Laminin Fibronectin 


































1 77/218 0.353 150/211 0.711 34/204 0.167 186/301 0.618 72/208 0.346 180/245 0.735 57/201 0.283 260/318 0.818 
2 53/213 0.249 149/239 0.623 60/229 0.262 217/323 0.672 49/206 0.238 202/260 0.777 53/186 0.285 202/267 0.757 
3 61/212 0.288 141/219 0.644 63/194 0.325 207/333 0.622 71/195 0.364 219/270 0.811 56/199 0.281 175/246 0.711 
Mean  0.297  0.659  0.251  0.637  0.316  0.774  0.283  0.762 





 Collagen-I Collagen-IV Laminin Fibronectin 


































1 57/454 0.126 324/496 0.653 39/401 0.095 307/494 0.621 32/315 0.102 458/698 0.616 50/324 0.154 364/724 0.641 
2 59/455 0.130 229/359 0.638 41/362 0.113 360/560 0.643 42/379 0.111 293/456 0.642 47/256 0.169 288/446 0.646 
3 58/449 0.129 267/423 0.631 41/392 0.105 312/482 0.647 35/295 0.119 438/698 0.628 37/256 0.145 286/430 0.665 
Mean  0.128  0.641  0.103  0.637  0.111  0.642  0.156  0.651 
SEM  0.001  0.006  0.005  0.4619  0.005  0.008  0.007  0.007 
 
The data presented here was used to determine the proliferative indices (PIs) presented in Figure 3.9.  In each experiment cellular proliferative index 
(Ki67-positive nuclei/ total DAPI-positive nuclei) was calculated by direct cell counting from 15 randomly selected high power photomicrographs from 





Adenocarcinoma Cell Lines 
 
 LNCap A549 MCF7 MDA 


































1 12/136 0.088 170/252 0.674 14/94 0.149 207/250 0.828 2/91 0.220 102/134 0.761 14/143 0.098 71/116 0.612 
2 12/90 0.133 121/177 0.684 26/147 0.177 172/287 0.670 16/137 0.117 134/153 0.876 17/187 0.091 94/144 0.653 
3 20/95 0.211 114/162 0.704 19/115 0.165 203/238 0.853 11/107 0.103 101/136 0.742 8/131 0.061 98/143 0.685 
Mean  0.144  0.687  0.164  0.783  0.147  0.793  0.083  0.650 
SEM  0.357  0.009  0.008  0.058  0.037  0.042  0.011  0.021 
 
 
 HepG2 Huh7 


















1 57/454 0.126 324/496 0.653 77/218 0.353 150/211 0.711 
2 59/455 0.130 229/359 0.638 53/213 0.249 149/239 0.623 
3 58/449 0.129 267/423 0.631 61/212 0.288 141/219 0.644 
Mean  0.128  0.641  0.297  0.659 
SEM  0.001  0.006  0.031  0.026 
 
 
The data presented here was used to determine the proliferative indices (PIs) presented in Figure 3.10.  In each experiment cellular proliferative index 
(Ki67-positive nuclei/ total DAPI-positive nuclei) was calculated by direct cell counting from 15 randomly selected high power photomicrographs from 









 Huh7 HepG2 














1 342/548 0.624 344/606 0.568 657/994 0.661 854/1359 0.628 
2 549/804 0.683 586/911 0.643 1292/2428 0.637 1165/1825 0.638 
3 364/579 0.629 659/946 0.682 786/1272 0.618 476/856 0.556 
Mea
n 
 0.645  0.631  0.639  0.608 




The data presented here was used to determine the proliferative indices (PIs) presented in Figure 3.12.  In each experiment cellular proliferative index 
(Ki67-positive nuclei/ total DAPI-positive nuclei) was calculated by direct cell counting from 15 randomly selected high power photomicrographs from 
Ki67- and DAPI-stained slides. The reference to support stiffness refers to the support stiffness on which the cells were cultured prior to transfer to 
tissue culture plastic.  
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Appendix 12   
 
A  Huh7 Cells 
 






























1 53/110 0.481 65/169 0.384 48/110 0.436 19/106 0.179 42/120 0.35 46/116 0.397 18/100 0.180 
2 31/81 0.382 76/160 0.475 15/100 0.15 27/86 0.314 34/65 0.523 35/125 0.278 26/111 0.234 
3 51/126 0.405 36/86 0.419 34/105 0.323 34/113 0.301 47/116 0.405 53/136 0.390 30/111 0.270 
4 38/101 0.376   25/96 0.260   48/146 0.329 53/138 0.384   
5 62/148 0.419       33/92 0.359 23/96 0.240   
Mean  0.413  0.426  0.293  0.265  0.393  0.338  0.228 
SEM  0.019  0.026  0.060  0.043  0.035  0.033  0.026 
 
B  HepG2 Cells 
 






























1 79/121 0.653 81/125 0.648 56/103 0.544 8/109 0.073 82/119 0.689 46/99 0.465 39/110 0.355 
2 75/122 0.615 100/142 0.744 49/90 0.544 2/42 0.048 113/187 0.711 65/142 0.458 44/131 0.336 
3 116/190 0.611 82/132 0.621 8/18 0.444 6/53 0.113 104/141 0.738 49/107 0.458 56/149 0.376 
4 105/175 0.600   37/75 0.493   97/156 0.622 115/260 0.442 39/101 0.386 
5 101/157 0.643   41/91 0.451   141/221 0.638 106/211 0.502 48/116 0.414 
Mean  0.624  0.658  0.495  0.078  0.680  0.465  0.373 
SEM  0.010  0.024  0.021  0.019  0.021  0.010  0.013 
 
 
The data presented here was used to determine the proliferative indices (PIs) presented in Figure 3.18.  In each experiment cellular proliferative index 
(Ki67-positive nuclei/ total DAPI-positive nuclei) was calculated by direct cell counting from 5 randomly selected high power photomicrographs from 




A Huh7 Cells 
 






















1 6/91 0.066 40/80 0.500 70/119 0.588 36/116 0.310 70/134 0.522 
2 5/60 0.083 46/86 0.535 83/133 0.624 49/109 0.450 56/115 0.487 
3 3/80 0.038 54/92 0.587 73/147 0.497 59/108 0.546 52/130 0.400 
4 7/64 0.109 53/93 0.570 58/109 0.532 37/77 0.481 48/95 0.505 
5 11/66 0.167 54/111 0.486 61/125 0.488 22/45 0.489 64/149 0.429 
Mean  0.093  0.536  0.546  0.455  0.469 
SEM  0.022  0.019  0.026  0.039  0.023 
 
B HepG2 Cells 
 






















1 9/92 0.098 132/205 0.644 178/243 0.733 64/116 0.552 72/129 0.558 
2 16/126 0.127 150/197 0.761 122/163 0.748 45/96 0.469 52/104 0.500 
3 10/84 0.119 119/167 0.713 164/215 0.744 25/72 0.347 93/162 0.574 
4 18/139 0.129 152/229 0.664 156/219 0.712 50/79 0.633 80/147 0.544 
5 15/103 0.146 147/199 0.739 108/147 0.735 20/49 0.408 98/149 0.658 
Mean  0.124  0.704  0.734  0.482  0.566 
SEM  0.008  0.022  0.006  0.051  0.025 
 
 
The data presented here was used to determine the proliferative indices (PIs) presented in Figure 3.19.  In each experiment cellular proliferative index 
(Ki67-positive nuclei/ total DAPI-positive nuclei) was calculated by direct cell counting from 5 randomly selected high power photomicrographs from 




A BMol Cells 
 
 Laminin Collagen-IV 


































1 2/107 0.019 47/169 0.278 76/182 0.418 125/229 0.546 9/226 0.040 93/226 0.411 95/225 0.422 118/211 0.559 
2 3/129 0.023 56/180 0.311 81/180 0.450 120/243 0.494 24/240 0.100 41/186 0.220 77/169 0.456 108/187 0.578 
3 8/154 0.052 39/164 0.238 79/194 0.407 107/217 0.493 9/210 0.043 110/244 0.451 51/172 0.297 111/183 0.607 
Mean  0.025  0.178  0.298  0.467  0.040  0.245  0.315  0.560 
SEM  0.005  0.045  0.057  0.027  0.013  0.063  0.045  0.019 
 
 
B Primary HPCs 
 
 Laminin Collagen-IV 


















1 10/337 0.030 41/550 0.075 8/321 0.025 40/418 0.096 
2 17/310 0.055 26/394 0.066 8/250 0.032 17/263 0.065 
3 15/311 0.048 34/406 0.084 15/282 0.053 29/287 0.101 
Mean  0.044  0.075  0.037  0.087 
SEM  0.008  0.005  0.008  0.011 
 
 
The data presented here was used to determine the proliferative indices (PIs) presented in Figure 4.7.  In each experiment cellular proliferative index 
(Ki67-positive nuclei/ total DAPI-positive nuclei) was calculated by direct cell counting from 15 randomly selected high power photomicrographs from 








Appendix 15: High power (x200) photomicrographs of immunostained liver sections from 12-
week-old Py/+ mice demonstrating features of overt CCF and age-matched wild-type controls 
(as indicated).  Sections are stained for the presence of the neutrophil marker Ly-6C/ GR1 
(A/B), T-lymphocyte marker CD3 and B-lymphocyte marker B220.  Control staining with 
omission of the primary antibody showed no significant staining (indented images).
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Matrix Stiffness Modulates Proliferation,
Chemotherapeutic Response, and Dormancy in
Hepatocellular Carcinoma Cells
Jörg Schrader,1,2* Timothy T. Gordon-Walker,1* Rebecca L. Aucott,1 Mariëlle van Deemter,1
Alexander Quaas,3 Shaun Walsh,4 Daniel Benten,2 Stuart J. Forbes,1 Rebecca G. Wells,5 and John P. Iredale1
There is increasing evidence that the physical environment is a critical mediator of tumor
behavior. Hepatocellular carcinoma (HCC) develops within an altered biomechanical envi-
ronment, and increasing matrix stiffness is a strong predictor of HCC development. The aim
of this study was to establish whether changes in matrix stiffness, which are characteristic of
inflammation and fibrosis, regulate HCC cell proliferation and chemotherapeutic response.
Using an in vitro system of ‘‘mechanically tunable’’ matrix-coated polyacrylamide gels, matrix
stiffness was modeled across a pathophysiologically relevant range, corresponding to values
encountered in normal and fibrotic livers. Increasing matrix stiffness was found to promote
HCC cell proliferation. The proliferative index (assessed by Ki67 staining) of Huh7 and
HepG2 cells was 2.7-fold and 12.2-fold higher, respectively, when the cells were cultured on
stiff (12 kPa) versus soft (1 kPa) supports. This was associated with stiffness-dependent regu-
lation of basal and hepatocyte growth factor–stimulated mitogenic signaling through extrac-
ellular signal-regulated kinase, protein kinase B (PKB/Akt), and signal transducer and
activator of transcription 3. b1-Integrin and focal adhesion kinase were found to modulate
stiffness-dependent HCC cell proliferation. Following treatment with cisplatin, we observed
reduced apoptosis in HCC cells cultured on stiff versus soft (physiological) supports. Interest-
ingly, however, surviving cells from soft supports had significantly higher clonogenic capacity
than surviving cells from a stiff microenvironment. This was associated with enhanced
expression of cancer stem cell markers, including clusters of differentiation 44 (CD44),
CD133, c-kit, cysteine-X-cysteine receptor 4, octamer-4 (CXCR4), and NANOG. Conclusion:
Increasing matrix stiffness promotes proliferation and chemotherapeutic resistance, whereas
a soft environment induces reversible cellular dormancy and stem cell characteristics in
HCC. This has implications for both the treatment of primary HCC and the prevention of
tumor outgrowth from disseminated tumor cells. (HEPATOLOGY 2011;53:1192-1205)
Hepatocellular carcinoma (HCC) is the thirdmost common cause of cancer-related mortal-ity worldwide.1 The majority (80%) of HCCs develop in the context of advanced liver fibrosisor cirrhosis and liver cirrhosis is the single most im-portant risk factor for HCC development.2 Liver
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extracellular matrix; ERK, extracellular signal-regulated kinase; FAK, focal adhesion kinase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HCC,
hepatocellular carcinoma; HGF, hepatocyte growth factor; HNF4a, hepatocyte nuclear factor 4 alpha; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide; OCT4, octamer-4; PA, polyacrylamide; PARP, poly-ADP-ribose polymerase; PE, phycoerythrin; CXCR4, cysteine-X-cysteine receptor 4; PKB/Akt, protein
kinase B; STAT3, signal transducer and activator of transcription 3; TGFb, transforming growth factor beta.
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fibrosis is defined by stereotypical changes in both the
biochemical and physical properties of the cellular
microenvironment. However, the role of mechanical
factors in modulating the growth and progression of
HCC remain poorly defined. Recent studies involving
ultrasound elastography (FibroScan) demonstrate that
liver stiffness measurements are a strong predictor of
HCC development.3 Furthermore, once established,
tumor development is associated with further increases
in matrix stiffness to values greater than those of the
surrounding hepatic parenchyma.4 It is therefore evi-
dent that HCC develops in a niche with mechanical
properties distinct from those encountered in the nor-
mal liver.
Cancer development and progression is dependent
on both intrinsic genetic abnormalities and external
structural determinants.5 Matrix stiffness has recently
been directly implicated in aiding tumor development.
Increases in matrix stiffness that enhance cell contrac-
tility have been found to be sufficient to enhance the
transformation of mammary epithelial cells.6 Con-
versely, a reduction in tissue stiffness by inhibition of
collagen cross-linking impedes malignant growth and
tumor development in a murine model of breast can-
cer.7 Cellular stiffness sensing relies upon intracellular
tension, which is determined by a dynamic equilib-
rium between forces generated by a contractile cyto-
skeleton and the elastic resistance (stiffness) provided
by the extracellular matrix (ECM). In this context,
cancer progression (tumor growth, invasion, and dis-
semination) is accompanied by changes in both the
mechanical properties of the cancer cell niche and
changes in cellular contractility (modified by genetic
and epigenetic factors) that regulate tumor cell
behavior.
HCC continues to have a poor prognosis (median
survival less than 12 months), reflecting its late presen-
tation and lack of effective therapies.8,9 The effective-
ness of both hepatic resection and liver transplantation
for HCC is limited by tumor recurrence, which can
occur months or years following resection of a primary
tumor.10 Furthermore, systemic chemotherapy has
proved ineffective both for the treatment of advanced
HCC and in an adjuvant/neoadjuvant setting for the
eradication of disseminated (dormant) tumor cells, the
progenitors of clinical metastases. The mechanisms
underlying chemotherapy resistance in HCC have not
been fully elucidated. Although it has previously been
demonstrated that the composition of the matrix can
enhance chemotherapy resistance in a range of epithe-
lial cancers,11,12 the role of matrix stiffness has not
been specifically addressed for HCC or other epithelial
cancers.
Here, we demonstrate that mechanical factors regu-
late both the proliferation and chemotherapeutic
response of HCC cells. In addition, we show that both
tumor cell differentiation and cancer stem cell charac-
teristics are influenced by the mechanical properties
(that is, stiffness) of the cancer cell niche.
Materials and Methods
Cell Culture and Microscopy. Human HCC cell
lines Huh7 and HepG2 (kindly provided by S. Wig-
more, Edinburgh, UK) were cultured in Dulbecco’s
modified Eagle medium (Gibco, Paisley, UK) supple-
mented with 10% fetal bovine serum, penicillin/strep-
tomycin and L-glutamine. For all experiments, cells
were plated at semiconfluent density in 1% fetal bo-
vine serum. Chemical reagents were purchased from
Sigma (Poole, UK) unless otherwise stated. Transform-
ing growth factor-beta (TGFb) and hepatocyte growth
factor (HGF) (Peprotech, London, UK) were used at
concentrations of 5 ng/mL and 10 ng/mL, respectively.
Anti–b1-integrin, clone 6S6 (Millipore, Watford, UK)
and control immunoglobulin G1 (IgG1; AbD Serotec,
Oxford, UK) were used for cell culture experiments at
50 lg/mL. Echistatin (Tocris, Bristol, UK) was used in
cell culture experiments at 100 nM concentration. The
chemical focal adhesion kinase (FAK) inhibitor,
PF573228 (Tocris, Bristol, UK) was solubilized in
dimethylsulfoxide (DMSO) and used for cell culture
experiments at a concentration of 1-5 lM. A detailed
description of microscopy and morphological analysis
can be found in the Supporting Methods online.
Preparation of Polyacrylamide Gel Supports. Po-
lyacrylamide (PA) gels of variable stiffness were pre-
pared on glass coverslips using modifications13 to the
method initially described by Pelham and Wang.14 A
detailed description can be found in the Supporting
Methods online.
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Immunofluorescence Staining. Cells were fixed in
4% paraformaldehyde in phosphate-buffered saline
and permeabilized with 0.2% Triton-X-100 in phos-
phate-buffered saline. Slides were stained with anti-
Ki67 (Novocastra, Newcastle, UK) and anti-vinculin
(Sigma, Poole, UK); corresponding Alexa Fluor-555
secondary antibodies were used for detection (Invitro-
gen, Paisley, UK). Actin stress fibers were stained with
Alexa-488 phalloidin (Invitrogen). Nuclear DNA was
counterstained with 40,60-diamidino-2-phenyl-indole
dihydrochloride (DAPI; Dako, Ely, UK). Cellular pro-
liferative index (Ki67-positive cells/total cells) was cal-
culated by direct cell counting from 15 randomly
selected high magnification photomicrographs from
Ki67-stained slides (n ¼ 3).
Western Blot. A detailed description of western
blotting and a complete list of antibodies are provided
in the Supporting Methods.
Immunohistochemistry. Human HCC specimens
were obtained from archived tissue held by Tayside
Tissue Bank and the Department of Pathology, Uni-
versity Medical Center Hamburg-Eppendorf with
appropriate ethical approval (UK-LREC: TR000216).
Immunohistochemistry was performed as previously
described.15 The primary antibodies and antigen re-
trieval regimes used were anti-pFAK (pY397) (Invitro-
gen, Paisley, UK/Microwave pH9) and anti-b1-integrin
(Abcam, Cambridge, UK/Microwave pH9). Negative
controls with isotype immunoglobulins (Santa Cruz,
Heidelberg, Germany) and species-specific serum alone
showed no specific staining.
Clonogenic Assay. Cells were plated at semi-conflu-
ent density onto PA gels. After 48 hours, cells either
received cisplatin (HepG2, 10 lM/Huh7, 20 lM) or
5-fluorouracil (5FU; 25 lM) or were left untreated in
plating medium. After 24 hours, the medium was
changed to normal culture medium and the cells were
incubated further for 48 hours, for a total of 5 days of
culture. Cells were then retrieved by trypsinization,
counted and plated at clonal density (10,000 cells/
well) into 12-well plates in normal culture medium.
Cells were fixed at between 5-10 days in 4% parafor-
maldehyde and stained with 0.5% crystal violet solu-
tion. Colonies were visualized with a VersaDoc system
and analyzed with Quantify-One (Bio-Rad Laborato-
ries, Hercules, CA).
Flow-Cytometric Analysis. Cells were harvested by
trypsinization and single cell suspension generated by
passing cells through a 40 lm cell strainer. Cells were
stained with the following antibodies: CD44-phycoery-
thrin (PE), CD117-PE (c-kit), CD133-PE, CD184-PE
(cysteine-X-cysteine receptor 4 [CXCR-4]), and corre-
sponding PE-labeled isotype controls (E-Bioscience,
Hatfield, UK). After staining, cells were washed, post-
fixed in 1% paraformaldehyde and analyzed on a
FACScan (BD Biosciences, Franklin Lakes, NJ). Data
analysis was performed using FlowJo software (TreeS-
tar, Inc., Ashland, OR).
cDNA Synthesis and Real-Time PCR. Relative
mRNA expression for genes of interest was determined
by real-time PCR using an Applied Biosystems 7700
Sequence Detection System. Primer sequences for the
genes of interest and the 18S housekeeping gene were
purchased from Applied Biosystems (Warrington, UK).
Statistics. Data are expressed as mean 6 standard
error of the mean (SEM) of at least three independent
experiments unless stated otherwise. Comparisons
between groups were performed using a two-tailed
Student t test.
Results
Increasing Matrix Stiffness Is Associated With a
Mesenchymal Shift in HCC Cells. The response of
HCC cells to alterations in matrix stiffness was investi-
gated using a system of mechanically-tunable ligand-
coated PA gels.13,14 In this system, matrix stiffness is
altered by modulating the bis-acrylamide crosslink den-
sity of thin PA gels without altering the surface com-
position or density of ligands to which the cells are
exposed.13 Matrix stiffness (expressed as shear modu-
lus, G0) was modeled across a range of pathophysiolog-
ically-relevant stiffness values (1-12 kPa) corresponding
to values encountered in normal and fibrotic livers.16
The PA gels used in this study were coated with colla-
gen-I, representing the predominant ECM protein
encountered in the fibrotic liver.
For both Huh7 and HepG2 cells we observed a
consistent morphological response to changes in sup-
port stiffness. HCC cells on soft (1 kPa) supports were
small and rounded in contrast to the well-spread and
flattened cells seen on stiff (12 kPa) supports (Fig. 1).
Differences in cellular spreading as a function of sup-
port stiffness develop rapidly (within 1 hour) and are
maximal at 24 hours (Supporting Fig. 1). Confocal
microscopy showed that increasing matrix stiffness was
associated with the development of prominent actin
stress fibers and mature (vinculin-positive) focal adhe-
sions (Fig. 2). These features were absent in cells cul-
tured on soft supports. The presence of stress fibers is
linked to acquisition of mesenchymal properties (mes-
enchymal-shift) and de-differentiation in epithelial
cells. In accordance with this we demonstrated up-
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regulation of the mesenchymal markers N-cadherin
(Huh7/HepG2) and vimentin (shown for Huh7;
vimentin is not expressed in HepG2 cells under either
condition) in HCC cells cultured on stiff supports
(Fig. 3A). There was no change in the expression of
the epithelial marker E-cadherin. HepG2 and Huh7
cells cultured on soft supports expressed higher levels
of albumin, hepatocyte nuclear factor-4a (HNF4a),
alpha-1-antitrypsin and alpha-fetoprotein (AFP) than
cells cultured on stiff supports (Fig. 3B). This suggests
that a soft environment promotes a differentiated he-
patocyte phenotype, whereas increasing support stiff-
ness is associated with cellular de-differentiation to-
ward a mesenchymal phenotype.
TGFb is a potent inducer of mesenchymal changes
in both primary and transformed epithelial cells. We
therefore investigated whether support stiffness regu-
lated TGFb-induced Smad signaling activity in HCC
cells. The Huh7 cell line demonstrated increased basal
activity of the TGFb signaling pathway (as indicated
by increased Smad3 phosphorylation) in cells cultured
on stiff supports (Fig. 3C,D). In addition, upon stim-
ulation with TGFb there was enhanced Smad2 and
Smad3 phosphorylation in cells from stiff supports.
Increasing Matrix Stiffness Promotes HCC Prolif-
eration. In both HCC cell lines, matrix stiffness regu-
lated HCC cell proliferation (Fig. 4A). The prolifera-
tive indices of Huh7 and HepG2 cells (assessed by
nuclear localization of Ki67) were 2.7-fold (P <
0.001) and 12.2-fold (P < 0.001) higher, respectively,
when the cells were cultured on stiff (12 kPa) versus
soft (1 kPa) supports. Maximal proliferative index was
seen when cells were cultured on collagen-I–coated
glass, which has a shear modulus several orders of
magnitude higher than any physiological matrix. Both
MTT assay (Supporting Fig. 2) and direct cell count-
ing (data not shown) confirmed an increase in total
cell number with increasing support stiffness. A similar
trend for cellular proliferation was observed in primary
mouse hepatocytes (Supporting Fig. 3). Matrix stiffness
had a corresponding effect on the expression of cell
cycle regulators of G1 progression (Fig. 4B,C). We
observed a strong reduction in the expression of
cyclin-D1 and cyclin-D3 in cells cultured on soft
Fig. 1. Changes in matrix stiffness regulate HCC cell morphology and spreading. Huh7 and HepG2 cells were cultured on collagen-I–coated
polyacrylamide (PA) gels with ‘‘tunable stiffness’’ (expressed as shear modulus, G0) in the range of 1-12 kPa and collagen-I–coated glass. The
stiffness values of the PA gel supports used were selected in order to reflect range of stiffness values encountered in normal and fibrotic livers.
Phase-contrast photomicrographs demonstrate the regulation of cellular morphology by support stiffness in both (A) Huh7 and (B) HepG2 cells.
The surface area (square micrometers) of (C) Huh7 and (D) HepG2 cells was calculated by digital image analysis of phase-contrast images of
cells on PA gel supports. In each case, values reflect the mean (6SEM) of measurements from 50 cells in three independent experiments (*P
< 0.05, **P < 0.01, and ***P < 0.001).
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supports. There was no evidence of up-regulation of
the cyclin-dependent kinase inhibitors p21cip or p27kip
on soft gels and indeed a moderate down-regulation of
p27kip was observed on soft gels. Induction of terminal
senescence on soft supports was excluded by showing
that upon transfer to a stiff matrix, cells resumed
Fig. 2. Changes in matrix stiffness regulate the formation of actin stress fibers and focal adhesion maturation in HCC cells. Confocal micros-
copy (!320 magnification) of (A) Huh7 and (B) HepG2 cultured on soft (1 kPa) and stiff (12 kPa) collagen-I–coated PA supports as indicated.
The photomicrographs displayed are of cells stained for the presence of actin stress fibers (phalloidin: green), mature focal adhesions (anti-vin-
culin: red), and nuclear DNA (DAPI: blue). The merged image (right panel) demonstrates the spatial relationship between actin stress fibers and
mature focal adhesions. Insets display high-magnification images for Huh7 and HepG2 cells cultured on stiff (12 kPa) supports demonstrating
the insertion of actin stress fibers into mature focal adhesions. In each image, the scale bars represent 20 lm.
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proliferation to levels comparable to cells coming from
a stiff matrix (Supporting Fig. 4A). Furthermore, cells
on both soft and stiff supports showed no evidence of
beta-galactosidase accumulation (data not shown). In
each cell line, differences in cellular proliferation as a
function of stiffness were evident across a wide range
of plating densities (Supporting Fig. 5).
In order to exclude a specific effect related to colla-
gen-I, we investigated the effect of different ECM
coatings on HCC cell proliferation on PA gels
(Fig. 4D). Although minor differences were observed
with respect to cellular morphology and spreading
(Supporting Fig. 6) when cells were plated on
collagen-I, collagen-IV, laminin and fibronectin-coated
Fig. 3. Increased matrix stiffness is associated with mesenchymal shift in HCC cells. (A) Western blot from whole-cell lysates showing expres-
sion of E-cadherin, N-cadherin, and vimentin in Huh7 and HepG2 cells cultured on soft (1 kPa) and stiff (12 kPa) collagen-I–coated PA gel sup-
ports (as indicated). (B) Western blots from whole-cell lysates showing expression of albumin, hepatocyte nuclear factor 4 alpha (HNF4a),
alpha-1-antitrypsin, and alpha-fetoprotein (AFP) in Huh7 and HepG2 cells. (C) Western blots from whole-cell lysates from Huh7 cells showing
the expression of phospho-Smad2, phospho-Smad3, and total Smad2/3 following stimulation with transforming growth factor beta (TGFb; 5 ng/
mL). In each western blot, equal quantities of protein were loaded and equal loading was confirmed in relation to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) expression. In each case, the western blots shown are representative examples from three independent experiments.
(D) The line graphs show a schematic representation of densitometry analysis of phosphorylated Smad2 and Smad3, expressed relative to
GAPDH. Each time point represents the mean of three independent experiments.
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gels, the biochemical composition of the surface coat-
ing did not significantly alter the stiffness-dependent
regulation of cell proliferation. In other words, the
physical rather than the biochemical properties of the
PA gels exerted the predominant effect on HCC cell
proliferation.
Fig. 4. Increased matrix stiffness promotes HCC cell proliferation. (A) Graphs showing the mean proliferative index (Ki67 positivity) of Huh7
and HepG2 cells cultured on collagen-I–coated polyacrylamide gel supports across a range of stiffness values (1-12 kPa), as indicated, and col-
lagen-I–coated glass (n ¼ 3). (B) Western blots from whole-cell lysates showing expression of cyclin-D1 and cyclin-D3 in Huh7 and HepG2 cells
cultured on soft (1 kPa) and stiff (12 kPa) supports, as indicated. (C) Western blots from whole-cell lysates showing expression of cyclin-depend-
ent kinase inhibitors, p21cip, and p27kip in Huh7 and HepG2, cultured on soft (1 kPa) and stiff (12 kPa) supports, as indicated. In each western
blot, equal quantities of protein were loaded and equal loading confirmed in relation to GAPDH expression. The western blots shown are repre-
sentative examples from three to six independent experiments. (D). Graphs showing the mean proliferative index (Ki67 positivity) of Huh7 (left
panel) and HepG2 (right panel) cells cultured on both soft (1 kPa) and stiff (12 kPa) polyacrylamide supports coated with collagen-I, collagen-
IV, laminin, or fibronectin (n ¼ 3). In each case, error bars represent SEM, *P < 0.05, **P < 0.01, and ***P < 0.001.
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Matrix Stiffness Modulates Basal and HGF-
Induced Signaling Responses. Using immunoblotting
with phosphorylation-specific antibodies we analyzed
stiffness-dependent differences in the activity of critical
mitogenic signaling pathways. Growth on stiff (12
kPa) versus soft (1 kPa) supports was associated with
enhanced FAK, extracellular signal-regulated kinase
(ERK), protein kinase B (PKB/Akt) (Huh7 cells
only), and signal transducer and activator of tran-
scription 3 (STAT3) phosphorylation (Fig. 5A). Sub-
strate stiffness significantly modulated growth factor-
induced mitogenic signaling in response to HGF.
Upon stimulating cells plated on both soft and stiff
PA gels with HGF, we observed an increase in the
magnitude of ERK, PKB/Akt, and STAT3 activation
in cells cultured on stiff gels (Fig. 5C, Supporting
Fig. 7). Substrate stiffness also modulated cyclin-D1
expression in response to HGF stimulation. Following
HGF stimulation in HepG2 and Huh7 cells, there
was up-regulation of cyclin-D1 expression in cells cul-
tured on both soft and stiff supports (Fig. 5B).
Importantly, the magnitude of cyclin-D1 induction
following HGF stimulation was substantially higher
in cells cultured on stiff supports.
b1-Integrin and Phospho-FAK Are Expressed in
Human HCC Tumors and Regulate the Stiffness-
Dependent Proliferation of Human HCC Cells In
Vitro. Integrins and integrin-associated focal adhesions
are known to be important mediators of mechanotrans-
duction. We therefore used immunohistochemistry to
investigate the prevalence of b1-integrin and phospho-
FAKTyr397 expression in HCC tissue from an unse-
lected cohort of 15 HCC specimens obtained at the
time of tumor resection or biopsy (Fig. 6A). b1-Integ-
rin was expressed in tumor tissue in all 15 of 15 HCC
specimens tested. In addition, we found up-regulation
of FAK expression in tumor tissue relative to the sur-
rounding parenchyma in 8/15 (53%) HCC specimens
tested. These results are consistent with published his-
tological studies.17,18 We subsequently investigated the
effect of the b1-integrin inhibition on HCC cell prolif-
eration in vitro using a function blocking anti–b1-
integrin antibody (6S6) and the disintegrin echistatin
(Fig. 6C). Anti–b1-integrin antibody and echistatin
promoted cellular rounding in both the Huh7 and
HepG2 cells cultured on collagen-I–coated 12 kPa
(stiff ) supports. Huh7 cell proliferation was reduced by
treatment with both 6S6 antibody (38% reduction, P
< 0.05) and echistatin (29% reduction, P ¼ 0.07) rel-
ative to relevant controls. Similarly, in HepG2 cells,
cell proliferation was reduced by treatment with both
6S6 antibody (92% reduction, P < 0.001) and echista-
tin (21% reduction, P < 0.01). The effect of FAK acti-
vation on HCC cell proliferation was investigated in
experiments with the small molecular FAK inhibitor
PF573228 (Fig. 6B,C). Treatment with PF573228 (5
lM) was associated with a reduction in the prolifera-
tion of both Huh7 (42% reduction, P < 0.01) and
HepG2 cells (45% reduction, P < 0.001) cultured on
collagen-I–coated 12 kPa polyacrylamide gels. Further-
more, inhibition of b1-integrin or FAK expression in
HepG2 cells with siRNA resulted in a significant
reduction in cellular proliferation relative to control
siRNA transfection (Supporting Fig. 8). A similar trend
in respect to cellular proliferation was observed follow-
ing siRNA-dependent inhibition of b1-integrin or FAK
expression in Huh7 cells, although in this case the
reduction was not statistically significant.
Matrix Stiffness Modulates HCC Apoptosis and Clone-
Forming Capability Following Chemotherapy. HCC is
resistant to treatment with conventional chemothera-
peutic agents. We therefore investigated whether the
stiffness of the cancer cell niche regulates the suscepti-
bility of HCC cells to chemotherapy-induced apopto-
sis. In both cell lines, there was decreased apoptosis in
cells cultured on stiff supports, as indicated by reduced
poly-ADP-ribose polymerase (PARP) cleavage (Fig.
7A). There was a nonsignificant trend toward increased
numbers of surviving cells on stiff supports (data not
shown). We also performed a series of clonogenic
assays to investigate whether changes in matrix stiffness
modulate the survival and behavior of tumor-initiating
cells after chemotherapy. Following cisplatin treatment,
the surviving cell population included an increased fre-
quency of clone-initiating cells for both HepG2 (2.4-
fold, P < 0.001) and Huh7 cells (2.2-fold, P < 0.05)
cultured on soft (1 kPa) versus stiff (12 kPa) supports
(Fig. 7B). In addition, there was a nonsignificant trend
toward an absolute increase in the total number of
clone-forming cells from soft supports (data not
shown). To assess the validity of this finding, experi-
ments were repeated using a second, unrelated chemo-
therapeutic agent, 5-fluorouracil (5-FU). Consistent
with our findings with cisplatin, following 5-FU chem-
otherapy there was an increased frequency of clone-ini-
tiating cells from HepG2 (3.6-fold, P < 0.001) and
Huh7 cells (1.9-fold, P < 0.05) cultured on soft versus
stiff supports. There was no difference in the fre-
quency of clone-initiating cells in untreated HepG2 or
Huh7 cells after culture on soft or stiff supports in the
absence of chemotherapy.
The paradoxical increase in the clone-initiating
capability of chemotherapy-treated cells from a low
stiffness environment could be explained by selective
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Fig. 5. Matrix stiffness regulates mitogenic signaling in HCC. (A) Western blots showing basal expression of phosphorylated and total FAK,
ERK, protein kinase B (PKB/Akt), and STAT3 in Huh7 and HepG2 cells cultured on soft (1 kPa) and stiff (12 kPa) supports, as indicated. (B)
Western blots showing cyclin-D1 expression in Huh7 and HepG2 cells cultured for 24 hours on soft (1 kPa) and stiff (12 kPa) supports in the
presence (þ) or absence (") of HGF (10 ng/mL). (C) Western blots showing a time-course analysis for expression of phosphorylated and total
ERK, PKB/Akt, and STAT3 in Huh7 cells cultured on soft (1 kPa) and stiff (12 kPa) supports. Whole-cell lysates were harvested at baseline and
specific time points (as indicated) following the addition of HGF (10 ng/mL) to culture media. In each western blot, equal quantities of protein
were loaded and equal loading was confirmed in relation to GAPDH expression. The line graphs (right panel) show a schematic representation of
densitometry analysis of phosphorylated ERK, PKB/Akt, and STAT3 expressed relative to GAPDH. Each time point represents the mean of three
independent experiments.
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enrichment for clone-initiating cells with stem cell char-
acteristics. We therefore performed flow-cytometric anal-
yses for putative cancer stem cell markers in HCC cells
cultured on soft (1 kPa) and stiff (12 kPa) supports,
both without and following cisplatin treatment (Fig.
8A). Culture on soft versus stiff supports was associated
with an enrichment for the cell surface markers CD133
(1.5-fold, P < 0.001), c-kit (1.3-fold, P ¼ 0.78), CD44
(6.4-fold, P < 0.001), and CXCR-4 (2.9-fold, P <
0.01). Following cisplatin treatment, there was statisti-
cally significant up-regulation of CD44 (1.7-fold, P <
0.01), CD133 (1.6-fold, P < 0.01) and c-kit (15.8-fold,
P < 0.01) for cells maintained on soft but not stiff sup-
ports. Additionally, real-time PCR demonstrated up-reg-
ulation of stem cell-associated transcription factors
OCT4 and NANOG in HepG2 cells cultured on soft
versus stiff supports, both in untreated controls (OCT4
2.0-fold increase, P < 0.05; NANOG 2.7-fold increase,
P < 0.05) and following cisplatin treatment (OCT4
2.0-fold increase, P < 0.05; NANOG 3.4-fold increase,
P < 0.05) (Fig. 8B).
Discussion
In this study, we demonstrated that the stiffness of
the subcellular matrix profoundly alters the phenotype
and behavior of HCC cells in vitro. Pathophysiological
increases in matrix stiffness, as encountered in fibrotic
and cirrhotic livers,19 promote the proliferation of
HCC cells. Our work defines novel mechanisms link-
ing the physical properties of the fibrotic liver and the
malignant behavior of HCC. Our data is consistent
with in vivo evidence, not only of de novo HCC devel-
opment and progression against a background of cir-
rhosis, but also animal studies showing that the induc-
tion of liver fibrosis is associated with accelerated
tumor growth following orthotopic HCC implanta-
tion.20,21 Furthermore, histological examination of
human HCC specimens demonstrates a significant
association between the presence of hepatic fibrosis
and enhanced tumor cell proliferation.22 Critically, our
findings suggest that a reduction in the stiffness of the
cancer cell niche, as would be encountered by a
Fig. 6. b1-Integrin and phospho-FAK are expressed in human HCC tumors and regulate the stiffness-dependent proliferation of human HCC
cells in vitro. (A) Low magnification ("50) photomicrographs from a human HCC resection specimen stained with hematoxylin and eosin (left
panel), anti–b1-integrin (middle panel) and anti-phospho-FAK (right panel). Negative control staining is represented by the indented images in
the top righthand corner of each image. b1-integrin is expressed in both the HCC tumor (HCC) and surrounding hepatic parenchyma (P), as indi-
cated. Phospho-FAKTyr397 is strongly expressed in the HCC tissue relative to the hepatic parenchyma. Scale bars represent 200 micrometers. (B)
Western blots showing the expression of phospho-FAKTyr397 in Huh7 and HepG2 cells either left untreated or treated for 24 hours with the focal
adhesion kinase (FAK) inhibitor PF573228 at concentrations of 1 lM and 5 lM, as indicated. In each western blot, equal quantities of protein
were loaded and equal loading confirmed in relation to GAPDH expression. (C) Graphs showing the mean proliferative index (Ki67 positivity) of
Huh7 and HepG2 cells cultured on 12 kPa (stiff) collagen-I-coated polyacrylamide supports. Cells were treated with the anti-b1-integrin antibody
6S6 (50 lg/mL), isotype control IgG1 antibody (50 lg/mL), echistatin (100 nm), PF573228 (1 lM), PF573228 (5lM), DMSO (vehicle con-
trol), or left in media alone (untreated control) for 24 hours, as indicated (n ¼ 3-5). In each case, error bars represent SEM, *P < 0.05, **P
< 0.01, and ***P < 0.001.
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disseminated tumor cell entering an unaffected second-
ary site, would be sufficient to promote reversible cel-
lular quiescence and cancer cell dormancy.
It has previously been demonstrated that matrix
stiffness can regulate proliferation in nontransformed
cells. More recently increased matrix stiffness has been
shown to promote cellular proliferation in glioma
cells.23 We have extended these findings to a range of
epithelial malignancies, including HCC (Supporting
Fig. 9). Furthermore, we have shown that b1-integrin
and FAK (the canonical mediator of integrin-related
signaling) regulate stiffness-dependent proliferation in
HCC cells. In both fibroblasts and nontransformed
mammary epithelial cells, a critical role for ERK-
induced cyclin-D induction has been established in the
stiffness-dependent regulation of cell proliferation.24 In
accordance with these findings we demonstrate both
an up-regulation of cyclin-D levels and increased mito-
genic signaling through ERK in HCC cells on stiff
substrates. Interestingly, reduced ERK activation has
previously been linked to cellular quiescence in a cell
line-specific model of cancer dormancy.25 Additionally,
for the first time, we demonstrate a role for matrix
stiffness in modulating the activation of the STAT3
pathway. STAT3 has recently been identified as a cen-
tral component in tumor progression and a potential
target of cancer therapy in HCC and other epithelial
malignancies.26 The STAT3 pathway is activated in
response to multiple cytokines and growth factors dur-
ing cancer-associated inflammation (e.g., interleukin-6,
interleukin-10, epidermal growth factor, and HGF).
Our findings demonstrate that matrix stiffness has a
substantial impact upon the intrinsic and extrinsic
(growth factor-induced) activation of the STAT3 path-
way. This indicates an additional role for biophysical
factors in regulating this critical signaling pathway.
Interactions between pathways conveying information
from both soluble mediators and the ECM are inte-
grated at the level of the cytoskeleton. In this context,
the role of cytoskeletal tension has been likened to a
cellular rheostat, acting to dampen or augment the
responses of multiple signaling pathways to growth
factor stimulation, thereby blocking or facilitating mi-
togenic responses.
Fig. 7. Matrix stiffness regulates apoptosis and clonogenic capacity following chemotherapy. (A) Western blot showing full-length (116 kDa) and
cleaved poly-ADP-ribose polymerase (PARP) (89 kDa) expression in Huh7 and HepG2 cells following treatment with cisplatin on soft (1 kPa) and stiff (12
kPa) supports, as indicated. In each western blot, equal quantities of protein were loaded and equal loading was confirmed in relation to GAPDH expres-
sion. The western blots shown are representative examples from three independent experiments. (B) Colony formation potential of Huh7 and HepG2 cells
following chemotherapy. Huh7 and HepG2 cells were cultured for 48 hours on either soft (1 kPa) or stiff (12 kPa) polyacrylamide supports. Cells were
then left untreated (left panel) or treated with cisplatin (middle panel) or 5-fluorouracil (5-FU) (right panel) for 24 hours prior to media change. After a fur-
ther 48 hours in culture, the cells were trypsinized and equal numbers re-plated at clonal density in 12-well plates. Clonogenic capacity was calculated by
direct counting of the resulting colonies. The results are expressed as the percentage colony formation relative to the number of colonies obtained from 1
kPa supports from three independent experiments. In each case, error bars represent SEM, *p<0.05, ***p<0.001 and ns=not significant.
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It has been proposed that the ECM is a critical reg-
ulator of cellular dormancy27; however the role of ma-
trix stiffness in regulating this process has not been
specifically addressed. The growth, invasion and dis-
semination of tumor cells are accompanied by dra-
matic changes in the mechanical properties (stiffness)
of the cancer cell niche. The bone marrow, a common
reservoir site for disseminated tumor cells, provides a
microenvironment with stiffness significantly lower
than that encountered in most epithelial tumors.28
Fig. 8. Matrix stiffness and chemotherapy regulate stem cell marker expression in HepG2 cells. (A) Quantification by flow cytometric analysis
of putative cancer stem cell markers CD133, c-kit, CD44 and CXCR-4 in HepG2 cells cultured for 5 days on soft (1 kPa) or stiff (12 kPa) sup-
ports. Cells were either left untreated (black) or treated for 24 hours with cisplatin (white). Results are representative of three independent
experiments. (B) Real-time quantitative PCR analysis of octamer-4 (OCT4) (left panel) and NANOG (right panel) expression in HepG2 cells cul-
tured for 5-days on soft (1 kPa) or stiff (12 kPa) supports. Cells were either left untreated (black) or treated for 24 hours with cisplatin (white).
Expression is relative to the 18S housekeeping gene. In each case, error bars represent SEM, *P < 0.05, **P < 0.01, and ***P < 0.001.
HEPATOLOGY, Vol. 53, No. 4, 2011 SCHRADER ET AL. 1203
Our findings suggest that a reduction in the stiffness
of the cancer cell niche would be sufficient to promote
reversible cellular quiescence (dormancy). Furthermore,
increases in environmental stiffness (as may occur with
inflammation, surgery or stromal reaction to tumor) or
alteration in the stiffness-sensing machinery of the cell
(as a result of genomic instability) might facilitate reac-
tivation. Indeed, early work on cancer cell dormancy
in animal models established inflammation and surgi-
cal trauma as a mechanism of reactivation of dormant
cells.29,30 More recently, fibrosis-associated collagen-I
has been linked to reactivation of tumor cells in an in
vivo model of cancer cell dormancy.31 With respect to
the liver, tumor growth and intrahepatic metastasis
have been shown to be enhanced in a fibrotic environ-
ment.20-22
The precise phenotype of disseminated tumor cells
derived from epithelial malignancies remains poorly
defined.32 During tumor dissemination, tumor cells
are believed to acquire mesenchymal properties, ena-
bling them to migrate through and invade surrounding
tissues and enter the bloodstream.33 However, at sec-
ondary sites, tumor cells are primarily detected by
their epithelial characteristics and outgrowing metasta-
ses recapitulate the epithelial phenotype of the primary
tumor.34 Despite our increasing understanding of the
regulation of epithelial-to-mesenchymal transition, the
reverse process—mesenchymal-to-epithelial transi-
tion—is largely uncharacterized. We have demon-
strated that HCC cells lose mesenchymal features,
including stress fibers, N-cadherin, and vimentin
expression, and the cells up-regulate markers of hepa-
tocyte differentiation when maintained in a soft envi-
ronment. This is consistent with previous findings
showing that nontransformed mammary epithelial cells
revert to an organized epithelial phenotype in a soft
environment6 and that hepatocytes retain an epithelial
phenotype on soft collagen gels.35 FAK activation has
been implicated in the process of epithelial-to-mesen-
chymal transition and responsiveness to TGFb.36 It
remains unclear whether reduced FAK activation and
TGFb signaling in cells in a low stiffness environment
is a mechanistic link to mesenchymal-to-epithelial
transition.
The high rate of chemotherapy resistance in HCC
is a major obstacle in treating patients with advanced
disease. Identifying the mechanism of this resistance
has the potential to reveal new treatment options for
this group of patients. We have provided evidence that
increasing ECM stiffness, as encountered by cells
within an established tumor,4 reduces chemotherapy-
induced apoptosis. However, the clinical utility of sys-
temic chemotherapy is also limited by the failure of
adjuvant/neoadjuvant chemotherapy to target dissemi-
nated tumor cells that give rise to late tumor recur-
rence and metastases.32,37 Intriguingly, we have been
able to demonstrate an increase in clone-initiating
capability following chemotherapy in cells from a low
stiffness environment. This was accompanied by an
increase of cells positive for cancer stem cell markers
(CD44, CD133, c-kit, CXCR-4, OCT4, and
NANOG).38 This provides a potential mechanism for
long-term survival and clone-initiating capability of
disseminated tumor cells in a soft environment (e.g.,
bone marrow) following chemotherapy. Whether the
higher frequency of cells with a cancer stem cell phe-
notype is due to positive selection or active induction
of cancer stem cell characteristics needs to be
determined.
In summary, we have provided evidence that the
biomechanical composition of the ECM is a critical
regulator of HCC behavior. We suggest that the high
stiffness environment encountered in chronic fibrotic
liver disease fosters HCC progression by promoting
cellular proliferation, a mesenchymal phenotype and
resistance to chemotherapy. Conversely, a soft physio-
logical environment (as might be encountered by a dis-
seminated tumor cell) induces cellular dormancy, a
stem cell phenotype and enhanced clonogenic capacity
following chemotherapy. Indeed, we propose that alter-
ations in the stiffness of the cancer cell niche are re-
sponsible for regulating cancer cell proliferation and
phenotype throughout the natural history of HCC.
Manipulation of environmental stiffness or interference
with the stiffness-sensing apparatus of HCC cells has
the potential to impede both tumor growth and reacti-
vation of dormant tumor cells, thereby limiting recur-
rence. In concert with future in vivo models of HCC,
these findings will provide a platform for the future
design of therapies targeting the biomechanical proper-
ties of the cancer cell niche.
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